-- phpMyAdmin SQL Dump
-- version 4.7.4
-- https://www.phpmyadmin.net/
--
-- Host: 127.0.0.1
-- Generation Time: Apr 24, 2020 at 11:19 AM
-- Server version: 10.1.30-MariaDB
-- PHP Version: 7.2.1

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET AUTOCOMMIT = 0;
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `hospital`
--

-- --------------------------------------------------------

--
-- Table structure for table `cancer_drugs`
--

CREATE TABLE `cancer_drugs` (
  `id` int(10) NOT NULL,
  `Name` varchar(84) NOT NULL,
  `EVS_ID` varchar(30) DEFAULT NULL,
  `Histology` varchar(97) DEFAULT NULL,
  `Do_not_code` varchar(11) NOT NULL,
  `Remarks` varchar(5880) DEFAULT NULL,
  `Alternate_Name` varchar(1215) DEFAULT NULL,
  `Primary_Site` varchar(246) DEFAULT NULL,
  `Abbreviation` varchar(40) DEFAULT NULL,
  `NSC_number` varchar(52) DEFAULT NULL,
  `Category` varchar(53) NOT NULL,
  `Subcategory` varchar(123) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `cancer_drugs`
--

INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1, '1,25-Dihydroxyvitamin D3', NULL, NULL, 'YES', 'Differentiation Inducing Agent; Vitamin', 'Calcijex , Calcitrol , Di-Vit-Sol , Multi-M , Rocatrol , Tolerex , Vivonex T.E.N.', NULL, NULL, NULL, 'Differentiation inducing agent', NULL),
(2, '1-Methyl-D-tryptophan', NULL, NULL, 'NO', 'This agent is being studied in the treatment of melanoma and many other types of cancers. Code in Other Therapy field until FDA approval.', NULL, 'Melanoma, Other types, NOS', NULL, NULL, 'Chemotherapy', 'Enzyme inhibitor'),
(3, '1018-ISS', NULL, NULL, 'NO', 'As of March 2015, this drug is still in clinical trials for various neoplasms as well as hepatitis viruses.', 'ISS 1018 CpG oligodeoxynucleotide', 'Lymphoma', NULL, NULL, 'Chemotherapy', 'Targeted therapy--antisense'),
(4, '109881', NULL, NULL, 'NO', 'RPR 109881 is a substance that  is being studied in the treatment of cancer. It belongs to the family of drugs called taxanes. As of March 2015, it has not received FDA approval for use in cancer treatment and is not currently in clinical trials.', 'RPR-109881 , RPR-109881A , taxoid 109881', 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Natural product--taxane'),
(5, '131I-MIBG', NULL, NULL, 'YES', 'Phase II Iodine labeled MIBG', 'I131 metaiodobenzylguanidine', 'Neuroblastoma', NULL, NULL, 'Radiation', 'Radioisotope'),
(6, '131I-TM-601', NULL, NULL, 'NO', 'The drug is tumor specific to malignant glioma of the brain.  It is administered intravenously to provide tumor-specific localization (via radiographic imaging) in patients with recurrent or refractory primary solid tumors with evidence of metastatic involvement.', 'Iodine I 131 TM-601', 'Glioma', NULL, NULL, 'Radiation', 'Immunotoxin conjugated with radiation (radioisotope)'),
(7, '17-DMAG', NULL, NULL, 'NO', 'Phase I solid tumors 2007 Binds to heat-shock protein 90. Information from NCI', NULL, 'Solid tumors', NULL, '707545', 'Chemotherapy', 'Targeted therapy--heat shock protein 90 inhibitor'),
(8, '2,4-Dinitrochlorobenzene', NULL, NULL, 'NO', 'Has been used as an immunostimulant in leprosy, AIDS, and some forms of cancer and in the treatment of alopecia and warts.', NULL, 'AIDS, being studied in Melanoma (EORTC-18851), Opportunistic infection', 'DNCB', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(9, '2-Alizapride Hydrochloride', NULL, NULL, 'YES', 'Anti-emetic agent; demonstrated relatively poor antiemetic activity in cancer patients receiving strongly emetogenic chemo., and offers no advantage over other effective antiemetic agents', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(10, '2B1 bispecific murine MAb', NULL, NULL, 'NO', 'Phase II Bi-specific Monoclonal antibody. NCI. (bsAb 2B1 targets the extracellular domains (ECD) of the HER2/neu protooncogene product and the human FcgammaRIII (CD16).', '2B1 , 2B1 antibody ,  bispecific', 'Breast cancer, Ovarian cancer', NULL, '673928', 'Biologic therapy (BRM, immunotherapy)', 'Passive monoclonal antibody'),
(11, '4\'-Hydroperoxycyclophosphamide', NULL, NULL, 'NO', 'Phase I/Phase II Used for purging of bone marrow for acute myeloid leukemia prior to autologus bone marrow transplant', NULL, 'AML, Breast', '4-HC', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(12, '4-Hydroxyphenyl retinamide', NULL, NULL, 'NO', 'Retinoid', 'Fenretinide', 'Kaposi\'s sarcoma, breast', '4-HPR', NULL, 'Differentiation inducing agent', NULL),
(13, '4-Nitroestrone', NULL, NULL, 'NO', 'Affects the aromatization process in converting androstinedione into estrone. Antitumor activity comparable to that of tamoxifen and nafoxidine. NCI.', NULL, 'Breast', NULL, '321803', 'Hormones and hormonal mechanisms', 'Estrogen'),
(14, '5\'-Inosinic acid polymers', NULL, NULL, 'NO', NULL, 'Poly(rI).poly(rC)', NULL, 'Poly I:C', '120949', 'Biologic therapy (BRM, immunotherapy)', NULL),
(15, '5-Aza-2\'Deoxy-cytidine', NULL, NULL, 'NO', NULL, 'Decytabine', 'CML', 'DAC', NULL, 'Chemotherapy', 'Cytostatic agent--DNA methyl transferase inhibitor'),
(16, '5-fluoro-2-deoxycytidine', NULL, NULL, 'NO', 'A substance being studied in the treatment of some types of cancer. It may prevent the growth of tumors by stopping cancer cells from dividing and by killing them. It is a type of anti-metabolite.', NULL, 'Advanced solid tumors', '5FD, FdCyd', '48006', 'Chemotherapy', 'Antimetabolite'),
(17, '5-FP', NULL, NULL, 'NO', 'Oral 5-FU prodrug that is converted in the liver to the active 5-FU.', '5-fluoro-Pyrimidinone', 'Breast, gastric, head & neck, liver cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(18, '566C80', NULL, NULL, 'YES', 'Treatment IND Pneumocystis in AIDS pts who do not respond to conventional treatment', NULL, 'Pneumocystis', NULL, NULL, 'AIDS drug', NULL),
(19, '6-Azuridine', NULL, NULL, 'NO', NULL, '6-Azauridine , 6-Azur , Azauridine , Ribo-azauracil , Ribo-azuracil , Riboazuracil', NULL, 'AzUR', '32074', 'Chemotherapy', 'Antimetabolite'),
(20, '6-Diazo-5-oxo-L-norleucine', NULL, NULL, 'NO', 'From Shepard\'s: tumor inhibiting glutamine analogue. Not found in Drugdex drug evaluation.', NULL, NULL, 'DON', NULL, 'Chemotherapy', 'Antibiotic'),
(21, '845 4B5', NULL, NULL, 'NO', 'March 2015: documentation that this drug is still being used in the treatment of cancer has not been found. Code with caution', NULL, 'Head & neck, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(22, '935U83', NULL, NULL, 'YES', 'Inhibits the HIV reverse transcriptase', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(23, '9OY-hPAM4', NULL, NULL, 'YES', 'Phase I&II Do Not Code as Immunotherapy: this agent is used as a sensetizer to deliver radioisotopes', '9OY-hPAM4', 'Pancreas', NULL, NULL, 'Other therapy', 'immunotherapy'),
(24, 'A 80967', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(25, 'A-77003', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(26, 'Abarelix', NULL, NULL, 'NO', 'Phase II GnRH antagonist. Praecis Pharmaceuticals.', 'Abarelix-Depot-F , Abarelix-Depot-M , Abarelix-L , Plenaxis , PPI 149 , PPI-149 , PPI149 , R 3827', 'breast, Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen production antagonist'),
(27, 'Abemaciclib', NULL, NULL, 'NO', 'The FDA has granted the CDK4/6 inhibitor abemaciclib (LY2835219) a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor (HR)-positive advanced breast cancer, based on data from a phase I study. \r\nCoding instructions: The drug is currently in clinical trials and has not yet recied FDA approval.  Code as Other Treatment and assign code 2. \r\n\r\nSeptember 28, 2017: FDA approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones.\r\n\r\nMarch 6, 2018 FDA has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.', 'LY2835219 , Verzenio', 'Breast', NULL, NULL, 'Chemotherapy', 'Cyclin-dependent kinase inhibitor'),
(28, 'Abiraterone acetate', NULL, NULL, 'NO', 'April 28, 2011: Zytiga received FDA approval for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.\r\nInhibitor of the steroidal enzyme 17 -hydroxylase/C17,20 lyase involved in testosterone production.', 'CB 7630 , CB-7630 , CB7630 , Zytiga', 'Prostate', 'AA', NULL, 'Hormones and hormonal mechanisms', 'Antiandrogenic'),
(29, 'Abraxane', NULL, NULL, 'NO', 'FDA approved to treat breast cancer and non-small cell lung cancer\r\n\r\nSeptember 6, 2013 FDA approval to use abraxane in combination with gemcitabine for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.', 'ABI 007 , ABI-007 , ABI007 , Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) , nab-Paclitaxel , nanoparticle paclitaxel , protein-bound paclitaxel', 'Metastatic breast cancer, NSCLC, Non small cell lung cancer, cervix, melanoma, pancreas', NULL, '900002', 'Chemotherapy', 'Taxane'),
(30, 'ABT 888', NULL, NULL, 'NO', 'Dec. 2013: received FDA approval to treat patients with advanced ovarian cancer. this drug is also in clinical trials for metastatic unresectable solid tumors and Non-Hodgkin lymphoma.', 'Veliparib', 'Ovary', NULL, NULL, 'Chemotherapy', 'PARP Inhibitor'),
(31, 'ABT-510', NULL, NULL, 'NO', 'As of March 2015, this drug has not received FDA approval and numerous clinical trials did not demonstrate definite clinical efficacy.', NULL, 'Liver, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(32, 'ABT-518', NULL, NULL, 'YES', 'As of March 2015, the manufacturer has stopped all clinical trials. \r\n\r\n.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Inhibitor--matrix metalloproteinase/antimitotic agent'),
(33, 'ABT-546', NULL, NULL, 'YES', 'As of March 2015, this drug has not received FDA approval and it is not in any clinical trials for use in treating cancers.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--enodthelin receptor antagonist'),
(34, 'ABT-751', NULL, NULL, 'NO', 'Phase II ALL, neuroblatoma Tubulin antagonist (tubulin binding agent). Abbott Laboratories.', 'ABT 751 , ABT751', 'neuroblastoma, Pediatric ALL', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--tubulin binding agent'),
(35, 'ABX-IL-8', NULL, NULL, 'YES', 'As of March 2015, this drug has not received FDA approval for use in the treatment of cancer. It is in various clinical trials for inflammatory diseases. \r\n\r\nHuman monoclonal antibody blocks IL-8', NULL, 'Skin cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--monoclonal antibody'),
(36, 'ABX-MAI', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Abgenix.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Passive monoclonal antibody'),
(37, 'Acalabrutinib', NULL, 'Mantle cell lymphoma', 'NO', 'October 31, 2017: FDA has granted accelerated approval to Calquence (Acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.\r\nNovember 21, 2019 FDA approved acalabrutinib (CALQUENCE) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).', 'Calquence', NULL, NULL, NULL, 'Chemotherapy', 'kinase inhibitor'),
(38, 'Acapodene', NULL, NULL, 'NO', 'Phase II Chemoprevention, gene therapy. FDA approved use on advanced breast cancer. Genotherapeutics. Promotes retargeted cytotoxicity against HER2/neu-positive cell lines.', 'FC-1157a , Toremifene', 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(39, 'Accutane', NULL, NULL, 'YES', 'Phase II/III A synthetic analogue of vitamin A. Rx of molluscum contagiosum virus. NCI.', '13 cis retinoic acid , 13-cis-retinoic acid , 13-cis-retinoid acid , 13-cis-Vitamin A acid , Accutane , Isotretinoin* , Neovitamin A acid , RO-4-3780', 'Prostate cancer', 'Vit A', '329481', 'Differentiation inducing agent', NULL),
(40, 'Acetaminophen', NULL, NULL, 'YES', 'Analgesic and antipyretic.', '222-AF , A.F , Abenol , Acephen , Aceta , Anacin , Apo-Acetaminophen , Atasol , Contac , Dolanex , Exdol , Feverall , Fevernol , Genapap , Genebs , Halenol , Korum , Liquiprin , Meda , Nebs , Neopap , Nilprin , Panadol , Panex , Paracetamol , Paralgin , PediApap , Pediatrix , Phenaphen , Robigesic , Rounox , Snaplets-FR , St. Joseph Aspirin-Free , Stanback , Suppap , Tantaphen , Tapar , Tempra , Tylenol , Uni-Ace , Valorin', NULL, NULL, NULL, 'Ancillary Agent', 'Ancillary'),
(41, 'Acetazolamide', NULL, NULL, 'YES', 'Carbonic anhydrase inhibitor, in the treatment of glaucoma; diuretic, adjunctive therapy in seizures.', NULL, NULL, 'ACZ', NULL, 'Ancillary Agent', 'Ancillary'),
(42, 'Acetylcysteine', NULL, NULL, 'YES', 'For prevention against liver damage in severe acetaminophen intoxication; useful in decreasing the number of exacerbations in patients with chronic bronchitis; protection against cytotoxic agents such as ifosfamide and cyclophosphamide.', NULL, 'AIDS, Opportunistic infection', NULL, '111180', 'Ancillary Agent', 'Ancillary'),
(43, 'Acitretin', NULL, NULL, 'YES', 'A metabolite of etretinate for treatment of psoriasis.', 'Etretin , Ro 10-1670 , Soriatane', NULL, NULL, NULL, 'Differentiation inducing agent', NULL),
(44, 'Acivicin', NULL, NULL, 'NO', 'Glutamine antagonist causing irreversible inhibitor of gamma-GT, a specific inhibitor of g-glutamyl transpeptidase and transmembrane glutathione transport. Potent antitumor and antileishmania agent. Induces apoptosis in human lymphoblastoid cells. Inhibitor of carbamoyl phosphate synthetase.', '126 , Antibiotic AT-125 , U-42', NULL, 'AT-125', '163501', 'Chemotherapy', 'Antitumor antibiotic'),
(45, 'Aclarubicin', NULL, NULL, 'NO', NULL, 'Aclacinomycin , Aclacinomycin- A# , Aclacinon , Aclaplastin , Aclarubein , Antibiotic MA 144-A1', 'Leukemia, solid tumors', 'ACM, ACM-A, ACR', '208734', 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(46, 'Acodazole', NULL, NULL, 'NO', NULL, '055435-65-9 , 055435659 , 55435-65-9 , Acetamide , EU-3120', NULL, 'AD-32', '305884', 'Chemotherapy', 'Akylating agent'),
(47, 'Acronine', NULL, NULL, 'NO', NULL, 'Acronycin# , Acronycine , Compound 42339', NULL, NULL, '403169', 'Chemotherapy', 'Plant alkyloid'),
(48, 'Acyclovir', NULL, NULL, 'YES', 'Antiviral agent.', 'Acycloguanosine , Avirax , BW-248U , BW248U , Zovirax', NULL, NULL, '335752', 'Ancillary Agent', NULL),
(49, 'Acyclovir Sodium', NULL, NULL, 'YES', 'Prescribed for HSV and VZV infections; anti-viral', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(50, 'Ad5CMV-p53 (adenovirus p53)', NULL, NULL, 'NO', 'Phase III Nucleoside analog gene therapy. Matrix Pharmaceuticals.', NULL, 'Glioma, Head & neck, lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'p53 tumor suppressor gene'),
(51, 'ADA Transduced T-cell', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '635386', 'Biologic therapy (BRM, immunotherapy)', NULL),
(52, 'Adefovir', NULL, NULL, 'YES', 'Adefovir is an antiviral agent (acyclic nucleotide), formerly an investigational drug, has been withdrawn from the investigational program. The manufacturer, Gilead, is not pursuing FDA-approval. Oral adefovir dipivoxil has shown efficacy in chronic hepatitis B infection and HIV infection in limited studies. Adefovir may also prove useful for preventing or treating opportunistic herpes virus infections in HIV-infected patients.', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(53, 'Adenazole', NULL, NULL, 'NO', 'Phase II Nucleoside analog. ICN Pharmaceuticals.', NULL, 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Nucleoside analog'),
(54, 'Adeno-Interleukin-2', NULL, NULL, 'NO', 'Phase I Adenoviral vector. Transgene.', NULL, 'other cancer, Skin', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(55, 'Adicillin', NULL, NULL, 'YES', 'Antibiotic', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(56, 'Ado-trastuzumab emtansine', NULL, NULL, 'NO', 'May 3, 2019: FDA approved ado-trastuzumab emtansine (KADCYLA) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. \r\n\r\nFebruary 22, 202: Kadycla received FDA approval for the treatment of metastatic HER-2 positive breast cancerin patients that had previously been treated with trastuzumab and a taxan, either separately or in combination.', 'KADCYLA , T-DM 1 , TDM 1 , Trastuzumab-MCC-DM1 antibody conjugate , Trastuzumab-MCC-DM1 Immunoconjugate', 'Metastatic HER-2 breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Antibody-drug conjugate'),
(57, 'Adozelesin', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Miscellaneous alkylating agent'),
(58, 'Adrenocorticotropic hormone', NULL, NULL, 'NO', 'Chief function is to stimulate the cortex of the adrenal gland to secrete adrenocortical steroids, chief among them cortisone-the stress hormone.', NULL, NULL, 'ACTH', '25933', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(59, 'Advexin', NULL, NULL, 'NO', 'Phase I (bladder, brain, ovarian, prostate)  phase II (breast, lung) phase III (head & neck) Gene therapy. Introgen Therapeutics, NCI.', 'Contusugene ladenovec', 'Bladder, brain, breast, head & neck, liver, lung, ovarian, prostate cancer', NULL, '683550', 'Biologic therapy (BRM, immunotherapy)', 'p53 tumor suppressor gene'),
(60, 'ADXS-HPV', NULL, NULL, 'NO', 'The FDA granted Orphan Drug designation to ADXS-HPV for treatment of stage II-IV invasive cervical cancer. Orphan drug designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the US. This drug is currently in several clinical trials showing promising results.  Code this drug as Other until final FDA approval is granted.', NULL, 'Cervix', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(61, 'AEE 788', NULL, NULL, 'NO', 'March 2015: several studies/clinical trials using this drug have been discontinued due to unacceptable toxicity. \r\n\r\nPhase I TKI that blocks EGFR, erbB-2, and alsoVEGFR-1 and VEGFR-2..', 'AEE-788 , AEE788', 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Tyrosine kinase inhibitor'),
(62, 'Affinitak', NULL, NULL, 'NO', 'Phase III (lung) Phase II NHL, ovarian Antisense. Eli Lilly. ISIS Pharmaceuticals.', 'Affinitac , Affinitak , CGP64128A , ISI641A , ISIS-3521 , LY900003', 'Lung, lymphoma, ovarian cancer', NULL, '719337', 'Chemotherapy', 'Targeted therapy'),
(63, 'Afinitor', NULL, NULL, 'NO', 'April 10, 2018: FDA approved everolimus tablets for oral suspension (Afinitor) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma\r\n\r\nMarch 2009/April 2010/May 2011:Everolimus has received FDA approval for treatment of advanced kidney cancer, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention. April 2010, progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011). \r\n\r\nFebruary 26, 2016: FDA approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of GI or lung origin with unresectable, locally advanced or metastatic disease.', 'Afinitor , Certican , Everolimus , RAD001', 'breast, Lung, other cancer', NULL, '733504', 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent and mTOR inhibitor'),
(64, 'Aflibercept', NULL, NULL, 'NO', 'Phase I NHL; Phase II 2007 for ovary, fallopian tube, primary peritoneal carcinoma VEGF blocker. Regeneron Pharmaceuticals.', 'AVE 0005 , AVE-0005 , AVE0005 , VEGF Trap', 'fallopian tube, Lymphoma, ovary, primary peritoneal carcinoma', NULL, '724770', 'Chemotherapy', 'Cytostatic agent--VEGF inhibitor'),
(65, 'AFP-Scan', NULL, NULL, 'YES', 'Phase II Diagnostic. Radiolabeled monoclonal antibody(conjugated mab) Immunomedics.', NULL, 'Liver cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(66, 'AFP464', NULL, NULL, 'NO', 'Phase I advanced solid tumors 2007 Aminoflavone prodrug.  Tigris Pharmaceuticals', 'AFP 464 , AFP-464', 'Solid tumors', NULL, '710464', 'Chemotherapy', 'Cytotoxic-cytostatic agent'),
(67, 'AG-2037', NULL, NULL, 'NO', 'Phase I breast, lung Phase II other Glycinamide ribonucleotide formyl transferase inhibitor. Pfizer, Agouron Pharmaceuticals.', 'AG2037', 'Breast, colon, lung, other cancer', NULL, NULL, 'Chemotherapy', 'Inhibitor--glycinamide ribonucleotide formyl transferase'),
(68, 'AG3340', NULL, NULL, 'NO', 'Phase III Selective matrix metalloproteinase inhibitor. Agouron Pharmaceuticals.', 'AG-3340', 'Prostate cancer', NULL, '700909', 'Biologic therapy (BRM, immunotherapy)', 'Inhibitor--matrix metalloproteinase'),
(69, 'AL-721', NULL, NULL, 'YES', 'A lipid compound composed of neutral lipids, phosphatidylcholine and phosphatidylethanolamine in a ratio of 7/2/1, respectively. Inhibits binding of HIV to target cells.', 'AL721', NULL, NULL, '615295', 'AIDS drug', NULL),
(70, 'Alanosine', NULL, NULL, 'NO', 'Phase II Antitumor antibiotic. Salmedix.', 'L-Alanosine , SDX 102 , SDX-102 , SDX102', 'Lung, pancreatic cancer, sarcoma', NULL, '153353', 'Chemotherapy', 'Antimetabolite'),
(71, 'Albendazole', NULL, NULL, 'YES', 'A broad-spectrum oral anthelmintic agent. Antifungal agent; Rx of microsporidiosis', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(72, 'Albuleukin', NULL, NULL, 'NO', 'Phase I Interleukin-2. Human Genome Sciences', NULL, 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(73, 'Albuterol Sulfate', NULL, NULL, 'YES', 'Bronchodilator for the treatment of asthma and reversible bronchospasm. It is also used to treat chronic bronchitis, pulmonary emphysema with reversible obstruction and prophylactically to prevent bronchospasm.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(74, 'Alectinib', NULL, 'Non-small cell lung cancer (NSCLC)', 'NO', 'UPDATE: December 11, 2015 FDA granted accelerated approval to alectinib for the treatment of anaplastic lymphoma kinase (ALK)  positive metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).\r\n\r\nNovember 6, 2017: FDA granted regular approval to alectinib  for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.', 'Alecensa , ALK inhibitor CH5424802', 'Lung', NULL, NULL, 'Chemotherapy', 'ALK Inhibitor'),
(75, 'Alemtuzumab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code alemtuzumab as BRM/Immunotherapy.For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.  \r\n\r\nFDA approved use on chronic lymphocytic leukemia.', 'Campath', 'Leukemia, lymphoma', NULL, '715969', 'Biologic therapy (BRM, immunotherapy)', 'Targeted therapy'),
(76, 'Alendronate Sodium', NULL, NULL, 'YES', 'Bone modulating drug; inhibits osteoclast-mediated bone resorption; suppressant; Alendronate is a potent aminobisphosphonate that is effective for prevention and treatment of postmenopausal osteoporosis and for treatment of glucocorticoid-induced osteoporosis. Alendronate is also effective for treating Paget\'s disease of bone [Prod Info Fosamax, 1999]', NULL, NULL, NULL, NULL, 'Ancillary Agent', 'Bisphosphonate'),
(77, 'Algestone Acetophenide', NULL, NULL, 'NO', NULL, 'SQ 15101 , SQ15101', NULL, 'SQ-15101', '67831', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(78, 'Alitretinoin', NULL, NULL, 'YES', 'Phase II (breast, sarcoma, skin) Phase III  APL A natural retinoid with actions similar to all-trans-retinoic acid (tretinoin). FDA approved use for Kaposi\'s sarcoma. Ligand Pharamceuticals, Vical, NCI.', NULL, 'Breast, Kaposi sarcoma, leukemia, sarcoma, skin cancer', '9cRA', '659772', 'Differentiation inducing agent', NULL),
(79, 'Allogeneic cells', NULL, NULL, 'NO', 'Bone marrow therapy. Killed tumor cells', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(80, 'Allogenic colon cancer vaccine', NULL, NULL, 'NO', 'Phase I Colon cancer vaccine. Immune Response Corp.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(81, 'Allogenic glioma cancer vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. Immune Response Corp.', NULL, 'Brain cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(82, 'Allopurinol', NULL, NULL, 'YES', 'A xanthine oxidase inhibitor indicated in the treatment of hyperuricemia, which is often observed in leukemia, lymphoma, polycythemia vera, myeloid metaplasia, and malignancies in patients receiving cancer chemo.', '1 Zyloprim , Alloprin , Allopur , Apo-Allopurinol , Atisuril , Bloxanth , BW-56-158 , Epidropal , Foligan , Gotax , HPP , Lopurin , Milurit , Novo-Purol , Purinol , Riva-Purinol , Uricemil , Uriprim , Urosin , Zurinol , Zyloprim , Zyloric', NULL, 'ALLO, HPP', '001390;1390', 'Ancillary Agent', NULL),
(83, 'Allovectin-7', NULL, NULL, 'NO', 'Phase II, Phase III metastatic melanoma Increases the ability of the immune system to recognize cancer cells and kill them. Gene based immunotherapy. Vical, Inc.', NULL, 'Head & neck cancer, melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(84, 'Alpha Interferon', NULL, NULL, 'NO', 'Rx of Kaposi\'s sarcoma; may interfere with release of virus from infected cells', NULL, NULL, 'INF', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(85, 'Alpha-APA derivatives', NULL, NULL, 'YES', 'Non-nucleoside reverse transcriptase inhibitor', 'R 18893 , R 89439 , R-18893 , R-89439 , R18893 , R89439', NULL, NULL, NULL, 'AIDS drug', NULL),
(86, 'Alpha-TGdR', NULL, NULL, 'NO', NULL, 'A-TGDR', NULL, NULL, '71851', 'Chemotherapy', 'Antimetabolite'),
(87, 'Alpharadin', NULL, NULL, 'NO', 'Alpharadin is currently in clinical trials for bone metastases from prostate and breast cancer. Radium 223 is a one targeting isoptope which kills cancer cells using alpha radiation. The FDA has recently granted Alpharadin Fast Track designation. Bayer Healthcare plans to submit for approval to regulatory authorities in Europe and the USA mid-year 2012. Code in Other Therapy field until approved.', 'Radium-223 chloride', 'Bone metastases', NULL, NULL, 'Radiation', 'alpha radiation (radiopharmaceutical)'),
(88, 'Alprazolam', NULL, NULL, 'YES', 'The efficacy of Alprazolam as an antidepressant requires further evaluation; sedative.', 'Alprazolam Intensol , Alti-Alprazolam , Apo-Alpraz , Med Alprazolam , Novo-Alprazol , Nu-Alpraz , U 31889 , U-31889 , U31889 , Xanax', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(89, 'Altretamine', NULL, NULL, 'NO', 'Antineoplastic. FDA approved for ovarian cancer use.', 'ENT 50852 , ENT-50852 , Hemel , Hexalen , hexamethyl- (8CI) , Hexamethylenamine , Hexamethylmelamine , Hexastat , Melamine , NC 195 , NCI-C50259', 'Ovarian cancer', 'HMM, HTM, HXM', '013875;13875', 'Chemotherapy', 'Ccytotoxic antineoplastic'),
(90, 'ALVAC-B7.1 Vaccine with StemSep', NULL, NULL, 'NO', 'Phase I ovarian, melanoma Vaccine. NCI.', NULL, 'Ovarian, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(91, 'ALVAC-CEA Vaccine', NULL, NULL, 'NO', 'Phase I Aventis Pasteur.', NULL, 'Colon cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(92, 'ALVAC-IL-12', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. NCI, Aventis Pasteur.', NULL, 'Skin cancer', NULL, '689514', 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(93, 'AlvacCEA/B7.1', NULL, NULL, 'NO', 'Phase II Vaccine. Therion Biologics.', NULL, 'Colorectal cancer', NULL, '715616', 'Biologic therapy (BRM, immunotherapy)', 'Adoptive immunotherapy'),
(94, 'Amadinone Acetate', NULL, NULL, 'NO', 'Progestin', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(95, 'Ambomycin', NULL, NULL, 'NO', 'Antitumor antibiotic', NULL, NULL, NULL, '53397', 'Chemotherapy', 'Antitumor antibiotic'),
(96, 'Amcinonide', NULL, NULL, 'NO', 'A fluorinated synthetic corticosteroid used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'Amcinopol , CL 34699 , CL-34699 , CL34699 , Cyclocort', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(97, 'AMD-3100', NULL, NULL, 'YES', 'Phase I May help G-CSF work better by making peripheral stem cells.  Chemokine co-receptor entry inhibition. AnorMed.', 'AMD 3100 , AMD3100', 'Leukemia, lymphoma, multiple myeloma', NULL, NULL, 'Ancillary Agent', NULL),
(98, 'AMD-473', NULL, NULL, 'NO', 'Phase II Platinum derivative. AnorMED.', 'AMD 473 , AMD473', 'Breast, lung, ovarian, pancreatic, prostate cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent'),
(99, 'Amdray', NULL, NULL, 'YES', 'Phase III p-Glycoprotein modulator. Novartis.', 'PSC 833 , PSC-833 , PSC833 , SDZ PSC 833 , Valspodar', 'Leukemia', NULL, '648265', 'Ancillary Agent', 'Multidrug resistance modulator'),
(100, 'Ametantrone Acetate', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.', 'CI 881 , CI881', NULL, 'CI-881', '287513', 'Chemotherapy', 'Anthracyline--no longer in use'),
(101, 'AMG 386', NULL, NULL, 'NO', 'Phase I New drug currently in trials, code as Other Therapy as it is not FDA approved', 'AMG 386', 'Breast, GYN', NULL, NULL, 'Chemotherapy', 'Angiopoietin inhibitor'),
(102, 'AMG 531', NULL, NULL, 'YES', 'Stimulates platelet (thrombocyte) recovery.  Amgen.', 'AMG-531 , AMG531 , Nplate , Romiplostim', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(103, 'AMG-479', NULL, NULL, 'NO', 'I, II New drug currently in trials, code in other therapy', NULL, 'Carcinoids, NSCLC, pancreas, solid tumors', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody inhibitor of IGF-IR'),
(104, 'Amifostine', NULL, NULL, 'YES', 'Phase III leukemia Phase II NHL, skin An organic thiophosphate cytoprotective agent; MedImmune Oncology; radioprotector; prevents nephrotoxicity, neurotoxicity', 'Ethanethiol , Ethiofos , Ethyol , Gammafos , WR 2721 , WR-2721 , WR2721 , YM 08310 , YM-08310 , YM08310', 'Breast, leukemia, lymphoma, NSCLC, prostate, skin cancer', NULL, '296961', 'Ancillary Agent', NULL),
(105, 'Amikacin Sulfate', NULL, NULL, 'YES', 'A semi-synthetic aminoglycoside antimicrobial; antimycobacterial', 'Amikacin , Amikacin Sulfate , Amikin , D-Streptamine , Mikasome', NULL, NULL, NULL, 'AIDS drug', NULL),
(106, 'Aminobenzoate Potassium', NULL, NULL, 'YES', 'Has been used in the treatment of various disorders associated with excessive fibrosis, such as scleroderma and Peyronie\'s disease; analgesic; Not found in Drugdex drug evaluation.', 'Pabalate-SF , Potaba', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(107, 'Aminocamptothecin', NULL, NULL, 'NO', 'CLL, breast, lung, lymphoma Topoisomerase I inhibitor.', '9-Aminocamptothecin', 'Leukemia, breast, lung cancer, lymphoma', '9-AC', '603071', 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(108, 'Aminoglutethimide', NULL, NULL, 'NO', 'Aminoglutethimide interrupts the production of cortisol, aldosterone, and estrogens.', 'Ba 16038 , Ba-16038 , Ba16038 , Cytadren , Elipten', NULL, 'AG, AGT', '330915', 'Hormones and hormonal mechanisms', 'Adrenocortical suppressant'),
(109, 'Aminopterin', NULL, NULL, 'NO', 'Phase II. Antifolate; antimetabolite; ILEX Oncology.', '4-Aminofolic acid , 4-Aminopteroylglutamate , A-Ninopterin , Aminopteridine , Aminopterin sodium , ENT 26079 , ENT-26079', 'Leukemia', 'APGA', '739;000739', 'Chemotherapy', 'Antimetabolite'),
(110, 'Aminosalicylate Calcium', NULL, NULL, 'YES', 'Bacteriostatic agent.', 'Parasal Calcium , Pascal', NULL, NULL, NULL, 'AIDS drug', NULL),
(111, 'Aminosalicylic Acid', NULL, NULL, 'YES', 'A highly specific, bacteriostatic agent active against Mycobacterium tuberculosis.', '4-Aminosalicylic acid , Aminosalicylate , Nemasol Sodium , Novo-5 ASA , P-Aminosalicylic acid , Pacer , Para-aminosalicylate , Para-aminosalicylic Acid , Rezispas , Teebacin Acid', NULL, 'PAS', NULL, 'AIDS drug', NULL),
(112, 'Aminosyn', NULL, NULL, 'YES', 'Prevents acivicin-induced toxicity', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(113, 'Aminothiadiazole', NULL, NULL, 'NO', NULL, '2-Aminothiadiazole , FDA 0084 , NIST4005-51-0 , NISTC4005510 , NSC 4728 , TF 128 , TF-128 , X 26', NULL, 'A-TD, ATDA', '47282', 'Chemotherapy', 'Enzyme inhibitor'),
(114, 'Amiodarone Hydrochloride', NULL, NULL, 'YES', 'A class III antiarrhythmic drug. Amiodarone should be reserved for the treatment of life-threatening or incapacitating arrhythmias or for use in patients who cannot benefit from other antiarrhythmic agents or nonpharmacologic therapy; cardiac depressant', '51087N , Alti-Amiodarone , Amio-Aqueous , Amiodarone , Braxan , Cordarone , Gen-Amiodarone , L-3428 , Med Amiodarone , Novo-Amiodarone , Pacerone , Procor , SKF-33134-A', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(115, 'Amonafide', NULL, NULL, 'NO', 'Amonafide is inactive in  most malignancies, and its toxicity is substantial. Some degree of antitumor activity has been observed in patients with advanced breast cancer and prostate cancer, and additional investigations in these malignancies are needed.', 'Benzisoquinolinedione , M-FA-142 , Nafidimide , Quinamed', NULL, 'BIDA', '308847;621093', 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(116, 'Amphotericin B', NULL, NULL, 'YES', 'A polyene antifungal.', 'Amphotericin B VHA Plus , Component of Mysteclin-F# , Fungilin , Fungizone', NULL, 'AMB', NULL, 'AIDS drug;Ancillary Agent', 'Antifungal agent'),
(117, 'Amphotericin B Cholesteryl Sulfate Complex', NULL, NULL, 'YES', 'A complex of amphotericin B and cholesteryl sulfate for intravenous administration.', 'Amphotec , Amphotericin B colloidal dispersion', NULL, 'ABCD', NULL, 'AIDS drug;Ancillary Agent', 'Antifungal agent'),
(118, 'Amphotericin B Lipid Complex', NULL, NULL, 'YES', 'A formulation of amphotericin B complexed with two phospholipids, dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG).', NULL, NULL, 'ABLC', NULL, 'AIDS drug;Ancillary Agent', 'Antifungal agent'),
(119, 'Amphotericin B Liposome', NULL, NULL, 'YES', 'A formulation of amphotericin B encapsulated in small unilamellar liposomes (AmBisome(R)); lipid components are hydrogenated phosphatidylcholine, cholesterol, and dimyristoyl phosphatidylglycerol.', 'AmBisome , Liposomal Amphotericin B', NULL, NULL, NULL, 'AIDS drug;Ancillary Agent', 'Antifungal agent'),
(120, 'Ampligen', NULL, NULL, 'YES', 'Nucleic acid antiviral agent that activates the 2-5A enzyme', NULL, NULL, NULL, '616524', 'AIDS drug', NULL),
(121, 'Amrubicin', NULL, NULL, 'NO', 'Phase II SCLC 2007 Synthetic 9-aminoanthracycline. Pharmion.', NULL, 'Small cell lung', 'AMR', NULL, 'Chemotherapy', 'Anthracycline'),
(122, 'Amsacrine', NULL, NULL, 'NO', 'A synthetic aminoacridine derivative with antineoplastic activity. Investigational drug.', 'Acridinyl anisidide , Amekrin , Amsa P-D , Amsidine , Amsidyl , CI 880 , CI-880 , CI880', 'All cancers', 'AMSA, m-AMSA', '249992', 'Chemotherapy', 'Miscellaneous agent'),
(123, 'AN-152/AN-238/AN-215', NULL, NULL, 'NO', 'Pre-clinical Cytotoxic conjugates. AEterna Laboratories.', 'AN152/AN238/AN215', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(124, 'Anagestone Acetate', NULL, NULL, 'NO', 'Progestin', 'Anatropin#', NULL, NULL, '73880', 'Hormones and hormonal mechanisms', 'Progestin'),
(125, 'Anagrelide HCl', NULL, NULL, 'NO', 'Platelet reducing agent; reduces risk of thrombosis, and to ameliorate associated symptoms of thrombocythemia', 'Agrylin', 'Essential thrombocythemia', NULL, '724577', 'Differentiation inducing agent', 'Code as \'other\' therapy for essential thrombocythemia ONLY;otherwise do not code'),
(126, 'Anastrozole', NULL, NULL, 'NO', 'FDA approved A selective aromatase inhibitor. FDA approved use in advanced  breast cancer of post menopausal women.   Approved 2005 for hormone receptor positive early breast cancer.  AstraZeneca.', 'Arimidex , ICI-D1033 , ZD 1033 , ZD-1033 , ZD1033', 'Breast cancer', NULL, '719344', 'Hormones and hormonal mechanisms', 'Non-steroidal Aromatase inhibitor'),
(127, 'Ancitabine Hydrochloride', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.', 'Ancytabine Hydrochloride , Cyclocytidine , Cyclocytidine Hydrochloride', NULL, NULL, '145668', 'Chemotherapy', 'Cytostatic agent--DNA synthesis inhibitor'),
(128, 'Angiostatin', NULL, NULL, 'NO', 'Phase II lung Phase I other Angiogenesis inhibitor. EntreMed.', NULL, 'Lung, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(129, 'Angiostatin w/ Paclitaxel & Carboplatin', NULL, NULL, 'NO', 'Phase II NSCLC Anti-angiogenic + taxane + platinum. EntreMed.', NULL, 'Lung cancer', NULL, NULL, 'Chemotherapy', 'combination chemo'),
(130, 'Angiozyme', NULL, NULL, 'NO', 'Phase II Antiangiogenic ribozymme. Chiron, Ribozyme Pharmaceuticals.', NULL, 'Breast, colorectal, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--VGF target antiangiogenic agant'),
(131, 'Anguidine', NULL, NULL, 'NO', NULL, 'ANG 66 , ANG-66 , ANG66 , Anguidin', NULL, 'ANG, DAS', '141537', 'Chemotherapy', 'mycotoxin;Protein synthesis inhibitor'),
(132, 'Anhydrovinblastine', NULL, NULL, 'NO', 'Phase I Third generation chemotherapeutic. Prescient NeuroPharma.', 'AVLB', 'Lung cancer', NULL, NULL, 'Chemotherapy', 'Vinca plant alkaloid'),
(133, 'Aniline mustard', NULL, NULL, 'NO', NULL, 'Lymphochin , Lymphocin , Lymphoquin , TL 476 , TL-476 , TL476', NULL, NULL, '18429', 'Chemotherapy', 'Alkylating agent'),
(134, 'Annamycin', NULL, NULL, 'NO', 'Phase II breast; phase I/III leukemia Liposomal anthracycline. Aronex Pharmaceuticals.', 'Annamycine', 'Breast cancer, leukemia', NULL, NULL, 'Chemotherapy', 'Anthracycline antibiotic'),
(135, 'Antabuse', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(136, 'Anthramycin', NULL, NULL, 'NO', NULL, '2-Propenamide , Antramycin', NULL, NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(137, 'Anthrapyrazole', NULL, NULL, 'NO', 'A potentially useful drug for the treatment of certain types of malignant neoplasms. Additional clinical trials are needed to assess the safety and efficacy.', 'CI 937 , CI-937 , CI937 , DUP 937 , DUP-937 , DUP937 , Moxantrazole , Teloxantrone', NULL, NULL, '355644', 'Chemotherapy', 'Topoisomerase inhibitor'),
(138, 'Anthrapyrazole C 1941', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic;topoisomerase II inhibitor'),
(139, 'Anti-B4-blocked Ricin', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(140, 'anti-CD72', NULL, NULL, 'NO', 'Pre-clinical Monoclonal antibody. Crucell.', NULL, 'Leukemia', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(141, 'Anti-CEA, I-131', NULL, NULL, 'NO', NULL, 'Antiferritin antibody I-131', NULL, 'I131', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(142, 'Anti-EpCam', NULL, NULL, 'NO', 'Pre--Clinical Monoclonal antibody. Crucell.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(143, 'Anti-gastrin Therapeutic Vaccine', NULL, NULL, 'NO', 'Phase III Gastroesophageal vaccine. Aphton, Aventis Pasteur.', 'G17DT', 'Colorectal, gastric, liver, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(144, 'Anti-PSMA Antibody', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Millenium Pharmaceuticals.', NULL, 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(145, 'anti-Tac(Fv)-PE38 (immunotoxin)', NULL, NULL, 'NO', 'Phase I Monoclonal antibody + toxin. NCI.', NULL, 'Leukemia', NULL, '676422', 'Biologic therapy (BRM, immunotherapy)', NULL),
(146, 'Antineoplaston A10', NULL, NULL, 'NO', 'Peptide derivative; ACS listed as unproven therapy', NULL, 'Breast, other cancer', NULL, '648539', 'Other therapy', 'Unproven therapy'),
(147, 'Antineoplaston AS2.1', NULL, NULL, 'NO', 'Peptide derivative; ACS listed as unproven therapy', NULL, 'Breast, other cancer', NULL, '620261', 'Other therapy', 'Unproven therapy'),
(148, 'Antithymocyte Globulin', NULL, NULL, 'YES', 'This drug is given along with other chemotherapy agents pre bone marrow transplant to help prevent graft versus host disease by acting as an immunosuppressant. It is also used to aplastic anemia whic is non-reportable.', 'Anti-thymocyte serum , Antilymphocyte Globulin , Thymoglobulin', NULL, 'ALG, ATG, HAHTGG', '720095', 'Biologic therapy (BRM, immunotherapy)', NULL),
(149, 'Anvirzel', NULL, NULL, 'NO', 'Phase I Plant derivative. Ozelle Pharmaceuticals.  Supposedly only available in Honduras', NULL, 'Lung, prostate, skin cancer', NULL, NULL, 'Other therapy', 'extract of oleander plant;Unproven therapy'),
(150, 'AP-23573', NULL, NULL, 'NO', 'Phase I Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Ariad Pharmaceuticals.', 'AP 23573 , AP23573', 'Lymphoma, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(151, 'Apaziquone', NULL, NULL, 'SEE_REMARKS', 'Code as chemotherapy when given to patients with superficial bladder cancer.\r\nDO NOT Code when given to any other solid tumors: it is a radiosensitizer.', 'EO9 , Neoquin', 'Bladder cancer', NULL, NULL, 'Ancillary Agent;Chemotherapy', NULL),
(152, 'APC 8024 Therapeutic Vaccine', NULL, NULL, 'NO', 'Phase I Colon cancer vaccine against HER2/neu expression. Dendreon.', 'APC-8024 , APC8024', 'Breast, colorectal, ovarian cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(153, 'Aphidicolin Glycinate', NULL, NULL, 'NO', NULL, 'ICI 137233 , ICI-137233 , ICI137233', NULL, NULL, '303812', 'Chemotherapy', 'Antimetabolite'),
(154, 'Apligraf (graftskin)', NULL, NULL, 'YES', 'Phase III Living human skin. Organogenesis, Novartis Pharm.', 'Armoderm , Corethium , Dermagraft , TransCyte', 'Skin cancer', NULL, NULL, 'Ancillary Agent', NULL),
(155, 'Apolizumab', NULL, NULL, 'NO', 'Phase I ALL, other, Phase II  NHL B-cell Disappointing Phase II results.  Antibody. Protein Design Labs, NCI.', 'Hu1D10 , Humanized 1D10 , Remitogen , SMART1D1D', 'Leukemia, lymphoma, other cancer', NULL, '704867', 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(156, 'Apra', NULL, NULL, 'NO', 'Phase II Anti-angiogenic. Cell Therapeutics.', 'CT 2584 , CT-2584 , CT2584', 'Prostate cancer, sarcoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(157, 'Aprepitant', NULL, NULL, 'YES', 'Anti-nausea agent.  Ortho McNeil.', 'Emend', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(158, 'Aptosyn', NULL, NULL, 'YES', 'Phase III NSCLC, prostate Phase I/II breast, colorectal Selective apoptotic antineoplastic drug (SAAND). Cell Pathways, Inc.', 'Exisulind , FGN-1 , Prevatac', 'Breast, colorectal, head & neck, lung, prostate cancer', NULL, '719619', 'Differentiation inducing agent', NULL),
(159, 'AR54', NULL, NULL, 'NO', 'Phase II Monoclonal antibody. AltaRx.', NULL, 'Ovarian cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy passive'),
(160, 'Aranesp', NULL, NULL, 'YES', 'Phase II Erythropoiesis stimulating protein. Amgen.', 'Darbepoetin alfa , NESP , Novel erythropoiesis-stimulating protein', 'Multiple myeloma', NULL, '729969', 'Ancillary Agent', 'Growth factor'),
(161, 'Aroplatin', NULL, NULL, 'NO', 'Phase II Liposomal platinum. Aronex Pharmaceuticals, Antigenics.', NULL, 'Colorectal, kidney, lung, ovarian, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent'),
(162, 'Arsanilic Acid', NULL, NULL, 'YES', 'The code AS-101 has been used for an immunomodulator under investigation in the treatment of AIDS. Pharmacopoeias: In US for veterinary use only.', 'Aminarsonic Acid , AS 101 , AS-101 , AS101', NULL, NULL, '618654', 'AIDS drug', NULL),
(163, 'Arzoxifene', NULL, NULL, 'NO', 'Phase III metastatic breast, Phase II ovarian Selective estrogen receptor modulator (SERM). Eli Lilly.', 'LY 353381 , LY-353381 , LY353381', 'Breast, endometrial cancer, ovarian', NULL, '714373', 'Hormones and hormonal mechanisms', 'Selective estrogen receptor modulator (SERM)'),
(164, 'AS-101', NULL, NULL, 'YES', NULL, 'AS 101 , AS101', NULL, NULL, NULL, 'AIDS drug', NULL),
(165, 'Asaley', NULL, NULL, 'NO', NULL, 'Asalex', NULL, NULL, '167780', 'Chemotherapy', 'Alkylating agent'),
(166, 'Asparaginase', NULL, NULL, 'NO', 'Antineoplastic.', 'Asnase , Asparaginase (Escherichia coli) , Colaspase , Crasnitin# , EC3.1.5.1. , Elspar , Kidrolase , L-Asparaginase , Leunase (enzyme) , MK-965 , Re-82-TAD-15', 'Acute lymphoblastic leukemia (ALL)', 'ASP, ASPA, L-ASE, L-ASP', '109229', 'Chemotherapy', 'Antineoplastic agent'),
(167, 'Asparaginase (Erwinia carotovora)', NULL, NULL, 'NO', NULL, 'Erwinia asparaginase', NULL, 'ASP, ASPA, L-ASE, L-ASP', '106977', 'Chemotherapy', 'Antineoplastic agent'),
(168, 'Asparaginase-PEG', NULL, NULL, 'NO', 'Merck', NULL, NULL, NULL, '624239', 'Chemotherapy', 'Antineoplastic agent'),
(169, 'Asparaginase-PEG (K-H)', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '644954', 'Chemotherapy', 'Antineoplastic agent'),
(170, 'Asparlas', NULL, 'Acute lymphoblastic leukemia (ALL)', 'NO', 'December 20, 2018 FDA approved Asparlas as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL).', 'calaspargase pegol-mknl', NULL, NULL, NULL, 'Chemotherapy', 'Antineoplastic agent'),
(171, 'Asperlin', NULL, NULL, 'NO', NULL, '933 , U 13933 , U-13 , U13933', NULL, NULL, '93158', 'Chemotherapy', 'No longer in use'),
(172, 'Aspirin', NULL, NULL, 'NO', 'Aspirin is approved treatment for Essential Thrombocythemia (ET) ONLY. The therapeutic dose for essential thrombocythemia is in the range of 70-100 mg/day (this is considered low-dose).\r\n\r\nAspirin for cardiovascular protection and pain control is in the range of 160 mg/day and higher.', 'Bayer Aspirin , Ecotrin , Empirin , many others , Measurin , St. Joseph Adult', 'Essential Thrombocythemia', 'ASA', NULL, 'Other therapy', 'Code as \'Other\' therapy for essential thrombocythemia ONLY;otherwise it is a differentiating agent (do not code)'),
(173, 'AT-101', NULL, NULL, 'NO', 'Phase II SCLC 2007 Pan-Bcl-2 inhibitor; induces apoptosis.  Ascenta Therapeutics.', 'AT 101 , AT101', 'Small cell lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(174, 'Atamestane', NULL, NULL, 'NO', 'Phase III metastatic Aromatase inhibitor. BioMedicines.', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Aromatase inhibitor'),
(175, 'Atevirdine Mesylate', NULL, NULL, 'YES', 'A non-nucleoside reverse transcriptase inhibitor. Clinical data are insufficient to determine the role of atevirdine in HIV infection or AIDS. Studies evaluating its efficacy in two- and three-drug combinations (eg, with zidovudine, didanosine, zalcitabine) are needed; direct comparisons of atevirdine monotherapy with zidovudine, zidovudine/atevirdine, delavirdine, and nevirapine are also needed.', 'U 85961 , U 87201E , U-85961 , U-87201E , U85961 , U87201E', NULL, NULL, NULL, 'AIDS drug', NULL),
(176, 'Atezolizumab', NULL, 'Non small cell lung cancer (NSCLC)', 'NO', 'December 3, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. \r\n\r\nMarch 18, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). \r\n\r\nMarch 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. \r\n\r\n12/6/2018 FDA approved atezolizumab (TECENTRIQ), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.  \r\n\r\n7/20/2018: FDA has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as an initial treatment for people with advanced or metastatic hepatocellular.\r\n\r\n4/23/2017: FDA granted accelerated approval to Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Tecentriq was previously approved for patients with locally advanced or mUC who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery or after surgery.\r\n\r\nOctober 18, 2016: FDA approved atezolizumab (TECENTRIQ) for treatment of patients with metastatic non-small cell lung carcinoma (NSCLC)whose disease has progressed during or following platinum-containing chemotherapy.\r\n\r\n May 18, 2016 FDA gave accelerated approval to atezolizumab injection (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.   \r\n\r\nFeb. 2015: FDA granted breakthrough designation to the immunotherapy MPDL3208A for patients with PD-L1 positive non-small cell lung cancer whose disease has progressed during or after platinum based chemotherapy and is an appropriate targeted therapy for those with an EGFR mutation-positive or ALK positive tumor.\r\n\r\n2014: FDA granted breakthrough designation to MPDL3208A for treatment of bladder cancer.', 'Anti-PD-L1 Monoclonal antibody MPDL3280A , RG7446 , anti-PDL1 , TECENTRIQ', 'Bladder, Lung, Liver, Breast', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(177, 'ATG J591RC', NULL, NULL, 'NO', 'Phase II Monoclonal antibody. Cell Therapeutics.', 'Anti-PSMA , ATG-J591:RC , ATGJ591:DM1 , BiJ-591 , huJ591 , J591 , MLN-2704 , MLN-5591DM1 , MLN-5591RL , MLN-591RL', 'Prostate cancer', 'MLN-591', NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(178, 'Atiprimod', NULL, NULL, 'NO', 'Phase II carcinoid 2007 Dual action anti-angiogenesis and apoptosis inducer. Callisto Pharmaceuticals.', 'Azaspirane , SK&F106615', 'carcinoid, Myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--anti-angiogenesis agent'),
(179, 'ATN-161', NULL, NULL, 'NO', 'Phase II glioma 2007 Attenuon.', 'ATN 161 , ATN161', 'Glioma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(180, 'Atovaquone', NULL, NULL, 'YES', 'An antiprotozoal agent; therapy for pneumocystic carinii; under investigation for Rx of cryptosporidiosis; effective for acute oral treatment of mild-to-moderate Pneumocystis carinii pneumonia', '566 , 566C80 , Acuvel , BW-566C , BW-A566C , Mepron , Metrone , Wellvone', NULL, NULL, NULL, 'AIDS drug', NULL),
(181, 'ATRA-IV', NULL, NULL, 'NO', 'Atra is currently in clinical trials for Head & Necks cancers. It is under investigation as treatment of Kaposi Sarcoma. DO NOT CODE ATRA has treatment for these sites/histologies until FDA approval. Code as either 2, 3, or 6 in Other Therapy field.\r\n\r\nATRA has received FDA approval for treatment of Acute Promyelocytic Leukemia (APL). ATRA should be coded \"1\" in Other Therapy field.\r\n\r\nLiposomal all-trans retinoic acid. Antigenics, Inc.', 'Vesanoid', 'Lymphoma, Acute promyelocytic leukemia', NULL, NULL, 'Differentiation inducing agent', 'Retinoid: please see Remarks for coding instructions'),
(182, 'Atragen', NULL, NULL, 'YES', 'Phase I/II (kidney).  Phase II NHL.  Prostate.  Skin.  Lipid based all trans-retinoic acid. Aronex Pharmaceuticals.', NULL, 'Kidney, Lymphoma, Prostate, Skin cancer', NULL, NULL, 'Differentiation inducing agent', 'Liposomal tretinoin'),
(183, 'Atrasentan', NULL, NULL, 'NO', 'Phase II/III Cytostatic selective endothelial-A receptor agonist. Abbott Laboratories.', 'ABT 627 , ABT-627 , ABT627', 'Bladder, breast, kidney, lung, other cancer, ovarian, prostate', 'Xinlay', '720763', 'Chemotherapy', 'Cytostatic agent'),
(184, 'Atripla', NULL, NULL, 'YES', 'HAART (Highly Active Anti-Retroviral Therapy) for AIDS. In some cases, HAART is given specifically to treat Kaposis Sarcoma. With AIDS-related KS, HAART has been shown to induce regression of KS. It is often used in combination with other cancer specific regimens. The agents in HAART vary and do not fall into our standard chemo, hormonal or immunotherapy classifications. Code HAART when given as treatment for KS in \"Other Treatment\" code 1.\r\n\r\nHAART is a customized combination of different classes of medications physician prescribe based on such factors as viral load, strain of virus, CD4+ count, and other consideration such as symptoms. Any combination of medications can be used in HAART.', 'Stribild', NULL, NULL, NULL, 'AIDS drug', NULL),
(185, 'Aut Tum Vac/BCG/IL-2', NULL, NULL, 'NO', NULL, 'Aut Tum Vac/BCG/IL-2', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(186, 'Aut Tum Vac/IL-2/BCG', NULL, NULL, 'NO', NULL, 'Aut Tum Vac/IL-2/BCG', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(187, 'Aut Tum Vac/IL-2/BCG, Tice BCG Vaccine, frozen', NULL, NULL, 'NO', NULL, 'Aut Tum Vac/IL-2/BCG , frozen , Tice BCG Vaccine', NULL, NULL, '624335', 'Biologic therapy (BRM, immunotherapy)', NULL),
(188, 'Autol Tumor-Trnsdcd/Gene for TNF (Cetus)', NULL, NULL, 'NO', NULL, 'Autol Tumor-Trnsdcd/Gene for TNF (Cetus)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(189, 'Autol Tumor-Trnsdcd/Gene for TNF (GTI),', NULL, NULL, 'NO', NULL, 'Autol Tumor-Trnsdcd/Gene for TNF (GTI)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(190, 'Autol Tumor-Trnsdcd/Gene for TNF-COMPA (Cetus),', NULL, NULL, 'NO', NULL, 'Autol Tumor-Trnsdcd/Gene for TNF-COMPA (Cetus)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(191, 'Autologous', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(192, 'Autologous CD8 Infusion', NULL, NULL, 'YES', 'CD8+ T-lymphocytes from an HIV-infected person are stimulated outside the body to replicate and then are reinfused into the patient of origin', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(193, 'Autologous Tumor Cell (BCG + IL-2 (Cetus),', NULL, NULL, 'NO', NULL, 'Autologous Tumor Cell (BCG + IL-2 (Cetus)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(194, 'Autologous Tumor Cell (BCG) + IL-2 (Bionetics),', NULL, NULL, 'NO', NULL, 'Autologous Tumor Cell (BCG) + IL-2 (Bionetics)', NULL, NULL, '624355', 'Biologic therapy (BRM, immunotherapy)', NULL),
(195, 'Autologous Tumor Cell Vaccine + BCG (Bionetics)', NULL, NULL, 'NO', NULL, 'Autologous Tumor Cell Vaccine + BCG (Bionetics)', NULL, NULL, '624335', 'Biologic therapy (BRM, immunotherapy)', NULL),
(196, 'Autologous Tumor Cell Vaccine + IL-2 (Cetus)', NULL, NULL, 'NO', NULL, 'Autologous Tumor Cell Vaccine + IL-2 (Cetus)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(197, 'Avapritinib', NULL, 'GIST', 'NO', 'January 10, 2020 The FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST).  Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.', 'Ayvakit', NULL, NULL, NULL, 'Chemotherapy', 'kinase inhibitor'),
(198, 'Avelumab', NULL, 'Merkle cell carcinoma, urothelial carcinoma', 'NO', 'May 14, 2019:  FDA approved avelumab (BAVENCIO) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). \r\n\r\n5/9/2017: The U.S. Food and Drug Administration granted accelerated approval to avelumab for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.  \r\n\r\n3/24/2017:The U.S. Food and Drug Administration granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.', 'Bavencio', 'Skin, Bladder', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(199, 'Avicine', NULL, NULL, 'NO', 'Phase III completed colorectal Phase I/II pancreatic, prostate Vaccine. AVI Biopharma, Abgenix.', NULL, 'Colorectal, pancreatic, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Active immunotherapy'),
(200, 'Avodart', NULL, NULL, 'NO', 'Phase III\r\nFDA approved use on benign prostatic hyperplasia. Avodart is not used to treat prostate cancer.', 'Dutasteride', 'Code as treatment for pancreatic cancer, Do Not Code as treatment for prostate cancer. this drug is used to help shrink the prostate.', 'GI198745', NULL, 'Chemotherapy', 'Cytostatic agent--alpha reductase inhibitor'),
(201, 'Avrend', NULL, NULL, 'NO', 'Phase II Glycoprotein. Immunex.', NULL, 'Kidney cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Stimulates T-cell dendritic cells'),
(202, 'Axitinib', NULL, NULL, 'NO', 'January 27, 2012: FDA approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to otherr drugs for this type of cancer.\r\nOrphan drug for pancreas, thyroid', 'AG 013736 , AG-013736 , AG013736 , Inlyta', 'Colorectal, kidney, melanoma, pancreas, thyroid', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(203, 'Azacitidine', NULL, NULL, 'NO', 'Phase II/III MDS, Phase I AML Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters;bone marrow aspirate; antimetabolite; also differentiation inducing agent.  NCI', '496 , 5-Azacitidine , 5-Azacytidine , Antibiotic U-18 , AZA-CR , Azacytidine , Ladakamycin , Mylosar , Vidaza', 'Leukemia', '5-AC, 5-AZA, 5-AZAC, 5-AZCR, AZC', '102816', 'Chemotherapy', 'Antimetabolite'),
(204, 'Azaguanine', NULL, NULL, 'NO', NULL, '8-Azaguanine , B-28 , B28 , Guanazol , Guanazolo , Pathocidin , Pathocidine , SF 337 , SF-337 , SF337', NULL, '8-AG, Azan, AZG', '749', 'Chemotherapy', 'Antimetabolite'),
(205, 'Azapicyl', NULL, NULL, 'NO', 'Antituberculin antibacterial', 'Azapicol , P 2292 , P-2292 , P2292', NULL, NULL, '68626', 'Chemotherapy', 'Chemotherapy--unclassified'),
(206, 'Azaserine', NULL, NULL, 'NO', NULL, '757 , Azaserin , CI 337 , CI-337 , CI337 , CN 15 , CN15757 , P-165', NULL, 'AZAS, AZS', '742', 'Chemotherapy', 'Antimetabolite'),
(207, 'Azathioprine', NULL, NULL, 'YES', 'Immunosuppressant, purine antimetabolite, kidney/heart transplantation, rheumatoid arthritis.', 'Azanin , Azathioprin , Azathioprinum , Azatioprin , Azothioprine , BW 57-322 , BW57322 , Imuran , Imurek , Imurel , Muran', NULL, 'ATP, AzAT', '039084;39084', 'Ancillary Agent', NULL),
(208, 'AZD 3409', NULL, NULL, 'NO', 'Phase II Farnesyl transferase inhibitor. AstraZeneca.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--inhibitor;farnesyl transferase'),
(209, 'AZD2281', NULL, NULL, 'NO', 'Phase I melanoma 2007 Small molecule inhibitor of Poly-ADP Ribose Polymerase or PARP.  Astra Zeneca, KuDOS Pharmaceuticals.', 'AZD 2281 , AZD-2281 , KU-0059436 , KU-59436', 'Melanoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(210, 'AZD6244', NULL, NULL, 'NO', 'Phase I&II New drug currently in trials, code as Other Therapy as it is not FDA approved', 'AZD6244', 'Multiple sites', NULL, NULL, 'Chemotherapy', 'Protein inhibitor'),
(211, 'Azetepa', NULL, NULL, 'NO', NULL, 'Azatepa , CL 25477 , CL-25477 , CL25477 , Thiatriamide', NULL, NULL, '64826', 'Chemotherapy', 'No longer in use'),
(212, 'Azidothymidine', NULL, NULL, 'NO', 'Used in treatment of Kaposi\'s sarcoma; inhibits reverse transcriptase', 'BW A 509U , BWA509U , Retrovir , Zidovudine', NULL, 'AZT', '602670', 'Chemotherapy', 'Cytostatic agent--reverse transcriptase inhibitor'),
(213, 'Azidouridine', NULL, NULL, 'YES', 'An antiviral drug undergoing phase I studies in ARC (AIDS-related complex) and AIDS (acquired immunodeficiency syndrome) patients.', NULL, NULL, 'AzdU', NULL, 'AIDS drug', NULL),
(214, 'Azimexon', NULL, NULL, 'NO', 'Synthetic chemical, immunomodulator', NULL, NULL, 'AMX', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(215, 'Azithromycin Dihydrate', NULL, NULL, 'YES', 'The prototype of a subclass of macrolide antibiotics known as the azalides.  Rx of Chlamydia; under investigation for Rx of Mycobacterium Avium Complex (MAC), toxoplasmosis, and cryptosporidiosis', 'CP 62993 , CP-62993 , CP62993 , Homoerythromycin A , Zithromax', NULL, NULL, NULL, 'AIDS drug', NULL),
(216, 'Azotomycin', NULL, NULL, 'NO', NULL, 'Antibiotic 1719 , Duazomycin-B', NULL, 'AZOT', '56654', 'Chemotherapy', 'Antitumor antibiotic'),
(217, 'BABS protein', NULL, NULL, 'NO', 'Pre-clinical Biosynthetic antibody binding site protein. Chiron.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(218, 'BACI', NULL, NULL, 'YES', 'Under investigation for Rx of cryptosporidiosis', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(219, 'Bactrim/Septra', NULL, NULL, 'YES', NULL, 'Bactrim DS , Co-Trimoxazole , Cotrim', NULL, 'TMP/SMX', '618652', 'Ancillary Agent;AIDS drug', 'Antibiotic'),
(220, 'Baker\'s antifol', NULL, NULL, 'NO', NULL, 'Baker\'s antifolante , triazinate', NULL, 'BAF, TZT', '139105', 'Chemotherapy', 'Antimetabolite'),
(221, 'BAM-002', NULL, NULL, 'NO', 'Phase II NSCLC Peptide. Novelos Therapeutics.', 'BAM 002 , BAM002', 'Lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(222, 'Basiliximab', NULL, NULL, 'YES', 'A chimeric interleukin-2 receptor monoclonal antibody. Immunosuppression.  Approved for renal transplantation.  Not anti-neoplastic.', 'CHI 621 , CHI-621 , CHI621 , Chimeric RFT5 , SDZ CHI 621 , chRFT5', NULL, NULL, NULL, 'Ancillary Agent', 'Immunosuppressive monoclonal antibody'),
(223, 'Batanopride Hydrochloride', NULL, NULL, 'YES', 'A 5-HT(3)-receptor antagonist under investigation as an antiemetic for the management of chemo-induced nausea and vomiting; Serotonin antagonist. Not found in Drugdex drug evaluation', 'BMY-25801-01 , BMY2580101', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(224, 'BBR 3464 and 5-FU', NULL, NULL, 'NO', 'Phase I Platinum compound. Hoffman LaRoche.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'combination chemo'),
(225, 'BBR3464', NULL, NULL, 'NO', 'Phase II NSCLC A novel cationic triplatinum complex. Hoffman-LaRoche.', 'BBR 3464 , BBR-3464', 'Lung, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent--triplatinum;Tri-nuclear platinum complex'),
(226, 'BCell-HDM', NULL, NULL, 'YES', 'Phase II Stem cell purging using High Density Microparticles (HDM) technology. BioTransplant, Eligix', NULL, 'Lymphoma', NULL, NULL, 'Ancillary Agent', NULL),
(227, 'BCG', NULL, NULL, 'NO', 'Immunomodulator', 'B 116328 , B-116328 , B116328', NULL, 'MER', '143769', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(228, 'BCG - Connaught', NULL, NULL, 'NO', NULL, 'BCG - Connaught', NULL, NULL, '116341', 'Biologic therapy (BRM, immunotherapy)', NULL),
(229, 'BCG - TheraCys', NULL, NULL, 'NO', NULL, 'BCG - TheraCys', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(230, 'BCG - Tice', NULL, NULL, 'NO', NULL, 'BCG - Tice', NULL, NULL, '614388', 'Biologic therapy (BRM, immunotherapy)', NULL),
(231, 'BCG Vaccine', NULL, NULL, 'NO', 'Treatment of bladder carcinoma in situ.', NULL, NULL, NULL, '116327', 'Biologic therapy (BRM, immunotherapy)', 'Immuntherapy active'),
(232, 'BCG Vaccine - Connaught', NULL, NULL, 'NO', NULL, 'BCG Vaccine - Connaught', NULL, NULL, '614389', 'Biologic therapy (BRM, immunotherapy)', NULL),
(233, 'BCI Immune Activator', NULL, NULL, 'NO', 'Phase III Immune activator; Intracel.', NULL, 'Bladder cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(234, 'Bcl-2/Bcl-x1 Inhibitor', NULL, NULL, 'NO', 'Pre-clinical Inhibtor of apoptosis. Abbott Laboratories.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(235, 'BCX-1777', NULL, NULL, 'NO', 'Phase II ALL, acute T-cell lymphoma Purine nucleoside phosphorylase inhibitor. BioCryst Pharmaceuticals.', 'BCX 1777 , BCX1777', 'Leukemia, lymphoma', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(236, 'BEC2', NULL, NULL, 'NO', 'Phase III SCLC, melanoma Anti-idiotype MAb. ImClone Systems.', NULL, 'Lung, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(237, 'Beclomethasone Dipropionate', NULL, NULL, 'YES', 'Beclomethasone is a synthetic corticosteroid used for asthma and allergic rhinitis; glucocorticoid', 'Beclodisk , Becloforte , Beclometasone , Beclovent , Beconase , Gen-beclo , Propaderm , Sch-18020W , Sch18020W , Vancenase , Vanceril', NULL, NULL, NULL, 'Ancillary Agent;Hormones and hormonal mechanisms', 'Glucocorticoid asthma drug'),
(238, 'Bectumomab', NULL, NULL, 'NO', 'A murine immunoglobulin (IgG2a) reactive with B-cell lymphomas and leukemias.', 'LL2 Fab , LL2 Monoclonal antibody', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy passive'),
(239, 'Belinostat', NULL, NULL, 'NO', 'July 3, 2014 FDA granted accelerated approval to Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)', 'Beleodaq , PXD 101 , PXD-101 , PXD101', 'CLL, Multiple myeloma, NHL, advanced malignancies, others, peripheral T-cell lymphoma (PTCL)', NULL, '726630', 'Chemotherapy', 'Cytostatic agent--histone deacetylation inhibitor;HDAC inhibitor'),
(240, 'Belotecan', NULL, NULL, 'NO', 'Belotecan is currently being studied in the treatment of non small cell lung cancer (NSCLC) and uterine cancer. These trials are currently limited to Korea. Code as \"Other\" treatment until FDA approval for treatment of cancers in the United States.', 'CKD-602', NULL, NULL, NULL, 'Chemotherapy', 'Topoisomerase Inhibitor'),
(241, 'Bemcentinib', NULL, 'Myeloid leukemia', 'SEE_REMARKS', '10/25/2019\r\nFDA has approved Fast Track designation for bemcentinib for treatment of elderly patients with acute myeloid leukemia (AML) whose disease has relapsed. CODE IN OTHER TREATMENT DATA FIELD UNTIL FINAL APPROVAL BY FDA', 'BGB324 , R428', NULL, NULL, NULL, 'Chemotherapy', 'AXL inhibitor'),
(242, 'Bendamustine', NULL, NULL, 'NO', NULL, 'Bendamustine HCI , Treanda , Bendeka', 'breast, CLL, HL, Multiple myeloma, NHL', NULL, NULL, 'Chemotherapy', 'Alkyalating agent'),
(243, 'Benorterone#', NULL, NULL, 'NO', 'Anti-androgen', 'SK&F-7690', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Anti-androgen--no longer in use'),
(244, 'Benzestrol', NULL, NULL, 'NO', 'Estrogen.  Another name for DES.  Used more in pregnancy; recently associated with increased risk of breast cancer in daughters and some genital malformations in sons of mothers who used DES.', 'Chemestrogen', NULL, NULL, '408889', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(245, 'Benznidazole', NULL, NULL, 'YES', 'Antiprotozoal; chemosensitizer', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(246, 'Benzodepa', NULL, NULL, 'NO', NULL, 'AB 103 , AB-103 , AB103 , Benzcarbimine , Dualar# , ENT 50451 , ENT-50451 , ENT50451', NULL, NULL, '37096', 'Chemotherapy', 'Alkylating agent'),
(247, 'Benzoylphenylurea', NULL, NULL, 'NO', 'Phase I advanced solid tumors 2007 NCI.', 'BPU', 'Advanced solid tumors', NULL, '639829', 'Chemotherapy', 'Antimitotic agent'),
(248, 'Benzquinamide Hydrochloride', NULL, NULL, 'YES', 'An effective antiemetic for preventing the nausea and vomiting that is associated with surgery and anesthesia.', 'Emete-Con , P 2647 , P-2647 , P2647 , Quantril', NULL, NULL, '64375;064375', 'Ancillary Agent', NULL),
(249, 'Besponsa', NULL, 'Acute lymphoblastic leukemia', 'NO', '8/17/2017\r\nThe U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.', 'Inotuzumab ozogamicin', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'A CD22-targeted cytotoxic immunoconjugate'),
(250, 'Bestatin', NULL, NULL, 'NO', 'Immunomodulator', NULL, NULL, 'BST', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(251, 'Beta Carotene', NULL, NULL, 'YES', 'Given by mouth to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria; dermatological agent-ultraviolet sunscreen', 'All-trans-beta-Carotene , beta , beta-Carotene , Max-Caro , Provatene , Provitamin A , Solatene', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(252, 'Beta LT', NULL, NULL, 'NO', 'Phase II low grade B-cell NHL, Phase II MM Immunomodulator. LifeTime Pharmaceuticals.', 'Beta-alathine', 'Lymphoma, multiple myeloma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(253, 'Beta-TGdR', NULL, NULL, 'NO', NULL, 'Thioguanine deoxyriboside', NULL, 'BTGR, TGdR', '71261', 'Chemotherapy', 'Antimetabolite'),
(254, 'Betamethasone', NULL, NULL, 'NO', 'A synthetic glucocorticoid, the most active of the anti-inflammatory steroids; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders', 'Becort , Betnesol , Celestone , Cuantin , Sch 4831 , Sch-4831 , Sch4831', NULL, NULL, '039470;39470', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(255, 'Betamethasone Acetate', NULL, NULL, 'NO', 'Glucocorticoid.  An ester of betamethasone, having the same actions as the base; used in combination with betamethasone sodium phosphate for intramuscular, intra-articular, intrasynovial, or intralesional injection.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(256, 'Betamethasone Benzoate', NULL, NULL, 'NO', 'Glucocorticoid.  The 17-benzoate ester of betamethasone, having the same actions as the base; used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'Benisone# , Uticort , W 5975 , W-5975 , W5975', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(257, 'Betamethasone Dipropionate', NULL, NULL, 'NO', 'Glucocorticoid. The 17,21-dipropionate ester of betamethasone, having the same uses as the base; used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', '\'Component of Lotrisone , Alphatrex , Betalene , Del-Beta , Diprolene , Diprolene Glycol , Diprosone , Maxivate , Occlucort , Psorion , Rhoprolene , Rhoprosone , Sch 11460 , Sch-11460 , Sch11460 , Taro-Sone , Topilene , Topisone , Valnac', NULL, NULL, '206525', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(258, 'Betamethasone Sodium Phosphate', NULL, NULL, 'NO', 'Glucocorticoid.  The disodium salt of the 21-phosphate ester of betamethasone, having the same actions as the base; used in combination with betamethasone acetate for intramuscular, intra-articular, intrasynovial, or intralesional injection.', 'B-S-P , Betnesol , Cel-U-Jec , Celestone , Celestone Phosphate , component of Celestone Soluspan , Selestoject', NULL, NULL, '90616', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(259, 'Betamethasone Valerate', NULL, NULL, 'NO', 'Glucocorticoid.  The 17-valerate ester of betamethasone, used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'Alphatrex , B-S-P , Beben , Benisone , Beta-Val , Betacort , Betaderm , Betagel , Betameth , Betamethasone 17alpha-valerate , Betatrex , Betnelan , Betnesol , Betnovate , Cel-u-jec , Celestoderm-V , Celestone , Celestone Phosphate , Dermabet , Diprolene , Diprosone , Ectosone , Luxiq , Maxivate , Metaderm , Novo-Betamet , Occlucort , Prelestone , Prevex B , Rholosone , Uticort , Valisone', NULL, NULL, '206540', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(260, 'Bethasone Benzoate', NULL, NULL, 'NO', NULL, 'Beben , Benisone , W-5975', 'adult leukemia and lymphoma, Childhood leukemia', NULL, NULL, 'Hormones and hormonal mechanisms', 'Corticosteroid'),
(261, 'Bevacizumab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE: 	This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy. \r\n\r\nFDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.\r\nFDA approved for colorectal cancer.\r\nFDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.\r\nNov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.\r\nIn clinical trials  Phase II and III for multiple myeloma\r\nDecember 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.\r\n\r\n6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheli¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgi¬cal resection\r\n\r\n\r\nJune 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. \r\n\r\nDecember 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy', 'Avastin , rhuMAB-VEGF', 'Breast- see remarks, Fallopian tube, Ovary, Peritoneum, colorectal, kidney, lung, multiple myeloma, Brain', NULL, '704865', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--antiangiogenesis agent;Recombinant human anti-VEGF.;Vascular endothelial growth factor receptor inhibitor'),
(262, 'Bexarotene', NULL, NULL, 'NO', 'Rexinoid, a selective retinoid X receptor (RXR) agonist. FDA approved therapy for cutaneous T-cell lymphoma. IS used off-lable for lung and breast cancer, also Kaposi\'s arcoma.', 'LGD 1069 , LGD-1069 , LGD1069 , Targretin', 'Breast, colorectal, Cutaneous T-cell lymphoma, head & neck, kidney, lung, prostate cancer', NULL, NULL, 'Chemotherapy', 'cytostatic agent--Retinoid X receptor agonist'),
(263, 'BI-RG-587', NULL, NULL, 'YES', 'Non-nucleoside reverse transcriptase inhibitor', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(264, 'BIBW 2992', NULL, NULL, 'NO', 'Phase II breast, H&N 2007 Dual inhibitor of EGFR and HER2.  Boehringer Ingelheim', 'BIBW-2992 , BIBW2992', 'Breast, H&N', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(265, 'Bicalutamide', NULL, NULL, 'NO', 'A pure nonsteroidal antiandrogen.', 'Casodex , ICD-176334 , ICI 176334 , ICI176334 , Propanamide', 'Prostate cancer', NULL, '722665', 'Hormones and hormonal mechanisms', 'Antiandrogenic'),
(266, 'Binimetinib', NULL, 'Melanoma', 'NO', 'June 27, 2018: FDA approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.', 'MEKTOVI , MEK162', NULL, NULL, NULL, 'Chemotherapy', 'MEK 1/2 Inhibitor'),
(267, 'Biomed 101 and Interleukin-2', NULL, NULL, 'NO', 'Phase II Leukotriene B4 receptor agonist & Th2 cytokine. BioMedicines.', NULL, 'Kidney cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(268, 'Biostim', NULL, NULL, 'NO', 'Has been used for its immunomodulating activity in the management of respiratory-tract infections, wounds, burns, and soft-tissue disorders, and has been used in immuno. No U.S. use information.', 'Acintor , Biostim , Citormon Dental , RU 41740 , RU-41740 , RU41740', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(269, 'Bisantrene Hydrochloride', NULL, NULL, 'NO', 'A guanidino substituted anthracene derivative that is thought to function as an intercalating agent. Not found in Drugdex drug evaluation.', 'Bisantrene , CL 216942 , CL-216942 , CL216942 , Orange Crush# , Zantrene', 'Leukemia', 'ADAH, ADC, ADCA', '337766', 'Chemotherapy', 'Topoisomerase inhibitor'),
(270, 'Bleomycin', NULL, NULL, 'NO', 'Phase III melanoma Anti-tumor antibiotic; Genetronics. FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin\'s and non-Hodgkin\'s lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.', 'Blenoxane , Bleo , Bleo-Cell , Bleo-S , Bleomycin for Injection , Bleomycin sulfate , Oil Bleo', 'Squamous cell cancers', 'BLE, BLEO, BLM', '125066', 'Chemotherapy', 'Antitumor antibiotic'),
(271, 'Blinatumomab', NULL, 'Relapsed or refractory B-cell precursor ALL (R/R ALL)', 'NO', 'December 3, 2014: FDA granted accelerated approval for blinatumomab for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lympoblastic leukemia (R/R ALL)\r\n\r\n7/14/2017FDA has approved the supplemental Biologics License Application for blinatumomab. The approval converts Blincyto’s accelerated approval to a full approval. The  approval also included the treatment of patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval expands the indication of Blincyto for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.\r\n\r\nMarch 29, 2018: FDA granted accelerated approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.', 'AMG103 , Blincyto', NULL, NULL, '765986', 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antiboies, bi-specific T-cell engagers'),
(272, 'BLP25', NULL, NULL, 'NO', 'Phase II/III NSCLC Phase I prostate Liposomal vaccine. Biomira, Merck KGaA.', 'BLP 25 , BLP-25', 'Lung, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(273, 'BMS 184476', NULL, NULL, 'NO', 'Phase II Taxane. Bristol-Myers Squibb.', 'BMS-184476 , BMS184476', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimitotic agent'),
(274, 'BMS 188797', NULL, NULL, 'NO', 'Phase I (colorectal, pancreatic) Phase II (gastric) Taxane analog. Bristol-Myers Squibb.', 'BMS-188797 , BMS188797', 'Colorectal, gastric, other cancer, pancreatic', NULL, NULL, 'Chemotherapy', 'Antimitotic agent'),
(275, 'BMS 214662', NULL, NULL, 'NO', 'Phase I Farnesyl transferase inhibitor. Bristol-Myers Squibb.', 'BMS-214662 , BMS214662', 'Colorectal, other cancer, pancreatic', NULL, '710086', 'Chemotherapy', 'Antimetabolite'),
(276, 'BMS 247615', NULL, NULL, 'NO', 'Phase I Topoisomerase II inhibitor. Bristol-Myers Squibb.', 'BMS247615', 'Colorectal, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(277, 'BMS 275291', NULL, NULL, 'NO', 'Phase II (breast, other) Phase III (NSCLC, ovarian) Selective matrix metalloprotease inhibitor. Bristol-Myers Squibb.', 'BMS-275291 , BMS275291', 'Breast, lung, other cancer, ovarian', NULL, '713763', 'Chemotherapy', 'Cytostatic agent--matrix metaloprotease inhibitor (MMPI)'),
(278, 'BMS 354825', NULL, NULL, 'NO', 'Phase I Bristol Myers Squibb.  Inhibits 5 different tyrosine kinase inhibitors.  Causes shrinkage of tumors.', 'BMS-354825 , BMS354825', 'CML', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(279, 'BMS 863233', NULL, NULL, 'YES', 'No current studies as of 2/2012. All previous clinical trials have been terminated.', NULL, 'CML, MDS', NULL, NULL, 'Chemotherapy', 'CDC7 Kinase Inhibitor- see remarks'),
(280, 'BMS-663513', NULL, NULL, 'NO', 'Phase I NSCLC 2007 Stimulates immune system.  Bristol Myers Squibb', 'BMS 663513 , BMS663513', 'NSCLC', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(281, 'BMS-936558', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', 'MDX 1106-04', 'melanoma, NSCLC, prostate, RCC', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'IgG4 mAb specific'),
(282, 'BNP1350', NULL, NULL, 'NO', 'Phase II BioNumerik Pharmaceuticals.', 'BNP 1350 , BNP-1350', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Camtothecin derivative--topoisomerase inhibitor'),
(283, 'BNP7787', NULL, NULL, 'NO', 'Phase III Karenitecin semisynthetic lipophilic derative of camptothecin.  Chemoprotectant for neuropathy. BioNumerik Pharmaceuticals.', 'BNP 7787 , BNP-7787', 'Breast cancer', NULL, '716976', 'Chemotherapy', 'Topoisomerase inhibitor'),
(284, 'Bolasterone', NULL, NULL, 'NO', NULL, 'Myagen# , U 19763 , U-19763 , U19763', NULL, NULL, '66233', 'Hormones and hormonal mechanisms', 'No longer in use'),
(285, 'Borocaptate Sodium B 10', NULL, NULL, 'YES', 'Radioactive agent. A boron-10 ((10)B) carrier for use in boron neutron capture therapy.', '\'Sodium borocaptate , Borolife , BSH , NASH', NULL, 'BSH, NASH', NULL, 'Ancillary Agent', NULL),
(286, 'Bortezomib', NULL, NULL, 'NO', 'November 14, 2014 update: FDA approved to treat multiple myeloma and Mantle cell lymphoma. In clinical trials for breast, colorectal, and lung cancer.', 'LDP-341 , MLN-341 , PS-341 , Velcade', 'Breast, Mantle cell lymphoma, colorectal, leukemia, lung cancer, multiple myeloma', NULL, '681239', 'Chemotherapy', 'Proteasome Inhibitor'),
(287, 'Bosutinib', NULL, NULL, 'NO', '9/4/2012: Bosulif received FDA approval as an Orphan Drug to treat CML \r\n\r\n12/19/2017: FDA granted accelerated approval to bosutinib for treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).', 'Bosulif , SKI 606 , SKI-606', 'CML', 'BOS', NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(288, 'Bovine Immunoglobulin Concentrate, Cryptosporidium parvum', NULL, NULL, 'YES', 'Orphan drug. Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients. Not found in Drugdex drug evaluation.', 'Sporidin-G', NULL, NULL, NULL, 'AIDS drug', NULL),
(289, 'Brentuximab vedotin', NULL, 'Mycosis fungoides, T-cell lymphoma', 'NO', '11/16/2018: Today, the U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.\r\n\r\nNovember 9, 2017: FDA granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. \r\n\r\nThe FDA approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an antibody: an antibody-drug conjugate. The antibody directs the drug to CD30, a target on lymphoma cells. Adectris was approved under the FDA\'s accelerated approval program. Adcetris is designed for individuals whose Hodgkin lymphoma continued to progress after autologous stem cell transplant, or after two previous treatments with chemotherapy and the patient cannot receive a transplant. Adectris can also be prescribed for individuals whose ALCL has progressed after one treatment with chemotherapy. \r\n\r\nMarch 20, 2018: FDA  approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.', 'Adcetris', 'Anaplastic large cell lymphoma (ALCL), Hodgkin Lymphoma', NULL, NULL, 'Chemotherapy', 'Antibody-drug conjugate;(ADC)'),
(290, 'Brequinar Sodium', NULL, NULL, 'YES', 'Immunosuppressant for transplant rejection.  No significant antitumor activity.', 'Biphenquinate , Brequinar , Brequinar sodium , Dup 785', NULL, 'BPQ', '368390', 'Ancillary Agent', 'Immunosuppressant for transplant rejection'),
(291, 'BrevaRex', NULL, NULL, 'NO', 'Phase I (pancreatic) Phase II (breast) Phase I/II MM Monoclonal antibody. AltaRex, Perdue Pharm.', NULL, 'Breast, multiple myeloma, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Passive monoclonal antibody'),
(292, 'Briciclib sodium', NULL, NULL, 'NO', 'This drug is in Phase I clinical trials.  Trial sites are limited to Colorado, Tennessee, and New York. Code in Other Therapy.', 'ON 013105', 'Leukemias, Solid tumors (See remarks)', NULL, NULL, 'Chemotherapy', 'analog'),
(293, 'Brigatinib', NULL, 'Non-small cell lung cancer (NSCLC)', 'NO', '4/28/2017: FDA granted an accelerated approval to brigatinib, trade name Alunbrig, for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.', 'Alunbrig', 'Lung', NULL, NULL, 'Chemotherapy', 'anaplastic lymphoma kinase'),
(294, 'Brivanib', NULL, NULL, 'NO', 'Phase II for HCC 2007 Bristol Myers Squibb.  Phase I clinical trials for advanced solid tumors 2006', 'BMS 582664 , BMS-582664 , BMS582664', 'hepatocellular carcinoma, Solid tumors', NULL, NULL, 'Chemotherapy', 'Antiangiogenic agent'),
(295, 'BRL 61063', NULL, NULL, 'YES', 'Exerts TNF-alpha (cachectin) inhibition', 'BRL-61063 , BRL61063', NULL, NULL, NULL, 'AIDS drug', NULL),
(296, 'Bromacrylide', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '66248', 'Chemotherapy', 'No longer in use'),
(297, 'Bromocriptine mesylate', NULL, NULL, 'NO', 'Phase II A vasoconstrictor. It inhibits the secretion of prolactin from the anterior pituitary.  Also used in the management of Parkinson\'s disease. Dopamine receptor agonist. Ergo Science.  Ergosel and Serotonin Agonist.  No U.S. use information.', 'Bromocriptine , Bromocriptine mesilate , Bromocriptine methanesulphonate , Parlodel', 'Breast cancer, pituitary tumors', NULL, NULL, 'Hormones and hormonal mechanisms', 'Inhibits prolactin secretion from pituitary gland'),
(298, 'Bromodeoxyuridine', NULL, NULL, 'YES', 'Radiosensitizer', 'Broxuridine', NULL, '5-BDU, 5-BUDR, BDU, BUdR, BrdUrd', '38297', 'Ancillary Agent', 'Radiosensitizer'),
(299, 'Bropirimine', NULL, NULL, 'NO', NULL, '461 , U-54', 'Bladder', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'changed from 1'),
(300, 'Brostallicin', NULL, NULL, 'NO', 'Phase II STS 2007 DNA intercalator.  Systems Medicine, Inc.; Cell Therapeutics.', 'PNU 166196A , PNU-166196A , PNU166196A', 'Soft tissue sarcoma', NULL, NULL, 'Chemotherapy', 'Alkylating agent'),
(301, 'Broxuridine', NULL, NULL, 'YES', 'A radiosensitizer; proposed as an antineoplastic agent. Radiation sensitizer in the treatment ofprimary brain tumors.', '5-Bromo-2\'-deoxyuridine , 5-Bromodeoxyuridine , Broxine/Neomark', NULL, 'BUdR', '38297', 'Ancillary Agent', 'Radiosensitizer'),
(302, 'Bruceantin', NULL, NULL, 'NO', NULL, 'Quassinoid', NULL, 'BRU', '165563', 'Chemotherapy', 'Natural product'),
(303, 'Bryostatin', NULL, NULL, 'NO', 'Phase I/II breast, cervical, gastric, head & neck, kidney, CML, AML, MDS, prostate, metas solid tumors Protein kinase activator. NCI.', 'B705008K112 , Bryostatin-1', 'Breast, cervical, esophageal, gastric, head & neck, kidney, leukemia, metastatic solid tumors, ovarian, prostate cancer', NULL, '339555', 'Chemotherapy', 'Protein kinase activator'),
(304, 'Bryostatin 1', NULL, NULL, 'NO', 'Bryostatin1 is being studied in the tretment of cancer and certain brain conditions such as Alzheimer disease and stroke. It is currently in numerous clinical trials for: Leukemia, lymphoma, MDS, colorectal, ovarian, kidney, melanoma, breast, gastric, GE and pancreas malignancies. Code as \"Other\" treatment until FDA approval is received.', 'Bryostatin', NULL, 'BRYO', NULL, 'Chemotherapy', 'Protein Kinase C Inhibitor'),
(305, 'BSI-201', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', NULL, 'metastatic breast, Pancreas', NULL, 'NCT00422682', 'Chemotherapy', 'PARP inhibitor'),
(306, 'Buserelin Acetate', NULL, NULL, 'NO', 'Buserelin is a synthetic gonadotropin-releasing hormone agonist.  It is a  synthetic version of the body\'s luteinizing hormone-releasing hormone (LHRH), which regulates the amount of testosterone in men and estrogen in women. Buserelin tells the body to stop making testosterone or estrogen, so the blood levels drop. Cancers that are stimulated by testosterone or estrogen stop dividing.', 'Busrelin Acetate , D-Ser (Bu(t))(6) Pro(9) NEt LHRH acetate , HOE 766 , HOE-766 , HOE766 , S74-6766 , Suprefact', 'Prostate cancer', NULL, '725176', 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone'),
(307, 'Busulfan', NULL, NULL, 'NO', 'Alkylating agent', 'Busulfanum , Busulfex , Busulphan , Joacamine , Mablin , Misulban , Mitostan , Myelosan (Russia) , Mylecytan , Myleran', 'CML', 'BSF, BU, BUS, BUSU', '750', 'Chemotherapy', 'Alkylating agent'),
(308, 'Buthionine Sulfoximine', NULL, NULL, 'NO', 'Phase 1 Neuroblastoma 2007 A glutathione-depleting agent. Place in therapy:  Undetermined due to insufficient clinical data.', NULL, 'Neuroblastoma', 'BSO', '326231', 'Chemotherapy', 'Antimetabolite'),
(309, 'Butoconazole', NULL, NULL, 'YES', 'An imidazole antifungal agent; topical antifungal agent', 'Butoconazole Nitrate , Femstat , Femstat-3 , Mycelex-3 , RS-35887', NULL, NULL, NULL, 'AIDS drug', NULL),
(310, 'BV ara-U', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(311, 'BW 256U87', NULL, NULL, 'YES', NULL, 'BW-256U87 , BW256U87', NULL, NULL, NULL, 'AIDS drug', NULL),
(312, 'BW 348U87', NULL, NULL, 'YES', NULL, 'BW-348U87 , BW348U87', NULL, NULL, NULL, 'AIDS drug', NULL),
(313, 'BW 882C87', NULL, NULL, 'YES', NULL, 'BW-882C87 , BW882C87', NULL, NULL, NULL, 'AIDS drug', NULL),
(314, 'BXQ-350', NULL, 'Glioblastoma Multiforme', 'NO', 'Feb. 2015: FDA granted an Orphan Drug Designation to BXQ-350 for the potential treatment of glioblastoma multiforme.', NULL, 'Brain', NULL, NULL, 'Chemotherapy', 'Anti-cancer nanovesicle technology;Target therapy'),
(315, 'C-Parvum', NULL, NULL, 'NO', 'Has been used in the treatment of malignant effusions, and has been tried as an adjuvant to cancer chemo. for its immunostimulant properties. It has also been used in the treatment of musculoskeletal and joint disorders; immunomodulator. No U.S. use information.', 'Arthrokehlan A , Coparvax , Coparvax (R) (Merrieux) , Corymunun , H37Ra', NULL, 'C.p., CPAR', '220537;197213', 'Biologic therapy (BRM, immunotherapy)', NULL),
(316, 'Cabazitaxel', NULL, NULL, 'NO', 'FDA approved June 17, 2010 for treatment of hormone-refractory prostate cancer.', 'Jevtana , XRP-6258', 'Prostate', NULL, NULL, 'Chemotherapy', 'Microtubule inhibitor'),
(317, 'Cabergoline', NULL, NULL, 'NO', 'Pharmacia, Upjohn.  Suppresses prolactin secretion by anterior pituitary.', 'Cabaser , Dostinex', 'Pituitary (prolactinoma)', NULL, NULL, 'Hormones and hormonal mechanisms', 'Prolactin supression'),
(318, 'Cabozantinib', NULL, 'Renal cell carcinoma (RCC), hepatocellular (HCC)', 'NO', 'Received approval under the FDA priority review program  November 29, 2012 for treatment of medullary cancer of the thyroid.\r\n\r\nApril 25, 2016: The FDA approved cabozantinib for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.\r\n\r\n1/14/2019 FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib', 'Cometriq , Cabomety', 'Thyroid, Kidney', NULL, '761968', 'Chemotherapy', 'kinase inhibitor'),
(319, 'cAC10-vcMMAE(4)', NULL, NULL, 'NO', 'Seattle Genetics', NULL, 'Hodgkin lymphoma', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent--conjugate'),
(320, 'Cactinomycin', NULL, NULL, 'NO', 'Antitumor antibiotic', 'Actinochrysin , Actinomycin C# , H.B.F. 386 , Sanamicia , Sanamycin , Sandamycin', NULL, NULL, '18268', 'Chemotherapy', 'Antitumor antibiotic'),
(321, 'Caffeine', NULL, NULL, 'YES', 'Used in CAC regimen.  Caffeine reduces the time a cell spends in G2 phase.', NULL, 'Pancreatic cancer', NULL, NULL, 'Ancillary Agent', NULL),
(322, 'CAL', NULL, NULL, 'NO', 'Phase II Chuga Biopharmaceuticals.', NULL, 'Breast cancer', NULL, NULL, 'Other therapy', 'Mechanism not known'),
(323, 'Calcitonin', NULL, NULL, 'YES', 'A polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals. In patients with hypercalcemia, salmon calcitonin produces a rapid serum calcium-lowering effect; regulates calcium', 'Calcimar , Calcitonin Salmon , Calsyn , Caltine , Cibacalcin , Miacalcin , Salcatonin (salmon source) , Thyrocalcitonin (thyroid source)', NULL, NULL, NULL, 'Ancillary Agent', 'Prevents calcium loss'),
(324, 'Calcium Carbonate', NULL, NULL, 'YES', 'Antacid, calcium supplement. Calcium carbonate has been designated an orphan product for use in the treatment of hyperphosphatemia in patients with end stage renal disease.', 'Alka-Mints , Alkets , Amitone , Anatacid , Apo-Cal , Biocal , Cal Carb-HD , Cal-500 , Cal-Guard , Cal-Plus , Cal-Sup , Calci-Chew , Calci-Mix , Calciday , Calcite , Calsan , Caltrate , Caltrate Jr. , Chooz , Component of Calcitrel , Component of Titralac , Dicarbosil , Equilet , Gencalc , Hi Potency Cal , Maalox Antacid , Maalox Quick Dissolve , Mallamint , Mega-Cal , Mylanta , Neo Cal , Nephro-Calci , Os-Cal , Oysco , Oyst-Cal , Oystercal , Pharmacal , Prevencal , R&D Calcium Carbonate/600 , Titralac , Titralac Extra Strength , Tums', NULL, NULL, '725280', 'Ancillary Agent', NULL),
(325, 'Calcium Gluconate', NULL, NULL, 'YES', 'The intravenous drug of choice for hypocalcemia; calcium replenisher.  Also osteoporosis, leg cramps, tetany. Calcium gluconate gel has been designated an orphan product for use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.', 'calcium salt (2:1) , Calgonate , Component of Calcet , D-Gluconic acid , H-F Antidote', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(326, 'Calusterone', NULL, NULL, 'NO', 'Antiestrogen inhibiting the hypothalamic-pituitary-ovarian axis through negative-feedback action (like fluoxymesterone, testolactone, medroxyprogesterone acetate). A synthetic androgen, is no longer marketed.', '550 , Dimethyltestosterone , Methosarb# , U 22550 , U-22 , U22550', NULL, 'CAL, CLS', '88536', 'Hormones and hormonal mechanisms', 'Anti-estrogen'),
(327, 'Camptothecin', NULL, NULL, 'NO', NULL, NULL, NULL, 'CAMP', '100880', 'Chemotherapy', 'Topoisomerase inhibitor'),
(328, 'Camptothecin Glycoconjugate', NULL, NULL, 'NO', 'Phase I Bayer.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(329, 'Cancer Vaccine', NULL, NULL, 'NO', 'Phase II Vaccine, FDA approved for bladder and breast cancer. Genzyme Molecular Oncology.', NULL, 'Bladder, breast, kidney, ovarian, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(330, 'Canvaxin', NULL, NULL, 'NO', 'Phase III metastatic colorectal, melanoma Vaccine. Cancer Vax Corp.', NULL, 'Colorectal, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(331, 'CAP-1', NULL, NULL, 'NO', 'Phase II NCI.', 'CAP-1 6D Peptide Vaccine , CEA peptide 9-MER', 'Gastric cancer', NULL, '672683', 'Chemotherapy', 'Antimetabolite'),
(332, 'Capecitabine', NULL, NULL, 'NO', 'FDA approved for colorectal cancer Capecitabine is an oral prodrug of both doxifluridine and 5-fluorouracil. FDA approved use in breast and colorectal cancers. Hoffman LaRoche.', 'Ro 091978 , Ro-09-1978 , Ro-091978 , Xeloda', 'Breast cancer, colorectal cancer', NULL, '712807', 'Chemotherapy', 'Antimetabolite'),
(333, 'Capreomycin Sulfate', NULL, NULL, 'YES', 'A cyclic polypeptide antimicrobial agent used to treat tuberculosis. Antimycobacterial drug', 'Capastal sulfate , Capastat Sulfate , Caprocin , Capromycin', NULL, NULL, NULL, 'AIDS drug', NULL),
(334, 'CAR-T', NULL, 'Acute lymphoblastic leukemia', 'NO', '8/30/2017: Food and Drug Administration approved CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (ALL).', 'Chimeric antigen receptor T-cell therapy , KTE-C19', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(335, 'Caracemide', NULL, NULL, 'NO', 'An inhibitor of nucleic acid and protein synthesis which is under investigation as an antineoplastic. Not found in Drugdex drug evaluation.', NULL, 'Renal cell cancer', NULL, '253272', 'Chemotherapy', 'Antimetabolite'),
(336, 'Carbenicillin', NULL, NULL, 'YES', NULL, 'Geocillin', NULL, NULL, NULL, 'Ancillary Agent', 'Antibiotic'),
(337, 'Carbenoxolone Sodium', NULL, NULL, 'YES', 'A derivative of glycyrrhizic acid, is investigational in the United States. Was one of the first agents used for the treatment of gastric and duodenal ulcers. Although effective, its use has largely been replaced by the histamine-2 receptor antagonists.', '18alpha-Carbenoxolone , 18alpha-Glycyrrhetinic Acid 3beta-O-Hemisuccinate , Biogastrone , Bioral , Carbeneoxolone , Carbenoxalone , Carbenoxolone Disodium Salt , Carbenoxolone Sodium , Duogastrone , Glycyrrhetinic Acid 3-O-hemisuccinate , Sanodin', NULL, NULL, '281727', 'Ancillary Agent', 'Anti-ulcer medication'),
(338, 'Carbetimer', NULL, NULL, 'NO', 'Has been investigated as an antineoplastic. Not found in Drugdex drug evaluation.No update from M\'dale. Pharmacia Corporation.', 'Carboxyimamidate , N-137 , Plimar', NULL, NULL, NULL, 'Chemotherapy', NULL),
(339, 'Carboplatin', NULL, NULL, 'NO', 'A platinum-salt alkylating agent.', 'JM 8 , JM-8 , JM8 , Paraplatin', 'All cancers', 'CBDCA', '241240', 'Chemotherapy', 'Alkylating agent;Platinum analog'),
(340, 'Carboxyamidotriazole', NULL, NULL, 'NO', 'Phase II Anti-angiogenic. NCI.', NULL, 'Kidney, lung, ovarian cancer', 'CAI', '609974', 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(341, 'Carfilzomib', NULL, NULL, 'NO', 'The FDA approved Kyprolis under the accelerated approval program on July 20, 2012 for the treatment of multiple myeloma.', 'Kyprolis', 'Multiple myeloma', NULL, NULL, 'Chemotherapy', 'Proteasome inhibitor');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(342, 'Carmustine', NULL, NULL, 'NO', 'Phase I FDA approved uses on brain tumor, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)', 'BiCNU , Carmustinea , DTI 015 , DTI-015 , DTI015 , WR 139021 , WR-139021 , WR139021', 'Brain, Hodgkin Lymphoma, Kidney cancer, Multiple myeloma, Non-Hodgkin lymphoma', 'BCNU', '409962', 'Chemotherapy', 'Alkylating agent'),
(343, 'Carubicin (HCl)', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation. No updates from M\'dale.', 'Carminomicin I , Carminomycin , Carminomycin HCl# , Carminomycin I , Carubicin , Karminomitsin , Karminomycin HCl', 'Leukemia, lymphoma, solid tumors', 'CMM', '275649;180024', 'Chemotherapy', 'Anthracycline antineoplastic antibiotic'),
(344, 'Casodex', NULL, NULL, 'NO', 'Anti-androgen', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Anti-androgen'),
(345, 'Casopitant', NULL, NULL, 'YES', 'Anti-emetic.  Glaxo Smith Kline', 'GW 679769 , GW-679769 , GW679769', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(346, 'Castanospermine', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(347, 'CAT-8015', NULL, NULL, 'NO', 'Phase I hairy cell, CLL, SLL 2007 Cambridge Antibody Technologies', 'CAT 8015 , CAT8015', 'CLL, hairy cell leukemia, small cell lymphoma', NULL, NULL, 'Chemotherapy', 'Immunotoxin'),
(348, 'Catumaxomab', NULL, NULL, 'NO', 'Used as palliative treatment for malignant ascites from ovarian primaries. It is an orphan drug and has not yet received FDA approval.', 'Removab', 'Ovary', NULL, NULL, 'Chemotherapy', 'Monoclonal antibody'),
(349, 'CB-10-277', NULL, NULL, 'NO', NULL, 'CB-10277 , CB10277', NULL, NULL, '208107', 'Chemotherapy', 'Antimetabolite'),
(350, 'CBT-1', NULL, NULL, 'YES', 'Multidrug resistance modulator blocks MDR pump in cell allowing chemotherapy drugs to work.  CBA Research, Pharma.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(351, 'CC-11006', NULL, NULL, 'NO', 'Phase I MDS 2007 Immunomodulator with multiple effects.  Celgene.', 'CC 11006 , CC11006', NULL, NULL, NULL, 'Chemotherapy', 'Cytostatic agent--anti-angiogenesis agent'),
(352, 'CD4-IgG', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(353, 'CD4-PE-40', NULL, NULL, 'YES', 'CD4 linked to Pseudomonas exotoxin (CD4-PE-40).', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(354, 'CD4-PE40', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(355, 'CDC-801', NULL, NULL, 'NO', 'In Clinical Trials TNF-alpha production inhibitor. Celgene.', 'CDC 801 , CDC801', 'Leukemia', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(356, 'CDC117', NULL, NULL, 'NO', 'Phase I Selective estrogen receptor modulator (SERM). Celgene.', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Selective estrogen receptor modulator (SERM)'),
(357, 'CEA (CAP1-6D) peptide vaccine', NULL, NULL, 'NO', 'Phase II pancreas 2007', NULL, 'Pancreas', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(358, 'CEA B7.1', NULL, NULL, 'NO', 'Phase II Aventis Pasteur.', NULL, 'Colon cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(359, 'CEA-Cide', NULL, NULL, 'NO', 'Phase I/II Anticarcinoembryonic antigen monoclonal antibody. Immunomedics.', NULL, 'Breast, colorectal, gastric, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(360, 'CEA-Scan', NULL, NULL, 'YES', 'Phase III Radiolabeled antibody. Immunomedics.', NULL, 'Breast, Lung cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(361, 'CEA-Tricom', NULL, NULL, 'NO', 'Phase I Vaccine, Therion Biologics.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(362, 'CEA-Vac', NULL, NULL, 'NO', 'Phase III (colorectal) Phase II (gastric, pancreatic) Phase I (lung) Anti-idiotype MAB vaccine. Titan Pharmaceuticals.', NULL, 'Breast, colorectal, gastric, lung, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(363, 'CEA-Vac-Triab', NULL, NULL, 'NO', 'Phase I/II Vaccine. Titan Pharmaceuticals.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(364, 'CeaVac Anti-idiotype antibody', NULL, NULL, 'NO', 'Phase III Monoclonal antibody vaccine mimicking the carcinoembryonic antigen (CEA).  Titan Pharmaceuticals.', NULL, 'Colon cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(365, 'Cediranib', NULL, NULL, 'NO', 'Phase I VEGF signaling inhibitor, anti-angiogenesis, tumor cell growth inhibitor', 'AZD 2171 , AZD-2171 , AZD2171 , Recentin , RecentinTM', 'glioblastoma, NSCLC, renal cell', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(366, 'Cefoperazone', NULL, NULL, 'YES', 'Third generation cephalosporin.  No indications for oncology.', 'Carbomycin , Carbomycin A , Cefomycin , Delta-mycin A4 , Lorizin , Magnamycin , Magnamycin A (antibiotic) , Megacef , Myticef , T-1551', NULL, NULL, '51001', 'Ancillary Agent', 'Antibiotic'),
(367, 'Ceftriaxone Sodium', NULL, NULL, 'YES', 'A third-generation cephalosporin with activity against Enterobacteriaceae similar to that of cefotaxime.', 'Ro-13-9904 , Rocephin', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(368, 'Celebrex', NULL, NULL, 'YES', 'Celebrex is a non steroidal anti-inflammatory drug.', NULL, 'Bladder, breast cancer', NULL, '719627', 'Ancillary Agent', 'pain control'),
(369, 'Celengitide', NULL, NULL, 'NO', 'Phase I Angiogenesis inhibitor. Merck KGaK.', NULL, 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(370, 'Cemiplimab', NULL, NULL, 'NO', '9/28/18: The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC', 'Libtayo , Cemiplimab-rwlc', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(371, 'CEP-2563', NULL, NULL, 'NO', 'Phase I Signal transduction modulator. Cephalon.', 'CEP 2563 , CEP2563', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--inhibitor--receptor tyrosine kinase'),
(372, 'CEP-7055', NULL, NULL, 'NO', 'Phase I Angiogenesis inhibitor. Sanofi-Synthelabo, Cephalon, Inc.', 'CEP 7055 , CEP7055', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(373, 'Cephalosporin', NULL, NULL, 'YES', NULL, 'Ancef , Apo-Cefaclor , Apo-Cephalex , Ceclor , Ceclor CD , Cedax , Cefaclor , Cefadroxil , Cefadyl , Cefamandole , Cefazolin , Cefdinir , Cefditoren , Cefepime , Cefixime , Cefizox , Cefobid , Cefonicid , Cefoperazone , Cefotan , Cefotaxime , Cefotetan , Cefoxitin , Cefpodoxime , Cefprozil , Ceftazidime , Ceftibuten , Ceftin , Ceftizoxime , Ceftriaxone , Cefuroxime , Cefzil , Cephalexin , Cephalothin , Cephapirin , Cephradine , Ceporacin , Ceptaz , Claforan , Duricef , Fortaz , Keflex , Keflin , Keftab , Kefurox , Kefzol , Mandol , Maxipime , Mefoxin , Monocid , Novo-Lexin , Nu-Cephalex , Omnicef , PMS-Cephalexin , Rocephin , Suprax , Tazicef , Tazidime , Vantin , Velosef , Zinacef', NULL, NULL, NULL, 'Ancillary Agent', 'Antibacterial'),
(374, 'Ceplene', NULL, NULL, 'NO', 'Phase II (kidney) Phase III (AML) Synthetic nucleoside analog. Maxim Pharmaceuticals.  Ceplene therapy has been developed to maintain the integrity of pivotal immune cells, in particular T cells and natural killer (NK) cells, in patients with cancer. Ceplene treatment aims at facilitating immune-mediated destruction of cancer cells, including leukemic cells, and also at improving the efficiency of T and NK cell-activating agents such as IL-2.', 'Maxemine', 'Kidney cancer, leukemia', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(375, 'Cereport', NULL, NULL, 'YES', 'Phase II Blood-brain barrier permeabilization. Alkermes.', 'Lobradimil , RMP 7 , RMP-7 , RMP7', 'Brain cancer', NULL, '724318', 'Ancillary Agent', 'Analogue of bradykinin'),
(376, 'Cetuximab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, cetuximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code cetuximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy. \r\n\r\nFDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas\r\nAnti-VEGFr chimeric monoclonal antibody.', 'C 225 , C-225 , C225 , Erbitux , IMC-C225', 'Breast, colorectal, head & neck, lung, ovarian, pancreatic cancer', NULL, '714692', 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody, anti-EGFR antibody'),
(377, 'CG 7980', NULL, NULL, 'NO', 'Pre-clinical Oncolytic virus; Cell Genesys', 'CG-7980 , CG7980', 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(378, 'CG 8840', NULL, NULL, 'NO', 'Pre-clinical Oncolytic virus. Cell Genesys', 'CG-8840 , CG8840', 'Bladder cancer', NULL, NULL, 'Chemotherapy', 'Oncolytic adenovirus'),
(379, 'CG7060', NULL, NULL, 'NO', 'Phase II Oncolytic virus. Cell Genesys.', 'CG 7060 , CG-7060', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Prostate-specific adenovirus'),
(380, 'CG7870', NULL, NULL, 'NO', 'Phase II PSA-dependent cytolytic adenovirus. Cell Genesys.', 'CG 7870 , CG-7870', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Prostate-specific adenovirus'),
(381, 'CG8900', NULL, NULL, 'NO', 'Pre-clinical Oncolytic virus. Cell Genesys.', 'CG 8900 , CG-8900', 'Liver cancer', NULL, NULL, 'Chemotherapy', 'Oncolytic adenovirus'),
(382, 'CGP 19835A', NULL, NULL, 'NO', NULL, 'CGP-19835A , CGP19835A', NULL, 'MTP-PE', '628280', 'Biologic therapy (BRM, immunotherapy)', NULL),
(383, 'Chimeric MAb14.18', NULL, NULL, 'NO', 'Phase II Anti-GD2 monoclonal antibody. NCI.', 'CH14.18', 'melanoma, Neuroblastoma', NULL, '623408', 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(384, 'CHIR-258', NULL, NULL, 'NO', 'Chiron.  Targets specific cytogenetic translocation in multiple myeloma; cytotoxic to myeloma cells.', 'CHIR 258 , CHIR258', 'Multiple myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(385, 'Chlorambucil', NULL, NULL, 'NO', 'A bifunctional alkylating antineoplastic agent. FDA approved uses on chronic lymphocytic leukemia, Hodgkins\' and non-Hodgkin\'s lymphoma.', 'Ambochlorin , CB-1348 , Chlorambucilum , Chloraminophene , Chlorbutin , Chlorbutine , Chlorbutinum , Ecloril , Leukeran , Leukersan , Leukoran , Linfilizin , Linfolysin , WR-139013', NULL, 'CHL, CLB', '3088;003088', 'Chemotherapy', 'Alkylating agent'),
(386, 'Chlorhexidine Gluconate', NULL, NULL, 'YES', 'Orphan Indication: For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.', 'Bactigras , Betasept , Chlorhexseptic , Dyna-Hex , Dyna-Hex2 , Exidine , Hexifoam , Hibiclens , Hibidil , Hibistat , Hibitane , K-Y Jelly , Lubricating Jelly , Oro-Clense , Perichlor , Peridex , Periochip , Periogard , Perisol , Rouhex-G , Savlodil , Spectro Gram 2 , Stanhexidine , Stanley Chlorhexidine , Steri-Stat', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(387, 'Chlormadinone Acetate', NULL, NULL, 'NO', 'Progestin used in oral contraceptive products. Not found in Drugdex drug evaluation.', 'Bovisynchron , Chlormadinone , Chlormadinonu (Polish) , Clordion , Gestafortin , Lormin , Lutinyl , Matrol , Synchrosyn , Synchrosyn P', NULL, 'CAP', '92338;092338', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(388, 'Chlornaphazine', NULL, NULL, 'YES', 'Has been used as a chemotherapeutic agent.  It is also capable of producing human bladder tumors and is mutagenic in experimental assays. Not found in Drugdex drug evaluation.', 'Aleukon , CB-1048 , CB1048 , Chlornaftina , Chlornaphazin , Chlornaphthin , Chloronaphthina , Chloronaphthine , Cloronaftina , Erysan , Nafticlorina , Naphthylamine mustard , R-48', NULL, NULL, '62209', 'Ancillary Agent', NULL),
(389, 'Chloroquinoxaline Sulfonamide', NULL, NULL, 'NO', 'Phase II Halogenated sulfonamide. NCI, Merck.', NULL, 'Lung cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(390, 'Chlorotrianisene', NULL, NULL, 'NO', 'Although it is synthetic estrogen used to suppress lactation in postpartum women, it is also used  for palliative treatment in inoperable prostatic carcinoma, and for replacement therapy of estrogen deficiency.', 'Anisene , Chloro-tris , Chlorotrianisine , Chlortrianizen , Clorestrolo , Clorotrisin , Hormonisene , Khlortri-anizen , Merbentul , Metace , Rianil , TACE', 'Prostate cancer', NULL, '010108;10108', 'Hormones and hormonal mechanisms', 'Estrogen'),
(391, 'Chlorozotocin', NULL, NULL, 'NO', 'Antineoplastic and Immunosuppressant. Analog of Streptozocin. From M\'dale.', 'SRI 5244 , SRI-5244 , SRI5244', 'Pancreatic cancer', 'CLZ, CZT, DCNU', '178248', 'Chemotherapy', 'Alkylating agent'),
(392, 'Chlorpromazine', NULL, NULL, 'YES', 'A phenothiazine antipsychotic, also to control nausea and vomiting.', 'Chlor-PZ# , Chlorpomanyl , Chlorpromazine Hydrochloride , Chlorpromazine Hydrochloride Intensol , Clorazine , Largactil , Novo-Chlorpromazine , Ormazine , Promachel , Promachlor , Promaz , Promosol , Psychozine , Sonazine , Thora-Dex No. 1 , Thora-Dex No. 2 , Thorazine', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(393, 'Chlorsulfaquinoxaline', NULL, NULL, 'NO', 'Merck', NULL, NULL, 'CQS', '339004', 'Chemotherapy', 'No longer in use'),
(394, 'Cholecalciferol', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation.', 'Activated 7-Dehydrocholesterol , D-Tabs , Delta-D , Vitamin D(3)', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(395, 'Chromic Phosphate P32', NULL, NULL, 'NO', 'Chromic phosphate ((32)P) is administered intraperitoneally or intrapleurally in the (FDA approved) treatment of malignant effusions; it may also be given by interstitial injection for the treatment of ovarian or prostatic carcinoma; also used I.V. in treatment of chronic myeloid and chronic lymphocytic leukemia and in palliative treatment of bone metastases.', 'Chromic Phosphate P 32 Suspension USP 26 , Chromphosphotope# , Phosphocol , Phosphocol P 32 , Phosphorus-32 , Sodium Phosphate ((32)P) Injection , Sodium Phosphate P 32 Solution USP 26', 'CLL and chronic myeloid leukemia, Ovarian and prostatic carcinoma, palliative in bone metastases', 'P32', NULL, 'Radiation', 'Radioisotope'),
(396, 'Chromomycin', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.\r\nThis agent is used as a fluorescent chromosome dye (NCI drug dictionary)', 'Aburamycin B , Antibiotic B 599 , Chromomycin A3 , Toyamicin , Toyomycin', NULL, NULL, '58514', 'Chemotherapy', 'No longer in use'),
(397, 'CI 1033 ErbB', NULL, NULL, 'NO', 'Phase II Tyrosine kinase inhibitor. Pfizer.', 'PD 183805 , PD-183805 , PD183805', 'Breast, Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(398, 'CI-1033', NULL, NULL, 'NO', 'Phase II Erb-b2 and EGFR dual kinase inhibitor. Pfizer, NCI.', 'CI 1033 , CI1033', 'Breast, head & neck, lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--dual inhibitor'),
(399, 'CI-921', NULL, NULL, 'NO', NULL, 'CI 921 , CI921', NULL, NULL, '343499', 'Chemotherapy', 'Topoisomerase inhibitor'),
(400, 'CI-937', NULL, NULL, 'NO', NULL, 'CI 937 , CI937 , Moxantrozole', NULL, NULL, NULL, 'Chemotherapy', 'Anthracycline'),
(401, 'CI-980', NULL, NULL, 'NO', 'Phase I/II Synthetic mitotic inhibitor. NCI.', 'CI 980 , CI980', 'Brain, leukemia, lung cancer', NULL, '635370', 'Chemotherapy', 'Cytostatic agent--mitotic inhibitor'),
(402, 'CI-994', NULL, NULL, 'NO', 'Phase II Histone deacetylase inhibitor. Pfizer.  Development halted after unsuccessful  clinical trials', 'CI 994 , CI994 , N-acetyldinaline', 'Pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(403, 'Cidofovir', NULL, NULL, 'YES', 'An acyclic nucleoside phosphonate derivative with antiviral activity.', 'GS-504 , HPMPC , Vistide', NULL, NULL, NULL, 'AIDS drug', NULL),
(404, 'Cilastatin Sodium', NULL, NULL, 'NO', 'Cilastatin sodium is an inhibitor of dehydropeptidase I, an enzyme found in the brush border of the renal tubules. Antibiotic', NULL, NULL, NULL, NULL, 'Chemotherapy', 'Antibiotic'),
(405, 'Cilengitide', NULL, NULL, 'NO', 'Phase II Angiogenesis inhibitor. Merck KGaA.', 'EMD 121974 , EMD-121974 , EMD121974', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(406, 'Cimetidine', NULL, NULL, 'YES', 'An H2-receptor antagonist, acid reducer; immunomodulatory effect', 'Acid Reducer 200 , Apo-Cimetidine , Cimeditine Hydrochloride , Gaviscon , Gaviscon All-Night , Guanidine , Heartburn 200 , Novo-Cimetine , Nu-Cimet , Peptol , SKF-92334 , Tagamet , Tagamet HB', 'Other', NULL, NULL, 'Ancillary Agent', NULL),
(407, 'Cingestol', NULL, NULL, 'NO', 'Progestin for contraception. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(408, 'Ciprofloxacin Hydrochloride', NULL, NULL, 'YES', 'A fluoroquinoline antimicrobial agent.', 'Bay-O-9867 , Ciloxan , Cipro', NULL, NULL, '620634', 'Ancillary Agent', 'Antibiotic'),
(409, 'Cirolemycin', NULL, NULL, 'NO', 'Mutagen--no longer on market', '241 , U 12241 , U-12 , U12241', NULL, NULL, '77950', 'Chemotherapy', 'No longer in use'),
(410, 'Cisplatin', NULL, NULL, 'NO', 'An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.', 'Cis-Platin , Cis-Platinum II# , Cisplatino (Spanish) , Cisplatinum , Cisplatyl , Neoplatin , Peyrone\'s chloride , Platinex , Platinol , Platinol-AQ , Platinol-AQ VHA Plus , Platinum', 'Bladder, ovarian, testicular cancer', 'CACP, CDDP, Cis-DDP, CPD, CPDC, CPDD, CP', '119875', 'Chemotherapy', 'Alkylating agent;Platinum analog'),
(411, 'Cladribine', NULL, NULL, 'NO', 'FDA approved for hairy cell leukemia treatment.\r\nCurrently in trials for other B cell leukemias and lymphomas, such as mantle cell lymphoma. Also used in the treatment of multiple sclerosis.', '2-Chlorodeoxyadenosine , Chlorodeoxyadenosine , CldAdo , Leustatin , RWJ 26251 , RWJ-26251 , RWJ26251', 'Leukemia, Leukemic reticuloendotheliosis', '2CdA', '105014', 'Chemotherapy', 'Antimetabolite;purine analogs'),
(412, 'Clarithromycin', NULL, 'MALT Lymphoma', 'SEE_REMARKS', 'Treatment of the H. pylori infection leads to regression of the lymphoma in about 8 out of every 10 people with gastric MALT lymphoma who showed evidence of an H. pylori infection. The treatment is most successful when the tumor has not extended very far through the stomach wall and has not spread to the lymph nodes.\r\nAn initial course of antibiotic treatment for H. pylori eradication is clarithromycin together with either amoxicillin or metronidazole. These antibiotics are usually given with a drug that cuts down the amount of acid the stomach produces (a proton pump inhibitor or \'PPI\' drug such as omeprazole). This combination of three drugs is often called ‘triple therapy’ and is taken for 10–14 days.\r\n\r\nCoding instructions: Code this drug Other Therapy ONLY when given for MALT lymphoma', 'A 56268 , A-56268 , A56268 , Biaxin', NULL, NULL, '643733', 'Other therapy', 'Antibiotic'),
(413, 'Clindamycin', NULL, NULL, 'YES', 'A lincosamide antimicrobial agent that is a semi-synthetic derivative of lincomycin; antiparasitic; Rx of PCP', 'Cleocin , Cleocin HCl , Clindamycin Hydrochloride , Dalacin , Dalacin C Hydrochloride , U 21251 , U-21251 , U21251', NULL, NULL, '618653', 'AIDS drug', 'Antibiotic'),
(414, 'Clindamycin Palmitate Hydrochloride', NULL, NULL, 'YES', NULL, 'Cleocin Pediatric , Clindamycin 2-Palmitate Hydrochloride , Dalacin C , U-25179E', NULL, NULL, NULL, 'Ancillary Agent', 'Antibiotic'),
(415, 'Clindamycin Phosphate', NULL, NULL, 'YES', NULL, 'C/T/S , Cleocin , Clinda-Derm , Clindets , Dalacin C Phosphate , Dalacin T , Dalacin Vaginal Cream', NULL, NULL, NULL, 'Ancillary Agent', 'Antibiotic'),
(416, 'Clocortolone Acetate', NULL, NULL, 'NO', 'Topical glucosteroid used for rashes and dermatitis', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(417, 'Clocortolone Pivalate', NULL, NULL, 'NO', 'A medium potency topical corticosteroid used for rashes and dermatitis', 'Cloderm , SH 863 , SH-863 , SH863', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(418, 'Clofarabine', NULL, NULL, 'NO', 'FDA approved for pediatric ALL; Phase II (AML, other) Phase I/II NHL Purine nucleoside.  Genzyme, Bioenvision, ILEX Therapeutics.', 'Clofarex , Clolar , Evoltra', 'ALL, AML, CML, Leukemia, lymphoma, myeloproliferative disease, other cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(419, 'Clofazimine', NULL, NULL, 'YES', 'An anti-leprosy agent with antimycobacterial and antiinflammatory activity.', 'B 663 , B663 , C30320 , G-30320 , Lamprene', NULL, NULL, '141046', 'AIDS drug', NULL),
(420, 'Clogestone Acetate', NULL, NULL, 'NO', 'Progestin', '440 , AY 11440 , AY-11 , AY11440', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(421, 'Clomegestone Acetate', NULL, NULL, 'NO', 'Progestin', 'SH 741 , SH-741', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(422, 'Clomesone', NULL, NULL, 'NO', 'Only in ReproTox, antineoplastic alkylating agent.', NULL, NULL, NULL, '338947', 'Chemotherapy', 'Alkylating agent'),
(423, 'Clometherone', NULL, NULL, 'NO', 'Androgen used in acne care.', '38000', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen.  Probably not cancer directed--verify with attending MD.'),
(424, 'Clomiphene Citrate', NULL, NULL, 'NO', 'Synthetic gonad-stimulating principle structurally related to the proestrogen chlorotrianisene, used to induce ovulation in certain forms of anovulatory infertility.  Not found in Drugdex drug evaluation.', 'Chloramiphene Citrate , Clomifene , Milophene , Serophene', NULL, NULL, '035770;151466;35770', 'Hormones and hormonal mechanisms', 'Gonadotropin stimulant.  Probably not cancer directed--verify with attending MD.'),
(425, 'Clonidine Hydrochloride', NULL, NULL, 'YES', 'A centrally acting alpha-adrenergic agonist antihypertensive agent; chronic pain in cancer; controls hot flashes in breast cancer therapy', 'Apo-Clonidine , Catapres , Catapres TTS , Clorpres , Combipres , Dixarit , Duraclon , Novo-Clonidine', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(426, 'Cloretazine', NULL, NULL, 'NO', 'Phase II AML 2007; orphan drug for AML Sulfonyl hydrazine prodrug (SHP). Vion Pharmaceuticals.', 'VNP 40101M , VNP-40101M , VNP40101M', 'AML, Leukemia, other cancers, SCLC', NULL, '734246', 'Chemotherapy', 'Alkylating agent'),
(427, 'Clotrimazole', NULL, NULL, 'YES', 'An imidazole antifungal drug; Rx of candidiasis;topical antifungal antibiotic', 'Canesten , Canesten Combi-Pak , Canestin , Clotrimaderm , Component of Lotrimax , Component of Lotrisone , Desenex AF , Femcare , Femizol , Fungoid , Gyne-Lotrimin , Lotrimin , Mycelex , Mycelex G Neo-Zol , Myclo-Derm , Myclo-Gyne', NULL, NULL, NULL, 'AIDS drug', NULL),
(428, 'CM101', NULL, NULL, 'NO', 'Phase II Anti-pathoangiogenic. CarboMed, Inc.', 'CM 101 , CM-101', 'Pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(429, 'CMVIg', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(430, 'CN706', NULL, NULL, 'NO', 'Phase II PSE gene targeted gene therapy via adenovirus.  PSA gene regulated cytolytic adenovirus. Calydon.', 'CN 706 , CN-706', 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(431, 'Codeine', NULL, NULL, 'YES', 'A narcotic analgesic.', 'Codein Contin , Codein Phosphate , Codein Phosphate Hypodermic , Codein Sulfate , Methylmorphine , Paveral', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(432, 'Coenzyme Q', NULL, NULL, 'YES', 'Under investigation for the management of Huntington\'s chorea. It has also been tried in conditions associated with coenzyme deficiency. Reduces myoclonic seizures', 'CO-10 , CO-Q , Coenzyme Q10 , Lipoquinone , Mega CoQ10 , Super CoQ10 , Ubidecarenone , Ubiquinone , Ubiquinone-Q10 , Ultra CoQ10', NULL, 'CoQ', NULL, 'Ancillary Agent', NULL),
(433, 'CoFactor', NULL, NULL, 'YES', 'Phase II advanced breast 2007 Used with 5FU. Biomodulator. Biokeys.', 'ANX 510 , ANX-510 , ANX510', 'breast cancer, Colorectal', NULL, NULL, 'Ancillary Agent', NULL),
(434, 'COL-3', NULL, NULL, 'NO', 'Phase I/II NCI, CollaGenex Pharmaceuticals.', NULL, 'Brain, other cancer, skin', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(435, 'Colcemid', NULL, NULL, 'NO', NULL, 'ALX 430033 , ALX-430-033 , ALX430033 , Demecolcine', NULL, NULL, NULL, 'Chemotherapy', 'Antimitotic agent'),
(436, 'Combid spansule', NULL, NULL, 'YES', 'Peptic ulcer drug', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(437, 'Combretastatin A4 Prodrug', NULL, NULL, 'NO', 'Phase I/II Vascular targeting agent. OxiGENE, Bristol-Myers Squibb.', NULL, 'Colon, head & neck, lung, other cancer, thyroid', 'CA4P', NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(438, 'Copanlisib Hydrochloride', NULL, 'Follicular lymphoma', 'NO', 'September 14, 2017: FDA approved Copanlisib hydrochloride (Aliqopa)  for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.', 'Aliqopa', NULL, NULL, NULL, 'Chemotherapy', 'Phosphatidylinositide 3-Kinase Inhibitor'),
(439, 'Copovithane', NULL, NULL, 'NO', NULL, NULL, NULL, 'CPV', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(440, 'Cordycepin', NULL, NULL, 'NO', 'Phase II Nucleoside analog transcriptional chain terminator. NCI., OncoVista', NULL, 'Leukemia, TdT positive ALL', NULL, '63984', 'Chemotherapy', 'Antitumor antibiotic'),
(441, 'Corticosteroids, adjunctive', NULL, NULL, 'YES', 'Rx of Pneumocystis pneumonia carinii', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(442, 'Corticotropin', NULL, NULL, 'NO', 'Corticotropin or ACTH is an anterior pituitary hormone that stimulates steroidogenesis and the secretion of adrenocortical hormone from the adrenal cortex.  Used subcutaneously or intramuscularly as an antiemetic in cancer chemotherapy.', 'Acthar , Adrenocorticotrophic hormone , Adrenocorticotropin , Cortigel , Cortrophin-zinc , Cotropic gel , H.P. Acthar', NULL, 'ACTH', NULL, 'Hormones and hormonal mechanisms', 'Pituitary hormone.  Probably not cancer directed--verify with attending MD.'),
(443, 'Cortisone Acetate', NULL, NULL, 'NO', 'A corticosteroid with both glucocorticoid and mineralocorticoid activity.  Used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders', '\'Compound E acetate , component of Neosone , Cortisone , Cortisone Acetate , Cortogen acetate# , Cortone , Cortone acetate', NULL, NULL, '9703', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(444, 'Cortivazol', NULL, NULL, 'NO', 'Adrenal cortex hormone, glucocorticoid. Used in arthritis care; anti-inflammatory activity comparable to prednisolone.  Not available in U.S.  Not found in Drugdex drug evaluation.', 'H 3625 , H-3625 , H3625 , MK 650 , MK-650 , MK650', NULL, NULL, '080998;80998', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(445, 'Corynebacterium granulosum (Bacteria & Fungi biological)', NULL, NULL, 'NO', NULL, 'Corynebacterium granulosum (Bacteria & Fungi biological)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(446, 'Corynebacterium parvum, Wellcome CN6134 (BW) (Bacteria & Fungi biological)', NULL, NULL, 'NO', NULL, 'Corynebacterium parvum , Wellcome CN6134 (BW) (Bacteria & Fungi biological)', NULL, NULL, '220537', 'Biologic therapy (BRM, immunotherapy)', NULL),
(447, 'Cosyntropin', NULL, NULL, 'NO', 'A synthetic tetracosapeptide;   adrenocorticotropic hormone having the corticotropic activity of corticotropin but lacking its allergenicity; used in the diagnosis of adrenal insufficiency by plasma cortisol response following subcutaneous, intramuscular, or intravenous injection.', 'Cortrosyn , Synacthen', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Adrenocotricotropic hormone.  Probably not cancer directed--verify with attending MD.'),
(448, 'Cotara (TNT - Tumor Necrosis Therapy)', NULL, NULL, 'NO', 'Phase III (brain) Phase I/II (colorectal) Phase I liver, pancreatic, sarcoma Radiolabeled monoclonal antibody. Peregrine Pharmaceuticals.', NULL, 'Brain, colorectal, liver, pancreatic cancer, sarcoma', NULL, '733969', 'Radiation', 'Radioisotope attached to monoclonal antibody'),
(449, 'Cotellic', NULL, 'Melanoma', 'NO', '11/10/2015: The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).\r\n\r\nCoding note: Cobimetinib is approved to be used along with vemurafenib and not as a single agent.', 'Cobimetinib', NULL, NULL, NULL, 'Chemotherapy', 'MEK inhibitor'),
(450, 'Cotrimoxazole', NULL, NULL, 'YES', 'An antibacterial agent comprised of trimethoprim and sulfamethoxazole.', 'Apo-Sulfatrim , Bactrim , Cotrim , Roubac , Septa , Septra , SMZ-TMP , Sulfamethoprim DS , Sulfamethoxazole and Trimethoprim , Sulfatrim , Sulfoxaprim , Sulmeprim , Trimeth-Sulfa 2S', NULL, NULL, NULL, 'AIDS drug', NULL),
(451, 'CP-724-714', NULL, NULL, 'NO', 'Phase I ErbB receptor tyrosine kinase inhibitors.  OSI Pharmaceuticals.', 'CP 724714 , CP-724714 , CP724714', 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(452, 'CP-870,893', NULL, NULL, 'NO', 'Phase II Anti CD40 monoclonal antibody', 'CP-870893 , CP870893', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(453, 'CP461', NULL, NULL, 'NO', 'Phase II kidney, prostate, CLL Apoptotic antineoplastic. Cell Pathways.', 'CP 461 , CP-461', 'Kidney, leukemia, other cancer, prostate', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(454, 'CP547632', NULL, NULL, 'NO', 'Phase I EGFR tyrosine kinase inhbibitor. Pfizer, OSI Pharmaceuticals.', 'CP 547632 , CP-547632', 'Breast, lung, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic inhibitor--VEGFR inhibitor'),
(455, 'CP609754', NULL, NULL, 'NO', 'Phase I Farnesyl transferase inhibitor. OSI Pharmaceuticals.', 'CP 609754 , CP-609754', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(456, 'CpG 7909', NULL, NULL, 'NO', 'Phase II (kidney); Phase I/II (lymphoma); Phase I/II stage IV melanoma Aventis Pharmaceuticals; Oligodeoxynucleotide; Immunomodulator; Coley Pharmaceuticals.', 'CpG-7909 , CpG7909', 'Breast, kidney cancer, melanoma, non-Hodgkin\'s\' lymphoma, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(457, 'CPX-1', NULL, NULL, 'NO', 'Phase II colorectal 2007 Celator Pharmaceuticals', 'Liposomal Irinotecan:Floxuridine', 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(458, 'Crisnatol Mesylate', NULL, NULL, 'NO', 'Crisnatol is reported to act as a topoisomerase inhibitor and an intercalator of DNA.', '770U82 , 77OU82 , BW 770 , BW 770U82 , BW A 773U , BW A770U , BW A770U mesylate , BW-770 , BW770 , Crisnatol mesylate', 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(459, 'Crizotinib', NULL, NULL, 'NO', 'August 26, 2011 Crizotinib received FDA approval to treat late-stage (locally advanced or metastatic) non-small cell lung cancer (NSCLC).  Code as chemotherapy for NSCLC.\r\nCurrently being tested in clinical trials for advanced disseminated anaplastic large-cell lymphoma.', 'PF-02341066 , Xalkori', 'Lung NSCLC', NULL, NULL, 'Chemotherapy', 'Kinase inhibitor;Targeted therapy anaplastic lymphoma kinase'),
(460, 'Cryptophycin', NULL, NULL, 'NO', 'Phase II Anti-microtubule compound. Eli Lilly.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimitotic  atimicrotubual'),
(461, 'CS-1008', NULL, NULL, 'NO', 'Phase II pancreas 2007 DR5:  Death Receptor 5.  A humanized version of the anti-TRAIL-R2 antibody TRA-8. Daiichi Sankyo.', 'CS 1008 , CS1008', 'Pancreas', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(462, 'CSF-2', NULL, NULL, 'YES', 'Has been effective in reducing the severity and duration of chemo.-induced myelosuppression in cancer patients receiving chemo..', 'Granulocyte-macrophage colony-stimulating factor , Molgramostinum , rhGM-CSF , rhu GM-CSF , Sch 39300 , Sch-39300 , Sch39300', 'AIDS, Opportunistic infection', 'rGM-CSF', NULL, 'Ancillary Agent', NULL),
(463, 'CSF-GM', NULL, NULL, 'YES', NULL, 'CSF-GM (H)/Yeast , CSF-GM E.coli (Hoechst) , CSF-Granulocyte-Macrophage (Schering Plough) , Recombinant (Immunex) , Sargramostim', NULL, NULL, '622183;617589;614629;613795', 'Ancillary Agent', NULL),
(464, 'CSF-Macrophage', NULL, NULL, 'YES', NULL, 'CSF-M , M-CSF (Cetus)', NULL, NULL, '635258;625377', 'Ancillary Agent', NULL),
(465, 'CT-2106', NULL, NULL, 'NO', 'Phase I Captothecin analog. Cell Therapeutics.', 'CT 2106 , CT2106', 'Colon cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(466, 'CTCE-9908', NULL, NULL, 'NO', 'Phase I-II Chemokine Therapeutics.  Orphan drug', 'CDCE9908 , CTCE 9908', 'glioblastoma, Osteosarcoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(467, 'CTL019', NULL, 'Diffuse large B-cell lymphoma', 'NO', '4/23/2017: FDA granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma who have failed two or more prior therapies', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'chimeric antigen receptor T cell (CAR-T)'),
(468, 'Cur-61414', NULL, NULL, 'NO', 'Phase I basal Hedgehog pathway inhibitor. Curis.', 'Cur61414 Cur 61414', 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(469, 'Curdlan Sulfate', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(470, 'CV787', NULL, NULL, 'NO', 'Phase I/II Prostatic specific adenovirus. Calydon.', 'CV 787 , CV-787', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic adenovirus'),
(471, 'CX-3543', NULL, NULL, 'NO', 'Phase I Cylene.  Ribosomal RNA biogenesis inhibitor; a pro-apoptotic antitumor agent', 'CX 3543 , CX3543', NULL, NULL, NULL, 'Chemotherapy', 'Cytostatic agent--histone deacetylation inhibitor'),
(472, 'CX-4945', NULL, NULL, 'NO', NULL, 'CX-4945', 'Breast, Colorectal, H&N, Kidney, Lung, Mult Myeloma, Prostate', NULL, NULL, 'Chemotherapy', 'CK2 inhibitor'),
(473, 'CX43', NULL, NULL, 'YES', 'Pre-clinical Gene therapy. Northwest Biotherapeutics.', 'CX 43 , CX-43', 'Prostate, breast cancer', NULL, NULL, 'Ancillary Agent', 'Wound healing'),
(474, 'CxcR4', NULL, NULL, 'NO', 'Pre-clinical Gene therapy. Northwest Biotherapeutics.', 'Cxc R4', 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(475, 'Cyclocytidine (HCl)', NULL, NULL, 'NO', 'Miscellaneous agent', 'Ancytabine , CycloCMP hydrochloride', NULL, 'CYC', '145668', 'Chemotherapy', 'Miscellaneous agent'),
(476, 'Cyclodisone', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '348948', 'Chemotherapy', 'Alkylating agent'),
(477, 'Cyclohexanecarboxamide', NULL, NULL, 'NO', NULL, 'Ba 24648', NULL, NULL, '51915', 'Chemotherapy', NULL),
(478, 'Cycloleucin', NULL, NULL, 'NO', NULL, 'CB 1639 , Cycloleucine , WR 14997', NULL, 'ACPC, CL, CYL', '1026', 'Chemotherapy', 'listed as immunosuppressant in NCI Ontology'),
(479, 'Cyclopentenyl-cytosine', NULL, NULL, 'NO', NULL, 'Cyclopentenylcytosine', 'AML', 'Ce-Cyd, CPE-C, CPEC', '375575', 'Chemotherapy', 'Cytostatic agent'),
(480, 'Cyclophosphamide', NULL, NULL, 'NO', 'An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm\'s tumor. Alkylating agent', 'Asta B 518 , B-518 , Clafen Claphene , Cyclophosphamid , Cyclophosphan , Cyclophosphane , Cytophosphan , Cytoxan , Endoxan , Endoxana , Enduxan , Genoxal , Neosar , Procytox , Sendoxan , Tymtram , WR-138719', 'Breast, leukemia, lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, retinoblastoma, soft tissue sarcoma, Wilm\'s tumor', 'CP, CPM, CTX, CTY, CYC, Cyclo, CYT, CYTO', '026271;26271', 'Chemotherapy', 'Alkylating agent'),
(481, 'Cycloserine', NULL, NULL, 'YES', 'An antibiotic (antimycobacterial product) that interferes with cell wall synthesis.', 'Cicloserina , Cycloserinum , D-Cycloserin , Seromycin', NULL, NULL, NULL, 'AIDS drug', NULL),
(482, 'Cyclosporine', NULL, NULL, 'NO', 'A cyclic polypeptide immunosuppressant agent.', '27-400 , Ciclosporin , Cyclosporin A , Cyclosporin# , Neoral , OL-27-400 , Sandimmune , SangCya', NULL, 'CYA', '290193', 'Biologic therapy (BRM, immunotherapy)', NULL),
(483, 'Cyproterone Acetate', NULL, NULL, 'NO', 'An antiandrogen with progestogenic activity.  A synthetic antiandrogenic steroid that has been used in the treatment of male sexual disorders', 'Androcur , Med Cyproterone , SH 714 , SH-714b , SH-881 , SH714 , SH881', NULL, NULL, '081430;81430', 'Hormones and hormonal mechanisms', 'Anti-androgen.  Probably not cancer directed--verify with attending MD.'),
(484, 'Cyramza', NULL, NULL, 'NO', 'May 10, 2019: FDA approved ramucirumab (CYRAMZA) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ? 400 ng/mL and have been previously treated with sorafenib. \r\n\r\nFDA approved ramucirumab for use as a single agent for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine or platinum containing chemotherapy.', 'Ramucirumab', 'Brain, CNS, Breast, Colorectal, Gastric, GE, Liver, Non-small cell lung cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), Urinary', NULL, '749128', 'Biologic therapy (BRM, immunotherapy)', 'Antiangiogenesis;Monoclonal antibody'),
(485, 'Cytarabine', NULL, NULL, 'NO', 'Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin\'s disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)', 'AC-1075 , Alexan , Ara-cytidine , Arabinocytidine , Arabinosylcytosine , Beta-Arabinosylcytosine , Cytarabin , Cytarabine , Cytarabinoside , Cytosar , Cytosar-U , Cytosine Arabinoside , Cytosine arabinoside hydrochloride , Spongocytidine HCL , Tarabine , Tarabine PFS , U-19920 , U-19920A , WR-28453', 'ALL, AML, CML, head and neck, Hodgkin\'s disease, leukemia, Meningeal leukemia, NHL', 'ara-C, CA, HDA, HDARA-C', '063878;63878', 'Chemotherapy', 'Antimetabolite'),
(486, 'Cytarabine Liposome', NULL, NULL, 'NO', 'A sustained-release formulation (lipid encapsulation) of the active ingredient cytarabine and is intended for direct administration into the cerebrospinal fluid. FDA conditional approval - no clinical benefit demonstrated.', 'DepoCyt , DepoFoam , DTC 101 , DTC-101 , DTC101', 'Gliomas', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(487, 'Cytembena', NULL, NULL, 'NO', 'Known carcinogen', 'MBBA , Mebryl (Czechoslovakia)', NULL, 'CTB', '104801', 'Chemotherapy', 'Cytostatic agent'),
(488, 'Cytomegalovirus Immune Globulin', NULL, NULL, 'YES', 'A preparation of immunoglobulin G (IgG) antibodies derived from a pool of healthy adult donors with high titers of antibodies directed against cytomegalovirus.', 'CMV immune globulin , CMV-IGIV , CytoGam', NULL, NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(489, 'Cytosine Deaminase Gene - Adenoviral Vector', NULL, NULL, 'NO', 'Phase I Gene therapy. GenVec.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(490, 'D1/3-MAGE-3 Peptide Vaccine', NULL, NULL, 'NO', 'Phase II NCI, GlaxoSmithKline.', 'Prot. D MAGE 3/his , SB Mage-3', 'Skin cancer', NULL, '719274', 'Biologic therapy (BRM, immunotherapy)', NULL),
(491, 'D3967', NULL, NULL, 'NO', 'Phase III Optical isomer of aminoglutethimide. CellTech, Chiroscience.', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Adrenocortical suppressant'),
(492, 'D4T', NULL, NULL, 'YES', 'Non-nucleoside reverse transcriptase inhibitor', 'Dideoxynucleoside (thymidine) analogue , Stavudine', NULL, NULL, NULL, 'AIDS drug', NULL),
(493, 'D63153', NULL, NULL, 'NO', 'Phase II LHRH antagonist. Aeterna Laboratories.', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH antagonist'),
(494, 'dabrafenib', NULL, 'NSCLC', 'NO', 'Dabrafenib was approved by the FDA May 29, 2013 for the treatment of metastatic or unresectable melanoma.\r\n\r\nJune 30, 2017 FDA granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist) administered in combination for patients with metastatic non-small cell lung cancer with BRAF V600E mutation as detected by an FDA-approved test. The two agents, sponsored by Novartis, are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC.\r\n\r\n5/4/2018 The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).', 'GSK2118436 , Tafinlar', 'Melanoma, Lung, Thyroid', NULL, '763760', 'Chemotherapy', 'BRAF inhibitor'),
(495, 'Dacarbazine', NULL, NULL, 'NO', 'FDA approved on Hodgkin\'s lymphoma, and metastatic melanoma.', 'Deticene , Detimedac , Dimethyl-triazeno-imidazole-carboxamide , DTIC-Dome , Fauldetic , Imidazole carboxamide , WR-139007', 'Hodgkin\'s disease, melanoma, Neuroblastoma, Soft tissue sarcomas', 'DIC, DTIC, ICDT, ICT', '45388;045388', 'Chemotherapy', 'Antimetabolite;Nonclassic alkylating agent'),
(496, 'Daclizumab', NULL, NULL, 'NO', 'An immunosuppressive, humanized immunoglobulin-G1 monoclonal antibody.Used for immunosuppression for kidney transplants', 'Dacliximab , HAT antibody , Ro 24-7375 , Ro-247375 , Ro247375 , Zenapax', NULL, NULL, '715173', 'Biologic therapy (BRM, immunotherapy)', NULL),
(497, 'Dacomitinib', NULL, 'NSCLC', 'NO', 'September 27, 2018: FDA approved dacomitinib tablets (VIZIMPRO) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.', 'Vizimpro', 'Lung', NULL, NULL, 'Chemotherapy', 'Small molecule inhibitor'),
(498, 'Dactinomycin', NULL, NULL, 'NO', 'FDA approved use on Ewing\'s sarcoma, rhabdomyosarcoma, gestational trophoblastic neoplasms, testicular carcinoma, Wilm\'s tumor (antitumor antibiotic)', 'Actinomycin , Actinomycin AIV , Actinomycin C1 , Actinomycin D , Actinomycin I1 , Actinomycin IV , Actinomycindioic D-acid dilactone , Cosmegen , Dactino-mycin D , Meractinomycin , Oncostatin K', 'Ewing\'s sarcoma, rhabdomyosarcoma, testicular cancer, Wilm\'s tumor', 'ACD, ACT, ACT-D, ACTD, Acto-D, AD, Dact', '003053;3053', 'Chemotherapy', 'Antitumor antibiotic'),
(499, 'Dalotuzumab', NULL, NULL, 'NO', 'As of November 2015, this drug is still in clinical trials and has not yet received FDA approval. Code in Other Treatment and assign code 2 until final approval received.', 'MK-0646', 'Colorectal, NSCLC, pancreas', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Humanized monoclonal antibody'),
(500, 'Danazol', NULL, NULL, 'YES', 'A synthetic steroid analog. Useful for the palliative treatment of fibrocystic breast disease. Antipituitary suppressant', '757 , Chronogyn# , Cyclomen , Danocrine , Win 17', NULL, NULL, '270916', 'Ancillary Agent;Hormones and hormonal mechanisms', NULL),
(501, 'Dapsone', NULL, NULL, 'YES', 'A sulfone antibiotic. Antileprotic, antiparasitic agent.', 'Avlosulfan', NULL, NULL, '6091;006091', 'AIDS drug', NULL),
(502, 'Darzalex', NULL, 'Multiple myeloma', 'NO', 'November 16, 2015: The U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.\r\n\r\nSeptember 25, 2016: Daratumumab received Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy.\r\n\r\n6/16/2017 FDA approved the immunotherapy Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.\r\n\r\n5/11/2018 FDA has approved Darzalex (daratumumab) in combination with Velcade (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant\r\n\r\nJune 27,2019. FDA approved daratumumab (DARZALEX) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.\r\n\r\n9/26/2019 FDA approved daratumumab (DARZALEX) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).', 'Daratumumab', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(503, 'Dasatinib', NULL, NULL, 'NO', 'FDA approved 2006; orphan drug for Ph+ ALL; Phase II breast, prostate, CLL Bristol-Myers Squibb.  Used when Gleevec fails for CML\r\n\r\nNovember 9, 2017: FDA granted regular approval to dasatinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.', 'Sprycel', 'breast, CLL, CML, Ph+ ALL, prostate', NULL, '732517', 'Chemotherapy', 'Cytostatic agent--multi-target kinase inhibitor'),
(504, 'Daunorubicin Citrate Liposome (encapsulated)', NULL, NULL, 'NO', 'Phase II NHL FDA approved use on Kaposi\'s sarcoma. NEXstar.', 'Cerubidine , Daunorubicin Liposomal , DaunoXome', 'Kaposi sarcoma, Lymphoma', NULL, '697732', 'Chemotherapy', 'Antitumor antibiotic'),
(505, 'Daunorubicin Hydrochloride', NULL, NULL, 'NO', 'FDA approved use on ALL and ANLL; antitumor antibiotic', 'Acetyladriamycin , Cerubidine , Dauno-blastin , Daunomycin , Daunomycin-HCl , Daunorubicin , Daunorubicine , FI-6339 , Leuk-aemomycin C , NDC-0082-4155 , RP-13057 , Rubidomycin , Rubidomycin HCl , Rubomycin C', 'Leukemia', 'Daun, Dauno, DNM, DNR, DRB', '082151;82151', 'Chemotherapy', 'Antitumor antibiotic'),
(506, 'Daurismo', NULL, 'AML', 'NO', '11/21/2018 The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.', 'Glasdegib', NULL, NULL, NULL, 'Chemotherapy', 'small molecule inhibitor'),
(507, 'DAVANAT', NULL, NULL, 'YES', 'Phase II colorectal 2007 A proprietary polysaccharide polymer comprised of mannose and galactose carbohydrates that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.  ProPharmaceutials', NULL, 'Colorectal', NULL, NULL, 'Ancillary Agent', NULL),
(508, 'DC Vax', NULL, NULL, 'SEE_REMARKS', '1/7/18 DC vax has not yet received FDA approval to treat brain tumors. Code in Other Treatment.', NULL, 'Brain cancer', NULL, NULL, 'Other therapy', 'Immuotherapy active'),
(509, 'DC Vax Injection', NULL, 'Glioblastoma Multiforme', 'SEE_REMARKS', 'DC Vax is dendrtitic cell immunotherapy. It is a personalized vaccine.  As of August 2015, DC Vax is still in Phase III clinical trials and has not yet received FDA approval.  Code as Other Treatment (assign code 2).', 'DCVax- L , DCVaz (R)-l', 'Brain', NULL, NULL, 'Other therapy', NULL),
(510, 'DCC 2036', NULL, NULL, 'NO', NULL, 'rebastinib', 'Chronic myeloid leukemia, CML', NULL, NULL, 'Chemotherapy', 'BCR ABL inhibitor'),
(511, 'DCVax-Lung', NULL, NULL, 'SEE_REMARKS', '1/7/18: This agent has not yet received FDA approval. Code in Other Treatment. \r\nPhase II NSCLC Dendritic cell based immunotherapy.', NULL, 'Lung cancer', NULL, NULL, 'Other therapy', NULL),
(512, 'DCVax-Prostate', NULL, NULL, 'SEE_REMARKS', '1/7/18: The FDA has not yet approved this agent as treatment for prostate cancer. Code in other Treatment.', NULL, 'Prostate cancer', NULL, NULL, 'Other therapy', NULL),
(513, 'DE-310', NULL, NULL, 'NO', 'Phase I DDS chemotherapeutic. Daiichi Pharmaceuticals.', 'DE 310 , DE310', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(514, 'Deazaquanine', NULL, NULL, 'NO', NULL, '695-73 , CI-908 mesylate , CI908 , Deazaguanine Mesylate , ICN 4221 , ICN4221 , PD 90 , PD9069573', NULL, 'CI-908', '261726', 'Chemotherapy', 'Antimetabolite'),
(515, 'Deazauridine', NULL, NULL, 'NO', NULL, '3-Deazauridine , DeazaUrd , Deazauridine , EO-26 , ICN 1007', NULL, 'DAU', '126849', 'Chemotherapy', 'Antimetabolite;enzyme inhibitor'),
(516, 'Decapeptyl', NULL, NULL, 'NO', 'Trademark for a preparation of triptorelin, a synthetic analogue of gonadorelin used as an antineoplastic in the palliative treatment of advanced ovarian carcinoma and in the treatment of prostatic carcinoma.', 'D-TrP6 (LH-RH)', 'Ovarian, prostate cancers', NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH agonist'),
(517, 'Decitabine', NULL, NULL, 'NO', 'FDA approved for MDS 2006, Phase I melanoma, Phase II NSCLC DNA methylation modulator. SuperGen. NCI,  MGI Pharma, Pharmachemie', 'Aza dC , Dacogen , Dezocitidine', 'CML, Leukemia, lung, MDS, skin cancer', 'DAC', '127716', 'Chemotherapy', 'Antimetabolite'),
(518, 'Deferoxamine', NULL, NULL, 'YES', 'Iron chelating agent; prevents cardiac toxicity', 'Desferal , Desferrioxamin , Desferrioxamine mesylate', NULL, NULL, '527604;644468', 'Ancillary Agent', NULL),
(519, 'Defosfamide', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, '40627', 'Ancillary Agent', NULL),
(520, 'Degarelix', NULL, NULL, 'NO', 'Approved', 'Firmagon', 'Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', 'GnRH receptor antagonist'),
(521, 'Dehydroemetine Hydrochloride', NULL, NULL, 'YES', 'Treatment of amoebiasis; investigational anti-infective available from the CDC by special request', '3-Dehydroemetine Hydrochloride , BT-436 , Mebadin , Ro-1-9334', NULL, 'DHE', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(522, 'Delavirdine Mesylate', NULL, NULL, 'YES', 'Antiviral agent, HIV reverse transcriptase inhibitor. Not found in Drugdex drug evaluation.', 'Piperazine , Rescriptor , U-90152-S', NULL, NULL, NULL, 'AIDS drug', NULL),
(523, 'Delmadinone Acetate', NULL, NULL, 'NO', 'A veterinary progestin, antiandrogen, and antiestrogen; administered to male cats and dogs to control hypersexuality and other aggressive behavior and to treat prostatic hypertrophy and tumors, and to female cats as an estrus suppressant.  Not found in Drugdex drug evaluation.', 'RS 1301 , RS-1301 , RS1301', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'anti-androgen;anti-estrogen.  Probably not cancer directed--verify with attending MD.;Progestin'),
(524, 'Demecolcine', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.', 'Colcemid', NULL, NULL, NULL, 'Chemotherapy', 'Antimitotic'),
(525, 'Dendritic cell-P53', NULL, NULL, 'NO', 'Phase II Information from NCI', 'Augologous dendritic cell adenovirus P53 vaccine', 'Small cell lung', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(526, 'Dendritic Cell/Tumor Cell Electrofusion Cancer Vaccine', NULL, NULL, 'NO', 'Phase I/II Vaccine. Genzyme Molecular Oncology.', NULL, 'Breast, kidney cancer, melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(527, 'Denileukin Diftitox', NULL, NULL, 'NO', 'Phase II CLL, NHL B-cell An interleukin-2 receptor-specific fusion protein.  FDA approved orphan drug for cutaneous T-cell lymphoma. Seragen, Elan Pharmaceuticals, Ligand Pharmaceuticals.', 'DAB-389 IL-2 , Interleukin-2 fusion protein , Interleukin-2 fusion toxin , LY 335348 , LY-335348 , LY335348 , Ontak', 'Leukemia, lymphoma', NULL, '714744', 'Biologic therapy (BRM, immunotherapy)', NULL),
(528, 'Denosumab', NULL, NULL, 'SEE_REMARKS', 'IMPORTANT CODING NOTE (JULY 12, 2013): This drug was approved by the FDA on June 13, 2013 to treat unresectable giant cell tumors of the bone in both adults and skeletally mature adolescents. If this drug is being prescribed to treat this type of tumor, code as BRM/Immunotherapy. For all other conditions listed in the November release information below, do not code, the drug is considered ancillary. \r\n\r\nNovember 18, 2010: Received FDA approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors.', 'Prolia , Xgeva', 'Bone metastases', NULL, NULL, 'Ancillary Agent;Biologic therapy (BRM, immunotherapy)', 'PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD;Prevents bone resorption--do not code;RANKL inhibitor'),
(529, 'DENSPM', NULL, NULL, 'NO', 'Phase II, Phase I pancreatic, phase I/II melanoma Polyamine analog. Pfizer, GelTex Pharamceuticals.', 'CI 1006 , CI-1006 , CI1006', 'Breast, colorectal, kidney, leukemia, lung, ovarian, pancreatic, skin cancer', NULL, NULL, 'Chemotherapy', 'Antimitotic'),
(530, 'Deoxycortone Acetate', NULL, NULL, 'NO', 'Used for adrenal insufficiency.  Not found in Drugdex drug evaluation.', '11-Deoxycorticosterone Acetate , Cortin , Decortone Acetate , Desoxycorticosterone Acetate , Desoxycortone Acetate , Desoxyn', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Corticosteroid.  Probably not cancer directed--verify with attending MD.'),
(531, 'Deoxycortone Pivalate', NULL, NULL, 'NO', 'A corticosteroid. Not found in Drugdex drug evaluation.', 'Deoxycorticosterone Pivalate , Deoxycorticosterone Trimethylacetate , Deoxycortone Trimethylacetate , Desoxycortone Pivalate', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Corticosteroid.  Probably not cancer directed--verify with attending MD.'),
(532, 'Deoxydoxorubicin HCI', NULL, NULL, 'NO', NULL, 'Esorubicin HCl , I-Dox , IMI 58 , IMI-58 , IMI58', NULL, '4-DxDx, DxDx', '267469', 'Chemotherapy', 'Antibiotic'),
(533, 'Deoxynojirimycin', NULL, NULL, 'YES', 'Undergoing phase II studies for treating ARC and AIDS; protein N-glycosylation inhibitor', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(534, 'Depsipeptide', NULL, NULL, 'NO', 'June 17, 2011: The FDA granted accelerated approval for an additional indication for Istodax (romidepsin) for treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. Istodax is also approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.\r\nPhase II (lung). Phase III, STS, H&N.  Phase I thyroid\r\nHistone deacetylase inhibitor. NCI, Fujisawa Pharmaceuticals.', 'FK 228 , FK-228 , FK228 , FR 901228 , FR-901228 , FR901228 , Istodax , Romidepsin', 'H&N, Lung cancer, lymphoma, soft tissue sarcoma, T cell lymphoma, thyroid', NULL, '630176', 'Chemotherapy', 'Natural product--microorganism toxin'),
(535, 'Descinolone Acetonide', NULL, NULL, 'NO', 'Glucocorticoid.  The 17-benzoate ester of betamethasone, having the same actions as the base; used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.  No longer in use.', '071 , CI 27071 , CI27071 , Cl-27', NULL, NULL, '44827', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(536, 'Desmethyl-misonidazole', NULL, NULL, 'YES', 'Radiosensitizer', 'Ro 59963 , Ro-5-9963 , Ro59963 , SR 1530 , SR-1530 , SR1530', NULL, 'DES-ME', '261036', 'Ancillary Agent', NULL),
(537, 'Desoxycortico-sterone Acetate', NULL, NULL, 'NO', 'Adrenocortical steroid.  Used as replacement therapy to treat adrenocortical insufficiency.', 'Cortate acetate , Decortin , Decost-erone , Decostrate# , Doca acetate# , Dorcostrin# , Percorten acetate# , Percotol , Primocort , Primocortan , Syncort', NULL, 'DCA, DOCA, DOXO', '9567', 'Hormones and hormonal mechanisms', 'Adrenocortical steroid.  Probably not cancer directed--verify with attending MD.'),
(538, 'Desoxycorticosterone Pivalate', NULL, NULL, 'NO', 'Adrenocortical steroid.  Used as replacement therapy to treat adrenocortical insufficiency.', NULL, NULL, NULL, '95278', 'Hormones and hormonal mechanisms', 'Adrenocortical steroid.  Probably not cancer directed--verify with attending MD.'),
(539, 'Detorubicin', NULL, NULL, 'NO', NULL, NULL, NULL, 'DTR', NULL, 'Chemotherapy', 'Anthracycline antibiotic'),
(540, 'Detox', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(541, 'Dexamethasone', NULL, NULL, 'SEE_REMARKS', 'NOTE* Dexamethosine may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy.\r\n\r\nA long-acting corticosteroid (glucocorticoid).  In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy.  25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy.   Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.', 'Aeroseb-Dex , AK-Dex , AK-Trol , Baldex , Component of Deronil , Component of Dexacidin , Component of Maxitrol , Dalalone , Decaderm , Decadrol , Decadron Tablets , Decajet , Decameth , Decasone , Decaspray , Deenar , Dex-4 , Dexacen , Dexacidin , Dexacort Phosphate , Dexameth , Dexasone , Dexasporin , Dexone , Dexsone , Dezone , Gammacorten , Hexadrol , Hexadrol Elixir , Hexadrol Tablets , Infectrol Sterile , Maxidex , Maxitrol , Miral , Mymethasone , Neo-Dexameth , Neodecadron , Neodexair , Ocu-Trol , Oradexon , PMS-Dexamethasone Sodium Phosphate , SK-Dexamethasone , Sofracort , Sofradex , Solurex , Spersadex , Sterile Dexamethasone Acetate , Tobradex , Turbinare Decaron Phosphate', NULL, 'DECA, DM, DSM', '345211', 'Ancillary Agent;Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(542, 'Dexamethasone Acetate', NULL, NULL, 'SEE_REMARKS', 'Adrenocortical steroid. In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy.  An ester of dexamethasone, having actions similar to those of the base and used in replacement therapy in adrenal insufficiency and as an anti-inflammatory and immunosuppressant; administered by intra-arterial, intramuscular, intralesional, or soft-tissue injection. Dexamethasone and other corticosteroids may be used to suppress white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.', 'Dalalone D.P. , Dalalone L.A. , Decadron-LA', NULL, 'DXM', NULL, 'Ancillary Agent;Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(543, 'Dexamethasone Dipropionate', NULL, NULL, 'NO', 'Adrenaocortical steroid.  In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy.  An ester of dexamethasone, having actions and uses similar to those of the base; administered by intra-articular, soft tissue, intravenous, or intramuscular injection, by inhalation, or applied topically to the skin and conjunctiva.  Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.', 'ST 12', NULL, NULL, NULL, 'Ancillary Agent;Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(544, 'Dexamethasone Sodium Phosphate', NULL, NULL, 'SEE_REMARKS', 'Glucocorticoid. In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy.  An ester of dexamethasone, having actions and uses similar to those of the base; administered by intra-articular, soft tissue, intravenous, or intramuscular injection, by inhalation, or applied topically to the skin and conjunctiva.   Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.', 'Component of NeoDecadron , Dalalone , Hexadrol', NULL, NULL, NULL, 'Ancillary Agent;Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(545, 'Dexormaplatin', NULL, NULL, 'NO', NULL, '938 , U 78938 , U-78 , U78938', NULL, NULL, NULL, 'Chemotherapy', 'Miscellaneous agent'),
(546, 'Dexrazoxane', NULL, NULL, 'YES', 'A cardioprotective agent, may have synergistic activity when given with other antineoplastic drugs. FDA approved for reducing cardiomyopathy related doxorubicin.  Little if any antitumor effect in multiple studies of various cancers.', 'ADR-529 , ICRF-187 , Zinecard', NULL, NULL, '169780', 'Ancillary Agent', 'Cardioprotectant'),
(547, 'Dextran Sulfate', NULL, NULL, 'YES', NULL, 'aerosolized) , Dextran , Dextran sulfate (inhaled , hydrogen sulfate , Uendex', NULL, NULL, '620255', 'AIDS drug', NULL),
(548, 'Dianhydrodulcitol', NULL, NULL, 'NO', 'Miscellaneous agent', 'Dianhydrogalactitol , Galactitol', NULL, 'DAG', '132313', 'Chemotherapy', 'Miscellaneous agent'),
(549, 'Dianoxide Furoate', NULL, NULL, 'YES', 'Antibiotic; Rx of amebiasis', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(550, 'Diaziquone', NULL, NULL, 'NO', 'Phase III Quinone derivative; Intravenous diaziquone has produced objective responses in some patients with brain tumors and head and neck cancer; high response rates have been seen with continuous infusions in acute myelogenous (nonlymphocytic) leukemia, although hematologic toxicity is severe. The drug has been effective intrathecally in meningeal malignancies. However, the overall role of diaziquone in cancer chemo is limited. Ilex Oncology.', 'Aziridinylbenzoquinone , CI 904 , CI-904 , CI904', 'Bladder, brain, skin cancer', 'AZQ', '182986', 'Chemotherapy', 'Alkylating agent'),
(551, 'diazooxonorleucine', NULL, NULL, 'NO', 'Phase II melanoma Dekk-Tec.', NULL, 'Skin cancer', NULL, NULL, 'Chemotherapy', 'Antiviral'),
(552, 'Dibromodulcitol', NULL, NULL, 'NO', 'Miscellaneous agent', 'Dibromdulcit , Elobromol , Mitolac , Mitolactol', NULL, 'DBD', '104800', 'Chemotherapy', 'Miscellaneous agent'),
(553, 'Dibromomannitol', NULL, NULL, 'NO', 'Alkylating agent; Not found in Drugdex drug evaluation.', 'Dibromannit , Mielobromol , Mitobron-itol , Myebrol , Myelobromol , R-54 , R54 , WR 220057 , WR-220057 , WR220057', NULL, 'DBM', '094100;94100', 'Chemotherapy', 'Alkylating agent'),
(554, 'Dichloroallyl  lawsone', NULL, NULL, 'NO', NULL, 'dichlorallyl- , Dichloroallyl lawsone , Dichloroallyl lawsone (DCL) , Dichloroallyllawsone , Dichlorolapachol , Dichlorolawsone , Lawsone', NULL, 'DCL', '126771', 'Chemotherapy', 'Antimetabolite'),
(555, 'Dichloromethotrexate', NULL, NULL, 'NO', NULL, 'DichloroMethotrexate', NULL, 'DCM, DCMTX', '29630', 'Chemotherapy', 'Antimetabolite;enzyme inhibitor'),
(556, 'Didanosine', NULL, NULL, 'NO', 'A purine nucleoside analogue with antiviral activity.', 'BMY 40900 , BMY-40900 , BMY40900 , DDI , Dideoxyinosine , Videx', NULL, 'ddl', '612049', 'AIDS drug', 'Antiviral'),
(557, 'Didemnin B', NULL, NULL, 'NO', 'Biologically active peptides extracted from a marine sea squirt of the genus Trididemnum, investigated as an antineoplastic. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, '325319', 'Chemotherapy', 'Antineoplastic with high toxicity'),
(558, 'Dideoxyadenosine', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation.', 'ddAdo', NULL, 'ddA', '98700', 'AIDS drug', NULL),
(559, 'Dideoxycytidine', NULL, NULL, 'YES', NULL, 'HIVID , Ro 24-2027 , Ro 242027 , Ro242027 , Zalcitabine', NULL, 'ddC', '606170', 'AIDS drug', NULL),
(560, 'Dienestrol', NULL, NULL, 'NO', 'A synthetic nonsteroidal estrogen structurally related to diethylstilbestrol.  A synthetic estrogen, administered orally in the management of menopausal symptoms, in the treatment of functional uterine bleeding, as a postpartum antigalactagogue, for palliative therapy in certain female breast cancers, and in the management of prostatic carcinoma.', 'Component of Estan# , Dehydrostilbestrol , Dienoestrol , Ortho Dienestrol , Synestrol#', 'Breast, prostate cancers', 'DV', '59809', 'Hormones and hormonal mechanisms', 'Estrogen'),
(561, 'Diethyldithiocarbamate', NULL, NULL, 'YES', 'An immunomodulating drug that has been investigated in HIV infection. It is also a chelator that has been used in the destruction of cisplatin wastes and has been suggested for use in nickel carbonyl poisoning. Not found in Drugdex drug evaluation.', 'Cuprol , Dithiocarb , Ditiocarb Sodium , Imuthiol , Thiocarb', NULL, 'DDC, DDTC, DEDC, DTC', '38583', 'Ancillary Agent', NULL),
(562, 'Diethylstilbestrol', NULL, NULL, 'NO', 'A nonsteroidal, synthetic stilbene derivative with estrogenic activity. FDA approved for advanced prostate carcinoma.', 'Acnestrol , Honvol , Stilbestrol#', 'Various cancers including prostate cancer', 'DES', '3070', 'Hormones and hormonal mechanisms', 'Estrogen'),
(563, 'Diethylstilbestrol Diphosphate', NULL, NULL, 'NO', 'Estrogen', 'Fosfestrol , Stilphostrol#', NULL, NULL, '10481', 'Hormones and hormonal mechanisms', 'Estrogen'),
(564, 'Diethylstilbestrol Dipropionate', NULL, NULL, 'NO', 'Estrogen', 'Dibestil#', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen'),
(565, 'Diethylstilbestrol NCO', NULL, NULL, 'NO', 'Estrogen', 'Bio-Des , Comestrol , Cyren A , Di-Estryl , Domestrol , Estilbin , Estrobene , Etrosyn , Fonatol , Graf-estrol , Hi-Bestrol , Nicroest , Nilestrol , Oestrogenine , Serral , Sexocretin , Sibol , Stil-betin# , Stil-Rol , Stilbestrol , Stilboestroform , Stilkap , Synth-oestrin , Syntofolin , Vagestrol#', NULL, 'DEB, DES', '3070', 'Hormones and hormonal mechanisms', 'Estrogen'),
(566, 'Diflucortolone', NULL, NULL, 'NO', 'A potent fluorinated topical corticosteroid; glucocorticoid.  A synthetic corticosteroid used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'Nerisone', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(567, 'Diflucortolone Pivalate', NULL, NULL, 'NO', 'Glucocorticoid.  A synthetic corticosteroid used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'SH 968 , SH-968 , SH968', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(568, 'Diglycolaldehyde', NULL, NULL, 'NO', NULL, 'Inosine dialdehyde , Wy 5321 , Wy-5321 , Wy5321', NULL, 'IdASTGDR, INOX', '118994', 'Chemotherapy', 'Antimetabolite'),
(569, 'Dihydroazacytidine', NULL, NULL, 'NO', NULL, 'Dihydro-5-azacytidine , H5AC HCl', NULL, '5-ACH, DHAC', '264880', 'Chemotherapy', 'Antimetabolite'),
(570, 'Dihydrolenperone', NULL, NULL, 'NO', NULL, 'Dihydro-lenperone', NULL, NULL, '343513', 'Chemotherapy', 'Unclassified antineoplastic'),
(571, 'Diltiazim Hydrochloride', NULL, NULL, 'YES', 'Calcium channel blocker, vasodilator. Effective in the treatment of angina pectoris due to coronary artery spasm and chronic stable angina pectoris, and to treat hypertension; diltiazem may be able to prevent coronary artery restenosis in heart transplant patients; diltiazem can decrease the frequency of PVCs associated with hypertensive left ventricular hypertrophy.', 'Apo-Diltiaz , Cardizem , Cartia , Dilacor , Novo-Diltazem , Nu-Diltiaz , Tiazac', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(572, 'Dimepranol Acedoben', NULL, NULL, 'YES', 'Immunomodulator; Component of Isoprinosine', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(573, 'Dimericine', NULL, NULL, 'YES', 'Phase III Repairs DNA damage in skin cells. AGI Dermatics.', NULL, 'Skin cancer', NULL, NULL, 'Ancillary Agent', NULL),
(574, 'Dimethyl sulfoxide', NULL, NULL, 'YES', NULL, 'Demasorb# , Demavet , Demeso , Demsodrox , Dermasorb , Dimexide , DMS-70 , DMS-90 , Dolicur , Dolisur , Domoso , Dromisol , Durasorb , Gamasol 90 , Hyadur , Infiltrin Methyl sulfoxide , Kemsol , Methyl sulphoxide , Rimso , Somipront , SQ 9453 , SQ-9453 , Sulfinylbismethane , Sulphinylbismethane , Syntexan', NULL, 'DMSO', '763;000763', 'Differentiation inducing agent', NULL),
(575, 'Dimethylbusulfan', NULL, NULL, 'NO', NULL, 'Dimethylmyleran', NULL, NULL, NULL, 'Chemotherapy', 'Alkylating agent'),
(576, 'Dinitrochlorobenzene', NULL, NULL, 'NO', 'Immunostimulant for AIDS patients.', '2 , 4-Dinitroclorobenceno', NULL, 'DNCB', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(577, 'Dinitrofluorobenzene', NULL, NULL, 'NO', NULL, NULL, NULL, 'DNFB', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(578, 'Diphenhydramine Hydrochloride', NULL, NULL, 'YES', 'Antihistamine, ethanolamine. One of the most widely used parenteral antihistamines for the treatment of anaphylaxis and severe allergic reactions.', 'Allerdryl , Allermax , Allernix , Anti-Itch , Banaril , Beldin , Belix , Benadryl , Benahist , Benaphen , Benoject , Caladryl , Component of Benylin , Compoz , Dermamycin , Dibenil , Diphen , Diphenacen , Diphenadryl , Diphenhist , Diphenylin , Dramaject , Fenylhist , Gen-D-Phen , Genahist , Hydramine , Hyrexin , Insomnal , Kendiphen , Lensen , Miles Nervine , Niramine , Nordryl , Nytol , Phenamin , PMS-Diphenhydramine , Scheinpharm Diphenhydramine , Sleep-ettes-D , Sleep-eze , Sleepwell 2-Nite , Sominex , Twilite , Unisom', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(579, 'Diphenidol Hydrochloride', NULL, NULL, 'YES', 'Diphenidol may be used to treat nausea and vomiting or vertigo. Because of its toxicity and lack of therapeutic advantage over other agents, diphenidol should not be carried on the hospital formulary. Anti-emetic', 'Difenidol , SKF 478 , SKF-478 , SKF478 , Vontrol', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(580, 'Dipyridamole', NULL, NULL, 'YES', 'A phosphodiesterase inhibitor which inhibits platelet aggregation. Although widely used, there is little evidence of the effectiveness of Dipyridamole and the emerging consensus does not support its use as an antithrombotic drug.', 'Apo-Dipyridamole , Dipridacot , Novo-Dipiradol , Persantine , Ra 8 , SK-Dipyridamol', NULL, NULL, '515776', 'Ancillary Agent', NULL),
(581, 'Disulfiram', NULL, NULL, 'YES', 'A thiuram derivative that interferes with aldehyde dehydrogenase.', 'Antabuse', NULL, NULL, NULL, 'AIDS drug', NULL),
(582, 'Docetaxel', NULL, NULL, 'NO', 'FDA approved for use on breast, prostate, stomach and NSCLC. Aventis Pharmaceuticals.', 'LIT-976 , RP-56976 , Taxotere', 'Breast, gastric, head & neck, non-small cell lung, ovarian, prostate cancer', NULL, '628503', 'Chemotherapy', 'Taxane'),
(583, 'Dolasetron Mesylate', NULL, NULL, 'YES', 'Antiemetic. Serotonin antagonist.', 'Anzemet , Hydrodolasetron , MDL-73147EF', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(584, 'Dolastatin 10', NULL, NULL, 'NO', 'Phase I/II (breast, kidney, leukemia) Phase II pancreatic Antimitotic pentapeptide. NCI.', NULL, 'Breast, kidney, leukemia, pancreatic cancer', NULL, '376128', 'Chemotherapy', 'Antimototic agent'),
(585, 'Domperidone', NULL, NULL, 'YES', 'A peripheral dopamine antagonist. Domperidone is used as an antiemetic and to treat postprandial dyspepsia.', 'Dom-Domperidone , Motilum , R-33812', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(586, 'DON', NULL, NULL, 'NO', 'Teratogenic', NULL, NULL, NULL, '7365', 'Chemotherapy', 'Miscellaneous agent'),
(587, 'Doxercalciferol', NULL, NULL, 'NO', 'Phase II Vitamin D. Bone Care International.', 'Hectorol', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Parathyroid hormone antagonist'),
(588, 'Doxorubicin', NULL, NULL, 'NO', 'Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm\'s tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic', '14-hydroxy-daunomycin , Adri-blastina (Italy) , Adriamycin , Adriamycin-TM , Caelyx , FT-106 , Hydroxydaunomycin , Myocet , Pegylated Liposomal Doxorubicin Hcl , Rubex , S-DOX , Stealth(R) Liposomal Doxorubicin', 'Bladder, breast, liver, multiple myeloma, ovarian, pancreatic, prostate cancer', 'ADM, ADR, ADRI', '123127', 'Chemotherapy', 'Antitumor antibiotic'),
(589, 'Doxorubicin, liposome-encapsulated', NULL, NULL, 'NO', 'DOXIL Injection received FDA approval February 4, 2013 for the treatment of ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy and also for AIDS-related Kaposi\'s sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy.\r\nFeb. 2015: FDA granted Orphan Drug Designation to liposomal doxorubicin for the treatment of Ewing\'s sarcoma, a rare cancer that develops in or around children\'s bones.', 'Doxil , Doxil injection , Evacet , LipoDox , Liposomal Doxorubicin , MCC-465 , Probenecid , TLC-Dox 99 , Urocidin', NULL, NULL, '712227, 620212', 'Chemotherapy', 'Antitumor antibiotic'),
(590, 'Doxorubicin-DNA complex', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(591, 'Dromostanolone Propionate', NULL, NULL, 'NO', 'An androgenic, anabolic steroid, used as an antineoplastic agent in the palliative treatment of advanced metastatic, inoperable breast cancer in certain postmenopausal women; administered intramuscularly.', '32379 , Compound 32379 , Drolban# , Drostanolone propionate , Emdisterone , Masterid , Masteril , Masterone , Nedrotestron propionate , Permastril', 'Breast cancer', 'NDHT', '12198', 'Hormones and hormonal mechanisms', 'Anabolic steroid'),
(592, 'Droperidol', NULL, NULL, 'YES', 'Droperidol is useful to produce tranquilization and to reduce the nausea and vomiting in surgical and diagnostic procedures. It is also used for premedication, induction, and as an adjunct in the maintenance of general and regional anesthesia.', 'Component of Innovar , Inapsine , MCN-JR-4749 , R-4749', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(593, 'DTI015', NULL, NULL, 'NO', 'Phase I/II Carmustine/BCNU for intratumoral (anti-neoplastic) injection. Direct Therapeutics.', 'BCNU/ethanol intratumoral injection , Carmustine in ethanol solvent , DTI 015 , DTI-015', 'Brain, kidney, liver cancer', NULL, NULL, 'Chemotherapy', 'Alkylating agent'),
(594, 'Duazomycin', NULL, NULL, 'NO', 'Teratogenic', 'A 10270A , Diazomycin A', NULL, NULL, '51097', 'Chemotherapy', 'Teratogenic--not in use'),
(595, 'Duborimycin', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Anthracycline antibiotic'),
(596, 'Durvalumab', NULL, 'Urothelial carcinoma, NSCLC', 'NO', 'May 1, 2017: FDA granted accelerated approval to durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.\r\n\r\nFeb 16, 2018 The FDA has approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).', 'IMFINZI', 'Bladder, Lung', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(597, 'Duvelisib', NULL, 'CLL', 'NO', 'September 24, 2018: FDA granted regular approval to duvelisib (COPIKTRA) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.', 'Copiktra', NULL, NULL, NULL, 'Chemotherapy', 'Small moleculr inhibitor'),
(598, 'Dydrogesterone', NULL, NULL, 'NO', 'Progestin.  Used mainly in the diagnosis and treatment of primary amenorrhea and severe dysmenorrhea, and in combination with estrogen in dysfunctional menorrhagia.   Not found in Drugdex drug evaluation.', 'Dehydroprogesterone , Didrogesteron , Diphaston , Dufaston , Duphaston , Duvaron , Gestatron , Hydrogesterone , Isopregnenone , Prodel , Retrone , Terolut', NULL, NULL, '92336;092336', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(599, 'E7070', NULL, NULL, 'NO', 'Phase II colorectal, head & neck Phase II NSCLC Disulphonamide. Eisai.', NULL, 'Colorectal cancer, head & neck, lung cancer', NULL, NULL, 'Chemotherapy', 'Antibiotic'),
(600, 'E7389', NULL, NULL, 'NO', 'Phase II many indications 2007 Eisai, NCI.', 'E 7389 , E-7389', 'advanced solit tumors, Breast, H&N, prostate', NULL, '707389', 'Chemotherapy', 'Vinca alkaloid'),
(601, 'EC-2101 Therapeutic, Multi-epitope Vaccine', NULL, NULL, 'NO', 'Phase I/II Epimmune.', NULL, 'Colon, lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(602, 'Echinomycin', NULL, NULL, 'NO', NULL, 'Echinomycin , Echinomycin A , Levomycin , Quinomycin A (9CI) , S-426-S (Lepetit)', NULL, NULL, '526417', 'Chemotherapy', 'Antitumor antibiotic'),
(603, 'Econazole (Econazole Nitrate)', NULL, NULL, 'YES', 'A topical imidazole antimycotic (antifungal) drug. The place in therapy of Econazole cannot be clearly stated at this time.', 'Ecostatin , Pevaryl , R 14827 , R-14827 , R14827 , Spectazol , SQ 13050 , SQ-13050 , SQ13050', NULL, NULL, NULL, 'AIDS drug', NULL),
(604, 'Edatrexate', NULL, NULL, 'NO', 'In clinical trials, EDATREXATE alone has been active in non-small cell lung cancer, advanced breast cancer, head and neck cancer, soft tissue sarcoma (malignant fibrous histiocytoma), and non-Hodgkin\'s lymphoma (diffuse histiocytic lymphoma).', '10-EdAM , CG 30694 , CGP-30694 , CGP30693 , EDAM-10 , EDAM10', NULL, NULL, '626715', 'Chemotherapy', 'Antimetabolite'),
(605, 'Edobacomab', NULL, NULL, 'NO', 'An immune globulin directed against gram-negative bacterial endotoxins.', 'XMMEN-OE5', NULL, 'E5', NULL, 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(606, 'Edotecarin', NULL, NULL, 'NO', 'Phase I Pfizer.', NULL, 'Leukemia, other cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(607, 'Edrecolomab', NULL, NULL, 'NO', 'Phase III\r\nIn clinical trials as antineoplastic agent.  Also used to detect colon cancer cells.  DETERMINE HOW DRUG IS USED AND CODE CATEGORY ACCORDINGLY.  A murine monoclonal antibody obtained from a fusion of BALB/c mouse cells and targeted at human colorectal tumor cells.', 'Mab 17-1A , Monoclonal antibody 17-1A , Monoclonal antibody CO17-1A , Panorex', 'Colorectal cancer', NULL, '377963', 'Chemotherapy', 'Targeted therapy'),
(608, 'EF-5', NULL, NULL, 'YES', 'Phase I Hypoxia detector. Etanidazole derivative. NCI.', 'EF5 , Etanidazole-F5', 'Breast, Cervical, Lung, Prostate cancer', NULL, '684681', 'Ancillary Agent', 'Used to detect oxygen levels in tumors'),
(609, 'Eflornithine', NULL, NULL, 'NO', 'Phase III A specific and irreversible inhibitor of the enzyme ornithine decarboxylase.Rx of Pneumocystis pneumonia carinii. ILEX Oncology.  Vaniqa inhibits facial hair growth.  Not a promising antitumor agent by itself, but may be effective as an adjunctive cytoinhibitory agent in select antineoplastic treatment regimens.', 'Alpha-DFMO HCl , alpha-Difluoromethylornithine , Alpha-Difluoromethylornithine Hydrochloride , DFMO , Difluoromethylornithine , Eflornithine Hcl , eflornithine hydrochloride , Eflornithine Monohydrochloride , MDL-71782 , MDL-71782A , Monohydrate , Ornidyl , RMI 71782 , Vaniqa', 'Bladder, brain (glioblastoma), childhood leukemia, CML, skin cancer', 'DFMO (HCl)', '337250', 'Chemotherapy', 'Miscellaneous agent'),
(610, 'EG009', NULL, NULL, 'NO', 'Phase II Gene therapy. Ark Therapeutics.', 'EG 009 , EG-009', 'Brain cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(611, 'Egf Cancer Vaccine', NULL, NULL, 'NO', 'Phase II NSCLC YM Bioscience.', NULL, 'Lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(612, 'EKB-569', NULL, NULL, 'NO', 'Phase I Epidermal growth factor receptor inhibitor. Wyeth Pharmaceuticals.', 'EKB 569 , EKB569', 'Other cancer', NULL, '729742', 'Chemotherapy', 'Cytostatic agent--EGFR inhibitor'),
(613, 'Eligard', NULL, NULL, 'NO', 'December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy. \r\n\r\nLupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.\r\n\r\nFOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment', 'Lupron , Leuprolide Acetate', 'Prostate cancer, Breast', NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH'),
(614, 'Elinafide', NULL, NULL, 'NO', 'Phase I DNA binding compound. ILEX Oncology.', 'LU 79553 , LU-79553 , LU79553', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(615, 'Elliott\'s B Solution', NULL, NULL, 'YES', 'FDA approved diluent for intrathecal therapy for leukemia and lymphoma.  Active Ingredient: Sodium chloride 730 mg; sodium bicarbonate 190 mg; glucose monohydrate 80 mg; magnesium sulfate heptahydrate 30 mg; potassium chloride 30 mg; calcium chloride dihydrate 20 mg; dibasic sodium phosphate heptahydrate 20 mg; phenolsulphonphthalein 10 micrograms; water to 100 mL', NULL, NULL, NULL, '614386', 'Ancillary Agent', 'Artificial cerebrospinal fluid'),
(616, 'Elotuzumab', NULL, 'Multiple myeloma', 'NO', 'November 30, 2015: FDA granted approval for Empliciti (elotuzumumab) in combination with two other therapies to treat patients with multiple myeloma who have received one to three prior medications.  It is approved in combination with other FDA-approved treatment for multiple myeloma called Revlimid (lenalidomide) and dexamethasone.', 'Empliciti , PDL063', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(617, 'Elsamitucin', NULL, NULL, 'NO', 'Phase II NHL A heterocyclic antitumor antibiotic related to chartreusin. Spectrum Pharmaceuticals, NeoTherapeutics.', 'BBM-2478A , BBM2478A , BMY 28090 , BMY-28090 , BMY28090', 'Lymphoma', NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(618, 'Eltrombopag', NULL, NULL, 'YES', 'Stimulates platelet (thrombocyte) recovery.  Glaxo Smith Kline.', 'Promacta , SB 497115 , SB-497115 , SB497115', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(619, 'EMD121974', NULL, NULL, 'NO', 'Phase I/II Anti-angiogenic. Merck KGaA, NCI.', 'Cilengitide , EMD 121974 , EMD-121974', 'Brain, other cancer, skin', NULL, '707544', 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(620, 'Emetine (Hydrochloride)', NULL, NULL, 'YES', 'A direct-acting amebicide.', 'Emetin , Emetine Dihydrochloride , Emetine Hydrochloride , Emetine monohydrochloride , Heptahydrate , Homofolic acid , Ipecine Hydrochloride', NULL, 'EMET', '33669', 'AIDS drug', NULL),
(621, 'EMLA Cream (lidocaine 2.5% and prilocaine 2.5%)', NULL, NULL, 'YES', 'Local anesthetics. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(622, 'Emofolin', NULL, NULL, 'NO', NULL, 'Emfolin sodium', NULL, 'MeTHHF', '139490', 'Chemotherapy', 'Folate antagonist'),
(623, 'Encorafenib', NULL, 'Melanoma', 'NO', 'June 27, 2018: FDA approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI) in  combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.', 'BRAFTOVI , LGX818', NULL, NULL, NULL, 'Chemotherapy', 'RAF Kinase Inhibitor'),
(624, 'Endorphin', NULL, NULL, 'YES', 'Pain control (Analgesic). Not found in Drugdex drug evaluation.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(625, 'Endostatin', NULL, NULL, 'NO', 'Phase I colorectal Phase II melanoma, other Anti-angiogenic. EntreMed.', NULL, 'Colorectal, other cancer, skin', NULL, '704805', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--antiangiogenesis agent'),
(626, 'Enfortumab vedotin', NULL, NULL, 'NO', 'March 30, 2018: FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors.', NULL, 'Bladder', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Antibody-drug conjugate'),
(627, 'Enhanzyn', NULL, NULL, 'NO', 'Phase III Vaccine. Corixa.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(628, 'Eniluracil', NULL, NULL, 'NO', 'Phase III Dihydropyrimidine dehydrogenase (DPD) inhibitor. Chemotoxic agent enhancer. It has been investigated as an adjunct to fluorouracil therapy in the treatment of colorectal, breast, and pancreatic cancer. GlaxoSmithKline.', '5-Ethynyluracil , 5-EU , 776C85 , GW-776C85', 'Breast cancer', NULL, '687296', 'Chemotherapy', 'Antimetabolite'),
(629, 'Enlimomab is', NULL, NULL, 'NO', 'An anti-ICAM-1 (intercellular adhesion molecule-1) murine monoclonal antibody.NO indications for cancer', 'Anti-ICAM-1 monoclonal antibody , BI-RR-0001 , BIRR 0001 , BIRR1 , Murine anti-CD54 monoclonal antibody , Murine anti-ICAM-1 monoclonal antibody , R6 5 D6 , R6.5 , RR1', 'colon', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monocolonalNo indications for cancer'),
(630, 'ENMD 0995', NULL, NULL, 'NO', 'Phase I Celgene.', NULL, 'Lymphoma, Multiple myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(631, 'Enpromate', NULL, NULL, 'NO', 'Lilly', '59156 , empromate', NULL, NULL, '112682', 'Chemotherapy', NULL),
(632, 'Enzalutamide', NULL, NULL, 'NO', 'December 16, 2019 FDA approved enzalutamide (XTANDI) for patients with metastatic castration-sensitive prostate cancer (mCSPC).\r\n\r\nMDV3100 received FDA approval to treat prostate cancer on August 31, 2012. It is an androgen receptor antagonist drug developed for the treatment of castration-resistant prostate cancer.', 'MDV3100 , Xtandi', 'Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen receptor'),
(633, 'Enzastaurin', NULL, NULL, 'NO', 'Phase II prostate 2007 Protein kinase C inhibitor and angiogenesis inhibitor. Lilly.', 'Enzastaurin Hcl , Enzastaurin hydrochloride , LY317615', 'Brain, lymphoma, prostate', NULL, NULL, 'Chemotherapy', 'Antiangiogenic agent'),
(634, 'Epipropidine', NULL, NULL, 'NO', NULL, 'Eponate , Epoxypropidin , LY 28002', NULL, NULL, '56308', 'Chemotherapy', NULL),
(635, 'Epirubicin', NULL, NULL, 'NO', 'FDA approved breast carcinoma adjuvant therapy.', '4\'-Epiadriamycin Hydrochloride , 4\'-Epidoxorubicin , 4-EA , Ellence , Epidoxorubicin , Epidoxorubicin Hydrochloride , Epirubicin Hydrochloride , IMI-28 , Pharmorubicin , Pidorubicin Hydrochloride', 'Breast cancer, Metastatic breast cancer, Gastric cancer', 'EPI, epi-ADR', '256942', 'Chemotherapy', 'Anthracycline;Antitumor antibiotic'),
(636, 'Epithilone D', NULL, NULL, 'NO', 'Phase I Polypeptide. Kosan BioSciences.  Roche', 'KOS 862 , KOS-862 , KOS862 , R 1492 , R-1492 , R1492', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimitotic agent'),
(637, 'Epoetin Alfa', NULL, NULL, 'YES', 'Epoetin alfa is a synthetic form of erythropoietin. Erythropoietin is a glycoprotein normally produced in the kidneys and is responsible for the stimulation of red blood cell production', 'Epogen , Eprex , Glycoform alpha , Human 1-165-erythropoietin , Procrit', NULL, NULL, NULL, 'AIDS drug;Ancillary Agent', 'Ancillary'),
(638, 'Epothilone', NULL, NULL, 'NO', 'Phase I/II, breast.  Phase III colorectal, other. Phase I pancreatic Epothilone analog.  Tubulin polymerizing agent. Non-taxane microtubule stabilizer. Antiproliferative agent. Novartis Pharmaceuticals. Bristol-Myers Squibb. NCI.', 'B/EPO906 , BMS 247550 , BMS-247550 , BMS247550 , EP 906 , Epithialone , EPO 906A , EPO906 , EPO906A , Epothilone B , Ixabepilone , Ixempra , Patupilone', 'Breast, colorectal, endometrial, other cancer, ovary, pancreatic, prostate', NULL, '710428;684363', 'Chemotherapy', 'Antimitotic agent'),
(639, 'Epratuzumab', NULL, NULL, 'NO', 'Phase I/II NHL Radiolabeled monoclonal antibody. Immunomedics.', '90Y-labeled Epratuzumab , hLL2 , LymphoCide , Y-Lymphocide', 'Lymphoma', NULL, '716711', 'Radiation', 'Radioisotope'),
(640, 'Equilin', NULL, NULL, 'NO', 'Estrogen isolated from urine of pregnant horses. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, '10971', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(641, 'ERA 923', NULL, NULL, 'NO', 'Phase II Tissue selective estrogen receptor modulator-SERM. Ligand Pharm, Wyeth Pharm.', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'SERM'),
(642, 'Erdafitinib', NULL, NULL, 'NO', 'April 12, 2019: The  FDA granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Patients should be selected for therapy with Balversa using an FDA-approved companion diagnostic device.\r\n\r\nFeb 26, 2018: FDA has granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer.', 'Balversa', 'Bladder', NULL, NULL, 'Chemotherapy', 'FGFR inhibitor'),
(643, 'Eribulin', NULL, NULL, 'NO', 'Eribulin mesylate was approved by the US FDA on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline and taxane-based chemotherapies. \r\n\r\nJanuary 28, 2016: FDA approved Halaven (eribulin) for the treatment of liposarcoma that cannot be removed by surgery (unresectable) or is advanced/metastatic. this treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.', 'B1939 , E7389 , ER-086526 , eribulin mesylate , Halaven', 'GYN, Metastatic breast, NSCLC, Pancreas, prostate, urinary sites, Soft tisse', NULL, 'NSC707389', 'Chemotherapy', 'Inhibitor of microtubular dynamics'),
(644, 'Erleada', NULL, NULL, 'NO', '9/20/2019 FDA has approved Erleada (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).\r\n\r\n\r\nFeb 14, 2018 FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-ap-proved treatment for non-metastatic, castration-resistant prostate cancer. This drug is an androgen receptor inhibitor.', 'Apalutamide', 'Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen receptor inhibitor'),
(645, 'Erlotinib', NULL, NULL, 'NO', 'July 2013 UPDATE: Tarceva received FDA approval as first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) mutations. Prior to July 2013, tarceva was approved for use in patients who had failed previous chemotherapy regimens. \r\n\r\nFDA approved for pancreas 2005, NSCLC 2004; Phase II (ovarian) Phase III (breast, head & neck)\r\nTyrosine kinase inhibitor. Epidermal growth factor inhibitor.', 'CP-358774 , Erlotinib HCl , OSI-774 , Tarceva', 'Breast, Non-small cell lung cancer (NSCLC), cervical, colorectal, gastric, head & neck, other cancer, ovarian, pancreatic', NULL, '718781', 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor;EGF inhibitor'),
(646, 'Erwinaze', NULL, NULL, 'NO', 'Erwinaze received FDA approval November 2011 for the treatment of acute lymphoblastic leukemia (ALL). The FDA has designated Erwinaze as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S.  It is manufactured by EUSA Pharmaceutical.', 'Asparaginase erwinia chrysanthemi', 'Acute lymphoblastic leukemia (ALL)', NULL, NULL, 'Chemotherapy', 'Antineoplastic agent'),
(647, 'Erythropoietin', NULL, NULL, 'YES', 'Antianemic agent. A glycoprotein normally produced in the kidneys and is responsible for the stimulation of red blood cell production; stimulates RBC production. (See BRMs)', 'Epoetin alfa , Epoetin beta , Epogen , Eprex , Eprox , glycoform beta , Procrit , rHu-EPO', 'AIDS, Opportunistic infection', 'EPO', '628281', 'Ancillary Agent', NULL),
(648, 'ESO-1:157-165 Peptide Vaccine', NULL, NULL, 'NO', 'Phase II NCI.', NULL, 'Other cancer', NULL, '717388', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(649, 'Estradiol', NULL, NULL, 'NO', 'Estrogen very rarely used for advanced ovarian and prostate cancers.', 'Alora , Aquadiol# , Beta-oestradiol , Climara , Combipatch , Component of Androgyn L.A. , Dihydrofolliculin , Dihydrotheelin , Dihydroxyoestrin , Diogyn , Diogynets , Esclim , Estrace , Estraderm , Estraderm TTS , Estring , Estrogel , Fempatch , Progynon# , Vagifem , Vivelle', NULL, NULL, '009895;9895', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(650, 'Estradiol Benzoate', NULL, NULL, 'NO', 'Estrogen ester of estradiol', 'Progynon B', NULL, NULL, '9566', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(651, 'Estradiol Cypionate', NULL, NULL, 'NO', 'Estrogen ester or estradiol', 'Component of Depo-Testadiol , DepGynogen , Depo-Estradiol', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(652, 'Estradiol Dipropionate', NULL, NULL, 'NO', 'Estrogen ester of estradiol', 'Ovocyclin dipropionate#', NULL, NULL, '3354', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(653, 'Estradiol Mustard', NULL, NULL, 'NO', 'Estrogen ester or estradiol', NULL, NULL, NULL, '112259', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(654, 'Estradiol Valerate', NULL, NULL, 'NO', 'Estrogen ester of estradiol.', 'Component of Deladumone , Component of Deluteval 2X# , Component of Ditate# , Delestrogen , Gynogen L.A.', NULL, NULL, '17590', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(655, 'Estramustine Phosphate Sodium', NULL, NULL, 'NO', 'A nitrogen mustard antineoplastic agent. Chemotoxic hormone.  An antineoplastic agent consisting of estradiol joined to nornitrogen mustard by a carbamate link, phosphorylated to make it water soluble; used for palliative treatment of metastatic or progressive carcinoma of the prostate. Single agent or combined with taxane for HRPC. FDA approved use on prostate cancer. Pharamcia.', 'Emcyt , Emcyt IV , Estracyt , Estramustine phosphate disodium , Leo 275 , Leo275 , Ro 21-8837 , Ro 21-8837/001 , Ro 218837 , Ro 22-2296/000 , Ro 222296/000 , Ro-218837', 'Prostate cancer', NULL, '089199;089201;89199', 'Chemotherapy', 'Antimicrotubule agent'),
(656, 'Estriol', NULL, NULL, 'NO', 'Estrogen.  The official preparation of the hormone, now rarely used; administered orally.', 'Theelol#', NULL, NULL, '12169', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(657, 'Estrogens, Conjugated', NULL, NULL, 'NO', 'A combination of the sodium salts of the sulfate esters of estrogenic substances.  Derived from pregnant mares\' urine or prepared synthetically from estrone and equilin; the actions and uses are those of estrogens, administered orally.', 'C.E.S. , Cenestin , Component of Cyclogesterin# , Component of Milprem , Component of PMB-200 , Component of PMB-400 , Component of Premarin with Methyltestosterone , Congest , Conjugated Estrogens , Conjugated Estrogens CSD , Estrocon , Estrofol , Estrogen , Genesis , Menotab , Premarin , Ultrogen', NULL, NULL, '18313', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(658, 'Estrogens, Esterified', NULL, NULL, 'NO', 'A combination of the sodium salts of the sulfate esters of estrogenic substances, principally estrone, having the the actions and uses of estrogens; palliative.', 'Amnestrogen# , Component of Estratest , Component of Menrium , Esterified Estrogens , Estratab , Evex , Menest , Neo-Estrone , SK-Estrogens', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(659, 'Estrone', NULL, NULL, 'NO', 'Estrogen used as replacement therapy in cases of hypogonadism, ovariectomy, primary ovarian failure, atrophic vaginitis, vasomotor menopausal symptoms, and vulvar squamous hyperplasia and in the treatment of abnormal uterine bleeding, but also used in advanced prostatic carcinoma.', 'Aquest , Crystogen , Femogen Forte , Follicular Hormone , Folliculin , Kestrone , Ketohydroxyoestrin , Neo-Amniotin , Neo-Estrone , Oestrilin , Sodestrin , Theelin , Ultrogen D.A. , Unigen , Wehgen', 'Prostate cancer', NULL, '9699', 'Hormones and hormonal mechanisms', 'Estrogen'),
(660, 'Estropipate', NULL, NULL, 'NO', 'Estrogen--compound of estrone sulfate and piperazine.', 'Component of Ortho-Cyclen , Estrone Piperazine Sulfate , Ogen , Ortho-Est , Piperazine Estrone Sulfate , Piperazine oestrone sulfate# , Sulestrex#', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(661, 'Etanercept', NULL, NULL, 'NO', 'TNF antagonist with limited applications in cancer.  Primarily a rheumatoid arthritis palliater.  Immunex.', 'Enbrel', 'CTCL', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Tumor necrosis factor modulator'),
(662, 'Etanidazole', NULL, NULL, 'NO', 'Hypoxic cell radiosensitizer. Chemo-/radiosensitization: not recommended at present; conclusive evidence of efficacy not established for any potential indication.', 'DUP 453 , DUP-453 , DUP453 , Radinyl , SP-2508 , SR 2508 , SR-2508 , SR2508', NULL, 'SN', '301467, 314055', 'Ancillary Agent', 'Radiosensitizer'),
(663, 'Ethacrynic Acid', NULL, NULL, 'YES', 'A short-acting loop diuretic. Ethacrynic acid is a potent, rapidly-acting diuretic that is generally reserved for patients who do not respond to thiazide diuretics. It has been used effectively to treat hypertension, congestive heart failure, and pulmonary edema.', 'Edecrin , Etacrynate , Etacrynic Acid , MK 595 , MK-595 , MK595', NULL, NULL, '85791', 'Ancillary Agent', 'Diuretic'),
(664, 'Ethambutol Hydrochloride', NULL, NULL, 'YES', 'A synthetic antimycobacterial agent. Under investigation for Rx of Mycobacterium Avium Complex (MAC; Rx of tuberculosis)', 'CL 40881 , CL-40881 , CL40881 , Etibi , Myambutol', NULL, NULL, NULL, 'AIDS drug', NULL),
(665, 'Ethidium chloride', NULL, NULL, 'NO', 'Mutagen--no longer on market', 'Babidium chloride , Homidium chloride , Novidium chloride', NULL, NULL, '84423', 'Chemotherapy', 'No longer in use'),
(666, 'Ethinyl Estradiol', NULL, NULL, 'NO', 'An orally effective semisynthetic derivative of estradiol, one of the most potent estrogens. It is a component of many oral contraceptives and is also used in estrogen replacement therapy.  Not found in Drugdex drug evaluation.', 'Alesse , Brevicon , Chee-O-Gen , Chee-O-Genf , Component of Brevicon , Component of Demulan , Component of Levlen , Component of Lo/Ovral , Component of Loestrin , Component of Lynoral# , Component of Modicon , Component of Nordette , Component of Norethrin 1/35E , Component of Norlestrin , Cyclen , Desogen , Diogyn E , Dyloform , Esteed , Estigyn , Estinyl , Eston-E , Estoral , Estrostep , Ethidol , Ethinoral# , Ethinyl Estradiol , Ethinyloestradiol , Eticyclin , Eticylol# , Etinestrol , Feminone , Gencept , Genora , Ginestrene , Halodrin , Inestra , Jenest , Levlen , Levora , Lo/Ovral , Loestrin , Marvelon , Menolyn , Microfollin , Min-Ovral , Minestrin , Mircette , Modicon , Necon , Nee , Nelova , Nelulen , Neo-Mens , Norcept-E , Norinyl , Novestrol , Oradiol , Orestralyn , Ortho Cyclen , Ortho Tro-Cyclen , Ortho-Cept , Ortho-Novum , Ovcon , Ovral , Palonyl Perovex , Preven , Spanestrin , Tri-Cyclen , Tri-Levlen , Tri-Norinyl , Triphasil , Triquilar , Trivora , Zovia', NULL, NULL, '010973;10973', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(667, 'Ethiodized Oil I-131', NULL, NULL, 'YES', 'Radiopaque organic iodine compound. Ethiodized Oil emulsion appears to be sensitive in detecting hepatic metastases, however, further studies are required to compare other imaging procedures before any recommendations can be made; radio-opaque medium.', 'Et esters iodinated , Ethiodol , Ethiodol-131# , Fatty acids , Iodised Oil , labeled with iodine-131 , Lipiodol , poppy seed-oil', NULL, NULL, '727255', 'Ancillary Agent', NULL),
(668, 'Ethionamide', NULL, NULL, 'YES', 'A bacteriostatic agent effective against mycobacteria (antimycobacterial drug).', '1314-TH , 1314TH , Ethionamidum , Etionamide , TH-1314 , TH1314 , Trecator-SC', NULL, NULL, NULL, 'AIDS drug', NULL),
(669, 'Ethoglucid', NULL, NULL, 'NO', NULL, 'Epodyl , Etoglucid , ICI 32865 , ICI-32865', NULL, NULL, '80439', 'Chemotherapy', 'Alkylating agent'),
(670, 'Ethyl-6-Mercaptopurine', NULL, NULL, 'NO', NULL, '79T61 , 9-Ethyl-6-MP', NULL, NULL, '14575', 'Chemotherapy', 'Antimetabolite'),
(671, 'Ethylchlorformate', NULL, NULL, 'NO', NULL, NULL, 'Bladder', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(672, 'Ethynylcytidine', NULL, NULL, 'NO', 'Phase II RNA polymerase inhibitor. GlaxoSmithKline.', 'SB 596168', 'Other cancer', NULL, NULL, 'Chemotherapy', 'RNA polymerase inhibitor'),
(673, 'Etidronate Disodium', NULL, NULL, 'YES', 'A bisphosphonate that acts on bone to slow the rate of bone turnover; calcium regulator. Treatment of hypercalcemia of malignancy.', 'Didrocal , Didronel , Disodium Etidronate', NULL, 'EHDP', NULL, 'Ancillary Agent', 'Bisphosphonate'),
(674, 'Etoposide', NULL, NULL, 'NO', 'Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.', 'Dom-Etoposide , Epipodophyllotoxin derivative , Epipodophyllotoxin ethylidene gluco-pyranoside , Eposine , Ethylidene-Lignan P , Etopophos , Podophyllotoxin derivative , Vepesid , VP 16-213 , VP-16 , VP-16213 , Toposar', 'Gastric cancer, Hodgkins lymphoma, Lung cancer (NSCLC, SCLC), Non-Hodgkin lymphoma, testicular cancer (Germ cell tumors)', 'EPEG, VP-16, VP-16-213', '141540', 'Chemotherapy', 'Epipodophyllotoxin, topoisomerase II inhibitor;Plant alkaloid'),
(675, 'Etoprine', NULL, NULL, 'YES', NULL, 'ethodichlorophen', NULL, 'DDEP', '3062', 'Ancillary Agent', NULL),
(676, 'Etretinate', NULL, NULL, 'YES', 'An oral retinoid (vitamin A analog).', 'Ro 109359 , Ro-10-9359 , Ro-109359 , Ro109359 , Tegison', NULL, NULL, NULL, 'Differentiation inducing agent', NULL),
(677, 'Exatecan mesylate', NULL, NULL, 'NO', 'Topoisomerase 1 inhibitor', 'DX-8951f', NULL, NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(678, 'Exemestane', NULL, NULL, 'NO', 'FDA approved postmenopausal breast cancer; Phase II/III for other sites Steroidal aromatase inhibitor. Pharmacia, Pfizer.  For adjuvant treatment of postmenopausal women with ER positive breast cancer who have completed 2-3 years of tamoxifen for completion of a total of 5 consecutive years of adjuvant hormonal therapy.', 'Aromasin , FEC 24304 , FEC-24304 , FEC24304 , Nikidess , PNU 155971 , PNU-155971 , PNU155971', 'Breast, other cancer', NULL, '713563', 'Hormones and hormonal mechanisms', 'Aromatase inhibitor'),
(679, 'F3TDR', NULL, NULL, 'NO', NULL, 'Fluridine , Trifluorothymidine , Trifluridine , Virophta , Viroptic', NULL, 'F3T, TFT', '075520, 529182', 'Ancillary Agent', 'Ophthalmic antiviral'),
(680, 'Fadrazole HCl', NULL, NULL, 'NO', NULL, 'CGS 16949A , CGS-16949A , CGS16949A', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Aromatase inhibitor'),
(681, 'Famciclovir', NULL, NULL, 'YES', 'An oral prodrug of the antiviral agent penciclovir.', 'BRL 39123A , BRL-42810 , Famvir', NULL, NULL, NULL, 'AIDS drug', NULL),
(682, 'Fansidar', NULL, NULL, 'YES', 'Antimalarial combination product. Prophylaxis for PCP and toxoplasmosis', 'Pyrimethamine/Sulfadoxine', NULL, NULL, '618943', 'Ancillary Agent;AIDS drug', NULL),
(683, 'Farletuzumab', NULL, NULL, 'NO', 'Phase II ovary 2007 A monoclonal antibody that targets folate receptor alpha (FRA) and works via suppression of FRA-mediated signal transduction inducing tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms. Morphotek.', 'MORAb 003 , MORAb-003 , MORAb003', 'Ovary', NULL, NULL, 'Chemotherapy', 'Cytotoxic monoclonal antibody'),
(684, 'Favid Vaccine', NULL, NULL, 'NO', 'Phase II Favrille.', 'Favid-04 vaccine', 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(685, 'Fazarabine', NULL, NULL, 'NO', NULL, '5-azocytosine arabinoside , Kymarabine', NULL, 'Ara-AC', '281272', 'Chemotherapy', 'Antimetabolite'),
(686, 'Felvizumab', NULL, NULL, 'NO', 'A monoclonal antibody directed against the fusion protein of respiratory syncytial virus (RSV).', 'HuRSV19VHFNS/VK , RSHZ19 , RSV monoclonal antibody , SB 209763 , SB-209763 , SB209763', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti-RSV Mab'),
(687, 'Fenretinide', NULL, NULL, 'YES', 'Phase I brain, Phase II lung, orphan drug status Ewing sarcomas\r\nA synthetic retinoid derivative under investigation as a chemopreventive agent. NCI., Cancer Research UK.\r\nStill under investigation as of April 2012', '4-HPR , McN-R-1967', 'Brain cancer, Ewings sarcoma family of neoplasms, Lung cancer', NULL, '374551', 'Ancillary Agent', 'Chemoprevention'),
(688, 'Fentanyl Citrate', NULL, NULL, 'YES', 'A potent narcotic analgesic for breakthrough cancer pain', 'Actiq , Duragesic , Fentaryl Oralet , Phentanyl Citrate , Sublimaze', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(689, 'Fialuridine', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation; Rx for cytomegalovirus', 'FIAU , Fluoroiodoarauracil', NULL, NULL, NULL, 'AIDS drug', NULL),
(690, 'Filgrastim', NULL, NULL, 'YES', 'A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia\r\n\r\nMarch 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product.  There are no differences in terms of safety and effectiveness from the reference product (neupogen)', 'G-CSF , GCSF , Neupogen , Recombinant human granulocyte colony-stimulating factor , Zarxio , r-G-CSF , r-met Hu G-CSF , rhG-CSF', NULL, NULL, '614371;614629', 'Ancillary Agent', NULL),
(691, 'Filmix', NULL, NULL, 'YES', 'Phase I Liquid Coated Microbubble (LCM) diagnostic. Cav-Con, Inc.', NULL, 'Liver cancer, Prostate', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(692, 'FLAG-003', NULL, 'Glioma', 'SEE_REMARKS', 'March 4, 2016: FDA and the European Medicines Agency both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma.\r\n\r\nOrphan status is granted by the FDA to promote the development of products that demonstrate promise for treatment of rare diseases, those that affect fewer than 200,000 Americans annually.\r\n\r\nCODE: code this drug in Other Treatment, assign code 2.', NULL, 'Brain', NULL, NULL, 'Other therapy', NULL),
(693, 'Flavone acetic acid', NULL, NULL, 'NO', 'Development discontinued', 'Flavone-8-Acetic Acid , flavonoid', NULL, 'FAA, FVA', '347512', 'Chemotherapy', 'No longer in use'),
(694, 'Flavopiridol', NULL, NULL, 'NO', 'Phase I CLL/SLL 2007I Cyclin-dependent kinase (CDKs) inhibitor. Aventis, NCI.', 'Alvocidib , HMR 1275 , L 866275 , L86-6275 , L866275', 'B-cell CLL, Colorectal, lung, other cancer, prolymphocytic leukemia arising from CLL, small lymphocytic lymphoma', NULL, '649890', 'Chemotherapy', 'Inhibitor'),
(695, 'Floxuridine', NULL, NULL, 'NO', 'FDA approved use for GI adenocarcinoma; antimetabolite', '2-Deoxy-5-fluorouridine , 5-Fluorouracil deoxyriboside , 5-Flurodeoxyuridine , Floxuridin , Fluorodeoxyuridine , FUDR , Sterile FUDR , WR-138720 , WR138720', 'Colorectal, Gastric cancer', '5-FUDR, 5-FURD, FUDR', '027640;27640', 'Chemotherapy', 'Antimetabolite'),
(696, 'FLT3 Ligand', NULL, NULL, 'NO', 'Phase III AML, skin Cytokine immunomodulator. NCI, Immunex Corp.', NULL, 'Leukemia, skin cancer', NULL, '696599', 'Biologic therapy (BRM, immunotherapy)', 'Cytokine'),
(697, 'Fluconazole', NULL, NULL, 'YES', 'Antifungal.', 'Apo-Fluconazole , Diflucan , Nu-Flucon , UK-49858', NULL, NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(698, 'Flucytosine', NULL, NULL, 'YES', 'A synthetic oral antifungal agent; adjunct to Amphotericin B', '5-Fluorocytosine , Ancobon , Ancotil , Novo-Triphyl , Ro-2-9915', NULL, '5-FC', NULL, 'AIDS drug', NULL),
(699, 'Fludarabine', NULL, NULL, 'NO', 'FDA approved use on chronic lymphocytic leukemia.', '2-FLAMP , 2-Fluoro-ARA AMP , 2-Fluoro-ara-AMP , Fludara , Fludarabine Monophosphate , Fludarabine Phosphate', 'CLL, Cutaneous T-cell lymphoma, Leukemia, Non-Hodgkin lymphoma (low grade)', '2-FAMP', '312887', 'Chemotherapy', 'Antimetabolite'),
(700, 'Fludrocortisone Acetate', NULL, NULL, 'NO', 'A potent oral mineralocorticoid; salt-regulating; adrenocorticoid steroid.   The acetate salt of a synthetic steroid with potent mineralocorticoid and high glucocorticoid activity, used in replacement therapy for primary or secondary adrenocortical insufficiency in Addison\'s disease and for the treatment of salt-losing adrenogenital syndrome', 'Florinef , Florinef Acetate , Fluorohydrocortisone', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Adrenocorticoid steroid.  Probably not cancer directed--verify with attending MD.'),
(701, 'Flugestone Acetate', NULL, NULL, 'NO', 'Progestin.  This is a vetinary hormone used intravaganially to control bleeding (mainly in sheep and goats)-do not know of human use.  Not found in Drugdex drug evaluation.', 'SC 9880 , SC-9880 , SC9880', NULL, NULL, '65411;065411', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(702, 'Flumethasone', NULL, NULL, 'NO', 'Glucocorticoid mainly used in animals--used topically for for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', '974 , U 19874 , U-10 , U10974', NULL, NULL, '54702', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(703, 'Flumethasone Pivalate', NULL, NULL, 'NO', 'A fluorinated topical corticosteroid pivalate salt of flumethasone, used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', 'Flumetasone , Locacorten , Locasalen', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(704, 'Fluoroadenosine', NULL, NULL, 'NO', 'A-1 adenosine receptor agonist', 'SRI-727', NULL, '2 FAS', '30605', 'Chemotherapy', 'No longer in use'),
(705, 'Fluorodopane', NULL, NULL, 'NO', NULL, 'Fluorodopan , Fluorothane , Fluorpan , Ftordopan , Ftorpan', NULL, NULL, '73754', 'Chemotherapy', 'Alkylating agent'),
(706, 'Fluorometholone', NULL, NULL, 'NO', 'A synthetic glucocorticoid used topically in the treatment of corticosteroid-responsive allergic and inflammatory conditions of the eye.', 'Component of FML-S Liquifilm , Component of Neo-Oxylone# , Cortilet , Delmeson , Fluoromethalone , FML Forte , FML Liquifilm , FML S.O.P. , Oxylone# , U-8614', NULL, NULL, '33001', 'Hormones and hormonal mechanisms', 'Corticosteroid.  Probably not cancer directed--verify with attending MD.'),
(707, 'Fluorometholone Acetate', NULL, NULL, 'NO', 'A topical corticosteroid used as an ophthalmic antiinflammatory agent.  The acetate salt of a synthetic glucocorticoid used topically in the treatment of corticosteroid-responsive allergic and inflammatory conditions.', 'Eflone , Flarex , Fluor-Op , FML , FML Forte , FML Liquifilm , FML S.O.P. , FML-S , FML-S Liquifilm , PMS-Fluorometholone', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Corticosteroid.  Probably not cancer directed--verify with attending MD.'),
(708, 'Fluorotestosterone', NULL, NULL, 'NO', 'Nonaromatizable androgen, as effective as testosterone', '6a-Fluorotestosterone , U-11207', 'Prostate cancer', NULL, '36091', 'Hormones and hormonal mechanisms', 'Androgen inhibitor'),
(709, 'Fluorothymidine', NULL, NULL, 'YES', NULL, NULL, NULL, 'FLT', NULL, 'AIDS drug', NULL),
(710, 'Fluorouracil', NULL, NULL, 'NO', 'Fluorinated pyrimidine; antimetabolite.  FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and  pancreatic cancer.\r\n\r\nNote: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.', '5-Fluorouracil , 5-Fluracil , Adrucil , Efudex , Fluoroplex , Fluracil , Fluril , Oracil , Ro 2-9757 , WR-69596', 'Breast- adjuvant setting and advanced disease, colorectal- adjuvant setting and advanced disease, GI malignancies: anal, esophageal, gastric and pancreatic, Head and Neck cancer, Hepatoma, Ovarian cancer, Skin-Basal cell carcinoma (topical applic', '5-FU, 5FU, FU', '019893;19893', 'Chemotherapy', 'Antimetabolite'),
(711, 'Fluosol DA', NULL, NULL, 'YES', 'A stable emulsion of 2 oxygen-carrying perfluorochemicals, perfluorodecalin and perfluorotri-n-propylamine. Radiation-sensitizing agent. Not found in Drugdex drug evaluation.', 'Fluorocarbon blood substitute , Perfluorochemical emulsion 20% , Synthetic blood substitute', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(712, 'Fluosol-DA', NULL, NULL, 'NO', 'In regimen with BCNU.  Hypoxic radiosensitizer', 'Fluosol DA (20%) , Fluosol-DA 20', 'Malignant glioma', NULL, NULL, 'Ancillary Agent', 'Radiosensitizer'),
(713, 'Fluoxymesterone', NULL, NULL, 'NO', 'A synthetic androgenic anabolic steroid used in the treatment of male hypogonadism and in the palliative therapy of inoperable female breast cancer in selected patients, administered orally.', 'Androfluorene , Android-F , Anrosterolo , Fluo-testin , Fluoximesterone , Flusteron , Flutestos , Halodrin , Halotestin , Neo-Ormonal , Ora-Testryl# , Oralsterone , Oratestin , Testoral , Ultandren', 'Breast cancer', 'FLU, FXM, HAL', '012165;12165', 'Hormones and hormonal mechanisms', 'Androgen'),
(714, 'Fluperolone Acetate', NULL, NULL, 'NO', 'Glucocorticoid; a dermatologic steroid used for skin inflamation.', 'Methral , P-1742', NULL, NULL, '67756', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(715, 'Fluprednisolone', NULL, NULL, 'NO', 'A synthetic glucocorticoid used in the treatment of various conditions responsive to the anti-inflammatory actions of glucocorticoids, administered orally. Not found in Drugdex drug evaluation.', '6alpha-Fluoroprednisolone , Alphadrol# , U-7800', NULL, NULL, '47439;047439', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(716, 'Fluprednisolone Valerate', NULL, NULL, 'NO', 'Glucocorticoid; an ester of fluprednisolone with actions similar to those of the base.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'No longer in use'),
(717, 'Flurandrenolide', NULL, NULL, 'NO', 'A fluorinated, low-potency synthetic corticosteroid used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.', '33379 , Cordran , Drenison , Fludroxycortide , Flurandrenolone#', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(718, 'Flurbiprofen', NULL, NULL, 'YES', 'Analgesic; anti-inflammatory', '182 , 322 , Ansaid , BTS 18 , U-27', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(719, 'Flurbiprofen Sodium', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory with analgesic and antipyretic activity. Flurbiprofen is effective in the treatment of rheumatoid arthritis, osteoarthritis, acute gout, dental pain, dysmenorrhea, gynecologic pain, soft-tissue trauma, cancer pain, ankylosing spondylitis, bursitis-tendonitis and fever.', 'Alti-Flurbiprofen , Ansaid , Apo-Flurbiprofen , Flurbiprofen Sodium , Froben , Novo-Flurbiprofen , Nu-Flurbiprofen , Ocufen', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(720, 'Flurocitabine', NULL, NULL, 'NO', NULL, 'AAFC , Ro 21-0702', NULL, NULL, '166641', 'Chemotherapy', 'Antimetabolite'),
(721, 'Flutamide', NULL, NULL, 'NO', 'A nonsteroidal nonhormonal antiandrogenic. FDA approved use on prostate cancer in combination with LHRH analog.', 'Apo-Flutamide , Euflex , Eulexin , Niftholide , Niftolid , Niftolife , SCH 13521', 'Prostate cancer', NULL, '147834', 'Hormones and hormonal mechanisms', 'Antiandrogenic'),
(722, 'Fondaparinux', NULL, NULL, 'YES', 'Anticoagulant', 'Arixtra , Fondaparinux sodium', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(723, 'Formocortal', NULL, NULL, 'NO', 'A glucocorticoid corticosteroid used topically for the relief of inflammation and pruritus in corticosteroid-responsive dermatoses.  Not found in Drugdex drug evaluation.', 'Deflamene , FI-6341 , Fluderma , Fluoroformylon', NULL, NULL, '150527', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(724, 'Foscarnet Sodium', NULL, NULL, 'YES', 'Treatment of cytomegalovirus retinitis and mucocutaneous herpes simplex infections in AIDS patients.', 'A-29622 , EHB-776 , Foscavir , Phosphonoformate Trisodium , Trisodium phosphonoformate', NULL, 'PFA', '313410', 'AIDS drug', NULL),
(725, 'Fosfestrol', NULL, NULL, 'NO', 'Another name for estrogen.  Not readily available in the U.S.  Not found in Drugdex drug evaluation.', 'Diethylstilbestrol Diphosphate , Fosfestrol Injection BP 2003 , Fosfestrol Tablets BP 2003 , Honvan , Honvan (FM) , Honvol , Phosphoestrolum , Ronvan , ST-52 , Stilboestrol Diphosphate , Stilphostrol , Stilphostrol (FM)', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(726, 'Fosquidone', NULL, NULL, 'NO', NULL, 'GR 63178K', NULL, NULL, NULL, 'Chemotherapy', 'Unclassified antineoplastic'),
(727, 'Fostriecin Sodium', NULL, NULL, 'NO', NULL, 'Antibiotic CI-920 , Antibiotic CL 1565A , Pyranone Phosphate', NULL, NULL, '339638', 'Chemotherapy', 'Topoisomerase inhibitor'),
(728, 'Fotemustine', NULL, NULL, 'NO', 'Demonstrated antitumor efficacy in disseminated malignant melanoma; there is also evidence of activity in malignant glioma and squamous cell lung carcinoma. Fotemustine may offer a toxicity advantage over other nitrosoureas.', 'S-10036', 'lung cancer, Melanoma', NULL, NULL, 'Chemotherapy', 'Nitrosourea alkylating agent'),
(729, 'Fowlpox B7.1 and vaccine B7.1', NULL, NULL, 'NO', 'Phase I Vaccine. NCI, Therion Biologics.', 'Recombinant Fowlpox-B7.1', 'Skin cancer', NULL, '679008', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(730, 'Fowlpox PSA Vaccine', NULL, NULL, 'NO', 'Phase I/II Vaccine. NCI, Therion Biologics. Tricom.', 'Prostvac-F , recombinant fowlpox-PSA (L-155)', 'Prostate cancer', NULL, '717171', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(731, 'Fowlpox TRICOM', NULL, NULL, 'NO', 'Phase II Information from NCI', 'Fowlpox-CEA-B7-1/ICAM-1/LFA-3 , rF-CEA(6D)TRICOM', 'Breast', 'CEA-TRICOM', NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(732, 'Fowlpox-CEA (6D)-Tricom', NULL, NULL, 'NO', 'Phase I Vaccine. NCI, Therion Biologics.', 'B7/ICAM/LFA3 , Fowlpox-(6D)-TRICOM', 'Breast, colorectal, lung cancer', NULL, '710068', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(733, 'Freund\'s adjuvant', NULL, NULL, 'NO', 'Bacteria and Fungi, mycobacteria biological', NULL, NULL, 'FCA', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(734, 'Fulphila', NULL, NULL, 'YES', '6/4/2018 The FDA approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.', 'pegfilgrastim-jmdb', NULL, NULL, NULL, 'Ancillary Agent', 'Biosimilar'),
(735, 'Fulvestrant', NULL, NULL, 'NO', 'FDA approved use on breast cancer Selective estrogen receptor downregulator (SERD). AstraZeneca.', 'Faslodex , Fulvestrant , ICI 182780 , ICI-182780 , ICI182780 , Zeneca 182780', 'Breast cancer', NULL, '719276', 'Hormones and hormonal mechanisms', 'SERD'),
(736, 'Furazolidone', NULL, NULL, 'YES', 'A bactericidal agent primarily used in the treatment of giardiasis and enteritis caused by susceptible organisms.', 'Furazolidonum , Furox , Furoxone , Nifurazolidonum', NULL, NULL, NULL, 'AIDS drug', NULL),
(737, 'Furosemide', NULL, NULL, 'YES', 'A short-acting loop diuretic, useful in treating edema associated with renal failure.', 'Albert Furosemide , Apo-Furosemide , Carpuject Furosemide , Disal , Frusemide , Frusetic , Fumide , Furomide MD , Furoside , Lasaject , Lasimide , Lasix , LB-502 , Lo-Aqua , Myrosemide , Novo-Semide , SK-Furosemide , Uritol', NULL, NULL, 'LB-502', 'Ancillary Agent', NULL),
(738, 'G17DT', NULL, NULL, 'NO', 'Phase III Anti-gastrin therapeutic vaccine. Aphton Corp.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(739, 'G207', NULL, NULL, 'NO', 'Phase II Genetically engineered herpes simplex virus. NeuroVir Therapeutics.', NULL, 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent--cytolytic virus'),
(740, 'Gallium Maltolate', NULL, NULL, 'NO', 'Gallium (semi metallic).', NULL, 'Hepatocellular carcinoma (HCC), Lymphoma, multiple myeloma, prostate cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent--soluble metal (like Platinum)'),
(741, 'Gallium Nitrate', NULL, NULL, 'NO', 'Phase II Inhibits calcium resorption from bone. Indicated for treating hypercalcemia related to cancer.', 'Gallium trinitrate , Ganite , WR-135675', 'Lymphoma', 'GAN', '015200;15200', 'Ancillary Agent', 'Bisphosphanate--do not code'),
(742, 'Gamma Interferon', NULL, NULL, 'YES', NULL, 'Actimmune', NULL, NULL, NULL, 'AIDS drug', NULL),
(743, 'Ganciclovir', NULL, NULL, 'YES', 'Therapy for immunosuppressed patients, bone marrow recipients. An antiviral agent that is effective in the treatment of infections caused by cytomegalovirus. Rx of AIDS-related retinopathies', '2 nor-Deoxyguanosine , BIOLF-62 , BW 759 , BW 759U , BW B759U , Cytovene , RS-21592 , Vitrasert', NULL, '2-NDG, DHPG', '716361;365633', 'Ancillary Agent;AIDS drug', NULL),
(744, 'Ganglioside', NULL, NULL, 'NO', 'Being evaluated in a variety of neurological disorders, including spinal cord injury.', 'Ganglioside GM-1 , Monosialganglioside', NULL, 'GM-1, GM2', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(745, 'Gardasil', NULL, NULL, 'YES', 'This is a vaccine that PREVENTS most types of cervical cancer.  It is not an anti-cancer drug. Merck.', NULL, 'Cervical cancer preventative', NULL, NULL, 'Ancillary Agent', NULL),
(746, 'Gastrimmune', NULL, NULL, 'NO', 'Phase I/II colorectal Phase III pancreatic Anti-gastrin 17 hormone.  For unresectable, advanced pancreating cancer patients not fit enough to receive gemcitabine. Aphton Corp, Aventis Pasteur.', NULL, 'Colorectal, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Therapeutic vaccine'),
(747, 'Gazyva', NULL, 'Chronic lymphocytic leukemia (CLL)', 'NO', 'November 1, 2013: Gazyva received FDA approval for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Gazyva was the first drug to receive breakthrough therapy designation from the FDA. \r\n\r\nNo NSC number available for this drug\r\n\r\nFebruary 26, 2016: The FDA approved Gazyva plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not rsepond to a Rituxan-containing regimen, or whose follicular lymphoma returned after such treatment.', 'GA101 , Obinutuzumab', 'Bone marrow', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(748, 'GBC-590 (complex carbohydrate)', NULL, NULL, 'NO', 'Phase II Carbohydrate based. Safe Science, Inc., GlycoGenesys.', NULL, 'Colorectal, pancreatic, prostate cancer', NULL, NULL, 'Chemotherapy', 'Antiangiogenesis agent'),
(749, 'GCS-100', NULL, NULL, 'NO', 'Phase II Lectin inhibitor. GlycoGensys.', NULL, 'Colorectal, pancreatic, prostate cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(750, 'GD0039', NULL, NULL, 'YES', 'Phase I/II, Phase I/II T-cell NHL Carbohydrate processing inhibitor (CPI). GLYCODesign.', NULL, 'Breast, colorectal, head & neck, kidney cancer, lymphoma', NULL, NULL, 'Ancillary Agent', NULL),
(751, 'GDC-0449', NULL, NULL, 'NO', NULL, 'GDC-0449', 'brain/cns, colorectal, GE, lung, ovarian, Pancreas, stomach', NULL, NULL, 'Chemotherapy', 'Hedgehog Pathway inhibitor'),
(752, 'Gefitinib', NULL, NULL, 'NO', 'FDA approved use on non-small cell lung cancer. In clinical trials for breast, kidney, colorectal, and gastric tumors.', 'Iressa , ZD 1839 , ZD-1839 , ZD1839', 'Breast, colorectal, gastric, kidney, lung cancer', NULL, '715055', 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(753, 'GEM 91', NULL, NULL, 'YES', 'One of the Oligodeoxyribonucleotide phosphorothioates. May inhibit HIV replication', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(754, 'GEM-231', NULL, NULL, 'NO', 'Phase I ovarian; Phase II other; Phase I/II breast; Phase I pancreatic Antisense. Hybridon.', NULL, 'Breast, cervical, colorectal, endometrial, lung, other cancer, ovarian, pancreatic', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(755, 'Gemcitabine', NULL, NULL, 'NO', 'FDA approved for breast. ovarian, pancreas, NSC lung \r\nGemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.', 'Gemcitabine Hydrochloride , Gemzar , LY 188011 , LY-188011 , LY188011 hydrochloride , Gemcitabine HCL', 'Bladder, Breast, non-small cell lung, ovarian, pancreatic cancer, Soft Tissue Sarcoma', NULL, '613327', 'Chemotherapy', 'Antimetabolite'),
(756, 'Gemtuzumab Ozogamicin', NULL, NULL, 'NO', 'September 1, 2017: FDA approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).  The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).\r\n\r\nMonoclonal antibody.  Gemtuzumab ozogamicin consists of a recombinant humanized anti-CD33 MAb conjugated to calicheamicin, a cytotoxic antibiotic. FDA approved for use on acute nonlymphocytic leukemia.', 'Anti-CD33 Monoclonal Antibody Calicheamicin , CDP 771 , CDP-771 , CDP771 , CMA-676 , hP67.6-calicheamicin , Mylotarg', 'Leukemia', NULL, '720568;716236', 'Biologic therapy (BRM, immunotherapy)', 'Targeted therapy'),
(757, 'Genasense', NULL, NULL, 'NO', 'Phase II (breast), Phase III AML, CLL, NSCLC, MM, prostate, melanoma, Phase I (colorectal), Phase I/II NHL, sarcoma Antisense.  Phosphorothioate antisense oligonucleotide which targets human Bcl-2 mRNA. Genta Inc., Aventis.', 'Augmerosen , Bcl-2 antisense Oligonucleotide , G 3139 , G-3139 , GC 3139 , GC-3139 , Oblimersen , Oblimersen sodium', 'Breast, colorectal, kidney, leukemia, lung, lymphoma, melanoma, multiple myeloma, pancreatic cancer, prostate, sarcoma', NULL, '683428', 'Chemotherapy', 'Apoptosis inducer'),
(758, 'Gene CC49-zeta', NULL, NULL, 'NO', 'Phase I Gene therapy modified TAG-72. Cell Genesys, Inc.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(759, 'Gene Therapy with Interleukin-2 and chemo.', NULL, NULL, 'NO', 'Phase III Gene therapy. Valentis.', NULL, 'Head & neck cancer', NULL, NULL, 'Chemotherapy', 'Chemo with gene therapy'),
(760, 'GeneVax', NULL, NULL, 'NO', 'Phase I Gene vaccine. Centocor.', 'Gene Vaccine', 'Breast, prostate  cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'immunotherapy active'),
(761, 'Genistein', NULL, NULL, 'NO', 'Phase II pancreas 2007 Antitumor, antimetastatic, antiangiogenesis properties. Isoflavone extracted from soy products.', 'Novasoy', 'Pancreas', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(762, 'Gentamicin', NULL, NULL, 'YES', NULL, 'Garamycin', NULL, NULL, NULL, 'Ancillary Agent', 'Antibiotic'),
(763, 'Genz-644282', NULL, NULL, 'NO', 'Phase I New drug currently in trials, code in Other Therapy', 'Genz-644282', 'Solid tumors', NULL, NULL, 'Chemotherapy', 'Topoisomerase 1 inhibitor'),
(764, 'Gestaclone', NULL, NULL, 'NO', 'Progestin', 'SH 1040 , SH-1040 , SH1040', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(765, 'Gestonorone Caproate', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.', 'Gestronol Hexanoate , SH 582 , SH-582 , SH582', 'Prostate cancer', NULL, '84054;084054', 'Hormones and hormonal mechanisms', 'Leuteinizing hormone antagonist'),
(766, 'Gilotrif', NULL, NULL, 'NO', 'On July 12, 2013, the FDA approved the use of Gilotrif (afatinib) for use in patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Concurrent with this action, FDA approved the therascreen EGFR RGQ PCR Kit (QIAGEN) for detection of EGFR mutations.\r\n\r\nJan 12, 2018 FDA granted approval to afatinib (Gilotrif) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.', 'Afatinib , BIBW 2992 , Tomtovok , Tovok', 'Lung (NSCLC)', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(767, 'Gilteritinib', NULL, 'AML', 'NO', '11/28/2018: FDA approved gilteritinib (XOSPATA) for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test', 'XOSPATA', NULL, NULL, NULL, 'Chemotherapy', 'RTK Inhibitor'),
(768, 'Glufosfamide', NULL, NULL, 'NO', 'Threshold Pharmaceuticals', NULL, 'Pancreas', NULL, NULL, 'Chemotherapy', 'Alkylating agent'),
(769, 'Glycine', NULL, NULL, 'YES', 'Irrigation fluid.', 'Aminoacetic acid , Corilin , Gly , Glycine Irrigation', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(770, 'GM.CD40L', NULL, NULL, 'NO', 'Information from NCI', 'GM-CSF-CD40L cell vaccine', 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(771, 'GMK Vaccine', NULL, NULL, 'NO', 'Phase III melanoma Vaccine. Progenic Pharmaceuticals.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(772, 'GnRH Pharmaccine', NULL, NULL, 'NO', 'Phase II prostate Pre-clinical breast Therapeutic vaccine. Aphton, GlaxoSmithKline.', NULL, 'Breast, prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone'),
(773, 'Gold Au 198', NULL, NULL, 'YES', 'Diagnostic aid, liver imaging; radioactive agent', 'Aurcoloid-198# , Aureotope# , Auroscan-198#', NULL, NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(774, 'Gold-198', NULL, NULL, 'NO', 'Treatment of malignant ascites and malignant pleural effusion,  given intravenously for the measurement of liver blood flow, in liver scanning, and for general investigations of the reticuloendothelial system', 'Au 198 , Au-198 , Au198', NULL, NULL, NULL, 'Radiation', 'Radioisotope'),
(775, 'Goserelin Acetate', NULL, NULL, 'NO', '2017: FDA approved Zoladex for treatment of breast and prostate cancers. \r\n\r\nCases diagnosed prior to 1/1/2017: code Zoladex in \"other \"treatment.', 'Decapeptide 1 , ICI 118630 , ICI118630 , LHR 606864 , LHR606864 , Zoladex', 'Breast, prostate cancer', NULL, '606864', 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone'),
(776, 'Gossypol acetic acid', NULL, NULL, 'YES', 'In trial with androgen ablation for newly diagnosed metastatic prostate cancer', 'Gossypol', 'Prostate cancer', 'Gossypol', NULL, 'Differentiation inducing agent', NULL),
(777, 'gp100 DNA Vaccine', NULL, NULL, 'NO', 'Phase I metastatic melanoma Vaccine. NCI, Vical, Powderject Vaccines.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(778, 'gp100 Peptide Vaccine', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. NCI.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(779, 'gp100 Plasmid Vector in Gold Particles', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. NCI.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(780, 'GP120 vaccine', NULL, NULL, 'NO', NULL, '3 (Biocine) , an envelope protein from HIV ENV 2 , Recombinant', NULL, NULL, NULL, 'AIDS drug', NULL),
(781, 'GPI-0100 Immune Enhancer (Adjuvant)', NULL, NULL, 'NO', 'Phase I Synthetic saponin. Galenica Pharmaceuticals.', NULL, 'Breast, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(782, 'GPX100', NULL, NULL, 'NO', 'Phase II Adriamycin analog. Gem Pharmaceuticals.', NULL, 'Breast cancer', NULL, NULL, 'Chemotherapy', 'Anthracycline;Antitumor antibiotics'),
(783, 'GPX150', NULL, NULL, 'NO', 'Phase I Adriamycin analog. Gem Pharmaceuticals.', NULL, 'Sarcoma', NULL, NULL, 'Chemotherapy', 'Anthracycline;Antitumor antibiotic'),
(784, 'Granisetron Hydrochloride', NULL, NULL, 'YES', 'A selective serotonin receptor antagonist, antiemetic.', 'BRL 43694 , BRL-43694 , BRL43694 , Kytril', NULL, NULL, NULL, 'Ancillary Agent', 'Antiemetic'),
(785, 'GS7904L', NULL, NULL, 'NO', 'Phase I Thymidine synthase inhibitor. OSI Pharmaceuticals.', 'OSI 7904L , OSI-7904L , OSI7904L', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Liposomal cytotoxic agent'),
(786, 'GSK-2118436', NULL, NULL, 'NO', 'I and II New drug currently in trials, code in other therapy', NULL, 'Melanoma', NULL, NULL, 'Chemotherapy', 'BRAF kinase inhibitor'),
(787, 'GTI-2040', NULL, NULL, 'NO', 'Phase II colorectal, kidney, NSCLC, prostate, Phase I other Antisense. Lorus Therapeutics, NCI.', NULL, 'Breast, colorectal, kidney, lung, other cancer, prostate', NULL, '722929', 'Chemotherapy', 'Antisense oligonucleotide'),
(788, 'GTI-2501', NULL, NULL, 'NO', 'Phase I Lorus Therapeutics.', NULL, 'Breast, colorectal, lung, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(789, 'Guanazole', NULL, NULL, 'NO', NULL, 'Guanazole , Guanazole (VAN 8CI) , Guanazole (VAN8CI) , MC 51762 , MC51762', NULL, NULL, '1895', 'Chemotherapy', 'Antimetabolite'),
(790, 'Guanfacine', NULL, NULL, 'YES', 'Rx of AIDS Dementia Complex', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(791, 'Guanfacine Hydrochloride', NULL, NULL, 'YES', 'A centrally acting antihypertensive.', 'BS-100-141 , LON-798 , Tenex', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(792, 'Gusperimus', NULL, NULL, 'NO', 'Not effective in a clinical trial for treating recurrent squamous cell cancer of the head and neck.  Some in vitro and in vivo antitumor activity against leukemia.', '15-Deoxyspergualin Hydrochloride , BMS-181173 , BMY-42215-1 , Deoxyspergualin Hydrochloride , Deoxyspergualin HCl , Gusperimus hydrochloride , Gusperimus trihydrochloride , Heptanamide , NTK-01', NULL, 'DSG', '356894', 'Chemotherapy', 'Antitumor antibiotic'),
(793, 'GVAX Lung Cancer Vaccine', NULL, NULL, 'NO', 'Phase I/II (breast, MM) Phase II AML, NSCLC, pancreatic, prostate Cell cancer vaccine with GM-CSF gene. Cell Genesys, Inc.', 'CG 8123 , CG-8123 , CG8123', 'Breast, leukemia, lung, multiple myeloma, pancreatic, prostate cancer', NULL, '730428', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(794, 'GVAX Prostate Cancer Vaccine', NULL, NULL, 'NO', 'Phase II Cell Genesys.', NULL, 'Pancreatic  caner', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(795, 'GW120918', NULL, NULL, 'NO', 'Phase I Multidrug resistance protein inhibitor. GlaxoSmithKline.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--inhibitor--tyrosine kinase'),
(796, 'GW572016', NULL, NULL, 'NO', 'Phase I ErbB-2 and EGFR dual kinase inhibtor. GlaxoSmithKline.', NULL, 'Other cancer', NULL, '727989', 'Chemotherapy', 'Cytostatic agent--inhibitor--tyrosine kinase'),
(797, 'H11-scFv', NULL, NULL, 'NO', 'Phase I/II Recombinant human monoclonal antibody fragment. Viventia Biotech.', NULL, 'Breast cancer, other cancer', 'H11', NULL, 'Chemotherapy', 'Cytostatic agent'),
(798, 'Halofuginone', NULL, NULL, 'NO', 'Phase II Collagen type 1 synthesis inhibitor. Collgard Biopharmaceuticals.', 'Halofuginone hydrobromide', 'Other cancer', NULL, '713205', 'Chemotherapy', 'antiangiogenesis agent;Cytostatic agent--inhibitor'),
(799, 'Haloperidol', NULL, NULL, 'YES', 'An antipsychotic agent.', 'Alti-Haloperidol , Apo-Haloperidol , Haldol , Haldol Decanoate , Halperon , Novo-Perdiol , Peridol , PMS-Haloperidol , R-1625', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(800, 'Haloprogesterone', NULL, NULL, 'NO', 'Progestin', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(801, 'Hematoporphyrin Derivative', NULL, NULL, 'YES', 'Emits fluorescence in neoplastic cells', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(802, 'Hemopure', NULL, NULL, 'YES', 'Phase II Biopure', 'HBOC201 , Hemoglobin glutamer-250', 'Brain cancer', NULL, NULL, 'Ancillary Agent', 'Alternative to blood transfusions'),
(803, 'Hepsulfam', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '329680', 'Chemotherapy', 'Alkylating agent'),
(804, 'HER-2/neu Vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. Corixa.', 'HER-2/NEU peptide vaccine', 'Breast, ovarian, prostate cancer', NULL, '694158', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(805, 'Heroin Hydrochloride', NULL, NULL, 'YES', 'There is no reason to use diamorphine over morphine or other potent opioids.', 'Diacetylmorphine dihydrochloride , Diacetylmorphine Hydrochloride , Diamorphine HCl , Diamorphine Hydrochloride , Heroin hydrochloride', NULL, NULL, '302357', 'Ancillary Agent', NULL),
(806, 'Herzuma', NULL, NULL, 'NO', '12/14/2018 FDA approved Herzuma (trastuzumab-pkrb) as a biosimilar to Herceptin (trastuzumab) for patients with HER2-overexpressing breast cancer. Herzuma is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.', 'Trastuzumab-pkrb', 'Breast', NULL, 'Biosimilar', 'Biologic therapy (BRM, immunotherapy)', NULL),
(807, 'Herzyme', NULL, NULL, 'NO', 'Phase I Anti-Her-2 ribozyme. Medizyme Pharmaceuticals.', NULL, 'Breast cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--anti-HER2'),
(808, 'Hexestrol', NULL, NULL, 'NO', 'Diethylstilbestrol derivative having the uses of estrogen; administered orally and parenterally', 'Cycloestrol , Estrifar , Estronal , Extra-Plex , Hexanoestrol , Hexestro-fen , Hexoestrol , Hormoestrol , Sinestrol , Synestrol , Synoestrol , Synthovo , Syntrogene', NULL, NULL, '9894', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(809, 'hIL13-PE38QQR (ligand targeted toxin)', NULL, NULL, 'NO', 'Phase I/II Immunotoxin. NeoPharm.', NULL, 'Kidney cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin'),
(810, 'Histrelin', NULL, NULL, 'NO', 'Phase III Gonadotropin releasing hormone antagonist. Shire Pharamceuticals Group.', 'ORF 17070 , RWJ 17070', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone'),
(811, 'HIV immunogen', NULL, NULL, 'YES', 'Inactivated virus incorporated in modified Freund\'s adjuvant', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(812, 'HIV-1 Immunogen', NULL, NULL, 'YES', 'A human immunodeficiency virus type 1 (HIV-1) therapeutic vaccine', 'GP120-Depleted HIV-1 Immunogen , HIV Immunotherapeutic , HIV Therapeutic Vaccine , HIV Vaccine , RG 83894 , Remune , Salk HIV Vaccine , Salk HIV-1 Immunogen Therapeutic Vaccine , Salk immunogen', NULL, NULL, NULL, 'AIDS drug', 'AIDS vaccine'),
(813, 'HLTV antibody', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(814, 'HMBA', NULL, NULL, 'YES', NULL, 'Hexamethylene bisacetamide , Hexamethylene diacetamide', NULL, NULL, '95580', 'Differentiation inducing agent', NULL),
(815, 'Homoharringtonine', NULL, NULL, 'NO', 'Phase II/III CML Plant alkaloid. NCI, American Bioscience. Later investigated as anti-angiogenic. ChemGenex Therapeutics.', 'Ceflatonin , Cephalotaxine', 'Leukemia, myeloid leukemia (CML) and myelodysplastic syndrome (MDS)', 'HH, HHT', '141633', 'Chemotherapy', 'Plant alkaloid'),
(816, 'HPA-23', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(817, 'HPMPC', NULL, NULL, 'YES', 'Under investigation of asymptomatic CMV infections', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(818, 'HPV vaccine', NULL, NULL, 'NO', 'Phase II Vaccine. MedImmune.', NULL, 'Cervical cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(819, 'HPV-16 E7: 86-93', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '719248', 'Biologic therapy (BRM, immunotherapy)', NULL),
(820, 'HPV16 E7 Peptide Vaccine', NULL, NULL, 'NO', 'Phase I Peptide vaccine. NCI.', 'HPV 16 E7:12-20', 'Cervical cancer', NULL, '673925', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(821, 'HPV16, E6 Peptide Vaccine', NULL, NULL, 'NO', 'Phase I Peptide vaccine. NCI.', 'HPV 16 E6:18-26', 'Cervical cancer', NULL, '673924', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(822, 'hR3', NULL, NULL, 'NO', 'Phase II Anti EGFr antibody. TheraCIM.', 'Naked humanized Mab to EGFr', 'Head & neck cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--anti-EGFR'),
(823, 'HS1-TK', NULL, NULL, 'NO', 'Phase I Gene therapy. Avax Therapeutics.', NULL, 'Brain cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(824, 'HSPE7', NULL, NULL, 'NO', 'Phase II completed Immunotherapeutic.  Anti-HPV.  StressGen Biotechnologies.', NULL, 'Cervical cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(825, 'HuC242-DMI/SB-408075 (cantuzumab mertasine)', NULL, NULL, 'NO', 'Phase I/II Monoclonal antibody. ImmunoGen, GlaxoSmithKline.', NULL, 'Colorectal, lung, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Monoclonal antibody combined with maytansinoid toxin'),
(826, 'HuLuc63', NULL, NULL, 'NO', 'Phase II Binds to myeloma cells and flags them for killing by the immune system.  BioPharma', 'HuLuc 63', 'Myeloma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(827, 'Human Growth Hormone', NULL, NULL, 'YES', 'Therapy for HIV-related wasting disease', 'Protropin (recombinant human growth hormone)', NULL, NULL, NULL, 'AIDS drug', NULL),
(828, 'Human leukocyte interferon (Meloy)', NULL, NULL, 'NO', NULL, 'Human leukocyte interferon (Meloy)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(829, 'Human leukocyte interferon (W-L)', NULL, NULL, 'NO', NULL, 'Human leukocyte interferon (W-L)', NULL, NULL, '340855', 'Biologic therapy (BRM, immunotherapy)', NULL),
(830, 'Human leukocyte interferon, Beta (Mochida)', NULL, NULL, 'NO', NULL, 'Beta (Mochida) , Human leukocyte interferon', NULL, NULL, '605606', 'Biologic therapy (BRM, immunotherapy)', NULL),
(831, 'Human T-Lymphotropic Virus Type III GP160 Antigens', NULL, NULL, 'YES', 'Under investigation in phase I to III trials.Not found in Drugdex drug evaluation.', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(832, 'HumaRAD', NULL, NULL, 'YES', 'Phase I ovarian Phase III head & neck Human antibody linked to radiosensitizer. Intracel.', NULL, 'Head & neck, Ovarian cancer', NULL, NULL, 'Ancillary Agent', 'Radiosensitizer linked to Mab'),
(833, 'HumaSPECT', NULL, NULL, 'YES', 'Phase II Diagnostic fully human monoclonal antibody. Intracel.', '88BV59 , 88BV59H21-2V67-66 , Votumumab', 'Ovarian cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(834, 'HuN901-DM1/BB-10901', NULL, NULL, 'NO', 'Phase II NSCLC A conjugate of the humanised N901 mAb with the maytansinoid, DM1, is a Tumour-Activated Pro-drug (TAP). British Biotech, ImmunoGen.', NULL, 'Lung cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin'),
(835, 'Hycanthone Mesylate', NULL, NULL, 'NO', 'Used as a schistosomicide. Owing to its toxicity and concern about possible carcinogenicity, mutagenicity, and teratogenicity, hycanthone has been replaced by other drugs such as praziquantel.', 'Etrenol , Hycanthone methanesulfonate , Hycanthone monomethanesulfonate , Hydroxylucanthone Methanesulphonate , Win-24933', NULL, NULL, '142982;134434', 'Chemotherapy', 'Alkylating agent'),
(836, 'Hydrazine Sulfate', NULL, NULL, 'YES', 'Hydrazine sulfate, which may influence carbohydrate metabolism, has been evaluated in clinical drug trials for its effects on anorexia and cachexia of advanced cancers, with disappointing results. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, '150014', 'Ancillary Agent', NULL),
(837, 'Hydrocortisone', NULL, NULL, 'YES', 'The official preparation, usually a topical agent and its salts are used in the treatment of inflammations, allergies, pruritus, collagen diseases such as rheumatoid arthritis and systemic lupus erythematosus, some neoplasms, acute or chronic adrenocortical insufficiency, severe status asthmaticus, and shock.\r\n\r\nDO NOT CODE unless the physician clearly states it is being prescribed to treat/destroy the cancer cells.', 'A-Hydrocort , AA-HC Otic , Acticort , Aeroseb-HC , AK-Spore HC , Ala-Cort , Ala-Scalp HP , Alocort , Alphaderm , Anucort-HC , Anusol-HC , Barriere HC , Bio sone , Caldecort , Cetacort , Clobetasol cream , Colocort , Cort-Dome , Cort-Eze , Cort-Nib , Cortacet , Cortaid , Cortamed , Cortate , Cortef , Cortef Acetate , Cortenema , Corticaine , Corticreme , Cortifoam , Cortiment , Cortizone , Cortoderm , Cortril , Delacort , Dermacort , Dermaflex HC , Dermicort , Dermolate , Dermtex HC with Aloe , Doctient HC , Emo-Cort , Genaspor , Gynecort , Hemarrhoidal HC , Hemcort HC , Hemorrhoidal , Hemril HC , Hi-Cor , Hycort , Hyderm , Hydrocortisone Acetate , Hydrocortisone Sodium Succinate , Hydrocortisone Valerate , Hydrocortone Acetate , Hydrocortone Phosphate , Hydromar , Hydrotex , Hytone , Kericort , Lacticare HC , Lanacort , Lifocort , Locoid , Massengill Medicated Soft Cloth Towelette , Maximum Strength Cortaid , Maximum Strength Hydrocortisone , Messengill Medicated soft Cloth Towelette , No More Itchies , Novo-Hydrocort , Nupercainal Hydrocortisone , Nutracort , Orabase HCA , Otisporin , Penecort , Preparation H , Prevex HC , Proctocort , Proctocream-HC , Proctozone-H , Recort Plus , Rectocort , Re', NULL, 'HC', '010483;10483', 'Hormones and hormonal mechanisms', 'Glucocorticoid');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(838, 'Hydrocortisone Acetate', NULL, NULL, 'NO', 'Glucocorticoid; an ester of hydrocortisone, having actions and uses similar to those of the base; administered by intra-articular, intralesional, or soft-tissue injection or applied topically to the skin, external acoustic canal, or conjunctiva.  Not in Drug Evaluations', 'Actinac , Alocort , Anodan-HC , Anucort-HC , Anugesic-HC , Anumed HC , Anuprep HC , Barseb , Caldecort , Carmol HC , Clocort , Coracin , Cort-Dome , Cortacet , Cortaid , Cortamed , Cortef , Cortef acetate , Corticaine , Cortifoam , Cortiment , Cortiprel , Cortoderm , Cortril acetate-AS , Dermaflex HC , Dermarest Dricort , Epifoam , Fernisone , Hemorrhoidal-HC , Hemril-HC , Hyderm , Hydrocort , Hydrocortisone 21-acetate , Hydrocortone , Komed-HC , Lanacort , Nupercainal HC , Orabase , Pharma-Cort , Rhulicort , Scalpicin , Wincort', NULL, NULL, '741', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(839, 'Hydrocortisone Sodium Phosphate', NULL, NULL, 'NO', 'Glucocorticoid; a water-soluble ester of hydrocortisone used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered intramuscularly, intravenously, or subcutaneously . Not found in Drugdex drug evaluation.', 'Hydrocortone Phosphate', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(840, 'Hydrocortisone Sodium Succinate', NULL, NULL, 'NO', 'Glucocorticoid; a water-soluble ester of hydrocortisone used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered intramuscularly, intravenously, or subcutaneously. Not found in Drugdex drug evaluation.', 'A-Hydrocort , Hydrocortisone 21-(sodium succinate) , Solu-Cortef', NULL, 'HDC', NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(841, 'Hydromorphone Hydrochloride', NULL, NULL, 'YES', 'A potent narcotic analgesic. It is used to alleviate moderate-to-severe, acute pain and chronic pain, particularly from terminal cancer.', 'Dilaudid , Hydromorph Contin , PMS Hydromorphone', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(842, 'Hydroxizine Hydrochloride', NULL, NULL, 'YES', 'An antihistamine that possesses significant central nervous system depressant activity.', 'Anxanil , Atarax , E-Vista , Hydrophed , Hyzine , Marax , Multipax , Neucalm 50 , Quiess , Theomax DF , Vistacon , Vistaject , Vistaril , Vistazine', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(843, 'Hydroxychloroquine Sulfate', NULL, NULL, 'YES', 'A synthetic antimalarial agent that is a 4-aminoquinoline derivative.', 'Plaquenil , Plaquenil Sulfate , Quineprox , Win-1258-2', NULL, NULL, NULL, 'AIDS drug', NULL),
(844, 'Hydroxypicolinaldehyde thiosemicarbazone', NULL, NULL, 'NO', NULL, NULL, NULL, '5-HP', '107392', 'Chemotherapy', 'Antimetabolite'),
(845, 'Hydroxyprogesterone Caproate', NULL, NULL, 'NO', 'A progestational agent, it has been shown useful as an adjuvant agent in the treatment of hormone responsive tumors.  A water-soluble ester of hydrocortisone used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered intramuscularly or intravenously.', '17-AHPC , 17-alpha-Hydroxyprogesterone , Component of Deluteval 2X# , Delalutin# , Duralutin , Gesterol , Gesterol LA 250 , Hy-Gestrone , Hydroxyprogesterone Hexanoate , Hylutin , Hyprogest , Pro-Depot , Prodrox , Proluton Depot', 'Endometrial cancer', NULL, '017592;17592', 'Hormones and hormonal mechanisms', 'Progestin'),
(846, 'Hydroxyurea', NULL, NULL, 'NO', 'FDA approved uses on chronic myelogenous leukemia, head and neck cancers, melanoma, and advanced ovarian cancer.', 'Carbamo-hydroximic acid , Carbamohydroxamic acid , Carbamoyl oxime , Droxia , Hidrix , Hydrea , Hydreia , hydroxy- , Hydroxycarbamide , Hydroxycarbamine , Hydroxyl-urea , Hydura , Litaler , Litalir , Onco-Carbide , Oxyurea , SQ-1089 , Urea , WR-83799', 'Brain cancer, CML, Head and neck cancers, Melanoma, Ovarian cancer, Essential thrombocytosis, Polycythemia Vera', 'HU, HUR, HYD', '032065;32065', 'Chemotherapy', 'Miscellaneous agent'),
(847, 'Hydroxyzine HC1', NULL, NULL, 'YES', 'Tranquilizer', 'Atarax , Component of Ataxaroid , Component of Cartrax , Component of Enarax , Component of Marax , Component of Vistrax , Quiess , Vistaril', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(848, 'Hynic-AnnexinV', NULL, NULL, 'YES', 'NDA submitted Imaging agent for cell death. North American Scientific.', NULL, 'Other cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(849, 'Hyperbaric Oxygen', NULL, NULL, 'NO', 'Radiation-sensitizing agent', NULL, NULL, NULL, NULL, 'Other therapy', 'Other cancer-directed'),
(850, 'Hypercin', NULL, NULL, 'YES', 'Phase II brain, T-cell Polycyclic dione. Nexell Therapeutics.', 'VIMRxyn', 'Brain cancer, Lymphoma', NULL, NULL, 'Ancillary Agent', 'Herbal derivative of St. John\'s Wort'),
(851, 'Hypericin', NULL, NULL, 'YES', 'Treatment of cutaneous T-cell lymphoma.', NULL, NULL, 'St. John\'s Wort', NULL, 'AIDS drug', NULL),
(852, 'Ibrutinib', NULL, NULL, 'NO', 'The FDA has given ibrutinib the breakthrough therapy designation. The FDA has granted approval for this drug November 13, 2013. This drug is in additional clinical trials looking at its effect in combination with other agents in treatment of other types of leukemic and lymphoid malignancies. \r\n\r\nMarch 4, 2016 The FDA has approved Imbruvica (ibrutinib) as first course treatment for patients with chronic lymphocytic leukemia.\r\n\r\nAugust 4, 2017: FDA has approved ibrutinib (Imbruvica) for adult patients with chronic graft versus host disease after failure of one or more lines of systemic therapy, making it the first FDA-approved therapy for the treatment of cGVHD.', 'Imbruvica , PCI-32765 , RESONATE', 'B-cell malignancies, CLL, Mantle cell lymphoma, Multiple myeloma, NHL, Waldentrom macroglobulinemia (WM), diffuese B-cell lymphoma', NULL, '748645', 'Chemotherapy', 'Bruton tyrpsine kinase (Btk)'),
(853, 'ICT-107', NULL, 'Glioblastoma', 'NO', 'ICT-107 is an autologous (patient-derived) dendritic cell (DC) immunotherapy that targets six different antigens (peptides that are tumor markers: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13Ra2) associated with glioblastoma, a form of brain cancer. At least four of these tumor-associated antigens are highly expressed on cancer stem cells (CSCs). ICT-107 is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with standard treatment of radiation and chemotherapy. ICT-107 is a cancer immunotherapy', NULL, 'Brain', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Patient derived dendritic cell immunotherapy'),
(854, 'Idarubicin', NULL, NULL, 'NO', 'An anthracycline antineoplastic agent. FDA approved uses on acute lymphocytic and non-lymphcytic leukemia.', '4-Demethoxydaunorubicin , Idamycin , Idamycin PFS , Idarubicin hydrochloride , IMI 30 , IMI-30 , SC-33428', 'Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic myelogenous leukemia in blast crises, Myelodysplastic syndromes (MDS)', '4-DMDR, IDA', '256439', 'Chemotherapy', 'Antitumor antibiotic'),
(855, 'Idhifa', NULL, 'AML', 'NO', 'August 1, 2017 FDA approved Idhifa (enasidenib) for treatment of relapsed or refractory acute myeloid leukemia (AML).', 'Enasidenib', NULL, NULL, NULL, 'Chemotherapy', 'IDH2 inhibitor'),
(856, 'Idiotype immuno.', NULL, NULL, 'NO', 'Phase III low grade B-cell NHL Idiotype vaccine. Genitope Corp.', NULL, 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(857, 'Idiotype KLH Lymphoma Vaccine', NULL, NULL, 'NO', 'Phase III NHL follicular Vaccine. NCI.', 'Lymphoma IG vaccine-KLH', 'Lymphoma', NULL, '659770', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(858, 'Idiotype Tumor Vaccine', NULL, NULL, 'NO', 'Phase III NHL Preventive vaccine. Biovest International.', NULL, 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(859, 'Idiotype Vaccine Idiotypic', NULL, NULL, 'NO', 'Phase I NHL B-cell Vaccine. Biomira.', NULL, 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(860, 'Idoxifene', NULL, NULL, 'NO', 'Phase II GlaxoSmithKline', 'CB-7432 , SB-223030', 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Antiestrogen'),
(861, 'Idoxuridine', NULL, NULL, 'YES', 'An antiviral agent used primarily in herpetic keratitis.  Idoxuridine is not recommended for inclusion on the hospital formulary since other agents are more effective; radiosensitizer', 'Allergan 211 , Dendrid , Emanil , Herpesil , Herpidu , Herplex , Herplex Liquifilm , Idexur , Idoxuridin , Idu-Oculos , Iducher , Idulea , Iduridin , Iododeoxyuridine , Joddeoxyuridin , Kerecid , Ophthalmadine , SK&F 14287 , Stoxil , Synmiol Dendrid Ophthalmic Solution', NULL, '5-IUDR, IDU, IDUR, IdUrd, IUdR', '39661;039661', 'Ancillary Agent', NULL),
(862, 'IFN: Leukocyte (Meloy)', NULL, NULL, 'NO', NULL, 'IFN: Leukocyte (Meloy)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(863, 'IFN: Rec Gamma (Schering)', NULL, NULL, 'NO', NULL, 'IFN: Rec Gamma (Schering)', NULL, NULL, '609473', 'Biologic therapy (BRM, immunotherapy)', NULL),
(864, 'Ifosfamide', NULL, NULL, 'NO', 'Antineoplastic with alkylating activity. FDA approved.', 'A-4942 , Asta Z-4942 , Cyfos# , Holoxan 1000 , Ifex , Ifosfamid , Ifoxan , Iphosphamid , Iphosphamide , Iso-endoxan , Isofosfamide , Isophos-phamide , Isophosphamide , Mitoxana , MJF 9325 , MJF-9325 , Naxamide# , Z4942', 'Bladder, Cervical cancer, Ewing sarcoma, Head and Neck, Hodgkin lymphoma, Non-Hodgkin lymphoma, Non-small cell and small cell lung cancer, Soft tissue sarcoma, osteogenic sarcoma, Testicular cancer', 'IFX, IPP', '109724', 'Chemotherapy', 'Alkylating agent'),
(865, 'IL-1 alpha (Immunex)', NULL, NULL, 'NO', NULL, 'IL-1 alpha (Immunex)', NULL, NULL, '640032', 'Biologic therapy (BRM, immunotherapy)', NULL),
(866, 'IL-1 alpha, Interleukin-1 alpha (Dainippon)', NULL, NULL, 'NO', NULL, 'IL-1 alpha , Interleukin-1 alpha (Dainippon)', NULL, NULL, '621381', 'Biologic therapy (BRM, immunotherapy)', NULL),
(867, 'IL-1 Beta (Syntex) + IL-2 (Cetus)', NULL, NULL, 'NO', NULL, 'IL-1 Beta (Syntex) + IL-2 (Cetus)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(868, 'IL-12 DNA Vaccine', NULL, NULL, 'NO', 'Phase I NCI.', 'pNGVL3-hIL 12', 'Other cancer', NULL, '709933', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(869, 'IL-2', NULL, NULL, 'NO', NULL, 'IL-2 , Recombinant Interleukin-2', NULL, NULL, '373364', 'Biologic therapy (BRM, immunotherapy)', NULL),
(870, 'IL-2 (CT)/MDELAK', NULL, NULL, 'NO', NULL, 'IL-2 (CT)/MDELAK', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(871, 'IL-2 (CT)/TIL (BiorExp)', NULL, NULL, 'NO', NULL, 'IL-2 (CT)/TIL (BiorExp)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(872, 'IL-2 (HR)', NULL, NULL, 'NO', NULL, 'IL-2 (HR)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(873, 'IL-2 (HR)/OKT 3-LAK', NULL, NULL, 'NO', NULL, 'IL-2 (HR)/OKT 3-LAK', NULL, NULL, '600664', 'Biologic therapy (BRM, immunotherapy)', NULL),
(874, 'IL-2 + IL-4 (Cetus + Sterling)', NULL, NULL, 'NO', NULL, 'IL-2 + IL-4 (Cetus + Sterling)', NULL, NULL, '620211', 'Biologic therapy (BRM, immunotherapy)', NULL),
(875, 'IL-2 + IL-4 HLR/STRLNG', NULL, NULL, 'NO', NULL, 'IL-2 + IL-4 HLR/STRLNG', NULL, NULL, '600664', 'Biologic therapy (BRM, immunotherapy)', NULL),
(876, 'IL-2 Jurkat Derived', NULL, NULL, 'NO', NULL, 'IL-2 Jurkat Derived', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(877, 'IL-2 Natural (Collaborative)', NULL, NULL, 'NO', NULL, 'IL-2 Natural (Collaborative)', NULL, NULL, '600663', 'Biologic therapy (BRM, immunotherapy)', NULL),
(878, 'IL-2 Polyethylene Glycol (Peg IL-2)', NULL, NULL, 'NO', 'Cetus', 'IL-2 Polyethylene Glycol (Peg IL-2)', NULL, NULL, '625376', 'Biologic therapy (BRM, immunotherapy)', NULL),
(879, 'IL-2 Recombinant', NULL, NULL, 'NO', NULL, 'IL-2 Recombinant', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(880, 'IL-2/AutoEduLymph (HLR)', NULL, NULL, 'NO', NULL, 'IL-2/AutoEduLymph (HLR)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(881, 'IL-2/TIL (HLR)', NULL, NULL, 'NO', NULL, 'IL-2/TIL (HLR)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(882, 'IL-2: Rec (Cetus) + TIL', NULL, NULL, 'NO', NULL, 'IL-2: Rec (Cetus) + TIL', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(883, 'IL-2: Rec (Cetus), Aldesleukin, Proleukin', NULL, NULL, 'NO', NULL, 'Aldesleukin , IL-2: Rec (Cetus) , Proleukin', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(884, 'IL-2: Rec (Shionogi), S6820', NULL, NULL, 'NO', NULL, 'IL-2: Rec (Shionogi) , S6820', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(885, 'IL-2: Rec.(HLR)', NULL, NULL, 'NO', NULL, 'IL-2: Rec.(HLR)', NULL, 'CYC', '600664', 'Biologic therapy (BRM, immunotherapy)', NULL),
(886, 'IL-3 + GM-CSF (Sandoz)', NULL, NULL, 'NO', NULL, 'IL-3 + GM-CSF (Sandoz)', NULL, NULL, '641115', 'Biologic therapy (BRM, immunotherapy)', NULL),
(887, 'IL-4 (K)/IL-2 (CT)', NULL, NULL, 'NO', NULL, 'IL-4 (K)/IL-2 (CT)', NULL, NULL, '620211', 'Biologic therapy (BRM, immunotherapy)', NULL),
(888, 'IL-4 (K)/IL-2 (HR)', NULL, NULL, 'NO', NULL, 'IL-4 (K)/IL-2 (HR)', NULL, NULL, '620211 600664', 'Biologic therapy (BRM, immunotherapy)', NULL),
(889, 'IL13-PE38QQR', NULL, NULL, 'NO', 'Phase I/II Cytokine plus psudomonas exotoxin A derivative. NeoPharm.', NULL, 'Brain cancer', NULL, '722759', 'Chemotherapy', 'Cytotoxic immunotherapy'),
(890, 'IL:-2 (HR)/OKT 3-LAK', NULL, NULL, 'NO', NULL, 'IL:-2 (HR)/OKT 3-LAK', NULL, NULL, '600664 618843', 'Biologic therapy (BRM, immunotherapy)', NULL),
(891, 'Ilmofosine', NULL, NULL, 'NO', 'Investigated for its antineoplastic properties. In M\'dale for archival purpose only.', 'BM 41440 , BM-41440 , BM41440', NULL, NULL, NULL, 'Chemotherapy', 'Antineoplastic no longer in use'),
(892, 'ILX-651', NULL, NULL, 'NO', 'Phase I Synthetic peptide. ILEX Oncology.', 'Tasidotin', 'Melanoma, non-small cell lung cancer, prostate', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(893, 'ILX23-7553', NULL, NULL, 'NO', 'Phase I Vitamin D analog. ILEX Oncology.', NULL, 'Colorectal, other cancer', NULL, NULL, 'Chemotherapy', 'Antineoplastic'),
(894, 'IM862', NULL, NULL, 'NO', 'Phase II, Phase III Kaposi sarcoma Phase II metastatic melanoma Anti-angiogenic. ALZA Pharmaceuticals, Cytran.', 'Fef5', 'Breast, colorectal, kidney, ovarian, prostate, sarcoma, skin cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--angiogenesis inhibitors'),
(895, 'Imatinib mesylate', NULL, NULL, 'NO', 'January 31, 2012: Gleevec received FDA approval for expanded use in pathients with rare gastrointestinal cancer.\r\nPhase II (gastric, other); orphan drug status for GIST, HES, CEL, Ph+ ALL, DFP, GIST\r\nTyrosine kinase inhibitor. FDA approved use on chronic myelogenous leukemia and GI stromal tumor gist. Novartis Pharmaceuticals, NCI.\r\nSeptember: A generic Gleevec tablet produced by Apotex Corporation released.', 'Gleevec , Glivec , STI 571 , STI-571 , STI571', 'aggressive mastocytosis, chronic eosinophilic leukemia, Colorectal, dermatofibrosarcoma protuberans, gastric, GIST, hypereosinophilic syndrome, leukemia, lung, other cancer, Ph+ALL', NULL, '716051', 'Chemotherapy', 'Targeted therapy--tyrosine kinase inhibitor'),
(896, 'Imbruvica', NULL, 'Marginal zone lymphoma', 'NO', '8/31/2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia\r\n\r\n1/27/2017: FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.', 'imbrutinib', NULL, NULL, NULL, 'Chemotherapy', 'Bruton\'s tyrosine kinase (BTK) inhibitor'),
(897, 'IMC-1c111', NULL, NULL, 'NO', 'Phase I Anti-angiogenic. ImClone Sytems,', 'Anti-TDR antibody', 'Colorectal, skin cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(898, 'IMC-A12', NULL, NULL, 'NO', '2012 Currently in multiple clinical trials for melanoma, GIST, and prostate \r\nCode as Other Terapy until FDA approval\r\nImClone', 'Cixutumumab', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti-insulin-like growth facotr-1 receptor (IGR-IR) monoclonal antibody'),
(899, 'Imexon', NULL, NULL, 'NO', 'Orphan drug for the treatment of multiple myeloma; synthetic chemical', NULL, NULL, NULL, '714597', 'Chemotherapy', 'Apoptosis inducer'),
(900, 'Imipenem', NULL, NULL, 'NO', 'Antibiotic', 'Component of Primaxin , Imipemide# , MK-787 , N-Formimidoyl thienamycin', NULL, NULL, NULL, 'AIDS drug', 'Antibiotic'),
(901, 'Imipenem and Cilastatin', NULL, NULL, 'YES', 'Imipenem is a thienamycin derivative with a broader antimicrobial spectrum and greater potency than any other beta-lactam antibiotic; cilastatin reduces imipenem metabolism by inhibiting dehydropeptidase.', 'Primaxin', NULL, NULL, NULL, 'AIDS drug', NULL),
(902, 'Imiquimod', NULL, NULL, 'NO', 'Phase III basal cell carcinoma; off-label use for cutaneous melanoma metastases Immune response modifer. 3M Pharmaceuticals.', 'Aldara , R-837 , R837 , S-26308 , S26308', 'Cervical cancer, melanoma, superficial basal cell carcinoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(903, 'Imlygic', NULL, 'Melanoma', 'NO', '10/27/2015: The FDA has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. IMLYGIC is the first oncolytic viral therapy approved by the FDA based on therapeutic benefit demonstrated in a pivotal study.', 'Talimogene Laherparepvec , T-VEC , TVEC', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Viral therapy'),
(904, 'ImmTher', NULL, NULL, 'NO', 'Phase II Muramyl dipeptide immunomodulator. Endorex.', 'GMTP-GDP', 'Sarcoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Passive immunotherapy'),
(905, 'Immune RNA', NULL, NULL, 'NO', 'Mammalian biological product; immunomodulator', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(906, 'Immunotoxin BL22', NULL, NULL, 'NO', 'Phase I Immunotoxin. NCI.', 'PE38 , RFB4(dsFv)', 'Leukemia, lymphoma', NULL, '691237', 'Chemotherapy', 'Immunotoxin'),
(907, 'IMREG-1', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation. Immunostimulant.', 'Imreg-1', NULL, NULL, NULL, 'AIDS drug', NULL),
(908, 'Imuthiol', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation. NDA.', NULL, NULL, 'DTC', NULL, 'AIDS drug', NULL),
(909, 'Imuvert', NULL, NULL, 'NO', 'Orphan drug. Treatment of primary brain malignancies.', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(910, 'Incel', NULL, NULL, 'NO', 'Phase II breast, other, ovarian, prostate, sarcoma, SCLC Multidrug resistant inhibitor (MDRI). Vertex Pharmaceuticals.', 'Biricodar dicitrate , VX-710', 'Breast, lung, other cancer, ovarian, prostate, sarcoma', NULL, '724636', 'Ancillary Agent', 'Inhibits multi-drug resistance'),
(911, 'Indicine-N-oxide', NULL, NULL, 'NO', NULL, 'Indicine , N-oxide', NULL, 'INDI, INO', '132319', 'Chemotherapy', 'antimitotic agent;Plant product'),
(912, 'Indium In 111 imciromab pentetate', NULL, NULL, 'YES', 'A labeled monoclonal antimyosin antibody (Fab fragment) used for the detection of myocardial necrosis.', NULL, NULL, NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(913, 'Indomethacin', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory agent; lowers blood calcium; analgesic', 'APO-Indomethacin , Indo-Lemmon , Indochron , Indocid , Indocin , Novo-Methacin , Nu-Indo', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(914, 'INDOXIMOD', NULL, NULL, 'SEE_REMARKS', '12/18/2019  INDOXIMOD (NLG-8189) chemotherapy. IDO inhibitor currently in Phase 1 and Phase 2 clinical trials for pediatric brain malignancies and AML. Code as “Other” treatment pending FDA approval.', 'NLG-8189', NULL, NULL, NULL, 'Chemotherapy', 'IDO inhibitor'),
(915, 'Infliximab', NULL, NULL, 'NO', 'A chimeric monoclonal antibody to tumor necrosis factor-alpha (TNF-alpha).', 'Anti-TNF monoclonal antibody , cA2 , Remicade', NULL, NULL, '728729', 'Biologic therapy (BRM, immunotherapy)', 'Antibody to TNF'),
(916, 'ING-1 Human Engineered Monoclonal Antibody', NULL, NULL, 'NO', 'Phase II Monoclonal antibody for adenocarcinoma; Xoma Ltd.', NULL, NULL, NULL, NULL, 'Chemotherapy', 'Cytotoxic and cytostatic'),
(917, 'INGN 201', NULL, NULL, 'NO', 'Phase III H&N 2007 Gene therapy; modified adenovirus. Aventis, Introgen Therapeutics, NCI.', 'INGN201 Adenoviral p53', 'Breast, H&N cancer, lung, ovarian', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--adenovirus'),
(918, 'INGN 225', NULL, NULL, 'NO', 'Patient\'s own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.  Introgen.', 'INGN-225 , INGN225', 'SCLC', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(919, 'INGN241', NULL, NULL, 'NO', 'Preclinical melanoma, Phase I other Adenoviral vector. Introgen Therapeutics.', NULL, 'other cancer, Skin', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(920, 'INGN251 (PTEN)', NULL, NULL, 'NO', 'Pre-clinical Gene therapy. Introgen Therapeutics.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(921, 'INNO-406', NULL, NULL, 'NO', 'Dual Bcr-Abl and Lyn-kinase inhibitor.  Innovive Pharmaceuticals', 'NS-187', NULL, NULL, NULL, 'Chemotherapy', 'Cytotoxic agent--multi-target kinase inhibitor'),
(922, 'Inolimomab', NULL, NULL, 'NO', 'An anti-interleukin-2 receptor monoclonal antibody.', 'Anti-CD25 monoclonal antibody B-B10 , Anti-interleukin-2 receptor monoclonal antibody , B-B10 , BT 563 , Leukotac', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', 'Monoclonal antibody'),
(923, 'Inosine - Component of Isoprinosine', NULL, NULL, 'YES', 'Inosine has been used in the treatment of anaemias and cardiovascular, liver, and skin disorders and has been used as a tonic; Component of Isoprinosine', 'Hypoxanthine Riboside', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(924, 'Inproquone', NULL, NULL, 'NO', 'on list of prohibited substances for cosmetics', 'E-39 , Inprochone , RP-6870', NULL, NULL, '17261', 'Chemotherapy', NULL),
(925, 'INS316', NULL, NULL, 'YES', 'Phase III Diagnostic. Inspire Pharmaceuticals.', 'UTP', 'Lung cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(926, 'Insulin-like Growth Factor', NULL, NULL, 'NO', NULL, 'IGF-1 , somatomedin C', NULL, NULL, '648120', 'Hormones and hormonal mechanisms', 'hormone??this is a gene identified;not a drug'),
(927, 'Interferon', NULL, NULL, 'NO', NULL, 'IFN: Immune , Immune interferon (Meloy)', NULL, NULL, '354655', 'Biologic therapy (BRM, immunotherapy)', NULL),
(928, 'Interferon Alfa-2a', NULL, NULL, 'NO', 'Antiviral agent.', 'Recombinant Leukocyte A interferon , Ro 22-8181 (HLR) , Roferon , Roferon-A', 'AIDS, Opportunistic infection', NULL, '367982', 'Biologic therapy (BRM, immunotherapy)', NULL),
(929, 'Interferon Alfa-2b', NULL, NULL, 'NO', 'Phase II/III MDS, melanoma FDA approved uses on Kaposi\'s sarcoma, hairy cell leukemia, follicular lymphoma, malignant melanoma. NCI, Schering-Plough. Recombinant analogue, bacterial', '(B) , Betaseron , Gamma Interferon , IFN: Rec Gamma (Biogen) , Intron A , Recombinant Alpha 2 interferon , Recombinant interferon Gamma , Sch-30500', 'Leukemia, melanoma', NULL, '377523', 'Biologic therapy (BRM, immunotherapy)', NULL),
(930, 'Interferon Alfa-n1', NULL, NULL, 'NO', 'Antiviral agent.', 'Human lymphoblastoid interferon (BW) , purified lymphoblastoid interferon , Wellferon', 'AIDS, Opportunistic infection', NULL, '339140', 'Biologic therapy (BRM, immunotherapy)', NULL),
(931, 'Interferon alfa-n3', NULL, NULL, 'NO', 'Phase II Antiviral agent. Schering-Plough, Interferon Sciences.', 'Alferon , Alferon N , Alferon N Injection , Alferon Rec Gamma (Biogen , Interferon alpha , Interferon Alpha-n3 , Leukocyte Interferon#', 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(932, 'Interferon alfacon-1', NULL, NULL, 'NO', 'Antiviral agent.', 'Consensus interferon , Infergen , Interferon consensus , Interferon-alpha consensus , r-MetHuIFN , Recombinant consensus interferon , rIFN-con-1', 'AIDS, Opportunistic infection', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(933, 'Interferon alpha-NS', NULL, NULL, 'NO', 'Phase I Th1 cytokine. Nastech Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(934, 'Interferon and Interferon inducers', NULL, NULL, 'NO', NULL, 'Human fibroblast interferon', NULL, 'IF, IFN', '335044', 'Biologic therapy (BRM, immunotherapy)', NULL),
(935, 'Interferon Beta (Natural)', NULL, NULL, 'YES', 'A glycoprotein with antiviral, antiproliferative, and immunomodulatory activity; many of its effects are similar to those of interferon alfa. Orphan drug.', 'Endogenous Interferon beta , Fibroblast Interferon , Human Fibroblast Interferon , IFN-beta , Natural Human Interferon beta', NULL, NULL, NULL, 'AIDS drug', NULL),
(936, 'Interferon Beta Gene Therapy', NULL, NULL, 'NO', 'Phase I Gene therapy. Biogen.', NULL, 'Brain cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(937, 'Interferon Beta Ser 17', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, 'ACTG 166', 'Biologic therapy (BRM, immunotherapy)', NULL),
(938, 'Interferon beta-1a', NULL, NULL, 'YES', 'Phase II brain, NSCLC Biogen, Serono.  Immunotherapy for multiple sclerosis', 'Avonex , Betaferon , IFN-beta , Rebif', 'Brain cancer, lung cancer', NULL, NULL, 'Ancillary Agent', NULL),
(939, 'Interferon beta-1b', NULL, NULL, 'YES', 'Antiviral agent.', 'Beta-ser-interferon , Betaseron , Recombinant interferon beta-1b , SH-Y-579A', 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent', NULL),
(940, 'Interferon Gamma', NULL, NULL, 'NO', NULL, NULL, 'Renal cell carcinoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(941, 'Interferon gamma-1b', NULL, NULL, 'NO', 'Antiviral agent. Genentech.', 'Actimmune , IFN-gamma , Immune Actimmune (Genentech) , Immune Interferon , Lymphocyte Interferon , Recombinant interferon Gamma (G) , rIFN-gamma , T-Interferon', 'AIDS, Opportunistic infection', NULL, '600662', 'Biologic therapy (BRM, immunotherapy)', NULL),
(942, 'Interferon natural', NULL, NULL, 'NO', 'Antiviral agent.', 'Endogenous interferon beta , Fibroblast interferon , Human fibroblast interferon , IFN-beta , Natural human interferon beta', 'AIDS, Opportunistic infection', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(943, 'Interferon-alpha', NULL, NULL, 'NO', 'Phase I completed Cytokine gene therapy intratumoral. Valentis.', NULL, 'Head & neck cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(944, 'Interleukin-1 beta', NULL, NULL, 'NO', 'Cytokine; endogenous Pyrogen', 'Catabolin , Endogenous Pyrogen Haematopoietin-1 , IL-1 Beta (Syntex) , Interleukin-1 Beta , Leucocyte Endogenous Mediator , Lymphocyte Activating Factor', 'AIDS, Opportunistic infection', 'IL-1', '628282', 'Biologic therapy (BRM, immunotherapy)', NULL),
(945, 'Interleukin-10', NULL, NULL, 'NO', 'A pleotropic cytokine.', 'IL-10', 'AIDS, Opportunistic infection', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(946, 'Interleukin-12', NULL, NULL, 'NO', 'Phase I/II Cytokine biologic response modifier (BRM). Genetics Institute, NCI, Valentis.', 'IL-12', 'Breast, cervical, head & neck, kidney, lung, melanoma, multiple myeloma, ovarian cancer', NULL, '672423', 'Biologic therapy (BRM, immunotherapy)', NULL),
(947, 'Interleukin-12, Interferon-alpha', NULL, NULL, 'NO', 'Phase I melanoma Combination gene therapy. Valentis.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(948, 'Interleukin-2', NULL, NULL, 'NO', 'Phase I (head & neck) Phase III (AML, NHL) Cytokine; Lymphokine; results in  proliferation and expansion of activated T-lymphocytes', 'Aldesleukin , BG-8301 , Costimulator , Epidermal thymocyte activating factor , Human Jurkat Tumor Derived (Dupont) , IL-2 /Adherent LAK (CT) , IL-2 Jurkat derived , Lymphocyte mitogenic factor , Proleukin , Ril-2 , T-Cell Growth Factor , Teceleukin , Thymocyte Stimulating Factor', 'AIDS, breast, head & neck cancer, leukemia, lymphoma, Opportunistic infection', 'ETAF, IL-2, Ril-2, TCGF', '364831', 'Biologic therapy (BRM, immunotherapy)', NULL),
(949, 'Interleukin-2 liposome', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(950, 'Interleukin-2/Super Antigen B Gene Combination', NULL, NULL, 'NO', 'Phase I/II metastatic melanoma Immunotherapy by direct injection. Valentis.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(951, 'Interleukin-21', NULL, NULL, 'NO', 'Pre-clinical Protein. ZymoGenetics, NovoNordisk A/S.', 'IL-21', 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(952, 'Interleukin-3', NULL, NULL, 'YES', 'Sandoz', 'IL-3 , ILE-964', NULL, NULL, '641115', 'AIDS drug', NULL),
(953, 'Interleukin-4', NULL, NULL, 'NO', 'Phase II A cytokine with immunomodulatory activity. NCI, Schering-Plough.', 'IL-4 , Interleukin-4 (Immunex) Eastman Kodak', 'Breast, colorectal, leukemia, lymphoma, melanoma, ovarian cancer', NULL, '620611;620211', 'Biologic therapy (BRM, immunotherapy)', NULL),
(954, 'Interleukin-6', NULL, NULL, 'NO', 'Cytokine.', 'B-cell differentiation factor , Beta-2-IF , Hepatocyte-stimulating factor , Interferon-beta-2 , Recombinant human interleukin-6 , RhIL-6 , SDZ ILS 969 , Sigosix', 'AIDS, Opportunistic infection', 'BCDF', '643497', 'Biologic therapy (BRM, immunotherapy)', NULL),
(955, 'IntraDose', NULL, NULL, 'NO', 'Phase II (breast, liver, pancreatic) Phase III (colorectal, localized melanoma) Targeted intratumoral (IT) therapy. Matrix Pharmaceuticals (breast, liver, pancreatic); Chiron Corp (colorectal, head & neck).', 'Cisplatin/epinephrine injectable gel', 'Breast, colorectal, head & neck, liver, melanoma, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent'),
(956, 'Intravenous Immune Globulin', NULL, NULL, 'NO', 'Immune deficiency and autoimmune disorders and B-cell chronic lymphocytic leukemia.', 'Gamimune-N , Gammagard , Gammar-IV , Intravenous immunoglobulin , Iveegam , Polygam , Sandoglobulin , Venoglobulin-I , Venoglobulin-S', 'AIDS, CLL, Opportunistic infection', 'IGIV, IVIG', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(957, 'INX-3001', NULL, NULL, 'NO', 'Phase I CML Antisense oligonucleotide.  Inex Pharmaceuticals.', 'C-myb antisense', 'Brain, kidney, leukemia, lung cancer', NULL, NULL, 'Chemotherapy', 'Targeted therapy'),
(958, 'INX-3280', NULL, NULL, 'NO', 'Phase I Antisense. Inex Pharmaceuticals.', NULL, 'Lymphoma', NULL, NULL, 'Chemotherapy', 'Targeted therapy'),
(959, 'Iobenguane I 131', NULL, NULL, 'YES', 'Radiodiagnostic.  DraxImage', 'Draximage MIBG , I 131 MIBG', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(960, 'Iobenguane I-131', NULL, NULL, 'NO', 'July 30, 2018: FDA approved iobenguane I 131 (AZEDRA) for adult and pediatric patients (12 years and older) with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.', 'AZEDRA', NULL, NULL, NULL, 'Radiation', 'Radioisotope'),
(961, 'Iodine-131 Tositumomab', NULL, NULL, 'NO', 'Phase II NHL A murine monoclonal antibody that binds to the CD20 (B1) antigen; it is radiolabeled with iodine-131 for use as selective radioimmuno. in B-cell lymphomas. GlaxoSmithKline.', '131-I-anti-B1 antibody , 131-I-Anti-B1 Monoclonal Antibody , Anti-CD20-murine monoclonal antibody-I-131 , B1 , B1 antibody , Bexxar , Tositumomab-I-131', 'Lymphoma', NULL, '715813', 'Radiation', 'Radioisotope attached to monoclonal antibody'),
(962, 'Iodoquinol', NULL, NULL, 'YES', 'A halogenated hydroxyquinoline, is a luminal amebicide. Antibiotic; Rx of amebiasis', 'Di-iodoxychinolinum , Diiodohydroxyquin , Diiodohydroxyquinoline , Diiodoxyquinoleine , Diodoquin , Diquinol , Sebaquin , Yodoxin', NULL, NULL, NULL, 'AIDS drug', NULL),
(963, 'Iotrex', NULL, NULL, 'NO', 'Proxima Therapeutics.  Organically bound Iodine 125', NULL, 'Brain', NULL, NULL, 'Radiation', 'Liquid radioisotope'),
(964, 'IPI-504', NULL, NULL, 'NO', 'Currently in phase II  and III trials for NCSLC and phase III trial for GIST (RING trial). Code as other therapy until FDA approval.', 'IPI-504 , Retaspimycin hydrochloride', 'breast, GIST, lung, melanoma, Myeloma, prostate, soft tissue, solid tumor', NULL, NULL, 'Chemotherapy', 'HPS90 inhibitor;Molecular inhibitor'),
(965, 'Ipilimumab', NULL, NULL, 'NO', 'March  25, 2011:  Ipilimumab (Yervoy) is FDA approved ONLY for the treatment of melanoma. Code as treatment when used for melanoma.\r\n4/16/2018 FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. \r\n\r\nIpilimumab is undergoing clinical trials for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer. Until FDA approval is received for treatment for these cancers, code in Other Therapy.\r\n\r\nJuly 28, 2017: Bristol-Myers Squibb Co. said FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.\r\n\r\n7/13/2018: FDA has granted accelerated approval to Yervoy (ipilimumab) for use in combination with Opdivo (nivolumab) for the treatment of patients 12 years of age and older with microsatellite in-stability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan', 'Yervoy', 'melanoma, Prostate cancer, colorectal', NULL, '720801 hybridoma derived;732442 transfectoma derived', 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(966, 'Ipomeanol', NULL, NULL, 'NO', 'Pre-clinical', '4-Ipomeanol', 'Lung cancer', NULL, '349438', 'Chemotherapy', 'Plant product'),
(967, 'Iproplatin', NULL, NULL, 'NO', NULL, '2-Propanimine , JM-9 , Platinum-complex (9CI)', NULL, 'CHIP', '256927', 'Chemotherapy', 'Miscellaneous agent'),
(968, 'Irinotecan', NULL, NULL, 'NO', 'Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer.  Pharmacia.', 'Camptosar , Camptosar Oral , Camptothecin-11 , CPT 11 , CPT-11 , CPT11 , U-101440E', 'Colorectal, head & neck, Non-small cell lung cancer (NSCLC), pancreatic cancer, Small cell lung cancer (SCLC)', NULL, '616348', 'Chemotherapy', 'Topoisomerase inhibitor'),
(969, 'Irofulven', NULL, NULL, 'NO', 'Phase II (brain, breast, cervical, gastric, liver, lung, melanoma, ovarian, pancreatic, prostate, sarcoma, primary peritoneal carcinoma) Phase I (leukemia, MM) Cytotoxic acylfulvene analog. MGI Pharma.', 'MGI 114 , MGI-114 , MGI114', 'Brain, breast, cervical, gastric, leukemia, liver, lung, melanoma, multiple myeloma, ovarian, ovary, pancreatic, primary peritoneal carcinoma, prostate cancer, sarcoma', 'HMAF, MGI-114', '683863', 'Chemotherapy', 'Alkylating agent'),
(970, 'ISF154', NULL, NULL, 'NO', 'Phase II CLL Immune-based targeted therapy. Tragen Pharmaceuticals.', NULL, 'Leukemia', NULL, NULL, 'Chemotherapy', 'Targeted therapy'),
(971, 'ISIS 2503', NULL, NULL, 'NO', 'Phase II, Phase II NSCLC Antisense anti RAS protein. ISIS Pharmaceuticals.', NULL, 'Breast, colorectal, lung, pancreatic cancer', NULL, '718878', 'Other therapy', 'Antisense compound;did not receive FDA approval'),
(972, 'Isoniazid', NULL, NULL, 'YES', 'An antimycobacterial agent which is bacteriocidal for both extracellular and intracellular organisms.', 'Cotinazin , Dinacrin , Ditubin# , Isolyn# , Isonicotinic acid hydrazide , Isonicotinohydrazide , Isotamine , Isozide , Laniazid , Niconyl# , Nidaton# , Nydrazid , Nydrazide , PMS-Isoniazid , Rimifon# , Teebaconin , Tisin# , Tyvid#', NULL, 'INH', '9659', 'AIDS drug', NULL),
(973, 'Isoprinosine', NULL, NULL, 'YES', 'Being investigated outside of the U.S. as an immunomodulator; preliminary clinical trials in patients with AIDS-related complex have been disappointing. Combination product: see Dimepranol Acedoben and Inosine', 'Immunoviral , Imunovir , Inosine Pranobex , Inovir , Isoprin , Isoprinosine', NULL, NULL, NULL, 'AIDS drug', NULL),
(974, 'Isopropamide Iodide', NULL, NULL, 'YES', 'Antimuscarinic with peripheral effects similar to those of atropine. Used with Prochlorperazine Maleate as Combid spansule; anticholinergic; anti-emetic It has been used as an adjunct in the treatment of benign peptic ulcer disease, in the relief of gastrointestinal and urinary-tract disorders associated with smooth muscle spasm, in rhinitis, and for the relief of symptoms of colds.', 'Darbid', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(975, 'Ispinesib', NULL, NULL, 'NO', 'Phase I CML, MDS, acute leukemias 2007 Kinesin spindle protein Inhibitor. GlaxoSmithKline; Cytokinetics.', NULL, 'acute leukemias, Breast, CML, MDS, ovarian cancer', NULL, '727990', 'Chemotherapy', 'Antimitotic agent'),
(976, 'Itraconazole', NULL, NULL, 'YES', 'Rx of Candidiasis; A triazole antifungal agent. The intravenous dose form of itraconazole is an alternative route of administration that will be advantageous in immunocompromised patients with serious fungal infections. Long term safety and efficacy trials are warranted.', '211 , R-51211 , R-52 , Sporanox', NULL, 'ITZ', '383507', 'AIDS drug', NULL),
(977, 'IV IL-2 Gene Medicine', NULL, NULL, 'NO', 'Phase I/II NSCLC Valentis.', 'Interleukin-2 gene medicine , intravenous', 'Lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(978, 'Ivosidenib', NULL, 'AML', 'NO', '7/20/18 The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML', 'Tibsovo', NULL, NULL, NULL, 'Chemotherapy', 'IDH1 Inhibitor'),
(979, 'J107088', NULL, NULL, 'NO', 'Phase II Indocarbazole topoisomerase 1 selective inhibitor. Merck.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(980, 'Javelin', NULL, NULL, 'NO', 'Phase I/II melanoma Vaccine. Mojave Therapeutics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(981, 'JNJ-68284528', NULL, 'Multiple myeloma', 'NO', '12/16/2019 FDA granted Breakthrough Therapy Designation for JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen-directed chimeric antigen receptor T-cell therapy in previously treated patients with multiple myeloma.', 'JNJ-4528', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'C-ART'),
(982, 'Kahalalide F', NULL, NULL, 'NO', 'Pre-clinical Diepsipeptide apoptotic. PharmaMar.', NULL, 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Natural product--sea slug'),
(983, 'Kanjinti', NULL, NULL, 'NO', 'June 13, 2019: FDA  approved Kanjinti (trastuzumab-anns), biosimilar to U.S.-licensed Herceptin (trastuzumab).\r\nA biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved biological product, known as a reference product. The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product.', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Biosimilar'),
(984, 'Karenitecin', NULL, NULL, 'NO', 'Phase II NCI', 'BNP 1350 , BNP-1350 , BNP1350', 'Brain', NULL, '710270', 'Chemotherapy', 'Topoisomerase inhibitor'),
(985, 'KB004', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', 'Anti-EphA3 antibody', NULL, NULL, NULL, 'Chemotherapy', 'Eph receptor tyrosine kinases'),
(986, 'KDR/VEGFR-2', NULL, NULL, 'NO', 'Pre-clinical Vascular endothelial growth factor tyrosine kinase inhibitor. Abbott Laboratories.', NULL, 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(987, 'Keratinocyte Growth Factor', NULL, NULL, 'YES', 'Phase II Amgen.', 'KGF', 'Other cancer', NULL, NULL, 'Ancillary Agent', NULL),
(988, 'Ketoconazole', NULL, NULL, 'NO', 'An imidazole antifungal agent, has been evaluated in the treatment of advanced prostate cancer, has been designated an orphan product for use in the treatment of nephrotoxicity induced by cyclosporine.', 'Apo-Ketoconazole , Nizoral , Norizol , Novo-Ketonconazole , Nu-Ketocon , R-41400', 'As a testosterone blocker for advanced prostate cancer, as an antifungal for AIDS, opportunistic infections', NULL, '317629', 'Hormones and hormonal mechanisms', 'Antiandrogenic'),
(989, 'Ketorolac Tromethamine', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory agent with potent analgesic properties.', 'Acular , Ketorolac Trometamol , RS-37619 , Toradol', NULL, 'BDPC, DPP', NULL, 'Ancillary Agent', NULL),
(990, 'Keytruda', NULL, 'Melanoma, NSCLC, Hodgkin lymphoma, urothelial carcinoma, GI adenocarcinoma, Merkle cell carcinoma', 'NO', 'January 8, 2020 The FDA approved pembrolizumab (KEYTRUDA) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. \r\n\r\n9/20/2019 FDA has granted accelerated approval to the combination of Merck’s Keytruda (pembrolizumab) plus Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.\r\n\r\nJuly 30, 2019 FDA approves pembrolizumab for advanced esophageal squamous cell cancer\r\n\r\nJune 10, 2019: FDA approved pembrolizumab (KEYTRUDA) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). \r\nFDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy\r\n\r\nApril 19, 2019: FDA approved pembrolizumab (KEYTRUDA) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). \r\n\r\nFebruary 15, 2019 FDA approved pembrolizumab (KEYTRUDA, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. \r\n\r\n12/19/2018 FDA granted accelerated approval to pembrolizumab (KEYTRUDA) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).  \r\n\r\nNovember 9, 2018: FDA granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.  \r\n\r\nOctober 30, 2018: FDA approved pembrolizumab (KEYTRUDA) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). \r\n\r\nAugust 17, 2018: FDA approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSqNSCLC), with no EGFR or ALK genomic tumor aberrations. .\r\n\r\nOn June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda®) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ?1) as determined by an FDA-approved test\r\n\r\n9/29/2017: FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine-and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.\r\n\r\n6/15/2018: FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy.\r\n\r\n5/23/217: FDA granted accelerated approval to pembrolizumab for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. May 23, 2017.  \r\n\r\n5/18/2017: FDA granted regular approval to pembrolizumab (KEYTRUDA) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.\r\n\r\n5/10/2017: The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). \r\n\r\n3/17/2017: FDA granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.\r\n\r\nSeptember 2014 FDA granted accelerated approval to pembrolizumab for treatment of patients with unresectable or metastatic melanoma and disease progression.\r\nUpdate to September 2014 announcement: Final FDA approval granted to Keytruda for treatment of patients with unresectable or metastatic melanoma.\r\n\r\nOctober 28, 2014 FDA has designated Keytruda as breakthrough therapy for treatment of patients with EGRF-negative and ALK-negative non-small cell lung cancer (NSCLC) who have progressed during or after platinum-based chemotherapy. \r\n\r\nAugust 9, 2016 FDA granted accelerated approval of Keytruda in the treatment of recurrent or metastatic Head & Neck Squamous Cell Carcinoma (SCC) with disease progression on or after platinum-containing chemotherapy. \r\n\r\nOctober 24, 2016 FDA approved pembrolizumab (KEYTRUDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.    \r\n\r\nBreakthrough therapy designation is used by the FDA to accelerate the development and evaluation of an investigational drug that is intended to ', 'MK-3475 , SCH 900475 , lambrolizumab , pembrolizumab', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(991, 'KOS-1022', NULL, NULL, 'NO', 'Phase I solid tumors; Phase I heme Kosan.  2nd generation geldanamycin analog', 'KOS 1022 , KOS1022', 'hematopoietic, Solid tumors', 'DMAG', NULL, 'Chemotherapy', 'Targeted therapy--heat shock protein'),
(992, 'KRN 5500', NULL, NULL, 'NO', 'Phase I NCI, Kirin.', NULL, 'Other cancer', NULL, '650426', 'Chemotherapy', 'Alkylating agent'),
(993, 'KS-IL2', NULL, NULL, 'NO', 'Phase II Interleukin-2. Lexigen Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(994, 'KSA Vaccine', NULL, NULL, 'NO', 'Phase II Vaccine. Jenner Biotherapies.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(995, 'KW-0761', NULL, NULL, 'NO', 'II New drug currently in trials, code in other therapy', NULL, 'Adult T-cell leukemia/lymphoma, peripheral T-cell leukemia/lymphoma', NULL, 'NCT00355472', 'Chemotherapy', 'Monoclonal antibody'),
(996, 'KW-2871', NULL, NULL, 'NO', 'Phase I/II melanoma Chimeric monoclonal antibody. Kyowa Hakko Kogyo Co.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(997, 'L-377,202', NULL, NULL, 'NO', 'Phase I Peptide doxorubicin conjugate. Merck.', NULL, 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(998, 'L-693,989', NULL, NULL, 'YES', 'Activity against PCP and Candida', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(999, 'L-697639', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1000, 'L-697661', NULL, NULL, 'YES', 'Inhibits HIV-1 reverse transcriptase', 'Pyridinone', NULL, NULL, NULL, 'AIDS drug', NULL);
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1001, 'L-778123', NULL, NULL, 'NO', 'Phase I Farnesyl protein transferase inhibitor. Development discontinued due to severe toxicities. Merck.', NULL, 'Pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Not in current use'),
(1002, 'L-BSO', NULL, NULL, 'YES', 'Radiosensitizer', NULL, NULL, NULL, '326231', 'Ancillary Agent', NULL),
(1003, 'L-Leucovorin', NULL, NULL, 'YES', 'Use in conjunction with high-dose methotrexate in the treatment of osteosarcoma, and in combination with 5-fluorouracil for the palliative treatment of metastatic adenocarcinoma of the colon and rectum.', 'Calcium levofolinate , Calcium Levoleucovorin , CL-307782 , Fusilev , Isovorin , Levofolinate , Levofolinate Calcium , Levofolinic acid , Levoleucovorin , Levoleucovorin calcium', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1004, 'L-VAX', NULL, NULL, 'NO', 'Phase I/II AML Vaccine. AVAX Technologies.', 'Autologous cell vaccine', 'Leukemia', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1005, 'LAF389', NULL, NULL, 'NO', 'Phase I Cytotoxic targeting methionine amniopeptide 1 & 2. Novartis Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--methionine aminopeptidase inhibitor'),
(1006, 'LAK cells', NULL, NULL, 'NO', NULL, 'Lymphocyte activated killer cells', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1007, 'Lamivudine', NULL, NULL, 'NO', 'Inhibits HIV replication through viral DNA chain termination. It is an antiretroviral agent that belongs to a class of drugs called nucleoside reverse transcripts inhibitors or \" NRTIs\".  LAMIVUDINE mimics a nucleoside base, which blocks further construction of the virus.', 'Combivir with Zidovudine , Epivir with Zidovudine , Epzicom with Abacavir , Kivexa with Abacavir , Trizivir with Zidovudine and Abacavir', 'HIV Virus', '3TC', NULL, 'AIDS drug', NULL),
(1008, 'Lanreotide Acetate', NULL, NULL, 'SEE_REMARKS', 'This drug is usually considered ancillary treatment for neuroendocrine tumors as it relieves symptoms of neuroendocrine tumors but does not kill the tumor cells. HOWEVER, as of June 1, 2019, Somatuline Depot is the 1st and only FDA-approved treatment for adults both to slow the growth of gastrointestinal and pancreatic neuroendocrine tumors (GEP NETs) that have spread or cannot be removed by surgery. It also treats carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.\r\n\r\nHow to code: IF given to treat carcinoid syndrome, do not code. If give or stated to be prescribed to treat the tumor, then code as hormone\r\n\r\nThis drug is indicated for the treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy, but also used for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy. It may be used to treat pituitary tumors. If so, code as hormonal treatment.', 'BIM 23104 , BIM-23014 , BIM23014 , Somatuline', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'growth hormone releasing hormone inhibitor;Somatostatin analogue'),
(1009, 'Lapatinib ditosylate', NULL, NULL, 'NO', 'GlaxoSmithKline.  FDA approved for breast 2007', 'GSK572016 , GW572016 , Tykerb', 'Breast', NULL, '727989', 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1010, 'LAQ824', NULL, NULL, 'NO', 'Phase I Histone deacetylase 1 & 2 inhibitor. Novartis Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--histone deacetylase inhibitor'),
(1011, 'Larotrectinib', NULL, NULL, 'NO', 'November 26, 2018: FDA granted accelerated approval to larotrectinib (VITRAKVI) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment', 'Vitrakvi', NULL, NULL, 'Trk Inhibitor', 'Chemotherapy', NULL),
(1012, 'Lasofoxifene', NULL, NULL, 'NO', 'Phase III Selective estrogen receptor modulator (SERM). Ligand Pharmaceuticals, Pfizer', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Selective estrogen receptor modulator (SERM)'),
(1013, 'LBH-589', NULL, NULL, 'NO', 'II New drug currently in trials, code in other therapy', 'Faridak', 'AML, Hodgkin lymphoma, MDS, multiple myeloma', NULL, NULL, 'Chemotherapy', 'Pan-DAC inhibitor'),
(1014, 'LDI-200', NULL, NULL, 'NO', 'Phase III MDS Phase II AML Signaling. Milkhaus Laboratories.', 'Human chorionic gonadotropin', 'Leukemia', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis stimulator'),
(1015, 'Lenalidomide', NULL, NULL, 'NO', 'May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). \r\n\r\n\r\n2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.\r\n\r\nJuly 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.\r\n\r\nFDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL\r\nThalidomide analog immunomodulatory derivative.\r\n\r\nFebruary 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.', 'Revlimid , lenalidomide', '5q- MDS, CLL, MDS, Multiple myeloma, melanoma, Lymphoma', NULL, '703813', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--antiangiogenesis agent'),
(1016, 'Lentinan', NULL, NULL, 'NO', 'A polysaccharide with immunomodulating activity. Undergoing evaluation for the treatment of acquired immunodeficiency syndrome (AIDS).(Bacteria & Fungi Lintinus Edodes biological) (immunomodulator)', NULL, 'AIDS, Opportunistic infection', 'LC-33', NULL, 'Biologic therapy (BRM, immunotherapy);AIDS drug', NULL),
(1017, 'Lenvima', NULL, NULL, 'NO', 'October 2014: FDA granted priority review status to lenvatinib mesylate as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer. Lenvatinib was granted orphan drug designation in various types of thyroid cancer in the US, Japan, and Europe. It is currently under investigation in thyroid, hepatocellular, endometrial, non-small cell lung cancer, and other solid tumor types. \r\n\r\nMay 13, 2016 FDA approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.  Lenvatinib was first approved in 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.\r\n\r\n August 16, 2018: FDA approved lenvatinib capsules (Lenvima) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).', 'E7080 , Lenvatinib , Lenvatinib mesylate', 'Lung, liver, lymphoma, thyroid', NULL, NULL, 'Chemotherapy', 'Multi-targeted kinase inhibitor;VEGFR inhibitor'),
(1018, 'LErafAON', NULL, NULL, 'NO', 'Phase I CML Phase II other Liposomal cRaf antisense oligomucleotide. NeoPharm.', NULL, 'Leukemia, other cancer', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(1019, 'Lestaurinib', NULL, NULL, 'NO', 'Phase II AML 2007 Tyrosine kinase inhibitor. Cephalon, Inc., TAP Pharmaceuticals.', 'CEP 701 , CEP-701 , CEP701 , KT 5555 , KT-5555 , KT5555', 'AML, leukemia, other cancer, Pancreatic, prostate', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1020, 'Letrazuril', NULL, NULL, 'YES', 'Antiprotozoal. Rx of Cryptosporidiosis. Not found in Drugdex drug evaluation.', NULL, 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1021, 'Letrozole', NULL, NULL, 'NO', 'A nonsteroidal aromatase inhibitor. FDA approved for therapy of breast cancer. Novartis.', 'CGS-20267 , Femara', 'Breast cancer', NULL, '719345', 'Hormones and hormonal mechanisms', 'Nonsteroidal aromatase inhibitor'),
(1022, 'Leucovorin', NULL, NULL, 'YES', 'The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.', 'Calcium folinate , Calcium leucovorin , Calcium leucovorin rescue , Citrovorum Factor , Citrovorum factor rescue , Folic acid , Folinic Acid , Lederfoline , Leucosar , Leucovorin Calcium , Leucovorin rescue , Wellcovorin', NULL, 'C.F., CF, CL', '3590;003590', 'Ancillary Agent', NULL),
(1023, 'Leukine', NULL, NULL, 'YES', 'On March 29, 2018: The FDA approved use of Leukine (sargramostim) to increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). Leukine can help patients with H-ARS by facilitating recovery of bone marrow cells that develop into white blood cells that help fight off infections.', 'CSF39300 , Granulocyte macrophage colony-stimulating factor , Prokine , rGM-CSF , rhu GM-CSF , Sargramostim , GM-CSF', 'other cancer, Skin', NULL, '617589;643496;613795', 'Ancillary Agent', NULL),
(1024, 'Leuprolide Acetate', NULL, NULL, 'SEE_REMARKS', 'December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy. \r\n\r\nLupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.\r\n\r\nFOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment\r\n\r\nFOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017: \r\nThe effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used \"off label\" for other conditions. Lupron should be coded as \"Other Therapy\" until such time that it receives FDA approval.', 'Abbott-43818 , Carcinil , Eligard , Leuprolide , Leuprorelin , Lupron , Lupron Depot , Lupron TAP , TAP-144 , Viadur', 'Prostate cancer, See remarks for other site information, Breast, Ovary', NULL, '377526', 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone agonist'),
(1025, 'Leuprorelin', NULL, NULL, 'NO', 'Phase II Sustained release leuprolide product. Epic Therapeutics.', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Gonadotropin-releasing hormone agonist'),
(1026, 'Leuvectin', NULL, NULL, 'NO', 'Phase II Immunotherapeutic protein. Vical.', NULL, 'Kidney, prostate, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1027, 'Levamisole', NULL, NULL, 'NO', 'Anthelmintic. Antiepileptic. Nootropic. Synthetic chemical, immunomodulator. FDA approved use on advanced colon carcinoma in conjunction with 5-FU.', 'Citarin L , Decaris , Ergamisol , ICI-59623 , Ketrax , l-Tetramisole , L-Tetramisole HCl , Levamisol , Levamisole hydrochloride , Levomysol HCL , R-12564 , Ripercol L , RP-20605 , Tetramizole , Tramisol , Tramisole', NULL, 'LEV', '177023', 'Biologic therapy (BRM, immunotherapy)', 'Immunomodulator'),
(1028, 'Levonantradol', NULL, NULL, 'YES', 'An antiemetic and analgesic. Not found in Drugdex drug evaluation.', '556-1 , CP-50 , Levonantradol HCl , Levonantradol hydrochloride', NULL, NULL, '331615', 'Ancillary Agent', NULL),
(1029, 'Levothyroxine Sodium', NULL, NULL, 'NO', 'Synthroid should be coded as hormonal treatment for thyroid cancer. After thyroid surgery, the thyroid hormone medication levothyroxine (Levothroid, synthroid, etc) is prescribed often for life. This drug has two benefits: it supplies the missing hormone the thyroid would normally produce, and it suppresses the production of thyroid-simulating hormone (TSH) from the pituitary gland. High TSH levels could conceivably stimulate any remaining cancer cells to grow.\r\n\r\nThis drug is more commonly used in patients with  papillary, follicular carcinomas or one of their variants.', 'Alti-Thyroxine , Eltroxin , Euthroid , Euthyrox , L-Thyroxine , L-Tyrosine , Levo-T , Levotabs , Levothroid , Levothyroxine , Levoxine , Levoxyl , Proloid , Sodium Levothyroxine , Synthroid , Synthrox , Thyroid USP , Thyrolar , Thyroxine , Thysin , Tirosint', 'Thyroid', 'T4', NULL, 'Hormones and hormonal mechanisms', 'Thyroid hormone--suppresses TSH'),
(1030, 'Levulan', NULL, NULL, 'YES', 'Phase I completed Photodynamic therapy.  Removes sun damage on skin.  DUSA Pharmaceuticals.', NULL, 'Bladder cancer', '5-ALA-PDT, ALA', NULL, 'Ancillary Agent', 'Photosensitizer'),
(1031, 'LGD1550', NULL, NULL, 'NO', 'Phase I/II Synthetic RAR selective retinoid. Ligand Pharmaceuticals.', 'LGD 1550 , LGD-1550', 'Cervical, head & neck, other cancer', NULL, NULL, 'Differentiation inducing agent;Differentiation', 'Synthetic aromatic retinoic acid agent'),
(1032, 'LHRH', NULL, NULL, 'NO', NULL, NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Hormone inhibitor'),
(1033, 'Lidocaine', NULL, NULL, 'YES', 'An antiarrhythmic and local anesthetic agent of the amide type.', 'Aloe Vera Gel , Alphacaine , Anestacon , Anucaine , Bactine , Banadyne-3 , D-Caine , Dermapain , Dilocaine , Duo-Trach Kit , Ela-Max , Embolex , Gold Bond Medicated Anti-Itch Cream , L-caine , Lida Mantle , Lidocaine Hydrochloride , Lidoderm , Lidoject-1 , Lidomantle-HC , Lidomar , Lidopen Auto-Injector , Mylocaine , Nervocaine , No More Ouchies , Nulicaine , SHO-caine , Solarcaine Aloe Extra Burn Relief , Ultracaine , Xylocaine , Xylocard , Zilatin-L', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1034, 'Lintuzumab', NULL, NULL, 'NO', 'Orphan drug for MDS, AML; Phase III for AML Anti-CD33 humanized recombinant monoclonal antibody', 'Hu-M195 monoclonal antibody , HuG1-M195 , HuG1-M195 monoclonal antibody , SGN 33 , SGN-33', 'AML, MDS', 'MOAB HuG1-M195, MOAB HuM195', NULL, 'Chemotherapy', 'Cytotoxic agent--Anti-CD33'),
(1035, 'Liothyronine Sodium', NULL, NULL, 'NO', 'This drug should be coded as hormonal treatment for thyroid cancer. After thyroid surgery, the thyroid hormone medication such as cytomel and synthroid  are prescribed often for life. This drug has two benefits: it supplies the missing hormone the thyroid would normally produce, and it suppresses the production of thyroid-simulating hormone (TSH) from the pituitary gland. High TSH levels could conceivably stimulate any remaining cancer cells to grow.', 'Basoprocin , Cynomel , Cyronine , Cytomel , Ibiothyron , L-Triiodothyronine , LT3 , Tertroxin , Thyrolar , Triostat', NULL, NULL, '80774', 'Hormones and hormonal mechanisms', 'Thyroid hormone--suppresses TSH'),
(1036, 'Liotrix', NULL, NULL, 'NO', 'Thyroid hormone.  A mixture of liothyronine sodium and levothyroxine sodium in a ratio of 1:4 in terms of weight; used for replacement therapy in conditions in which there is deficient production of thyroid hormones, administered orally.', 'Euthroid , Thyrolar', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Thyroid hormone--suppresses TSH'),
(1037, 'Liposomal SN38', NULL, NULL, 'NO', 'Phase II colorectal 2007 NeoPharm.  Sencor.', 'LE-SN38 , Liposomal SN38 , Liposome Encapsulated SN38 , SN 38 , SN-38', 'Colorectal', NULL, '732234', 'Chemotherapy', 'Metabolite of CPT-11;topoisomerase inhibitor'),
(1038, 'Liposome Encapsulated Mitoxantrone', NULL, NULL, 'NO', 'Phase II Antineoplastic agent. NeoPharm.', 'LE Mitoxantrone , Liposomal Mitoxantrone', 'Other cancer', 'LEM', NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(1039, 'Liposome Encapsulated Paclitaxel', NULL, NULL, 'NO', 'Phase II/III, Phase II ovarian, Phase III NSCLC Taxane. Neopharm, Pharmacia.', 'LE Paclitaxel , Liposomal Paclitaxel', 'Breast, gastric, head & neck, lung, ovarian cancer', 'LEP', NULL, 'Chemotherapy', 'Natural product'),
(1040, 'Liposome encapsulated recombinant interleukin-2', NULL, NULL, 'NO', 'Treatment of brain and CNS, kidney and renal pelvis tumors.', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1041, 'Liquid IL-2', NULL, NULL, 'NO', 'Phase I Chiron.', NULL, 'Breast cancer, non-Hodgkin\'s lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1042, 'Lithium Carbonate', NULL, NULL, 'YES', 'A monovalent cation with antimanic, antipsychotic, and antidepressant activity.', '467-61 , C.P. 15 , Carbolith , Cibalith , Duralith , Eskalith , Lithane , Lithium Citrate , Lithizine , Lithobid , Lithonate , Lithotabs , Priadel', NULL, NULL, '16895;016895', 'Ancillary Agent', NULL),
(1043, 'LMB-1 Immunotoxin', NULL, NULL, 'NO', 'Phase I Immunotoxin. NCI.', NULL, 'Colorectal cancer', NULL, '651311', 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1044, 'LMB-7 Immunotoxin', NULL, NULL, 'NO', 'Phase I Immunotoxin. NCI.', 'LMB-7 single chain immunotoxin', 'Colorectal cancer', NULL, '658931', 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1045, 'LMB-9', NULL, NULL, 'NO', 'Phase I Immunotoxin. NCI, IVAX.', NULL, 'Breast, colorectal, gastric cancer', NULL, '691236', 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1046, 'LMB-9 Immunotoxin', NULL, NULL, 'NO', 'Phase I Immunotoxin. NCI.', NULL, 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1047, 'Lometrexol Sodium', NULL, NULL, 'NO', NULL, 'LY 264618 disodium , LY264618 disodium', NULL, NULL, '660025', 'Chemotherapy', 'Antimetabolite--Antifolate'),
(1048, 'Lomotil', NULL, NULL, 'YES', 'Anti-diarrheal', 'Atropine and Diphenoxylate , Atropine Sulfate and Diphenoxylate Hydrochloride , Di-Atro , Dipehnatol , Diphenoxylate and Atropine Sulfate , Diphenyxylate HCl and Atropine Sulfate , Diphenyxylate Hydrochloride and Atropine , Diphenyxylate Hydrochloride and Atropine Sulfate , Diphenyxylate with Atropine , Diphenyxylate with Atropine Sulfate , Lofene , Lomanate , Lonox , Motofen , SK-Dipehnoxylate , Unilom', 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(1049, 'Lomustine', NULL, NULL, 'NO', 'Cell-cycle nonspecific antineoplastic agent;alkylating agent. FDA approved uses in brain tumor and Hodgkin\'s lymphoma.', 'Belustine (nitrosourea) , CeeNu , Chloroethylcyclohexylnitrosourea , ICIG 1109 , RB1509 , WR-139017', 'Brain tumors: primary or metastatic, Hodgkin lymphoma, Non-Hodgkin lymphoma', 'CCNU', '079037;79037', 'Chemotherapy', 'Alkylating agent'),
(1050, 'Lonafarnib', NULL, NULL, 'NO', 'Phase II NSCLC Farnesyl protein transferase inhibitor. Schering-Plough.', 'Sarasar', 'leukemia, Lung cancer', NULL, '719467', 'Chemotherapy', 'Cytostatic agent--farnesyl transferase inhibitor'),
(1051, 'Lonidamine', NULL, NULL, 'YES', 'Currently being investigated as an antineoplastic. Radiation-sensitizing agent', 'AF-1890 , Diclondazolic Acid', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1052, 'Lonsurf', NULL, NULL, 'NO', 'February 22, 2019 FDA has approved Lonsurf (a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor) as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/ neu-targeted therapy.\r\n\r\nSeptember 22, 2015: U. S. Food and Drug Administration approved the drug LONSURG which is a combination pill of trifluridine and tipiracil for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- , and irinotecan-based chemotherapy, an anti-VEGF biologic product, and an anti-EGFR monoclonal antibody, if RAS wild-type.', NULL, 'Colorectal, Gastroesophageal', NULL, NULL, 'Chemotherapy', NULL),
(1053, 'Lorazepam', NULL, NULL, 'YES', 'An effective antianxiety and hypnotic agent for insomnia and as premedication to surgical procedures. The drug is also indicated parenterally for status epilepticus. Orally in combination with antiemetic agents it is used for the treatment of chemo.-induced emesis.', 'Altivan , Alzapam , Apo-Lorazepam , Ativan , Loraz , Novo-Lorazem , Nu-Loraz , Riva-Lorazepam , Wy-4036', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1054, 'Lorlatinib', NULL, 'NSCLC', 'NO', 'November 2, 2018:  FDA granted accelerated approval to lorlatinib (LORBRENA) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.', 'Lorbrena', 'Lung', NULL, NULL, 'Chemotherapy', 'ALK Inhibitor'),
(1055, 'Lovastatin', NULL, NULL, 'NO', 'Extends survival for hepatoma.  Lipid regulating drugs. Inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme.  Not shown to be very effective for either cancer.', '6alpha-Methylcompactin , L-154803 , L154803 , MB-530B , Mevacor , Mevinolin# , MK-803 , MK803 , Monacolin K , Monacolin-K', 'AML, Hepatoma, stomach', NULL, '633781', 'Chemotherapy', 'Cytostatic agent--apoptosis stimulator'),
(1056, 'Loviride', NULL, NULL, 'YES', 'A nonnucleoside HIV-1 reverse transcriptase inhibitor. Janssen has discontinued development of loviride (September, 1997).', 'R-89439', NULL, NULL, NULL, 'AIDS drug', NULL),
(1057, 'Loxoribine', NULL, NULL, 'YES', 'Immunostimulant; vaccine adjuvant', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1058, 'Lucanthone', NULL, NULL, 'NO', 'Phase I Topoisomerase II inhibitor. SuperGen.', NULL, 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(1059, 'Lucent Protein', NULL, NULL, 'NO', 'Phase II BioMedicines.', NULL, 'Gastric, liver cancer', NULL, NULL, 'Ancillary Agent', 'Delivery mechanism'),
(1060, 'Lung Cancer Vaccine', NULL, NULL, 'NO', 'Phase II NSCLC Vaccine. NovRx.', NULL, 'Lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1061, 'Lutrin', NULL, NULL, 'NO', 'Feb 2, 2018 FDA has approved lutetium Lu 177 dotatate, a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroen-teropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.\r\n\r\nSee program manuals for coding instrcutions', 'Lutetium texaphyrin , Motexafin lutetium , Lutetium Lu77 , Lutathera', 'Breast, prostate cancer, GI sites', 'LU-177', '695239', 'Radiation', 'Radiosensitizer'),
(1062, 'LY-2181308', NULL, NULL, 'NO', 'II New drug currently in trials, code in other therapy', NULL, 'AML, Prostate', NULL, NULL, 'Chemotherapy', 'Apoptosis protein inhibitor'),
(1063, 'LY2275796', NULL, NULL, 'NO', 'Isis-Lilly.  Antisense agent in phase I trials 2006', 'LY 2275796 , LY-2275796', NULL, NULL, NULL, 'Chemotherapy', 'Antiangiogenic agent'),
(1064, 'LY2603618', NULL, NULL, 'NO', 'Phase I&II New drug currently in trials, code as Other Therapy as it is not FDA approved', 'LY2603618', 'NSC Lung, Pancreas', NULL, NULL, 'Chemotherapy', 'Chk2 inhibitor'),
(1065, 'LY573636', NULL, NULL, 'NO', 'Phase II soft tissue sarcoma, ovary 2007; Phase I advanced solid tumors 2007 Lilly', 'LY 573636 , LY-573636', 'advanced solid tumors, ovary, STS', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1066, 'LymphoRad 131', NULL, NULL, 'NO', 'Phase I Human protein. Human Genome Sciences.', 'I-131 Labeled B-Lymphocyte Stimulator , Radiolabeled BLyS Protein', 'Multiple myeloma', NULL, NULL, 'Radiation', 'Radioisotope'),
(1067, 'LymphoScan', NULL, NULL, 'YES', 'Phase III NHL B-cell Diagnostic. Immunomedics.', 'ImmuRaid-LL2 , LL2 Fab\' , LL2 Monoclonal antibody', 'Lymphoma', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(1068, 'Lynestrenol', NULL, NULL, 'NO', 'Progestin. Not found in Drugdex drug evaluation.', 'Ethynylestrenol , Exluton , Linestrenol , Org 485-50 , Orgametril# , Orgametrol , Ovoresta M', NULL, '37725', '37725', 'Hormones and hormonal mechanisms', 'No longer in use'),
(1069, 'Lynparza', NULL, NULL, 'NO', 'December 14, 2014: The US Food and Drug Administration (FDA) approved Lynparza (olaparib) for women with advanced ovarian cancer caused by a mutated BRCA gene, and who have already had several other treatments. It’s the first drug of its kind, a PARP inhibitor, to be approved in the US. The FDA also approved a test called BRACAnalysis specifically to identify women who may be candidates for treatment with Lynparza.\r\n\r\nAugust 17, 2017: The U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.\r\n\r\nJan. 12, 2018: The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.', 'Olaparib', 'Ovary', NULL, NULL, 'Chemotherapy', 'PARP Inhibitor'),
(1070, 'M-Azido-Pyrimethamine Ethane Sulphonate', NULL, NULL, 'NO', 'Development discontinued 1989 after Phase I trials', NULL, NULL, 'MZPES', NULL, 'Chemotherapy', 'No longer in use'),
(1071, 'M-Vax', NULL, NULL, 'NO', 'Phase II/III stage II and IV melanoma Autologous cell vaccine. Avax Technologies.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1072, 'M40403', NULL, NULL, 'NO', 'Phase I Human superoxide dismutase. MetaPhore Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Ancillary Agent', 'Antioxidant;protectant'),
(1073, 'MAb antibody 3A1', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. NCI.', NULL, 'Breast cancer', NULL, '603570', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1074, 'MAb antibody B3', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. NCI.', 'Mab-B3', 'Breast cancer', NULL, '651310', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1075, 'MAb CC-49', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Patented Mab used as delivery mechanism for radioisotopes.  NCI, Dow Chemical.', 'LU-177 , Moab CC-49/TAG72 , Y-90', 'Lung cancer', NULL, '623111 Centocor;620537 Dow', 'Radiation', 'Radioisotope conjugated to monoclonal antibody'),
(1076, 'Mab Hefi-1', NULL, NULL, 'NO', 'Phase I NCI.', NULL, 'Lymphoma', NULL, '603573', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1077, 'MAbHu1D10', NULL, NULL, 'NO', 'Phase I NHL B-cell', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1078, 'MAbHum291 anti-CD3', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. NCI, Protein Design Labs.', NULL, 'Lymphoma', NULL, '711007', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1079, 'Macrobead', NULL, NULL, 'NO', 'Macrobeads consist of small beads that contain mouse cancer cells from a mouse kidney cancer line. The cells in the beads produce substances that have been shown to slow or stop the growth of tumors in Phase I saftey trials. It is now in being elvaluated for its effect on tumor growth. Current clinical trials include: prostate, pancreas (all stages), and colorectal cancers that no longer respond to standard therapies. Capture treatment using macrobeads in \"Other Therapy\". Assign code 2 for any experimental or newly developed treatment, such as this, that differs greatly from proven cancer therapy.', 'Macrobead', 'Colorectal, Pancreas, Prostate', NULL, NULL, 'Other therapy', 'See remarks'),
(1080, 'Mafosfamide', NULL, NULL, 'NO', 'Mafosfamide is a derivative of cyclophosphamide that has been used to treat bone marrow for transplantation. It is also under investigation in the treatment of neoplastic meningitis.', 'Mafosfamide L-lysine', NULL, NULL, '345842;626122', 'Chemotherapy', 'Alkylating agent'),
(1081, 'MAGE-12:170-178', NULL, NULL, 'NO', 'Phase II Peptide vaccine. NCI.', NULL, 'Breast, skin cancer', NULL, '715072', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1082, 'MAGE-A3 peptide vaccine', NULL, NULL, 'NO', 'Phase III melanoma 2007 Code as Other Treatment', NULL, 'Melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1083, 'Magnesium Sulfate', NULL, NULL, 'YES', 'Anticonvulsant, electrolyte replenisher, laxative.', 'Agobyl , Alsilax , Citrocarbonate , Epsom Salts , Osmopak Plus , X-Prep Bowel Evacuation Kit-2', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1084, 'Malathion', NULL, NULL, 'YES', 'Rx for ectoparasites; Pediculocide', 'Butanedioic acid , Ovid , Ovide , Prioderm', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1085, 'Mannitol', NULL, NULL, 'YES', 'An osmotic diuretic.', 'Aldisine , Cordycepic Acid , Manita , Manna Sugar , Mannite , Mannitol Hexanitrate , Osmitrol , Resectisol', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1086, 'Mannomustine', NULL, NULL, 'YES', NULL, 'Degranol , Mannit-Lost , Mannit-Mustard , Mannitol Mustard', NULL, 'BCM', '9698', 'Ancillary Agent', NULL),
(1087, 'Mannosulfan', NULL, NULL, 'NO', NULL, 'R-52 , Zitostop', NULL, NULL, '201289', 'Chemotherapy', 'Alkylating agent'),
(1088, 'Marcellomycin', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '265211', 'Chemotherapy', 'Anthracycline antibiotic'),
(1089, 'Marimastat', NULL, NULL, 'NO', 'Phase III Matrix metalloproteinase inhibitor. Schering-Plough.', 'BB-2516 , Marmistat , TA-2516', 'Pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1090, 'Marimistat', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '719333', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1091, 'MART-1', NULL, NULL, 'NO', 'Phase I metastatic melanoma Vaccine. NCI.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Cytokine'),
(1092, 'MART-1 with gp100 (in vivo) Vaccine', NULL, NULL, 'NO', 'Phase II melanoma Vaccine. Genzyme.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1093, 'Masoprocol', NULL, NULL, 'NO', 'A topical drug used for the treatment of precancerous skin lesions known as actinic keratoses.', 'Actinex , C-205 , CHX-100 , CHX-2053 , CHX-2054 , Gebrentil , meso-NDGA', NULL, NULL, '4291', 'Chemotherapy', 'Topical antineoplastic'),
(1094, 'Matrix Metalloproteinease Inhibitor', NULL, NULL, 'NO', 'Phase III, Phase III NSCLC Protein inhbitor. Bristol-Myers Squibb.', NULL, 'Colorectal, lung cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'This is a mechanism of action'),
(1095, 'Maxy-G34', NULL, NULL, 'YES', 'Colony stimulating factor for neutropenia.  Maxygen.', 'Maxy G34 , PEG G-CSF', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1096, 'Maytansine', NULL, NULL, 'NO', 'Natural product', 'Ansamacrolide compound , Maitansine , Maysanine , Maytansin , Maytansine (USAN) (9CI) , Maytansine(USAN (9CI)', NULL, 'MTS', '153858', 'Chemotherapy', 'Antimitotic'),
(1097, 'MDAM', NULL, NULL, 'NO', 'Phase I BioNumerik Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1098, 'MDL 28574', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1099, 'MDL-72222', NULL, NULL, 'YES', 'Anti-emetic', 'Serotonin antagonist', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1100, 'MDL-73147EF', NULL, NULL, 'YES', 'Anti-emetic', 'Serotonin antagonist', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1101, 'MDX-010 and Melanoma Vaccine', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. Medarex.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1102, 'MDX-060', NULL, NULL, 'NO', 'Phase I Hodgkin\'s, anaplastic large cell NHL Medarex.', NULL, 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody that targets CD 30 (TNF)'),
(1103, 'MDX-210', NULL, NULL, 'NO', 'Phase II (breast) Phase II AML Phase II/III ovarian Monoclonal antibody. Medarex, IDM.', NULL, 'Breast, leukemia, ovarian cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--anti HER2'),
(1104, 'MDX-22', NULL, NULL, 'NO', 'Phase II AML Monocloal antibody. Medarex.', NULL, 'Leukemia', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1105, 'MDX-220 (bispecific antibody)', NULL, NULL, 'NO', 'Phase I/II (colorectal) Phase II (prostate) Monocloncal antibody. Medarex.', NULL, 'Colorectal, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1106, 'MDX-447 (biospecific antibody)', NULL, NULL, 'NO', 'Phase II Monoclonal antibody. Medarex.', NULL, 'Breast, colorectal, head & neck, kidney cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--EGFR inhibitor'),
(1107, 'MDX-H210 (bispecific antibody)', NULL, NULL, 'NO', 'Phase III Anti-her2/Neu + anti-CD4 monocloncal antibody. Medarex.', NULL, 'Colorectal, kidney, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1108, 'Mecasermin', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation.', 'CEP-151 , IGF-I , Insulin-like Growth Factor I (Human) , rhIGF-1 , Somatomedin C', NULL, NULL, NULL, 'AIDS drug', NULL),
(1109, 'Mechlorethamine', NULL, NULL, 'NO', 'FDA approved uses on bronchogenic carcinoma, chronic lymphocytic leukemia, Hodgkin\'s lymphoma, Non-Hodgkin lymphoma, lymphosarcoma, and malignant effusion.', 'Chlorethazine Hydrochloride , Chlormethine Hydrochloride , Dichloromethyl-diethylamine-HCl , Mechlorethamine Hydrochloride , Meclorethamine , Mustargen , Mustargen-HCl , Mustine , Nitrogen Mustard , WR-147650 , Valchlor', 'CLL, Cutaneous T-cell lymphoma (topical use), Hodgkin lymphoma, lung cancer, Non-Hodgkin lymphoma', 'HN2, NH2, NH2-HCl', '000762;762', 'Chemotherapy', 'Alkylating agent'),
(1110, 'MEDI-503/51', NULL, NULL, 'YES', 'Phase II HPV-11 vaccine. MedImmune.', NULL, 'Cervical cancer', NULL, NULL, 'Ancillary Agent', 'HPV vaccine--preventive'),
(1111, 'MEDI-551', NULL, NULL, 'NO', 'Phase I New drug currently in trials, code in Other Therapy', 'MEDI-551', 'B-cell malignancies', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Humanized Monoclonal Antibody  BRM'),
(1112, 'Medrogestone', NULL, NULL, 'NO', 'A progestational agent, (any of a group of hormones secreted by the corpus luteum and placenta and in small amounts by the adrenal cortex, including progesterone; they induce the formation of a secretory endometrium) used in the treatment of menstrual disorders and for the prevention of postmenopausal endometrial hyperplasia; administered orally.   Not found in Drugdex drug evaluation.', 'AY-62022 , R-13-615', NULL, NULL, '123018', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(1113, 'Medroxyprogesterone', NULL, NULL, 'NO', 'Medroxyprogesterone has received FDA approval for treatment of advanced and recurrent endometrial cancers. This drug lessens the tumor burden allowing for surgical treatment. If given prior to surgical treatment, code as neo-adjuvant therapy.\r\n\r\n In clinical trials for breast cancer and Renal Cell Carcinoma of the kidney.', 'Medroxyprogesterone', 'breast cancer, Endometrial cancer', 'MPA', NULL, 'Hormones and hormonal mechanisms', 'Hormone'),
(1114, 'Medroxyprogesterone Acetate', NULL, NULL, 'NO', 'A synthetic progestogen (progestin). FDA approved palliative uses in advanced endometrial carcinoma and advanced renal cell carcinoma; administered intramuscularly.  This drug lessens the tumor burden allowing for surgical treatment. If given prior to surgical treatment, code as neo-adjuvant therapy. Also used orally in the treatment of secondary amenorrhea and functional uterine bleeding and as a contraceptive.', 'Alti-MPA , Amen , Curretab , Cycrin , Depcorlutin , Depo-Provera , Farlutin , Gestapuran , Lutopolar , Lutoral , Medroxypro-gesterone Acetate , Oragest , Perlutex , Proclim , Prodasone , Progestal , Provera , Proverone , Repromap , Repromix , Sirprogen , U-8839 , Veramix', 'Endometrial cancer, renal cancer', 'DMPA, MAP, MPA', '026386;26386', 'Hormones and hormonal mechanisms', 'Progestin'),
(1115, 'Medrysone', NULL, NULL, 'NO', 'A synthetic corticosteroid (glucocorticoid) used topically in the treatment of corticosteroid-responsive allergic and inflammatory conditions of the eye.', 'GSH-1043 , HMS , Hydroxymesterone , Hydroxymethylprogesterone , Medrisona , Medrocort# , Methylhydroxyprogesterone , U-8471', NULL, NULL, '063278;63278', 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(1116, 'Meg-CSF', NULL, NULL, 'YES', NULL, 'megakaryocyte colony stimulating factor', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1117, 'Megestrol Acetate', NULL, NULL, 'SEE_REMARKS', 'A synthetic progestin; appetite stimulant. FDA approved palliative uses in advanced endometrial carcinoma and advanced breast carcinoma.  Also for the treatment of anorexia, cachexia, and significant weight loss in patients with acquired immunodeficiency syndrome; administered orally.\r\n\r\nMegace may be coded as first course treatment (hormone) when given in combination with other antineoplastic drugs. Megace is most often given for advanced breast and endometrial cancers, but it\'s use is not limited to advanced/metastic/recurrent disease.\r\n\r\nDO NOT code when given as an appetite stimulant.', 'Apo-Megestrol , BDH-1298 , Compound 5071 , Magace , Megace , SC-10363', 'Breast cancer, endometrial cancer', NULL, '71423;071423', 'Hormones and hormonal mechanisms;AIDS drug', 'Progestin'),
(1118, 'Melanoma peptide vaccine', NULL, NULL, 'NO', 'Phase II melanoma 2007', NULL, 'Melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1119, 'Melengestrol Acetate', NULL, NULL, 'NO', 'Anti-neoplastic; progestin.  Synthetic forms of the naturally occurring hormone, progesterone. By negative feedback, it reduces pituitary function, thus reducing circulating levels of all female sex hormones.  Used mainly in animals.', '5373 , BDH-1921', NULL, 'MGA', '70968', 'Hormones and hormonal mechanisms', 'Progestin--see remarks'),
(1120, 'Melphalan', NULL, NULL, 'NO', 'Alkylating antineoplastic agent. FDA approved uses on multiple myeloma and epithelial non-resectable ovarian carcinoma.\r\nAlso used in the high-dose chemotherapy and transplant setting.\r\nMechanism of action: Analog of nitrogen mustard', 'Alanine mustard , Alkeran , CB-3025 , DL Sarcolysine , DL-O-Sarcolysin , L-Phenylalanine Mustard , L-Sarcolysin , Melfalan , Phenylalanine Mustard , Sarcolysine , Sarkoklorin , Sarkolizin , WR-19813', 'Multiple myeloma, ovarian cancer, Polycythemia Vera', 'L-PAM, MPL, PAM', '8806;008806;57199', 'Chemotherapy', 'Alkylating agent'),
(1121, 'Menogaril', NULL, NULL, 'NO', NULL, '7-Omen , Tomosar , U-52047', 'Solid tumors', 'MEN', '269148', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1122, 'Meperidine Hydrochloride', NULL, NULL, 'YES', 'A synthetic narcotic analgesic.', 'Component of Mepergan , Demeol Hydrochloride , Demerol , Isoipecaine Hydrocholoride , M epadin# , Petahdol , Pethidine , Pethidine Hydrochloride', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1123, 'Meprednisone', NULL, NULL, 'NO', 'Synthetic glucocorticoid used in the treatment of inflammatory, allergic, rheumatic, and other corticosteroid-responsive diseases, such as certain endocrine, respiratory, neoplastic, and collagen diseases, administered orally.  Not found in Drugdex drug evaluation.', 'Betapar# , Sch-4358', NULL, NULL, '527579', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1124, 'Merbarone', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '336628', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1125, 'Mercaptopurine', NULL, NULL, 'NO', 'Antimetabolite antineoplastic agent. FDA approved uses on acute lymphocytic leukemia.', '6-Mercaptopurine , 6-Mercaptopurine Monohydrate , 6-Thiohypoxanthine , 6-Thiopurine , 6-Thioxopurine , Ismipur , Leukerin , Leupurin , Merca-leukin , Mercapurin , Mern , Metacaptopurine , Purine-6-thiol Monohydrate , Purinethiol , Purinethol , Purixan', 'Leukemia', '6-MP, MP', '000755;755', 'Chemotherapy', 'Antimetabolite'),
(1126, 'Mercaptopurine riboside', NULL, NULL, 'NO', NULL, '6-Mercaptoinosine , 6-Mercaptopurine-ribonucleoside , 6-Thioinosine', NULL, '6-MPR', '4911', 'Chemotherapy', 'Antimetabolite'),
(1127, 'Mesna', NULL, NULL, 'YES', 'A prophylactic detoxifying agent used to inhibit hemorrhagic cystitis caused by ifosfamide. FDA approved for bladder protection when using cyclophosphamide (prevents bladder toxicity).', 'D 7093 , Mesna rescue , Mesnex , Mesnex uroprotection , Mesnum , Mistabron , Mitexan , Mucofluid , Sodium 2-mercaptoethanolsulfonate , UCB 3983 , Uromitexan', NULL, NULL, '113891', 'Ancillary Agent', NULL),
(1128, 'Mesterolone', NULL, NULL, 'NO', 'Androgen with actions and uses similar to those of testosterone.  Not found in Drugdex drug evaluation.', 'SH 723 , SH-723 , SH723', NULL, NULL, '075054;75054', 'Hormones and hormonal mechanisms', 'Androgen'),
(1129, 'Mestranol', NULL, NULL, 'NO', 'Estrogen; the 3-methyl ether of ethinyl estradiol, used as the estrogen component of several progestin-estrogen oral contraceptives.', 'Component of Enovid , Component of Norethin 1/50 M , Component of Norinyl , Component of Norquen , Component of Ortho-Novum , Component of Ovulen', NULL, NULL, '84032', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(1130, 'Metastat', NULL, NULL, 'NO', 'Phase I/II brain, skin Phase II sarcoma Multiple protease inhibitor. Taisho Pharmaceuticals, Collagenex Pharmaceutical.', 'COL-3', 'Brain, sarcoma, skin cancer', NULL, '683551', 'Chemotherapy', 'Cytostatic agent--matrix metaloprotease inhibitor (MMPI)'),
(1131, 'Methadone Hydrochloride', NULL, NULL, 'YES', 'A long-acting narcotic analgesic.', 'Adanon HCl# , Component of Mespergan , Diskets , Dolophine , Dolophine Hydrochloride , Methadose', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1132, 'Methandrostenolone', NULL, NULL, 'NO', 'Androgen used especially in the adjunctive treatment of senile and postmenopausal osteoporosis and in selected cases of pituitary dwarfism, administered orally. Not found in Drugdex drug evaluation.', 'Abirol , Anabolin , Compound 17309 , Crein , Danabol , Dehydromethyltestosterone , Dianabol# , Geabol , Metaboline , Metanabol , Metandienon , Metandrostenolone , Methandrostenolone , Naposim , Nerobol , Protobolin , Stenolon', NULL, 'MA', '042722;42722', 'Hormones and hormonal mechanisms', 'Androgen.  Probably not cancer directed--verify with attending MD.'),
(1133, 'Methionyl Interferon-Consensus', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1134, 'Methotrexate', NULL, NULL, 'NO', 'FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and  osteosarcoma.', 'Amethopterin , Antifolan , CL-14377 , Folex , Methotrexate Sodium , Mexate , Mexate AQ , Rheumatrex , WR-19039', 'Acute lymphoblastic leukemia (ALL), Bladder cancer, Breast, Gestational trophoblastic cancer, head & neck cancer, lymphoma, Meningeal leukemia, Non-Hodgkin lymphoma, Osteogenic sarcoma, Primary CNS lymphoma', 'MTX', '740;000740', 'Chemotherapy', 'Antimetabolite'),
(1135, 'Methyl methanesulphonate', NULL, NULL, 'NO', 'Known genotoxin', 'Methyl methanesulfonate , Methyl-methane sulfonate', NULL, NULL, '50256', 'Chemotherapy', 'Alkylating agent'),
(1136, 'Methylene Dimethane Sulfonate', NULL, NULL, 'NO', 'No published data since 1989; negative Phase II trial for ovary and soft tissue', NULL, NULL, 'MDMS', NULL, 'Chemotherapy', 'Not in current use'),
(1137, 'Methylmercaptopurine riboside', NULL, NULL, 'NO', NULL, '977 (biochemical modulator) , Methylthioinosine , SQ 21', NULL, '6-MMPR', '40774', 'Chemotherapy', 'Protein kinase inhibitor'),
(1138, 'Methylphenidate Hydrochloride', NULL, NULL, 'YES', 'A piperidine-derivative stimulant.', 'Metadate-ER , Mthylin , PMS-Methylphenidate , Ritalin , Ritalin-SR', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1139, 'Methylprednisolone', NULL, NULL, 'NO', 'Code this drug as hormone therapy when given in multi-drug regimens.', 'A-Methapred , Cordex Forte , Depmedalone , Depo-Medrol , Depo-Predate , Depoject , Depopred , Dopmedrol , Enpak Refill , Mar-Pred , Medrate , Medrol , Medrone , Methyl Prednisolone , Methylone , Pre-Dep , Promacortine , Rep-Pred , Urbason', NULL, NULL, '019987;19987', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1140, 'Methylprednisolone Acetate', NULL, NULL, 'NO', 'This drug should be coded as hormone therapy when given in multi-drug regimens.', 'Adlone , Component of Neo-Medrol , D-Med , Depmedalone , Depo-Medrol , Depo-Predate , Depoject , Depopred , Dura-Meth , Duralone , M-Prednisol , Mar-Pred , Medralone , Medrol , Medrol Acetate , Medrol Veriderm , Mep-40 , Methylone', NULL, NULL, '48985', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1141, 'Methylprednisolone Sodium Phosphate', NULL, NULL, 'NO', 'The drug should be coded as hormone therapy when given in multi-drug regimens.', '019E , Medrol Stabisol# , U-12', NULL, NULL, '48989', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1142, 'Methylprednisolone Sodium Succinate', NULL, NULL, 'SEE_REMARKS', 'Code this drug when given with other chemotherapy agents ONLY.', 'A-Methapred , Solu-Medrol', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(1143, 'Methyltestosterone', NULL, NULL, 'NO', 'A a synthetic androgen derived from cholesterol, having actions similar to those of testosterone used as replacement therapy for androgen deficiency in males, in the palliation of certain inoperable mammary cancers, and to prevent postpartum breast pain and engorgement in the non-nursing mother; administered orally or sublingually; 17-alpha-alkyl substituted synthetic androgen.', 'Android , Andrometh , Androsan , Androsten , Anertan , Component of Estratest , Component of Premarin with Methyl-testosterone , Dumogran , Homandren , Malestrone , Metandren , Methyltestosteronum , Metrone , Neo-Hombreol-M# , Oreton Methyl , Steronyl , Synandrets , Synandrotabs , Testoviron , Testred (ICN) , Virilon', 'Breast cancer', NULL, '009701;9701', 'Hormones and hormonal mechanisms', 'Androgen'),
(1144, 'Methynodiol Diacetate', NULL, NULL, 'NO', 'Progestin', 'SC-19198', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'No longer in use'),
(1145, 'Metoclopramide', NULL, NULL, 'YES', 'A gastrointestinal prokinetic agent which increases gastrointestinal motility; anti-emetic.', 'AHR-3070-C , Apo-Metoclop , Clopra , Emex , Gastrobid , Maxolon , Metaclopramide hydrochloride , Metoclopramide Intensol , Mexeran , Octamide , Octamide PFS , Reclomide , Reglan', NULL, 'MCP', NULL, 'Ancillary Agent', NULL),
(1146, 'Metoprine', NULL, NULL, 'NO', 'Anti-metabolite', 'Delcronol', NULL, 'DDMP', '7364', 'Chemotherapy', 'Antimetabolite'),
(1147, 'Metronidazole', NULL, 'MALT Lymphoma', 'SEE_REMARKS', 'Treatment of the H. pylori infection leads to regression of the lymphoma in about 8 out of every 10 people with gastric MALT lymphoma who showed evidence of an H. pylori infection. The treatment is most successful when the tumor has not extended very far through the stomach wall and has not spread to the lymph nodes\r\n\r\nAn initial course of antibiotic treatment for H. pylori eradication is clarithromycin together with either amoxicillin or metronidazole. These antibiotics are usually given with a drug that cuts down the amount of acid the stomach produces (a proton pump inhibitor or \'PPI\' drug such as omeprazole). This combination of three drugs is often called ‘triple therapy’ and is taken for 10–14 days.\r\n\r\nCoding Instructions: Code this drug as Other Therapy ONLY when given for MALT lymphoma', 'Component of Flagyl I.V. RTU , Falgyl , Femazole , Helidac Therapy: Part II , Lagyl , Metizol , Metro I.V. , MetroCream , MetroGel , Metrolotion , Metronid , Metryl , Neo-Metric , Neo-Nidazol , Nidagel , Norritate , Protostat , Satric , Trikacide', 'AIDS, Opportunistic infection', NULL, '50364;050364', 'Ancillary Agent;AIDS drug;Other therapy', NULL),
(1148, 'Meturedepa', NULL, NULL, 'NO', NULL, 'AB-132 , Turloc', NULL, NULL, '51325', 'Chemotherapy', 'Alkylating agent'),
(1149, 'Metvix', NULL, NULL, 'NO', 'NDA submitted basal cell Photodynamic therapy. Phtocure.', NULL, 'Skin cancer', NULL, NULL, 'Other therapy', 'Photodynamic therapy');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1150, 'Metyrosine', NULL, NULL, 'YES', 'A tyrosine hydroxylase inhibitor. Antihypertensive, pheochromocytoma. \r\n\r\nTherapy for malignant pheochromocytoma.\r\n\r\nThis drug is now rarely used in medicine and its main use is in scientific research are to investigate the effects of catecholamine depletion on behaviour.', 'Demser , Methyl tyrosine , Metirosine , alpha MT , alpha-MPT', 'Malignant pheochromocytoma', NULL, NULL, 'Ancillary Agent', 'Antihypertensive'),
(1151, 'Mexiletine Hydrochloride', NULL, NULL, 'YES', 'Oral mexiletine will be indicated for treatment of chronic ventricular arrhythmias; the drug has not proven to be superior to older agents (quinidine) or newer agents (flecainide). Therapy for HIV-related neuropathy.', 'Mexitil', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1152, 'MG98', NULL, NULL, 'NO', 'Phase II (head & neck, kidney Phase II AML MDS Antisense oligonucleotide; second generation mRNA inhibitor.  MGI Pharma.', NULL, 'Head & neck, kidney cancer, leukemia', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(1153, 'MGCD0103', NULL, NULL, 'NO', 'Methylgene. HDAC inhibitor in Phase I trials 2006.', 'MGCD 0103 , MGCD-0103', 'AML, MDS', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--histone deacetylation inhibitor'),
(1154, 'MGS rCEA (recombinant carcinoembryonic antigen)', NULL, NULL, 'NO', 'Phase I Recombinant carcinoembryonic antigen. Protein Sciences.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1155, 'MGV Vaccine', NULL, NULL, 'NO', 'Phase I (colorectal, gastric, lung) Phase I/II (SCLC, lymphoma, neuroblastoma, sarcoma) Vaccine. Progenics Pharmaceuticals.', 'GM2-KLH/QS-21 , GM2/GD2 gangliosides-KLH vaccine , VMO (vaccinia melanoma oncolysate vaccine)', 'Colorectal, gastric, lung cancer, lymphoma, neuroblastoma, sarcoma', NULL, '725532;713762', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1156, 'Mibolerone', NULL, NULL, 'NO', 'Anabolic androgen. Not found in Drugdex drug evaluation.', 'Miboleron , U-10997', 'Prostate cancer', NULL, '72260', 'Hormones and hormonal mechanisms', 'Androgen'),
(1157, 'Miconazole', NULL, NULL, 'YES', 'Antifungal.', 'Absorbine Antifungal Foot Powder , Anusol Antifungal Foot Powder , Breezee Mist Antifungal , Curex , Desenex , Diabet-X Plus , Femizol-M , Fungoid , Lotrimin AF , M-Zole , Massengill Gyn , Micatin , Miconazole Nitrate , Micotrex , Mitrazol , Monistat , Monistat-Derm , Ony-Clear , Podactin , Podiatrx-AF , Triple Care Antifungal , Triple Care EPC , Zeasorb AF', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1158, 'Midazolam Hydrochloride', NULL, NULL, 'YES', 'An anesthetic adjunct; CNS depressant.', 'Ro 21-3981/003 , RO21-3981 , Versed', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1159, 'Midostaurin', NULL, NULL, 'NO', '4/28/2017: FDA approved midostaurin, trade name Rydapt, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.', 'Rydapt , Midostaurine', 'Leukemia, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--protein kinase inhibitor'),
(1160, 'Mifepristone', NULL, NULL, 'NO', 'A progesterone receptor antagonist, which may be used to induce abortions during early pregnancy.', 'RU 38486 , RU 486 , RU-486 , RU486', NULL, NULL, '652104', 'Hormones and hormonal mechanisms', 'Progesterone receptor agonist'),
(1161, 'Milodistim', NULL, NULL, 'YES', 'A granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein.  A hematopoietic growth factor; regulates proliferation and differentiation of hematopoietic and lymphoid cells', 'IL-3 + GM-CSF , Multi-colony-stimulating factor (multi-CSF) , PIXY-321', 'AIDS, Opportunistic infection', 'IL-3', '643496;645014', 'Ancillary Agent', 'Fusion molecule with GM-CSF'),
(1162, 'Miltefosine', NULL, NULL, 'NO', 'A novel antineoplastic agent. It is an alkylphosphocholine with anti-tumor activity. It has been promising in the treatment of visceral Leishmaniasis. It has been shown to have topical activity in the treatment of skin metastases in patients with breast cancer and in cutaneous lymphomas.', 'D18506 , Hexadecylphosphocholine , Miltefosin , Miltefosina , Miltefosinum , Miltefostine', 'cutaneous lymphomas, Skin metastases in breast ca', 'HDPC, He-PC, HeDC, HPC', NULL, 'Chemotherapy', 'Topical antineoplastic'),
(1163, 'Mirena IUD', NULL, NULL, 'SEE_REMARKS', 'Coding Instructions: Mirena IUD is not a FDA approved treatment for stage I endometrial cancer. It has been used in various clinical trials with questionable results. Code the treatment in \"Other Therapy\" and assign code 1: patient received a hormone therapy that could not be coded to hormone.\r\n\r\nIntrauterine devices (IUDs) – used to prevent pregnancy – may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility. In a small, early study (2010), carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone. The treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer. It is important to note that this treatment has not received finally FDA approval but may still be prescribed off-label. If the physician states it is prescribed to shrink the cancer then code as Other treatment. If given to control bleeding consider it palliative treatment.', NULL, 'Cervix, Endometrium', NULL, NULL, 'Other therapy', NULL),
(1164, 'Mirostepin', NULL, NULL, 'YES', 'Phase I Myeloid progenitor inhibtory factor. Human Genome Sciences', 'MPIF-1', 'Breast cancer', NULL, NULL, 'Ancillary Agent', NULL),
(1165, 'Misonidazole', NULL, NULL, 'YES', 'No current usage information, radiosensitizer. Not found in Drugdex drug evaluation.', 'Ro-7-0582 , SRI-1354', NULL, 'MNI', '261037', 'Ancillary Agent', NULL),
(1166, 'Mitindomide', NULL, NULL, 'NO', NULL, 'Benzenebismaleimide adduct , CAS 10403-51-7', NULL, NULL, '284356', 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(1167, 'Mitocarcin', NULL, NULL, 'NO', 'Antibiotic', NULL, NULL, NULL, '24281', 'Chemotherapy', 'Antitumor antibiotic'),
(1168, 'Mitocromin', NULL, NULL, 'NO', 'Antibiotic', 'B 35251', NULL, NULL, '77471', 'Chemotherapy', 'Antitumor antibiotic'),
(1169, 'Mitoguazone', NULL, NULL, 'NO', 'A hydrazone antitumor agent. At present, mitoguazone should be available on an as-needed basis in institutions routinely treating cancer patients, including AIDS-related non-Hodgkin\'s lymphoma.', 'Methyl G , Methyl-GAG , Methylglyoxal Bisguanylhydrazone , mitoguazone dihydrochloride', 'AIDS, Opportunistic infection', 'MeG, MeGAG, MGA, MGBG, MGGH', '32946', 'Chemotherapy', 'Antineoplastic hydrazone'),
(1170, 'Mitolactol', NULL, NULL, 'NO', 'An anticancer agent. Main role at present is in the treatment of malignant gliomas in combination regimens.', NULL, NULL, 'DBD', '104800', 'Chemotherapy', 'Alkylating agent'),
(1171, 'Mitomalcin', NULL, NULL, 'NO', 'Antibiotic', NULL, NULL, NULL, '113233', 'Chemotherapy', 'Antitumor antibiotic'),
(1172, 'Mitomycin', NULL, NULL, 'NO', 'FDA approved for treatmen of many cancers.', 'Ametycine , Mito-Medac , Mitocin , Mitocin-C , MitoExtra , Mitomycin-C , Mitomycin-X , Mutamycin , Mutamycine', 'Breast, Cervical cancer, Gastric cancer, Head and Neck (in combination with radiation therapy), Non-small cell lung cancer (NSCLC), Pancreatic cancer, Superficial bladder cancer', 'MITC, Mito, MITO-C, MMC, MTC', '26980;026980', 'Chemotherapy', 'Alkylating agent'),
(1173, 'Mitopodozide', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '72274', 'Chemotherapy', 'Plant product'),
(1174, 'Mitosper', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '117032', 'Chemotherapy', 'Plant product'),
(1175, 'Mitotane', NULL, NULL, 'NO', 'Antineoplastic. FDA approved use on inoperable adrenal cortical carcinoma.', NULL, NULL, 'o, o.p\'-DDE, p\'DDD', '38721;038721', 'Chemotherapy', 'Miscellaneous agent'),
(1176, 'Mitoxantrone', NULL, NULL, 'NO', 'Antibiotic-class antineoplastic. FDA approved uses in adult acute non-lymphocytic leukemia, and prostate cancer pain reduction in combination with prednisone. Novantrone is a synthetic antineoplastic anthracenedione', 'CL 232315 , Mitoxantrone Hydrochloride , Mitozantrone , Novantrone', 'Acute myelogenous leukemia (AML), Breast, Non-Hodgkin lymphoma, Prostate- advanced hormone-refractory', 'DAD, DHAD, DHAQ', '301739', 'Chemotherapy', 'Antitumor antibiotic'),
(1177, 'Mitozolomide', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '353451', 'Chemotherapy', 'Alkylating agent'),
(1178, 'MK-0752', NULL, NULL, 'NO', 'Phase I&II New drug currently in trials, code in Other Therapy', 'MK-0752', 'brain, Breast, CNS', NULL, NULL, 'Chemotherapy', 'Notch inhibitor'),
(1179, 'MK-2206', NULL, NULL, 'NO', 'Currently in Phase 1 trials as part of a regimen. Code this agent in Other as it is not FDA approved', 'MK-2206', 'Breast, melanoma', NULL, NULL, 'Chemotherapy', 'Protein inhibitor'),
(1180, 'MK-5108', NULL, NULL, 'NO', 'i New drug currently in trials, code in other therapy', NULL, 'solid tumors', NULL, NULL, 'Chemotherapy', 'Aurora-A kinase inhibitor'),
(1181, 'MLN518', NULL, NULL, 'NO', 'Phase I AML Phase I AML FLT-3 receptor tyrosine kinase inhibitor. Millenium Pharmaceuticals.', 'CT 53518 , CT-53518 , CT53518', 'Leukemia', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--receptor tyrosine kinase inhibitor'),
(1182, 'MLN576', NULL, NULL, 'NO', 'Phase I Dual inhibition of topoisomerase I and II. Millenium Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--topoisomerase inhibitor'),
(1183, 'MLN591', NULL, NULL, 'NO', 'Phase I Anti-prostate specific membrane antibody. Millenium Pharmaceuticals.', 'J591 , MLN2704', 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody  for prostate specific membrane'),
(1184, 'MN rgp120/HIV-1', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1185, 'Mobista', NULL, NULL, 'NO', 'Phase II NHL Recombinant human Flt3 ligand. Immunex.Functions:  stimulate blood stem cells, replace cells after chemotherapy damage,  increase population of NK\'s (natural killer cells), NK\'s target tumor cells, reduced tumors in animal models.  Current testing for prostate cancer, melanoma and non-Hodgkin\'s lymphoma.', NULL, 'Lymphoma', NULL, NULL, 'Ancillary Agent', 'Flt3  ligand'),
(1186, 'Molybdenum', NULL, NULL, 'YES', 'Meyabolic therapy', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1187, 'Monamulizmab-kpkc', NULL, 'Mycosis fungoides, Sezary syndrome', 'NO', '8/8/18 The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS', 'Poteligeo', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1188, 'Monoclonal Antibody MoAB', NULL, NULL, 'NO', NULL, 'New monoclonal antibodies are rapidly being developed. Therefore , please see the new edition of Biologic Therapy of Cancer that will be available soon (Item 6 , References). , they will not be listed individually. They should be coded as biological response modifiers. For an up-to-date list', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1189, 'Monoclonal CC-49 Delta CH2', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. NCI.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1190, 'Montanide 15A-51', NULL, NULL, 'YES', 'Ancillary drug', 'Montanide 15A-51', NULL, NULL, NULL, 'Ancillary Agent', 'Ancillary'),
(1191, 'Mopidamol', NULL, NULL, 'NO', 'Formerly used as an antineoplastic. phosphodiesterase inhibitor which inhibits platelet aggregation.  Not found in Drugdex drug evaluation.', NULL, NULL, 'Ra-233', NULL, 'Chemotherapy', 'Not in current use'),
(1192, 'Morphine Sulfate', NULL, NULL, 'YES', 'Analgesic and narcotic (sedative).', 'Astramorph , Duramorph , Infumorph , Kadian , MS Contin , MSIR , Oramorph , Roxanol', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1193, 'Motesanib', NULL, NULL, 'NO', 'Phase III NSCLC 2007, Phase I Colorectal 2007 Angiogenesis inhibitor.  Amgen.', 'AMG 706 , AMG-706 , AMG706', 'Colorectal, NSCLC', NULL, NULL, 'Chemotherapy', 'Cystostatic agent--tyrosine kinase inhibitor'),
(1194, 'Moxetumomab pasudotox', NULL, 'Leukemia', 'SEE_REMARKS', 'September 13, 2018: FDA  approved moxetumomab pasudotox-tdfk (LUMOXITI), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).', 'Lumoxiti', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti-CD22 antibody'),
(1195, 'MPC-7869', NULL, NULL, 'NO', 'Phase III Signal transduction and transcriptor modulator. Myriad Genetics.', 'Flurizan', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Signal transduction modulator'),
(1196, 'MPI5020', NULL, NULL, 'YES', 'Phase II Radiopotentiator. Matrix Pharmaceuticals.', NULL, 'Breast cancer', NULL, NULL, 'Ancillary Agent', 'Radiopotentiator'),
(1197, 'MS-275', NULL, NULL, 'NO', 'Phase I Histone deacylate. NCI, Mitsui Pharmaceuticals, Berlex Laboratories.', 'MS 275 , MS275', 'Leukemia, lymphoma, other cancer', NULL, '706995', 'Chemotherapy', 'Cytostatic agent--histone deacetylase inhibitors'),
(1198, 'MSL-109', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1199, 'MTC-DOX (Doxorubicin)', NULL, NULL, 'NO', 'Phase II Anthracycline antibiotic.   Doxorubicin conjugated to magnetic targeted carrier (MTC technology). FeRx Inc.', NULL, 'Liver cancer', NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic conjugated to delivery mechanism'),
(1200, 'Mucopirocin', NULL, NULL, 'YES', NULL, 'Bactroban , Mupirocin , Pseudomonic Acid , Pseudomonic Acid  A', NULL, NULL, NULL, 'AIDS drug', NULL),
(1201, 'Multikine (Leukocyte Interleukin Injection)', NULL, NULL, 'NO', 'Phase I/II, orphan drug status for neoadj H&N Immunomodulator. CEL-SCI, Corp.', 'Multikine', 'head & neck cancer, Prostate', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1202, 'Mupirocin', NULL, NULL, 'YES', 'A topical antibiotic.', NULL, 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent', 'Topical antibiotic'),
(1203, 'MVA-BN-HER2', NULL, NULL, 'NO', 'Phase I breast 2007 B N ImmunoTherapeutics', NULL, 'Breast', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1204, 'MVA-Muc1-IL2', NULL, NULL, 'NO', 'Phase II Vaccine. Transgene.', 'TG 4010 , TG-4010 , TG4010', 'Breast, lung, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1205, 'Mvasi', NULL, NULL, 'NO', 'Sept. 14, 2017: The FDA approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. It is approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers. Specifically, the approved indications include:\r\n\r\n    Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment. Mvasi is not indicated for the adjuvant treatment of surgically resected colorectal cancer.\r\n    Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line bevacizumab product-containing regimen. Mvasi is not indicated for the adjuvant treatment of surgically resected colorectal cancer.\r\n    Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.\r\n    Glioblastoma with progressive disease following prior therapy, based on improvement in objective response rate. No data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab', 'Benacizumab-awwb', 'See remarks', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'bio-similar'),
(1206, 'MVE-2', NULL, NULL, 'NO', 'Immunomodulator', NULL, NULL, NULL, '332586', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1207, 'MX6', NULL, NULL, 'NO', 'Phase II JUN kinase activator retinoid related molecule. Topical treatment for cervical dysplasia.  Maxia Pharmaceuticals.', NULL, 'Cervical cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis stimulator'),
(1208, 'Mycophenolate Mofetil', NULL, NULL, 'YES', 'An immunosuppressive agent.  Not shown to have any antitumor effectiveness.  Roche.', '3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl- , 4-Hexenoic acid , Cellcept , Lilly-68618 , Mycophenolic Acid , RS-61443', NULL, NULL, '724229', 'Ancillary Agent', 'Immunosuppressant for transplantation'),
(1209, 'Mycophenolic acid', NULL, NULL, 'YES', 'Not shown to have any antitumor effectiveness', NULL, NULL, NULL, '129185', 'Ancillary Agent', 'Immunosuppressant for transplantation'),
(1210, 'Myeloma-derived Idiotypic Antigen Vaccine', NULL, NULL, 'NO', 'Phase II Vaccine. NCI.', NULL, 'Multiple myeloma', NULL, '678327', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1211, 'Mylovenge', NULL, NULL, 'NO', 'Phase II Vaccine. Dendreon.', NULL, 'Multiple myeloma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Dendritic cell vaccine'),
(1212, 'Myristic acid analogs', NULL, NULL, 'YES', 'Prevents assembly of new virus from polyproteins and viral RNA', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1213, 'N-acetylcysteine', NULL, NULL, 'YES', 'Cysteine precursor; may indirectly inhibit HIV replication', 'NAC', NULL, 'NAC', NULL, 'AIDS drug', NULL),
(1214, 'N-Methylformamide', NULL, NULL, 'NO', 'The ability of MMF to induce terminal differentiation (to nonreplicating cells) in neoplastic tissues has made it the subject of investigation as a possible cancer chemotherapeutic agent.', 'N-methyl-formamide', NULL, 'MMF', '3051', 'Chemotherapy;Differentiation', 'Dual properties--code as chemotherapy'),
(1215, 'N1177', NULL, NULL, 'YES', 'Phase I lymphatic metastasis diagnosis Radio contrast agent. Elan.', NULL, 'Other cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(1216, 'N2 Transduced TIL', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '622283', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1217, 'N2-TIL/ADA Gene', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '635386', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1218, 'Nabilone', NULL, NULL, 'YES', 'Phase IV 2007 A synthetic cannabinoid used orally as an antiemetic drug for the control of nausea and vomiting induced by cancer chemo; tranquilizer', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1219, 'Nafarelin Acetate', NULL, NULL, 'NO', 'A synthetic analogue of luteinizing hormone releasing hormone (LHRH; GnRH); LHRH agonist activity.  A synthetic preparation of gonadotropin-releasing hormone, used in the treatment of central precocious puberty; administered by nasal spray.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH agonist.  Probably not cancer directed--verify with attending MD.'),
(1220, 'Nafazatrom', NULL, NULL, 'NO', NULL, 'Bay g 6575 , BAY G6575 , Bay-g 6575 , BAY-G6575', NULL, NULL, NULL, 'Chemotherapy', 'Cytostatic agent--lipooxygenase inhibitor'),
(1221, 'Nafoxidine HCL', NULL, NULL, 'NO', 'A selective estrogen response modulator--an estrogen antagonist/agonist similar to Raloxifene, tamoxifen', NULL, NULL, 'NAFO, NFX', '70735', 'Hormones and hormonal mechanisms', 'Antiestrogen--SERM'),
(1222, 'Nalaxone Hydrochloride', NULL, NULL, 'YES', 'Opioid (narcotics) antagonist.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1223, 'Naltrexone Hydrochloride', NULL, NULL, 'YES', 'Opiate (narcotics) antagonist.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1224, 'Nandrolone Decanoate', NULL, NULL, 'NO', 'An androgenic-anabolic steroid that differs from testosterone in not having a methyl group attached to carbon 10 of the steroid nucleus; it has anabolic effects that are more pronounced than its androgenic effects.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen'),
(1225, 'Nandrolone Phenpropionate', NULL, NULL, 'NO', 'Anabolic; an ester of nandrolone having a moderate duration of action, used in the treatment of metastatic breast cancer and of severe growth retardation in children, and as an adjunct in the treatment of chronic wasting diseases; administered intramuscularly.', NULL, 'Breast cancer', 'NPP, NTPP', '023162;23162', 'Hormones and hormonal mechanisms', 'Anabolic steroid'),
(1226, 'Naproxen Sodium', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory agent (anti-inflammatory; analgesic; antipyretic).', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1227, 'Naptumomab estafenatox', NULL, NULL, 'NO', 'Phase III renal cell 2007 TTS:  Tumor Targeted Superantigen; targets 5T4 on cells and activates lymphocytes to destroy those cells.  Active Biotech Research.', 'ABR 217620 , ABR-217620 , ABR217620 , Anyara', 'Kidney', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy'),
(1228, 'NB1011', NULL, NULL, 'NO', 'Phase II Thymidylate synthase substrate. Elan Corp.', 'NB 1011 , NB-1011', 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent and thymidylate synthase inhibitor'),
(1229, 'NBI-3001', NULL, NULL, 'NO', 'Phase II Cytokine plus pseudomonas exotoxin. Neurocrine Biosciences.', 'NBI 3001 , NBI3001', 'Brain, kidney cancer', NULL, NULL, 'Chemotherapy', 'Interleukin conjugated with pseudomonas toxin'),
(1230, 'Nebacumab', NULL, NULL, 'NO', 'An immune globulin directed against gram-negative bacterial endotoxins.', 'Centocor , Centoxin , HA-1A , Human anti-endotoxin monoclonal antibody', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1231, 'Necitumumab', NULL, 'Non-small cell lung cancer (NSCLC)', 'NO', 'November 24, 2015: Portrazza received FDA approval for use in combination with two forms of chemotherapy to treat patients with advanced/metastatic squamous non-small cell lung cancer (NSCLC) who have previously received medication specifically for treating their advanced lung cancer.', 'Portrazza , IMC 11F8', 'Lung', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti-EFRG monoclonal antibody'),
(1232, 'Nedaplatin', NULL, NULL, 'NO', 'Has shown efficacy in various malignancies, including gastrointestinal and cervical cancer, although clinical data remain limited.', '254-S , Aqupla', NULL, NULL, '375101D', 'Chemotherapy', 'Miscellaneous agent'),
(1233, 'Nelarabine', NULL, NULL, 'NO', 'FDA approved 2005 for ALL, CLL, cutaneous T cell NHL Prodrug of guanine arabinoside. NCI, GlaxoSmithKline.', 'ARA-G , Arranon , Compound 506U78', 'T-cell ALL, T-cell lymphoblastic lymphoma', NULL, '686673', 'Chemotherapy', 'Antimetabolite'),
(1234, 'NeoTide', NULL, NULL, 'YES', 'Phase I Synthetic peptide radiopharmaceutical. DiaTide/Berlex Imaging.', 'RE-188 P2045', 'Lung cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(1235, 'Neovastat', NULL, NULL, 'NO', 'Phase I (breast); Phase II (MM, prostate); Phase III (NSCLC); Phase I/II (plaque psoriasis) Angiogenesis inhibitor derived from shark cartilage extract. AEterna Laboratories.', 'AE 941 , AE-941 , AE941 , Neovasta , Neovastal', 'Breast, kidney, lung, multiple myeloma, prostate cancer', NULL, '706456', 'Chemotherapy', 'Cytostatic agent--anti-angiogenesis agent'),
(1236, 'Neratinib', NULL, NULL, 'NO', 'July 17, 2017 FDA approved neratinib (NERLYNX) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.', 'HKI 272 , HKI272 , HKI-272', 'breast, Non-small cell lung', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1237, 'Netivudine', NULL, NULL, 'YES', 'Not found in Drugdex drug evaluation. A synthetic nucleoside analogue structurally related to thymidine, with activity against varicella-zoster virus.', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1238, 'Neugene', NULL, NULL, 'NO', 'Phase I Antisense. AVI BioPharma.', NULL, 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Antisense drug'),
(1239, 'Nevirapine', NULL, NULL, 'YES', 'A nonnucleoside antiretroviral agent.', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1240, 'Niacin', NULL, NULL, 'YES', 'Vitamin, antilipidemic; therapy for patients on parenteral nutrition.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1241, 'Nifedipine', NULL, NULL, 'YES', 'A calcium channel  blocking agent (antagonist).', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1242, 'Nilotinib', NULL, NULL, 'NO', 'Orphan drug for GIST\r\nIn clinical trials for patients resistant to Gleevec. .\r\nFDA approved (June 2010) for treatment of CML\r\n\r\nMarch 26, 2018: The FDA has expanded the indication for Tasigna (nilotinib) to include treatment of first-and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.', 'AMN 107 , AMN-107 , AMN107 , Tasigna', 'CML, GIST', NULL, '900001', 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(1243, 'Nilutamide', NULL, NULL, 'NO', 'A nonsteroidal antiandrogen used as an antineoplastic in treatment of prostatic carcinoma; administered orally.', 'ANAN , Anadron , Nilandron', 'Prostate cancer', NULL, '684588', 'Hormones and hormonal mechanisms', 'Nonsteroidal antiandrogen'),
(1244, 'Nimodipine', NULL, NULL, 'YES', 'Nimodipine is effective in preventing cerebral artery spasm and improving cerebral blood flow. Nimodipine appears effective in reducing the neurologic deficits seen after subarachnoid hemorrhage, severe head injury, and acute stroke. Oral calcium-channel blocking agent under investigation for the Rx of AIDS dementia complex', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1245, 'Ninlaro', NULL, 'Multiple myeloma', 'NO', 'November 20, 2015: The U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.', 'Ixazomib', NULL, NULL, NULL, 'Chemotherapy', 'Proteasome inhibitor'),
(1246, 'Nintedanib', NULL, NULL, 'NO', 'Inhibits VEGF, PDGF and FGF receptor kinases and members of the Src family of tyrosine kinases', 'BIBF 1120 , BIBF-1120', NULL, NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1247, 'Niraparib', NULL, NULL, 'NO', '10/25/2019 FDA approved Zejula (niraparib) for treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer.\r\n\r\n3/28/2017: The U.S. Food and Drug Administration approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.', 'MK-4827 , Zejula', 'Ovary, prostate, Fallopian tubes, Primary peritoneal', NULL, NULL, 'Chemotherapy', 'PARP inhibitor'),
(1248, 'Nitrofurazone', NULL, NULL, 'YES', 'Used as adjunctive therapy for second- and third-degree burns and for preparation of surfaces prior to skin grafting.', NULL, 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent', 'Topical anti-infective'),
(1249, 'Nitromifene Citrate', NULL, NULL, 'NO', 'Anti-estrogen', NULL, 'Breast cancer', NULL, '110407', 'Hormones and hormonal mechanisms', 'Anti-estrogen'),
(1250, 'Nivazol', NULL, NULL, 'NO', 'Glucocorticoid.  The synthetic steroid that lacks three of the substituents considered to be important for glucocorticoid activity.  Many newer agents have replaced its use.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(1251, 'Nivestym', NULL, NULL, 'YES', '7/20/18 FDA approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). This is the second approved biosimilar to Neupogen approved in the U.S. \r\nNivestym is approved for the same indications as Neupogen, and can be prescribed by a health care professional for:\r\n•       patients with cancer receiving myelosuppressive chemotherapy;\r\n•       patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;\r\n•       patients with cancer undergoing bone marrow transplantation;\r\n•       patients undergoing autologous peripheral blood progenitor cell collection and therapy; and\r\n•       patients with severe chronic neutropenia', 'Filgrastin-aafi', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1252, 'NKTR-214', NULL, 'Melanoma', 'NO', '8/2/2019 FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.', 'Bempegaldesleukin', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1253, 'NM-3', NULL, NULL, 'NO', 'Phase I Angiogenesis inhibitor. ILEX Products.', NULL, 'Breast, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1254, 'Nocardia rubra', NULL, NULL, 'NO', 'Bacteria and Fungi biological; immunomodulator', NULL, NULL, 'N-CWS', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1255, 'Nocodazole (Belgium)', NULL, NULL, 'NO', NULL, '934 , R 17 , R 17934 , R-17934 , R17934', NULL, NULL, '238159', 'Chemotherapy', 'Antimitotic anti-microtubule agent'),
(1256, 'Nogalamycin', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '70845', 'Chemotherapy', 'No longer in use'),
(1257, 'Norelin', NULL, NULL, 'NO', 'Phase I GnRH based vaccine. YM BioSciences.', NULL, 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1258, 'Norethandrolone', NULL, NULL, 'NO', 'Synthetic androgen; anabolic steroid given orally.  Equal to testosterone in anabolic activity, but having less androgenic activity.  Not found in Drugdex drug evaluation.', NULL, 'Aplastic anemia', NULL, '009893;070581', 'Hormones and hormonal mechanisms', 'anabolic steroid;Androgen'),
(1259, 'Nortriptyline Hydrochloride', NULL, NULL, 'YES', 'Tricyclic antidepressant.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1260, 'Noscapine', NULL, NULL, 'NO', 'Phase II 2007 Over-the-counter cough suppressor in Europe and Japan found to have anticancer activity.  Interferes with microtubule function and division of cancer cells in a way similar to taxanes.  Information from NCI.', 'Anarcotine , Narcotine', 'CLL, NHL', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antimicrotubular'),
(1261, 'NOV-002', NULL, NULL, 'YES', 'Phase III NSCLC, Phase II ovary 2007 Chemoprotectant and immunomodulator.  Novelos Therapeutics', 'Glutathione disulfide', 'NSCLC, Ovary', NULL, NULL, 'Ancillary Agent', NULL),
(1262, 'NovoTTF-100A system', NULL, NULL, 'NO', 'May 31, 2019: FDA has approved a tumor-treating fields device in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, or metastatic malignant pleural mesothelioma. \r\nThe device, the NovoTTF-100L System (Novocure), is the first treatment for MPM approved by the FDA in 15 years, since pemetrexed was approved in 2004. TTF therapy uses electric fields to disrupt solid tumor cancer cell division.\r\n\r\nThe NovoTTF-100A system treats recurrent glioblastoma multiforme (GBM). The NovoTTF-100A system is a first-of-its-kind treatment that fights cancerous brain tumors using electrical energy fields. It is a portable battery or power-supply operated device which produces chagning electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the head of the patient by electrically-insulated surface electrodes. TTFields stop the growth of tumor cells resulting in cell death of the rapidly dividing cancer cells.  The frequency of the TTFields used for a particular treatment is specific to the size of the cell type being treated. This system is intended as a treatment for adult patients (22 years of age or older) with confirmed glioblastoma multiforme, following confirmed recurrence in an upper region of the brain (supratentorial) after receiving chemotherapy. The device is intended to be used as a stand-alone treatment, and is intended as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.', 'NovaTTF , OPTUNE', 'Brain (Recurrent Glioblastoma Multiforme) GBM', NULL, NULL, 'Other therapy', NULL),
(1263, 'Nubeqa', NULL, NULL, 'NO', 'July 30, 2019 FDA approved darolutamide (NUBEQA) for non-metastatic castration-resistant prostate cancer.', 'Darolutamide', 'Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen receptor'),
(1264, 'NV1020', NULL, NULL, 'NO', 'Phase II Herpes simplex type 1 virus. MediGene.', NULL, 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Oncolytic virus'),
(1265, 'NY-ESO-1', NULL, NULL, 'NO', 'Phase III melanoma 2007', NULL, 'Melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1266, 'NY-ESO-1/gp100/MART-1', NULL, NULL, 'NO', 'Currently in clinical trials and is not yet approved by the FDA. If being  given as treatment, code in Other Therapy.', 'NY-ESO-1/gp100/MART-1', 'Melanoma (see Remarks)', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Dendritic cell vaccine'),
(1267, 'Nylestriol', NULL, NULL, 'NO', 'Estrogen', NULL, 'Prostate cancer', NULL, '101105', 'Hormones and hormonal mechanisms', 'Estrogen'),
(1268, 'Nyotran', NULL, NULL, 'YES', 'Phase II (kidney, prostate) Phase II (AML, NHL) Liposomal polyene antifungal. Aronex Pharmaceuticals, Abbott Laboratories.', NULL, 'Kidney, Leukemia, Lymphoma, Prostate cancer', NULL, NULL, 'Ancillary Agent', 'Antifungal'),
(1269, 'Nystatin', NULL, NULL, 'YES', 'Topical antifungal antibiotic; Rx of Candidiasis', 'Candistatin , Mycostatin , Mykinac , Nadostine , Nilstat , Nyaderm , Nystain Vaginal Tablets , Nystat-Rx , Nystex , Nystop , O-V Statin , PMS-Nystatin , Pedi-Dri , component of Myco-Triacet II , component of Mycolog II , component of Mytrex , component of Terrastatin , component of Tetrastatin', NULL, NULL, NULL, 'AIDS drug;Ancillary Agent', 'Antifungal'),
(1270, 'O-6-Benzylguanine', NULL, NULL, 'NO', 'Phase III (brain), Phase II (colorectal, melanoma) AGT inhibitor, cell signal transduction modulator. NCI, Pacific Pharmaceuticals, AOI Pharmaceuticals.', 'O6-benzylguanine', 'Brain, colorectal, multiple myeloma, sarcoma, skin cancer', 'O-BG, O6-BG', '637037', 'Chemotherapy', 'Antineoplastic enzyme inhibitor'),
(1271, 'O-Vax', NULL, NULL, 'NO', 'Phase II Autologous cell vaccine. Avax Technologies.', NULL, 'Ovarian, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1272, 'Obatoclax', NULL, NULL, 'NO', 'Phase II SCLC, advanced solid tumors Bcl-2 antagonist.  Gemin X.', 'GX15-070 , GX15-070MS', 'advanced solid tumors, Small cell lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1273, 'OctreoTher', NULL, NULL, 'NO', 'Phase II Somatostatin analog. Novartis.', NULL, 'other cancer, Pancreatic', NULL, NULL, 'Radiation', 'Radioisotope attached to somatostatin peptide analog'),
(1274, 'Octreotide Acetate', NULL, NULL, 'SEE_REMARKS', 'Remark added 11/18/2015: Sandostatin us usually prescribed to treat side-effects/symptoms from TSH-secreting pituitary adenomas. Studies show this may also shrink tumors or inhibit further growth. If the physician states this agent is being prescribed to shrink the tumor, then code as hormone treatment. \r\n\r\nPlease note: not all drugs classified as hormone treat malignant neoplasms.', 'L-Cysteinamide , Minisomatostatin , SMS-201-995 , Sandostatin , Sandostatin LAR Depot , Somatostatin analog', NULL, 'SMS', '685403', 'Ancillary Agent;Hormones and hormonal mechanisms', 'Relief of symptoms'),
(1275, 'ODN698', NULL, NULL, 'NO', 'Phase II Antisense oligodeoxynucleotide against c-raf. Novartis Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(1276, 'Odomzo', NULL, 'Basal Cell Carcinoma (BCC)', 'SEE_REMARKS', 'July 24, 2015: The U. S. Food and Drug Administration approved sonidegib (Odomzo Capsules) for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.\r\n\r\nCoding instructions: Please review your registry list of reportable tumors to determine if you should code this drug as treatment for a reportable tumor.', 'Sonidegib', 'Skin', NULL, NULL, 'Chemotherapy', NULL),
(1277, 'Oestradiol Benzoate', NULL, NULL, 'NO', 'British spelling of estrogen.  Not found in Drugdex drug evaluation.', 'Beta-oestradiol Benzoate , Climacteron , Dihydroxyoestrin Monobenzoate , Estradiol Benzoate', NULL, NULL, '9566', 'Ancillary Agent', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(1278, 'Oestradiol Cypionate', NULL, NULL, 'NO', 'British spelling of estrogen. Not found in Drugdex drug evaluation.', 'Andro/Fem , Depandrogyn , Depgynogen , Depo-Testadiol , Depogen , Depotestogen , Duo-Cyp , Dura-Estrin , Dura-Testrin , E-Cypionate , Estra-D , Estradiol Cipionate , Estradiol Cypionate , Estro-Cyp , Estroject , Oestradiol Cyclopentylpropionate , T-E Cypionate , Test-Estro', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(1279, 'Oestradiol Dipropionate', NULL, NULL, 'NO', 'British spelling of estrogen. Not found in Drugdex drug evaluation.', 'Dihydroxyoestrin Dipropionate , Estradiol Dipropionate', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(1280, 'Oestradiol Valerate', NULL, NULL, 'NO', 'British spelling of estrogen. Not found in Drugdex drug evaluation.', 'Ardefem , Deladiol , Deladumone , Delestrogen , Dioval , Duogex L.A. , Duragen , Estra-L , Estra-Testrin , Estradiol Valerate , Estrand , Femogex , Gynogen , Menaval , Neo-Pause , Testaval 90/4 , Valergen , Valertest', NULL, NULL, '17590', 'Hormones and hormonal mechanisms', 'Estrogen.  Probably not cancer directed--verify with attending MD.'),
(1281, 'Oestriol', NULL, NULL, 'NO', 'Oestriol (Estriol) is a naturally occurring estrogen. Estriol succinate is given orally for menopausal symptoms; the sodium succinate salt has been given parenterally to treat hemorrhage and thrombocytopenia. Chronic estrogen therapy is approved for palliative treatment in inoperable progressing breast cancer; palliative treatment of advanced androgen-dependent carcinoma of the prostate. Several studies suggest that estrogen replacement therapy may decrease risk of developing colon or colorectal cancer.', 'Estriol , Estriol Sodium Succinate , Estriol Succinate , Follicular Hormone Hydrate , Oestrifen (FM) (United Kingdom) , Oestril Succinate , Oestrilin (FM) (Canada) , Oestrilin (vaginal cream-Canada) , Oestrilir N (FM) (Germany) , Oestring (Sweden) , Oestriol Sodium Succinate , Sinapause , Styptanon , Styptanon (FM) , Synapausa , Synapause , Synapause (FM)', 'may be preventive in colon and colorectal cancer, Palliative treatment in breast and prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen'),
(1282, 'Ofatumumab', NULL, NULL, 'NO', 'April 17, 2014 FDA approved ofatumumab in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine based therapy is considered inappropriate. \r\n\r\nAs of October 2014, in clinical trials for follicular lymphoma', 'Arzerra , HuMax-CD 20', 'Chronic lymphocytic leukemia (CLL), Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1283, 'Ofloxacin', NULL, NULL, 'YES', 'An oral fluoroquinolone antibiotic with a broad antibacterial spectrum (antimycobacterial drug)', 'Apo-Oflox , DL-8280 , Floxin , HOE-280 , Ocuflox , Ofloxacine', NULL, NULL, NULL, 'AIDS drug', NULL),
(1284, 'Ogivri', NULL, NULL, 'NO', '12/1/2017: FDA approved Ogirvi as a biosimilar to Herceptin for treatment of patients with HER2-overexpressing breast or metastatic stomach (gastric or gastroesophageal junction adenocarcinoma).', 'trastuzumab-dkst', 'Breast', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'bio-similar'),
(1285, 'OGX-011', NULL, NULL, 'NO', 'Phase II prostate 2007 Antisense clusterin inhibitor.  Abrogates anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death.  ISIS Pharmaceuticals., OncoGenex Technologies', 'Antisense Clusterin , Antisense Testosterone-Repressed Prostate Message 2 , Antisense TRPM-2 , clusterin antisense oligonucleotide , ISIS 112989 , ISIS-112989 , ISIS112989 , TRPM-2 Antisense', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(1286, 'OK-432', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1287, 'Olaprib', NULL, NULL, 'NO', '12/19/2018 FDA approved olaparib (LYNPARZA) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy\r\nDecember 27, 2019. The FDA approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.', 'LYNPARZA', 'Ovary, Fallopian tube, Peritoneum, Pancreas', NULL, NULL, 'Chemotherapy', 'PARP Inhibitor'),
(1288, 'Olaratumab', NULL, 'Sarcoma', 'NO', 'October 19, 2016: FDA granted accelerated approval to olaratumab (LARTRUVO) for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate.   This drug has been approved for use in combination with doxorubicin.', 'Lartruvo', 'Soft tissue', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1289, 'Omacetaxine', NULL, NULL, 'NO', 'Approved under the FDA\'s accelerated approval program October 26, 2012 to treat CML.', 'Homoharringtonine , Omacetaxine mepesuccinate , Omapro , Synribo', 'Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic myelogenous leukemia (CML), Myelodysplastic syndrome (MDS)', 'INN', '102816', 'Chemotherapy', 'Alkaloid;Protein inhibitor'),
(1290, 'ON 01910.Na', NULL, NULL, 'NO', 'Phase I', 'ON 01910.Na , Estybon', 'CLL, Leukemia, Liver, lymphoma, MDS, ovary', NULL, NULL, 'Chemotherapy', 'Polio-like kinase'),
(1291, 'Onco-TCS', NULL, NULL, 'NO', 'Phase III relapsed NHL, Phase II lung (SCLC), orphan drug ALL Liposomal vincristine. Inex Pharmaceuticals, Hana Biosciences', 'Marqibo , VSLI ( Vincristine Sulfate Liposome for Injection)', 'ALL, leukemia, Lung cancer, lymphoma', NULL, NULL, 'Chemotherapy', 'Plant alkaloid--antimetabolite'),
(1292, 'Oncolar', NULL, NULL, 'NO', 'Phase III Growth hormone releasing hormone inhibitor.  Novartis Pharmaceuticals.  Known primarily for symptom control of neuroendocrine tumors.  Some antitumor activity in metastatic breast cancer.', 'Octreotide pamoate', 'Breast cancer', NULL, '685403', 'Hormones and hormonal mechanisms', 'Growth hormone releasing hormone inhibitor'),
(1293, 'Oncolym', NULL, NULL, 'NO', 'Phase I (brain) Phase II NHL B-cell intermediate grade Monoclonal antibody. I-131 conjugated to LYM-1 monoclonal antibody.  Berlex Laboratories.', NULL, 'Brain cancer, lymphoma', NULL, NULL, 'Radiation', 'Radioisotope'),
(1294, 'Oncomyc-NG', NULL, NULL, 'NO', 'Phase II Antisense. AVI BioPharma.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antisense oligonucleotide'),
(1295, 'Onconase', NULL, NULL, 'NO', 'Phase II (breast, kidney), Orphan drug for mesothelioma A ribonuclease with antitumor activity. Alfacell Corp.  Sometimes misspelled ranprinase.', 'P-30 Protein , Ranpirnase', 'Breast, kidney, lung cancer, mesothelioma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis stimulator'),
(1296, 'Oncophage', NULL, NULL, 'NO', 'Phase I/II (pancreatic) Phase II (colorectal, gastric, NHL) Phase III (kidney, melanoma, sarcoma) Vaccine. Antigenics.', 'Heat shock protein-peptide complex , HSPPC-96', 'Colorectal, gastric, kidney, lymphoma, pancreatic, sarcoma, skin cancer', NULL, '725085', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1297, 'OncoVAX Autologous Vaccine', NULL, NULL, 'NO', 'Phase II/III Autologous vaccine. Intracel Resources.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1298, 'OncoVex GM-CSF', NULL, NULL, 'NO', 'Phase I Herpes simplex type 1 virus. BioVex Limited.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Oncolytic virus'),
(1299, 'Ondansetron', NULL, NULL, 'YES', 'Serotonin antagonist; anti-emetic; antischizophrenic; anxiolytic', 'GR-38032F , Ondanserin , Ondansetron hydrochloride , Zofran', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1300, 'Onivyde', NULL, NULL, 'SEE_REMARKS', 'October 22, 2015 The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy', 'Irinotecan liposome injection , irinotecan liposome , liposome irintecan , PEP02', 'Pancreas', NULL, NULL, 'Chemotherapy', 'analog'),
(1301, 'Ontruzant', NULL, NULL, 'NO', '1/18/2019 FDA today approved Ontruzant (trastuzumab-dttb), a biosimilar to U.S.-licensed Herceptin (trastuzumab).', 'trastuzumab-dttb', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Biosimilar'),
(1302, 'ONYX-015', NULL, NULL, 'NO', 'Phase I (ovarian) Phase I/II (brain) Phase II (sarcoma) Phase II/III (NSCLC) Phase III (colorectal, head & neck, liver, pancreatic) Recombinant adenovirus. Onyx Pharmaceuticals, Pfizer.', 'ONYX 015 , ONYX015', 'Brain, colorectal, head & neck, liver, lung, ovarian, pancreatic cancer, sarcoma', NULL, '688653', 'Chemotherapy', 'Oncolytic virus');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1303, 'Opdivo', NULL, 'Melanoma, NSCLC, Renal cell carcinoma (RCC), Hodgkin lymphoma, urothelial carcinoma', 'NO', '8/26/018: FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb Company Inc.) for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. \r\n\r\n4/16/2018 FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. \r\n\r\n12/20/2017: FDA approved Opdivo for adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. \r\n8/1/2017: FDA granted accelerated approval to nivolumab (OPDIVO) for the treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.\r\n2/2/2017: FDA approved the nivolumab (Opdivo) injection for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy\r\n\r\nOpdivo received FDA approval December 22, 2014 for the treatment of patients with unresectable or metastatic melanoma and disease progression. \r\nMarch 2015: FDA expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.\r\nSeptember 30, 2015:Opdivo received FDA approval for use in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.\r\nNovember 24, 2015: FDA approved Opdivo (nivolumab) to treat patients with advanced/metastatic renal cell carcinoma.\r\n\r\n May 17, 2016 FDA granted accelerated approval to nivolumab (Opdivo, marketed by Bristol-Myers Squibb) for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (Adcetris).\r\n\r\nNovember 10, 2016 FDA approved nivolumab (OPDIVO), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.', 'BMS 936558 , MDX 1106 , ONO 4538 , nivolumab', 'Kidney, Bladder, Lung, Skin', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'braf inhibitor'),
(1304, 'Oprelvekin', NULL, NULL, 'NO', 'A thrombopoietic growth factor.  Stimulates platelets.', NULL, NULL, 'rhIL-11, rIL-11', '722848', 'Ancillary Agent', 'Growth Factor'),
(1305, 'Optimized gp100 naked DNA Vaccine with IL-2', NULL, NULL, 'NO', 'Phase II metastatic melanoma Vaccine. Antigenics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1306, 'Oregovemab', NULL, NULL, 'NO', 'Phase II Monoclonal antibody. Abbott, Unither Pharmaceuticals.', 'Mab-B43.13 , Monoclonal antibody B43.13 , OvaRex', 'Ovarian cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody targeting CA-125'),
(1307, 'OSI-211', NULL, NULL, 'NO', 'Phase II SCLC, ovarian Toposiomerase I inhibitor. OSI Pharmaceuticals, Gilead Sciences.', NULL, 'Lung, ovarian cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(1308, 'OSI-7836', NULL, NULL, 'NO', 'Phase I OSI Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1309, 'Ovidrel', NULL, NULL, 'NO', 'Phase II Recombinant human chorionic gonadotropin (r-hCG). Serono.', 'Choriogonadotrophinl Human Chorionic Gonadotropinl Profasi HP', 'Breast cancer, Kaposi sarcoma', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent for KS only;otherwise a hormone (hCG)'),
(1310, 'Ovine Sialomucin', NULL, NULL, 'NO', 'Immunomodulator', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1311, 'Oxaliplatin', NULL, NULL, 'NO', 'A platinum-containing antineoplastic that is usually given in combiantion with 5-FU.', '1-OHP , 1670 RBl Eloxatin , Eloxatin , L-OHP , Oxalatoplatin , Oxalatoplatinum , PR-54780 , RP-54780 , Transplatin', 'Colorectal, gastro-esophageal cancers, metastatic, liver, ovarian, pancreatic cancer', NULL, '266046', 'Chemotherapy', 'Platinum analog'),
(1312, 'Oxandrolone', NULL, NULL, 'NO', 'A synthetic derivative of testosterone; androgenic-anabolic steroid; administered orally.', '8075 C. B. , Anavar , Oxandrin , Protivar , SC-11585 , Vasorome', NULL, NULL, '67068;067068', 'Hormones and hormonal mechanisms', 'Anabolic-androgenic steroid.  Probably not cancer directed--verify with attending MD.'),
(1313, 'Oxisuran', NULL, NULL, 'NO', 'Most references were from 1970-1985.', 'W-6495', NULL, NULL, '356716', 'Chemotherapy', 'No longer in use'),
(1314, 'Oxothiazolidine Carboxylate', NULL, NULL, 'YES', 'Oxothiazolidine carboxylate is a cysteine prodrug.', 'Procysteine', NULL, 'OTC, OTZ', NULL, 'AIDS drug', NULL),
(1315, 'Oxymetholone', NULL, NULL, 'NO', 'An androgenic-anabolic steroid.', 'Adroyd# , Anadrol , Anapolon , CI-406 , Drostanolone , Medrotestron , Metholone , Ora-Testryl', NULL, 'HMD', '26198', 'Hormones and hormonal mechanisms', 'Androgenic anabolic steroid'),
(1316, 'Oxytocin', NULL, NULL, 'NO', 'A synthetically prepared hormone which stimulates contractions of uterine smooth muscle and milk ejection; contributes to second stage of labor; tumor marker.', 'Pitocin , Syntocinon , Toesen', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Pituitary hormone.  Probably not cancer directed--verify with attending MD.'),
(1317, 'P16 Program', NULL, NULL, 'NO', 'Pre-clinical Gene therapy. Introgen Therapeutics.', NULL, 'Pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1318, 'P53 and RAS vaccine', NULL, NULL, 'NO', 'Phase I/II Vaccine. NCI.', NULL, 'Breast, cervical, colorectal, lung, ovarian, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1319, 'p53 Tumor Suppressor Gene', NULL, NULL, 'NO', 'Phase II (head & neck) Phase III (ovarian) Gene therapy. Schering-Plough.', NULL, 'Head & neck, liver, ovarian cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1320, 'PACLIMER Microspheres', NULL, NULL, 'NO', 'Phase I/II Taxane biopolymer drug delivery. Guilford Pharmaceuticals.', NULL, 'Pancreatic cancer', NULL, '715074', 'Chemotherapy', 'Taxane'),
(1321, 'Paclitaxel', NULL, NULL, 'NO', 'Phase I (gastric) FDA approved uses on breast, ovarian, non-small cell lung cancers, and Kaposi\'s sarcoma.  Bristol-Myers Squibb.', 'BMS-181339-01 , BMY-45622 , Taxol', 'breast, Gastric, head & neck cancer, Kaposi\'s sarcoma, non-small cell lung cancers, ovarian', NULL, '125973;673089', 'Chemotherapy', 'Mitotic inhibitor;plant alkaloid;Taxane'),
(1322, 'Paclitaxel poliglumex', NULL, NULL, 'NO', 'Phase II prostate 2007 Cell Therapeutics, Inc.', 'CT 2103 , CT-2103 , CT2103 , Xyotax', 'breast, esophagus, NSCLC, ovary, Prostate, stomach', 'PPX', NULL, 'Chemotherapy', 'Taxane'),
(1323, 'Padcev', NULL, 'Urothelial', 'NO', '12/19/2019 The FDA granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in urothelial cancers. Padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-L1 inhibitor and a platinum-containing chemotherapy. Padcev represents a new type of therapy for patients with advanced urothelial cancer whose disease has progressed on chemotherapy and immunotherapy.', 'enfortumab vedotin-ejfv', 'Bladder', NULL, NULL, 'Chemotherapy', 'antibody and microtubule inhibitor conjugate'),
(1324, 'Palbociclib', NULL, NULL, 'NO', 'The FDA has granted a breakthrough therapy designation to Palbociclib (PD 0332991). this drug has been approved for use in combination with letrozole for the treatment of postmenopausal women with ER+, HER2 negative locally advanced or metastatic breast cancer as an initial endocrine-based therapy. \r\n\r\nFebruary 19, 2016 FDA  approved palbociclib (IBRANCE Capsules, Pfizer, Inc.) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.', 'IBRANCE , PD 0332991 , PD 332991', 'Breast', NULL, NULL, 'Chemotherapy', 'CDK Inhibitor'),
(1325, 'Paleonosetron', NULL, NULL, 'YES', 'Anti-emetic.  Taiko Pharmaceuticals', NULL, NULL, 'PALO', NULL, 'Ancillary Agent', NULL),
(1326, 'Palifermin', NULL, NULL, 'YES', 'Protectant for oral mucositis due to chemotherapy.  Amgen.', 'Kepivance , rHuKGF', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1327, 'Palonosetron', NULL, NULL, 'YES', 'Anti-emetic; used to reduce nausea and vomiting from chemotherapy', 'Aloxi', NULL, NULL, NULL, 'Ancillary Agent', 'Anti-emetic'),
(1328, 'Pamidronate Disodium', NULL, NULL, 'YES', 'A bisphosphonate bone-resorption inhibitor; antihypercalcemic. FDA approved use in multiple myeloma bone metastasis.', 'Aminohydroxypropylidene biphosphonate , Aredia , CGP 23339AE', 'hypocal-cemia, Multiple myeloma bone metastasis', 'AHPrBP, APD', '720699', 'Ancillary Agent', NULL),
(1329, 'Pancratistatin', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '349156', 'Chemotherapy', 'Plant product'),
(1330, 'Pancreatic tumor cell vaccine', NULL, NULL, 'NO', 'Phase II pancreas 2007', NULL, 'Pancreas', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1331, 'Panitumumab', NULL, NULL, 'NO', 'FDA approved for colorectal 2006. The FDA categorized this agent as chemotherapy.\r\nMay 2014 Update: The FDA approved vectibix for use in combination with FOLFOX as a first-line treatment  in patients with wild-type KRAS metastatic colorectal cancer\r\n\r\nNovember 18, 2015: IMPORTANT UPDATE- CATEGORY CHANGE-After careful review, panitumumab has changed categories from chemotherapy to BRM/Immunotherapy. This drug was originally classified as a chemotherapeutic agent by the FDA in 2006. The Physicians Cancer Chemotherapy Drug Manual states this drug is an immunotherapy agent as far back as 2007. You do not need to review and recode old cases but may immediately begin  coding this agent as immunotherapy. It is important to note SEER*RX follows FDA guidelines for assigning drug categories and any update to this drug may not have been received by SEER. \r\n\r\n6/30/2017\r\nFDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. \r\nVectibix is the first-and-only fully human monoclonal anti-epidermal growth factor receptor antibody approved by the FDA for this patient population.', 'ABX-EGF (anti-EGFr) , Vectibix', 'Colorectal, kidney, lung, prostate cancer', NULL, '742319', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--monoclonal antibody'),
(1332, 'Panobinostat', NULL, 'Multiple myeloma', 'NO', 'Feb. 2015: FDA granted accelerated approval to panobinostat in combination with bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. \r\n\r\nthis drug has been found to stop the growth of blood vessels to tumors.', 'FARYDAK , LBH589', NULL, NULL, NULL, 'Chemotherapy', 'HDAC inhibitor'),
(1333, 'PanVac', NULL, NULL, 'NO', 'Phase I Therion Biologics.', NULL, 'Pancreatic  caner', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1334, 'Panzem', NULL, NULL, 'NO', 'Phase I breast Phase II MM, prostate Antiangiogenic. EntreMed.', '2ME2', 'Breast, multiple myeloma, prostate cancer', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1335, 'Papaverine Hydrochloride', NULL, NULL, 'YES', 'Antispasmodic agent; vasodilator; smooth muscle relaxant', 'Cerespan , Copavin , Dipav , Lempav Ty-Med , Neopavrin Forte , Papaverine , Para-Time , Pavabid , Pavacap Unicelle , Pavacen , Pavaco , Pavagen , Pavakey S.A. , Pavamar , Pavarine Spancaps , Pavased , Pavasule , Pavatym , Paverolan Lanacaps , Prapav Timecelles , Vasospan', NULL, NULL, '136630', 'Ancillary Agent', NULL),
(1336, 'Para-aminosalicylic acid', NULL, NULL, 'YES', 'Antimycobacterial drug', 'Teebacin', NULL, 'PAS', NULL, 'AIDS drug', NULL),
(1337, 'Paramethasone Acetate', NULL, NULL, 'NO', 'A synthetic corticosteroid (glucocorticoid) used chiefly for its anti-inflammatory and antiallergic actions; administered orally.', 'Haldrone , Stemex', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid.  Probably not cancer directed--verify with attending MD.'),
(1338, 'Paromomycin Sulfate', NULL, NULL, 'YES', 'An amebicidal aminoglycoside antibiotic. Under investigation for Rx of cryptosporidiosis', 'Aminosidin Sulfate , Catenulin Sulfate , Crestomycin Sulfate , Humatin , Hydroxymycin Sulfate , Monomycin A Sulfate , Paucimycin Sulfate', NULL, NULL, NULL, 'AIDS drug', NULL),
(1339, 'Pasireotide', NULL, NULL, 'NO', 'Novartis.  Inhibits hormone secretion.', 'SOM230', 'Carcinoids', NULL, NULL, 'Hormones and hormonal mechanisms', 'Hormone'),
(1340, 'Paxoral', NULL, NULL, 'NO', 'Phase II Taxane. Ivax.', 'Oral Paclitaxel , Paclitaxel Oral', 'Breast, gastric lung cancer', NULL, NULL, 'Chemotherapy', 'Taxane'),
(1341, 'Pazopanib', NULL, NULL, 'NO', 'Received FDA approval April 26, 2012 for treatment of advanced soft tissue sarcoma  in patients who have received prior chemotherapy.', 'GW 786034 , GW-786034 , GW786034 , Votrient', 'Renal cell, Sarcoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(1342, 'PCNU', NULL, NULL, 'NO', NULL, 'Nitrosourea', NULL, NULL, '95466', 'Chemotherapy', 'Nitrosourea'),
(1343, 'PD 0332991', NULL, NULL, 'NO', 'Currently in trials. This drug is being used in combination with the aromatase inhibitor letrozole (Femara) to treat women with advanced breast cancer.', 'PD 991', 'ER positive/ HER2-negative breast cancer', NULL, NULL, 'Chemotherapy', 'investigational cell-cycle inhibitor'),
(1344, 'PD-0325901', NULL, NULL, 'NO', 'Pfizer.', 'PD 0325901 , PD0325901', 'Breast, colorectal, melanoma, non-small cell lung', NULL, NULL, 'Chemotherapy', 'MEK inhibitor'),
(1345, 'Pefloxacin', NULL, NULL, 'YES', 'A fluoroquinolone antimicrobial agent. Under investigation for Rx of PCP', '1589-RB , EU-5306 , Pefloxacine , Perfloxacin , RB-1589', NULL, NULL, NULL, 'AIDS drug', NULL),
(1346, 'PEG Paclitaxel', NULL, NULL, 'NO', 'Phase I Taxane. Enzon.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Natural product'),
(1347, 'PEG-IL-2', NULL, NULL, 'NO', NULL, 'Aldesleukin , Interleukin-2 , Macrolin (FM) (DI) , Proleukin , Proleukin (FM)', 'acute myeloid leukemia, HIV, melanoma, Metastatic renal cell carcinoma, non-Hodgkin\'s lymphoma', NULL, '625376', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1348, 'Pegaspargase', NULL, NULL, 'NO', 'FDA approved use in ALL 2006 A modified version of the antineoplastic enzyme L-asparaginase.', 'Oncaspar , PEG-Asparaginase , PEG-L-Asparaginase', NULL, 'PEGLA', NULL, 'Chemotherapy', 'Antineoplastic enzyme'),
(1349, 'Pegfilgrastim', NULL, NULL, 'YES', 'Phase III Granulocyte colony stimulating factor. Amgen.  Kirin (Japan).', 'KRN125 , Neulasta , PEG filgrastrim , Pegylated filgrastrim , SD/01', 'Breast cancer', NULL, '725961', 'Ancillary Agent', 'Growth Factor'),
(1350, 'Peginterferon alfa-2a', NULL, NULL, 'NO', 'Phase II (kidney, skin) Phase III CML Pegylated interferon alfa 2a. Hoffmann-LaRoche.', 'Pegasys', 'Kidney, leukemia, skin cancer', NULL, '729130', 'Biologic therapy (BRM, immunotherapy)', 'Primarily for Hepatitis C infection'),
(1351, 'Peginterferon alfa-2b', NULL, NULL, 'NO', 'March 29, 2011: Received FDA approval as a new adjuvant treatment for melanoma with microscopic or gross nodal involvement.\r\nPhase II CML', 'Sylatron', 'Leukemia, other cancer, skin', NULL, '720033', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1352, 'Peliomycin', NULL, NULL, 'NO', 'Antibiotic', 'Oligomycin B', NULL, NULL, '76455', 'Chemotherapy', 'Antitumor antibiotic'),
(1353, 'Pemetrexed', NULL, NULL, 'NO', 'Phase II (breast, colorectal, ovarian, pancreatic) Phase III (gastric, lung) Multi-targeted antifolate. Eli Lilly.', 'Alimta , LY 231514 , LY231514 , Pemecad', 'Breast, colorectal, gastric, mesothelioma, non-small cell lung, ovarian, pancreatic cancer', 'LY-231514', '698037', 'Chemotherapy', 'Antimetabolite'),
(1354, 'Pemtumomab', NULL, NULL, 'NO', 'Phase II; Phase III ovarian Not significantly better than standard treatment in clinical trials.  Further development unlikely.  Yttrium-90 labelled mouse monoclonal antibody (MAB) designed for administration into the peritoneal cavity and directed against MUC-1, a form of mucin found on various cancer cells.  Abbott Laboratories, Antisoma.', 'R 1549 , R-1549 , R1549 , Theragyn', 'Gastric, ovarian cancer', NULL, NULL, 'Radiation', 'Radioisotope'),
(1355, 'Penberol', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Antineoplastic--unclassified'),
(1356, 'Penciclovir', NULL, NULL, 'YES', 'An antiviral agent.', 'BRL-39123 , Denavir , Vectavir', NULL, NULL, NULL, 'AIDS drug', NULL),
(1357, 'Penclomedine', NULL, NULL, 'NO', NULL, NULL, NULL, 'PEN', '338720', 'Chemotherapy', 'Alkylating agent'),
(1358, 'Pentacea', NULL, NULL, 'NO', 'Phase II SCLC Bispecific antibody.  Monoclonal antibody targets tumor cells that express CEA.  Then second part of antibody conjugated to radiation source attaches to monoclonal antibody.  IBC Pharmaceuticals.', NULL, 'Lung cancer', NULL, NULL, 'Radiation', 'Radioisotope'),
(1359, 'Pentamethylmelamine HCl', NULL, NULL, 'NO', 'Water soluble analog of altretamine', 'Pentamethylmelamine monoHCl , PMM HCl', NULL, 'PMM', '118742', 'Chemotherapy', 'Cytotoxic antineoplastic'),
(1360, 'Pentamidine', NULL, NULL, 'YES', 'Rx or prophylaxis of PCP; antiparasitic.', 'Lomidine , NebuPent , Pentam 300', NULL, NULL, '9921', 'AIDS drug', NULL),
(1361, 'Pentamidine Isethionate', NULL, NULL, 'YES', 'An antiprotozoal agent.', 'NebuPent , Pentacarinat , Pentam 300 , Pneumopent', NULL, NULL, '620107', 'AIDS drug', NULL),
(1362, 'Pentamustine', NULL, NULL, 'NO', NULL, 'Salisburystin', NULL, 'NCNU', '324595', 'Chemotherapy', 'Alkylating agent'),
(1363, 'Pentosan Polysulfate Sodium', NULL, NULL, 'YES', 'Being investigated in the acquired immunodeficiency syndrome-inhibits replication of HIV in-vitro; no evidence to date of anti-tumor activity.', 'Elmiron , Fibrase (DI) , Fibrezym , Fibrocid (FM) , Fibrocide , Hemoclar , Hoe/Bay 946 , Lelong Contusions (FM) , Pentosan Polysulfate , Polyanion , PZ-68 , SP54 , Tavan-SP-54 , Thrombocid , Thrombocid (FM) , Xylan Polysulfate Sodium', NULL, NULL, '626201', 'AIDS drug', NULL),
(1364, 'Pentostatin', NULL, NULL, 'NO', 'Phase III CLL, Phase IV NHL A purine analogue antineoplastic. FDA approved use on hairy cell leukemia. Parke-Davis. Transition state inhibitor of ADA. SuperGen.', '2\'-Deoxycoformycin , CI-825 , CL-67310465 , Co-Vidarabine , Covadarabibe , Nipent', 'Leukemia', '2\'DCF, DCF', '218321', 'Chemotherapy', 'Antimetabolite'),
(1365, 'Pentoxifylline', NULL, NULL, 'YES', 'A methylxanthine derivative which reduces blood viscosity and improves erythrocyte flexibility; vasodilator; radiation-sensitizing agent. Being aggressively investigated for its clinical utility in infectious disease (including HIV infection), and as adjunctive therapy in oncology.', 'Agapurin , Albert Pentoxifyline , Apo-Pentoxifyline SR , Artal , Azupentat , BL-191 , Claudicat , Dinostral , Dospan Pento , Durapental , Elastab , Elorgan , Fixoten , Flexital , Flexital (FM) , Haemodyn , Henovas , Herden , Kentadin , Oxopurin , Oxpentifylline , Penlol , Pento , Pento-Puren , Pentoflux , Pentohexal , Pentolab , Pentomer , Pentox , Pentoxi , Pentoxifylline Extended-Release Tablets USP 26 , Pentoxil , Pentoximed , Pentoxin , Pentoxy , Perental , Peridane , Peripan , Previscan (DI) , Ralofekt , Rentylin , Retimax , Sipental , Sufisal , Torental , Trenlin , Trental , Vasofyl , Vasonit', NULL, NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(1366, 'Peplomycin Sulfate', NULL, NULL, 'NO', 'A bleomycin analogue used as an antineoplastic. At present, peplomycin or its combinations cannot be recommended over first-line chemotherapeutic regimens. Further comparative studies will more clearly establish its place in therapy, including its suitability as a replacement for (or alternative to) bleomycin.', 'NK-631 , Pepleomycin', NULL, NULL, '276382', 'Chemotherapy', 'Antitumor antibiotic'),
(1367, 'Peptichemio', NULL, NULL, 'NO', NULL, NULL, NULL, 'PTC', NULL, 'Chemotherapy', 'Antimetabolite and alkylating agent'),
(1368, 'Peptide T', NULL, NULL, 'YES', 'It has been investigated for the treatment of HIV infection and HIV-associated neurological and neuropsychiatric impairment and disorders. Not found in Drugdex drug evaluation.', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1369, 'Peptide Vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. NCI', NULL, 'Sarcoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1370, 'Perfosfamide', NULL, NULL, 'NO', 'Antineoplastic agent.', 'Pergamid', NULL, '4 HC', '181815', 'Chemotherapy', 'Alkylating agent'),
(1371, 'Perifosine', NULL, NULL, 'NO', 'Phase II trials 2007 Signal transduction inhibitor, apoptosis inducer. AEterna Laboratories. Keryx Pharmaceuticals.  AOI Pharmaceuticals.', 'D 21266 , D-21266 , D21266 , KRX 0401 , KRX-0401 , KRX0401 , octadecylphosphopiperidine', 'Head & neck, melanoma, metastatic cancers, pancreatic, prostate cancer, sarcoma', NULL, '639966', 'Chemotherapy', 'Cytostatic agent--AKT inhibitor'),
(1372, 'Perillyl Alcohol', NULL, NULL, 'YES', 'Phase II Monoterpene. NCI.', NULL, 'Pancreatic cancer', NULL, '641066', 'Ancillary Agent', 'Cancer preventive'),
(1373, 'Peripheral Blood Lymphocytes Transduced with a Gene Encoded Chimeric T Cell Receptor', NULL, NULL, 'NO', 'Phase I NCI.', NULL, 'Ovarian, pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1374, 'Permethrin', NULL, NULL, 'YES', 'Permethrin has been shown to be effective in the treatment of head lice and scabies (ectoparasites).', 'A-200 , Acticin , Elimite , FMC-33297 , Nix , NRDC-143 , OMS-1821 , PP-557 , Rid , S-3151 , WL-43479', NULL, NULL, NULL, 'AIDS drug', NULL),
(1375, 'Perphenazine', NULL, NULL, 'YES', 'Effective in the treatment of manifestations of psychosis including schizophrenia and severe nausea and vomiting, including postoperative vomiting and nausea and vomiting secondary to narcotics, chemo., and radiation.', 'Component of Estrafon , Component of Triavil , Trilafon', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1376, 'Pertuzumab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy. \r\n\r\nFDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.\r\n\r\nPerjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.', 'Omnitarg , Perjeta , R1273', 'Breast', NULL, '900005', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic agent--tyrosine kinase inhibitor;Humanized monoclonal antibody'),
(1377, 'Pexidartinib', NULL, 'Giant cell tumors', 'SEE_REMARKS', '11/6/2015: The FDA granted Breakthrough Therapy Designation to Pexidartinib for treatment of tenosynovial giant cell tumor where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity. FDA has not yet granted full approval to this drug.\r\n\r\nCoding instructions: Until this drug receives final FDA approval, code in Other Treatment and assign code 2.', 'PLX3397', NULL, NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1378, 'PF-02341066', NULL, NULL, 'NO', 'I, III New drug currently in trials, code in other therapy', NULL, 'anaplastic large-cell lymphoma, Solid tumors', NULL, 'NCT00585195 and NCT00932451', 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1379, 'Phenesterine', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '104469', 'Chemotherapy', NULL),
(1380, 'Phenoxodiol', NULL, NULL, 'NO', 'Phase II Signal transduction inhibitor. Novogen, Marshall Edwards.', NULL, 'other cancer, Ovarian', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--signal transduction inhibitor'),
(1381, 'Phenylacetate', NULL, NULL, 'YES', 'Phase II For hyperammonemia. Cell differentiator inducer. NCI, Elan Pharmaceuticals.', NULL, 'Leukemia, lymphoma', NULL, NULL, 'Ancillary Agent', NULL),
(1382, 'Phenylbutyrate', NULL, NULL, 'YES', 'Phase II Aromatic fatty acid cell differentiation inducer. NCI, Elan Pharmaceuticals.', 'Buphenyl', 'Brain, Colorectal cancer', NULL, '657802', 'Differentiation inducing agent', 'Differentiating agent'),
(1383, 'Phetharbital', NULL, NULL, 'YES', NULL, 'Fedibaretta , N-Phenylbarbitol , Phenidiemal , Pyrictal', NULL, NULL, '85043', 'Ancillary Agent', 'Barbiturate'),
(1384, 'Phosphoramide mustard', NULL, NULL, 'NO', NULL, 'Phosphamide', NULL, 'PDA', '69945', 'Chemotherapy', 'No longer in use'),
(1385, 'PHY906', NULL, NULL, 'YES', 'Ancillary agent consisting of four traditional Chinese medicine herbs to counteract the effects of chemotherapy.  PhytoCeutica.', 'PHY 906 , PHY-906', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1386, 'Phyllanthoside', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '328426', 'Chemotherapy', 'Plant alkaloid'),
(1387, 'PI-166', NULL, NULL, 'NO', 'Phase I Selective inhibitor of carbohydrate protein interactions. Progen Industries.', NULL, 'Liver cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent'),
(1388, 'PI-88', NULL, NULL, 'NO', 'Phase II melanoma Oligosaccharide. Medigen Biotechnology.', NULL, 'melanoma, Skin cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1389, 'Pibenzimol HCl', NULL, NULL, 'NO', NULL, 'Bisbenzamide , Bisbenzimidazole , Hoechst No. 33258 , Pibenzimol HCl', NULL, NULL, '322921', 'Chemotherapy', 'Antineoplastic--antimitotic'),
(1390, 'Picibanil', NULL, NULL, 'NO', 'A biologic response modifier currently being investigated in the treatment of cancer.', NULL, NULL, 'OK-432', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1391, 'Picoplatin', NULL, NULL, 'NO', 'Phase II AnorMed.', 'AMD 473 , AMD473 , NX 473 , NX473', 'breast, ovarian, Prostate, small cell lung', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent--platinum compound'),
(1392, 'Pimonidazole', NULL, NULL, 'YES', 'Radiosensitizer', 'Pimonidazole HCl , Ro 03-8799', NULL, NULL, '318502', 'Ancillary Agent', 'Radiosensitizer'),
(1393, 'Piperazine', NULL, NULL, 'YES', 'Anthelmintic agent.', 'Antiren , Component of Wazine-34 , Dispermine , Eraverm , Hexahydropyrazine , Lumbrical , Piperazidine , Piperazin , Pipersol , Pyrazine Hexahydride , UN 2579 , UN 2685 , Uvilon , Vermex , Versol , Wurmirazin', NULL, NULL, '474', 'Ancillary Agent', 'Antihelminthic'),
(1394, 'Piperazinedione compound', NULL, NULL, 'NO', 'Miscellaneous agent', 'Actinomycete fermentation product , Compound 593A , Crystalline antibiotic', NULL, 'PZD', '135758', 'Chemotherapy', 'Alkylating agent'),
(1395, 'Pipobroman', NULL, NULL, 'NO', 'Considered an alkylating agent. FDA approved use in chronic granulomatous leukemia refractory to busulfan.', 'A-8103 , Amedel , Vercyte', NULL, 'PIBR', '025154;25154', 'Chemotherapy', 'Alkylating agent'),
(1396, 'Piposulfan', NULL, NULL, 'NO', NULL, 'A-20968 , Ancyte#', NULL, 'PISU', '47774', 'Chemotherapy', 'Antineoplastic alkylating agent'),
(1397, 'Piqray', NULL, NULL, 'NO', 'May 24, 2019: The FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.', 'Alpelisib', 'Breast', NULL, NULL, 'Chemotherapy', 'PI3K inhibitor'),
(1398, 'Pirarubicin', NULL, NULL, 'NO', 'Has activity in a variety of malignancies, including lung cancer, breast cancer, malignant lymphoma, acute leukemia, and malignant pleural mesothelioma.', '1609RB , Tepirubicin , Tetrahydropyranyl-doxorubicin , Theprubicin , THP-doxorubicin', NULL, 'THP-ADM', '333054', 'Chemotherapy', 'Antitumor antibiotic--anthracycline'),
(1399, 'Piritrexim', NULL, NULL, 'NO', 'Phase II Code in Other Therapy', 'Piritrexim , Piritrexim Isethionate', 'Urinary tract', NULL, NULL, 'Chemotherapy', 'Folate antagonists'),
(1400, 'Piritrexim Isethionate', NULL, NULL, 'YES', 'A dihydrofolate reductase inhibitor. Piritrexim is an alternative to methotrexate, and may possess activity in some patients with methotrexate resistance. Promising results have been reported in head and neck cancer, metastatic melanoma, Kaposi\'s sarcoma, and bladder cancer; also Rx for PCP. However, additional (larger) studies are needed to define the role of piritrexim.', 'BW-301U , Prirtrexim', NULL, NULL, '351521', 'AIDS drug', NULL),
(1401, 'Piroxantrone Hydrochloride', NULL, NULL, 'NO', '2010: The FDA granted fast track designation for pixantrone in patients who had previously been treated two or more times for relapsed or refractory agressive NHL. The trial was not sufficient to support approval. In April2010 the FDA asked for an additional trial.  This drug is available in Europe via the Named-Patient Basis. \r\nInvestigated. Not found in Drugdex drug evaluation.', 'Anthrapyrazole Dihydrochloride , Anthrapyrazole hydrochloride , CI-942 , Oxanthrazole , Oxantrazole hydrochloride', NULL, NULL, '349174', 'Chemotherapy', 'Antitumor antineoplastic--topoisomerase inhibitor'),
(1402, 'Piroxicam', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory agent.', 'Alti-Piroxicam , Apo-Piroxicam , Brexidol , CP-16171 , Dom-Piroxicam , Feldene , Fexicam , Med Piroxicam , Novo-Pirocam , Nu-Pirox', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1403, 'pivaloyloxymethylbutyrate', NULL, NULL, 'NO', 'Phase II Cell differentiation inducer. Titan Pharmaceuticals.', 'Pivanex', 'Liver, lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agentclinical trial halted due to safety issues'),
(1404, 'Pixantrone dimaleate', NULL, NULL, 'NO', 'Phase II NHL Topoisomerase inhibitor. Hoffman-La Roche, Novuspharma.', 'BBR 2778 , BBR-2778 , BBR2778', 'Lymphoma', NULL, NULL, 'Chemotherapy', 'Anthracycline--topoisomerase inhibitor'),
(1405, 'PKI-166', NULL, NULL, 'NO', 'Phase II Signal transduction inhibitor. Novartis.', NULL, 'Breast, colorectal, gastric, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1406, 'Platelet Factor 4', NULL, NULL, 'YES', 'Under investigation for Rx of Kaposis\'s sarcoma', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1407, 'Plerixafor', NULL, NULL, 'YES', 'This drug is often given along with a G-CSF to moblize hematopoietic stem cells prior to transplant.', 'Mozobil', 'MM, Multiple myeloma, NHL, Non-hodgkins Lymphoma', NULL, NULL, 'Ancillary Agent', 'Immunostimulate'),
(1408, 'Plevitrexed', NULL, NULL, 'NO', 'Phase II.  Orphan drug for stomach, ovarian BTG International', 'BGC 9331 , BGC-9331 , BGC9331 , Plevitrexed', 'ovary, pancreas, Stomach', 'Px', NULL, 'Chemotherapy', 'Cytostatic agent--thymidylate synthesis inhibitor'),
(1409, 'Plicamycin', NULL, NULL, 'NO', 'Antibiotic antineoplastic (I.e. anti-tumor antibiotic) agent. FDA approved use in testicular carcinoma.', 'A-2371 , Antibiotic LA 7017 , Aureolic acid , Mithracin , Mithramycin# , PA-144', NULL, 'MITH, MTH', '024559;24559', 'Chemotherapy', 'Antitumor antibiotic'),
(1410, 'Plitidepsin', NULL, NULL, 'NO', 'Phase I NHL; Phase II myeloma 2007 Aplidine interferes with protein synthesis through a GTP dependant inhibition of the elongation factor 1-a and decreases the expression of the VEGF-RI gene.  Anti-VEGF-R1 gene. PharmaMar.', 'Aplidin , Aplidine', 'Lymphoma, myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent'),
(1411, 'PMEA', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1412, 'Pneumococcal Vaccines', NULL, NULL, 'YES', 'Specifically designed to protect against infection from Streptococcus pneumoniae.', 'Pneumovax , Pneumovax 23 (Pneumococcal Vaccine Polyvalent) , Pnu-Imune-23 , Prevnar', NULL, NULL, '731759;722400', 'AIDS drug', NULL),
(1413, 'Podofilox', NULL, NULL, 'YES', 'Has been used effectively to treat genital warts and perianal warts caused by human papilloma virus. Its safety and efficacy for treating warts located on other areas of the skin has not been studied.', 'Condyline , Condylox , Podophyllotoxin , Wartec', NULL, NULL, NULL, 'AIDS drug', NULL),
(1414, 'Polifeprosan 20 with Carmustine Implant', NULL, NULL, 'NO', 'FDA approved 2/25/03 Biodegradable wafer (polifeprosan 20) impregnated with carmustine.  Guilford Pharmaceuticals.', 'Gliadel Wafer', 'Brain cancer', NULL, '714372', 'Chemotherapy', 'Alkylating agent'),
(1415, 'Polivy', NULL, 'DLBCL', 'NO', 'June 10, 2019: The FDA granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma', 'Polatuzumab', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti-body conjugate'),
(1416, 'Poly A: Poly U', NULL, NULL, 'NO', 'A double-stranded polyribonucleotide comprising polyadenylic and polyuridylic acids, and is believed to be a stimulant of the immune system. It has been studied as an adjuvant in the management of operable solid tumors.', 'Poly A:U , Poly AU', NULL, NULL, '609390', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1417, 'Poly I: Poly C', NULL, NULL, 'YES', 'A synthetic double-stranded polyribonucleotide complex of equimolar concentrations of polyinosinic and polycytidylic acids, described as a mismatched double-strand RNA.', 'POLY I:C', 'AIDS, Opportunistic infection', NULL, '120949', 'AIDS drug', NULL),
(1418, 'Poly I: Poly C12U', NULL, NULL, 'NO', 'Phase II kidney, skin A synthetic mismatched polymer of double-stranded RNA with antiviral and immunomodulatory activity. It is widely known as Ampligen which is a trade-mark. It is under investigation in the treatment of AIDS and HIV infection, and also in renal cell carcinoma, chronic fatigue syndrome, and melanoma. Hemisphere Biopharma.', 'Ampligen , Poly(I): Poly(C(12) , U)', 'Kidney, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1419, 'Poly I:Poly C with Poly-L-lysine stabilizer', NULL, NULL, 'NO', 'Interferons and Interferon inducers', NULL, NULL, 'Poly IC/LC, Poly-ICLC', '301463', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1420, 'Polyestradiol Phosphate', NULL, NULL, 'NO', 'A polymer of estradiol phosphate having estrogenic activity similar to that of estradiol; used in the palliative therapy of prostatic carcinoma, administered intramuscularly. Not found in Drugdex drug evaluation.', 'Estradurin , Leo-114', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen'),
(1421, 'Polyethylene Glycol', NULL, NULL, 'YES', 'An osmotic agent. Commonly used as a base for chemotherapy agents.', 'Carbowax Sentry , Colon Electrolyte Lavage Preparation , Colyte , Component of Pluracol E400 , E1450 , E600 , PEG 3350 , PEG-ELS , Polyethylene Glycol-Electrolyte Lavage Solution', NULL, 'PEG', NULL, 'Ancillary Agent', NULL),
(1422, 'Polysaccharide-K', NULL, NULL, 'NO', 'A protein-bound polysaccharide isolated from a fungus and claimed to have immunostimulant and antineoplastic properties.', NULL, NULL, 'PS-K, PSK', NULL, 'Chemotherapy', 'Cytostatic agent--tyrosine kinase inhibitor'),
(1423, 'Pomalidomide', NULL, NULL, 'NO', 'FDA approval granted February 8, 2013 as a treatment for relapsed and refractory multiiple myeloma for patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of last therapy. . This drug is a derivative of thalidomide that is anti-angiogenic and also acts as an immunomodulator.', 'CC-4047 , Pomalyst', 'Multiple myeloma', NULL, '767909', 'Biologic therapy (BRM, immunotherapy)', 'TNF-alpha production inhibitor/thalidomide analogue'),
(1424, 'Ponatinib', NULL, NULL, 'NO', 'Ponatinib received FDA approval December 14, 2012.\r\n\r\nImportant note October 31, 2013: The FDA has asked the manufacturer of Iclusig to suspend marketing and sales of the drug because of life-threatening blood clots and severe narrowing of blood vessels.\r\n\r\nDecember 12, 2016: Ponatinib received full FDA approval for treatment of adult patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).', 'Iclusig', 'CML, Chronic myeloid leukemia, Ph+ALL, Philadelphia-chromosome positive acute lymphoblastic leukemia, Acute lymphoblastic leukemia, ALL', NULL, NULL, 'Chemotherapy', 'kinase inhibitor'),
(1425, 'Porfimer Sodium', NULL, NULL, 'YES', 'Phase III Photosensitizing agent used in the photodynamic therapy (PDT) of tumors. Makes tumor cells more sensitive to light therapy but does not kill cancer cells by itself.  FDA approved uses in esophageal cancer, and non-small cell lung cancer. Axcan Pharma, Sanofi Winthrop.', 'CL-184116 , Dihematoporphyrin Ether , Dihematoporphyrin ethers , Photofrin , Photofrin II', 'Head & neck cancer', NULL, '603062', 'Ancillary Agent', 'Radiosensitizer'),
(1426, 'Porfiromycin', NULL, NULL, 'NO', 'Treatment of head and neck cancer. Treatment of cervical cancer.', '743 , ENT-50825 , Methyl Mitomycin , N-Methylmitomycin C , Porfiromycine , Promycin , Regamycin# , U 14743 , U-14 , U-14743 , U14743', NULL, 'PORF', '056410;56410', 'Chemotherapy', 'Antitumor antibiotic'),
(1427, 'PR-104', NULL, NULL, 'NO', 'Phase I solid tumors 2007 Proacta, Inc.', 'PR 104 , PR104', 'Solid tumors', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1428, 'PR-171', NULL, NULL, 'NO', 'Phase I Proteolix', 'PR 171 , PR171', 'lymphoma, Multiple myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--proteasome inhibitor'),
(1429, 'Pralatrexate', NULL, NULL, 'NO', 'Approved for treatment of peripheral T-cell lymphoma.', 'Folotyn', 'Lung cancer, lymphoma', 'PDX', NULL, 'Chemotherapy', 'Antimetabolite--antifolate'),
(1430, 'Pravastatin', NULL, NULL, 'NO', 'Pravachol is also prescribed to treat high cholestrol.', 'Pravachol', 'Hepatoma', NULL, NULL, 'Chemotherapy', 'Antioangiogenic agent;Cytostatic agent--Ras inhibitor'),
(1431, 'Prednimustine', NULL, NULL, 'NO', 'Prednisolone ester of chlorambucil.  Not found in Drugdex drug evaluation.', 'Leo-1031 , Sterecyt', NULL, NULL, '134087', 'Chemotherapy', 'Alkylating agent'),
(1432, 'Prednisolone', NULL, NULL, 'NO', 'A synthetic corticosteroid (glucocorticoid) and an analogue of cortisol.  Administered orally in replacement therapy for adrenocortical insufficiency and as an anti-inflammatory in a wide variety of conditions.', 'component of Ataraxoid , Component of K Predne-Dome# , Cortalone , Delta-Cortef , Fernisolon , Fernisolone-P , Hydeltra , Meti-Derm , Minims Prednisolone , Novo-Prednisolone , Paracortol# , Pre-Pred , Predne-Dome# , Prednicen , Prelone , Ster 5 , Sterane , Vitacort', NULL, 'PRDL', '009120;9120', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1433, 'Prednisolone Acetate', NULL, NULL, 'NO', 'The 21-acetate ester of prednisolone, administered by intra-articular, intramuscular, or soft-tissue injection in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders and applied topically to the conjunctiva in the treatment of allergy and inflammation.', 'AK-Tate , Alto-Pred LA-100 , Articulose , DepPredalone , Diopred , Econopred , I-Prednicet , Key-Pred , Meticortelone acetate , Niscort , Nisolone , Ophtho-Tate , Pred Forte , Pred Mild , Pred-G , Predair-A , Predaject , Predalone , Predate , Predcor , Predicort , Savacort , Sholone-50 , Sterane IM and IA', NULL, NULL, '10966', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1434, 'Prednisolone Sodium Hemisuccinate', NULL, NULL, 'NO', 'An ester of hydrocortisone, having actions and uses similar to those of the base.', 'Meticortelone Soluble , Prednisolone , Prednisolone sodium succinate , Solu-Decortin (glucocorticoid)', NULL, NULL, '9151', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1435, 'Prednisolone Sodium Phosphate', NULL, NULL, 'NO', 'Glucocorticoid; a water-soluble ester of prednisolone, having a rapid onset and short duration of action; administered by intravenous or intramuscular injection when rapid effect is needed, or applied topically to the conjunctiva.', 'AK-Pred , Alto-Pred , Component of Optimyd , Component of Vasocidin Solution , Hydeltrasol , I-Pred , Inflamase , Key-Pred SP , Metreton , Nor-Pred S , Ocu-Pred , Pediapred , Predate , Predate-S , PSP-IV , Solu-Predalone', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1436, 'Prednisolone Sodium Succinate', NULL, NULL, 'NO', 'A sterile prednisolone sodium succinate prepared from the succinate ester of prednisolone with the aid of sodium carbonate.', 'Prednisolone sodium hemisuccinate', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1437, 'Prednisolone Tebutate', NULL, NULL, 'NO', 'Glucocorticoid; an ester of prednisolone having a slow onset and long duration of action, used as an anti-inflammatory; administered by intra-articular, intralesional, or soft-tissue injection.', 'Hydeltra-TBA , Norpred TBA , Predalone T.B.A. , Predate TBA , Predcor TBA , Prednisol TBA , Prednisolone TBA , TBA Pred', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1438, 'Prednisone', NULL, NULL, 'SEE_REMARKS', 'A synthetic corticosteroid and an analogue of cortisol (glucocorticoid).\r\n\r\nPrednisone may be coded as treatment (hormonal) for all sties and histologies. It is most often used as part of a drug regimen.\r\n\r\nDo not code Prednisone when it is given to treat symptoms. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.\"', 'Alti-Prednisone , Alto-Pred , Ancortone , Apo-Prednisone , Colisone , Cortan , Dacortin , Delta-Dome# , Deltasone , Deltra , Fernisone Buffered , Keysone , Liquid Pred , Meticorten , Novo-Prednisone , Orasone , Panasol , Paracort# , Prednicen M , SK-Prednisone , Sterapred DS , Ultracorten , Winpred', 'Prednisone is used to treat multiple sites and histologies', 'PDN, PRD, PRED', '10023;010023', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1439, 'Pregnenolone', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation (alternative medicine product). Neurosteroid class; precursor hormone to more than 150 human steroid hormones.  An intermediate compound in the synthesis of the steroid hormones, converted into progesterone, estradiol, estrone, aldosterone and cortisol.  There is a synthetic preparation of this hormone, used in the treatment of rheumatoid arthritis.  Contraindicated in those with hormone-dependent prostate cancer.', 'Formula 405 , Pregnenolone succinate', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Precursor steroid.  Probably not cancer directed--verify with attending MD.'),
(1440, 'Pretarget Carcinoma', NULL, NULL, 'NO', 'Phase I CC49-streptavidin fusion protein. NeoRx', NULL, 'Gastric cancer', NULL, NULL, 'Radiation', 'Radioisotope bound to streptavidin'),
(1441, 'Pretarget Lymphoma', NULL, NULL, 'NO', 'Phase I Anti-CD20 streptavidin fusion protein (B9E9). NeoRx.', NULL, 'Lymphoma', NULL, NULL, 'Radiation', 'Radioisotope bound to streptavidin'),
(1442, 'Prevpac', NULL, NULL, 'YES', 'Treats H. pylori infection that can trigger MALT lymphoma.  DOES NOT treat MALT lymphoma directly.', NULL, NULL, NULL, NULL, 'Ancillary Agent', 'Ancillary antibiotic'),
(1443, 'Primaquine Phosphate', NULL, NULL, 'YES', 'Antimalarial.; anti-parasitic. Being evaluated in combination with clindamycin for treatment of Pneumocystis carinii pneumonia infections.', '272 , Primaquine , SN-13', NULL, NULL, '14976', 'AIDS drug', NULL),
(1444, 'PRO64553', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Seattle Genetics, Genentech.', 'PRO-64553 , PRO64553 , SGN 14 , SGN-14 , SGN14', 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic Monoclonal antibody targeted to CD40'),
(1445, 'Proact', NULL, NULL, 'NO', 'Phase III osteosarcoma Immunomodulator. Jenner Biotherapies.', NULL, 'Sarcoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1446, 'Probenecid', NULL, NULL, 'YES', 'A uricosuric agent; increases excretion of uric acid in respiratory acidosis', 'Benemid , Benuryl , Pro-Biosan 500 Kit , Probalan , SK-Probenecid', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1447, 'Procarbazine', NULL, NULL, 'NO', 'An orally administered hydrazine derivative antineoplastic agent. FDA approved in stages III, IV Hodgkin\'s lymphoma.', 'Ibenzmethyzin Hydrochloride , Matulane , Methylhydrazine , N-Methylhydrazine , Natulan , Natulane , Procarbazine hydrochloride , Ro-4-6467 , Ro4-6467/1', 'Brain tumors adjuvant and/or advanced disease, Cutaneous T-cell lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma', 'IBZ, MIH, PCB, PCH, PCI, PCZ', '077213;77213', 'Chemotherapy', 'Nonclassic alkylating agent'),
(1448, 'Procarbazine Hydrochloride', NULL, NULL, 'NO', 'An orally administered hydrazine derivative antineoplastic agent. FDA approved in stages III, IV Hodgkin\'s lymphoma.', 'Ibenzmethyzin Hydrochloride , Matulane , Methylhydrazine , N-Methylhydrazine , Natulan , Natulane , Ro-4-6467 , Ro4-6467/1', NULL, 'IBZ, MIH, PCB, PCH, PCI, PCZ', '077213;77213', 'Chemotherapy', 'Alkylating agent'),
(1449, 'Prochlorperazine', NULL, NULL, 'YES', 'A phenothiazine antiemetic.', 'Chlormeprazine , Compazine , Component of Eskatrol# , PMS-Prochlorperazine , Prochlorpemazine , Stemetil', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1450, 'Prochlorperazine Maleate', NULL, NULL, 'YES', 'Antiemetic; anticholinergic', 'Compazine , Nu-Prochlor , Prochlorperazine Dihydrogen Maleate , Prochlorperazine Dimaleate , Stemetil , Used with Isopropamide Iodide as Combid spansule', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1451, 'Progesterone', NULL, NULL, 'NO', 'A progestational (progestin) agent.  The principal progestational hormone of the body, liberated by the corpus luteum, placenta, and in minute amounts by the adrenal cortex; it prepares the uterus for the reception and development of the fertilized ovum by transforming the endometrium from the proliferative to the secretory stage and maintains an optimal intrauterine environment for sustaining pregnancy.', 'Component of Cyclogesterin# , Corluvite , Crinone , Gesterol , Gesterol 50 , Lipo-Lutin# , Luteal hormone , Luteinol , Nalutron# , PMS-Progesterone , Pregnenedione , Progelan , Progestaject , Progestasert , Progesteronum , Progestin , Progestronaq-LA , Prometrium , Syngesterone , Syngestrets', NULL, NULL, '9704;009704', 'Hormones and hormonal mechanisms', 'Progestin.  Probably not cancer directed--verify with attending MD.'),
(1452, 'Promazine Hydrochloride', NULL, NULL, 'YES', 'Antipsychotic.', 'Prozine , Sparine', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1453, 'Promethazine Hydrochloride', NULL, NULL, 'YES', 'Antihistamine with potent sedative properties; anti-emetic.', 'Anergan , Anergan 25 , Anergan 50 , Component of Phenergan VC , Component of Phenergan-D , Ganphen , Histantil , K-Phen 50 , Mepergan , Pentazine , Phenameth , Phenazine , Phenergan , PMS-Promethazine , Promet 50 , Promethazine Fortis , Promethazine VC Plain , Promethegan , Prorex , Prothazine , Ramsed , Remsed , Shaogan , V-Gan', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1454, 'ProMune', NULL, NULL, 'NO', 'Phase II NSCLC 2007 Immune response modifier. Coley Pharmaceuticals, Pfizer', 'CpG  ODN 7909 Adjuvant , CpG Oligodeoxynucleotide , PF 3512676 , PF-3512676 , PF3512676 , R 161460 , R-161460 , R161460', 'basal cell, Breast, kidney, lung, lymphoma, melanoma, NHL, skin cancer', NULL, '731581', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1455, 'Propranolol', NULL, NULL, 'YES', 'Propranolol is used to treat benign hemangiomas in children and infants. This condition is a malformation and not a tumor. It is not reportable.', 'Inderal', 'Benign hemangioma', NULL, NULL, 'Other therapy', 'Beta blocker');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1456, 'Proscar', NULL, NULL, 'YES', 'Finasteride is also prescribed for treatment of BPH and hair loss in men. Finasteride has been found to increase risk of high-grade prostate cancer and has not received FDA approval as treatment for prostate cancer.', 'Finasteride , Propecia', 'Prostate', NULL, NULL, 'Hormones and hormonal mechanisms', '5-alpha-reductase inhibitor'),
(1457, 'PROSTVAC-VF', NULL, NULL, 'NO', 'Phase II Vaccine. Therion Biologics.', NULL, 'Prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1458, 'Protease inhibitor', NULL, NULL, 'YES', 'Inhibits the protease enzyme necessary for formation of functional, infectious virions', 'Ro 31-8959', NULL, NULL, NULL, 'AIDS drug', NULL),
(1459, 'Protein A Staphylococcus Aureus', NULL, NULL, 'NO', NULL, 'Cowan I', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1460, 'Proteinase 3 Peptide Vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. NCI.', NULL, 'Leukemia', NULL, '698102', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1461, 'Prothecan', NULL, NULL, 'NO', 'Phase II Toposiomerase I inhibitor. Enzon.', 'PEG-Camptothecin', 'Gastric, lung, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(1462, 'Protirelin', NULL, NULL, 'NO', 'Synthetic thyrotropin-releasing hormone.', 'Abbott-38579 , hyroliberin , Lopremone , Refefact TRH , Thypinone , Thyrel TRH , Thyrotropin-releasing hormone , TRF , TRH', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Thyrotropin releasing hormone.  Probably not cancer directed--verify with attending MD.'),
(1463, 'Provenge Therapeutic Vaccine', NULL, NULL, 'NO', 'Phase III Dendreon.', 'APC 8015 , APC-8015 , APC8015 , PAP-loaded DC , Sipuleucel-T', 'Prostate cancer', NULL, '720270', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1464, 'Pseudomonas aeruginosa', NULL, NULL, 'NO', 'Bacterial and Fungi biological', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1465, 'PSK', NULL, NULL, 'NO', 'Bacteria and Fungi biological', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1466, 'Psoralen', NULL, NULL, 'NO', 'A photoactive agent (photosensitizer). FDA approved use as palliation in cutaneous T-cell lymphoma.', '8-methoxypsoralen , 8-MOP , Methoxsalen , Methoxypsoralen , MOP , Oxsoralen , Oxsoralen Ultra , Photochemo. , Ultramop , Uvadex', NULL, NULL, '45923;045923', 'Ancillary Agent', 'code to Other Therapy when used in combination with Ultraviolet A light (PUVA therapy);Photosensitizer'),
(1467, 'Pure anti-estrogen', NULL, NULL, 'NO', 'Phase III Anti-estrogen. Schering-Plough.', NULL, 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Antiestrogen'),
(1468, 'Puromycin (HCl)', NULL, NULL, 'NO', NULL, '1-MM , 3123L , 536 , CL-16 , P-638 , Puromycin , Stillo-mycin , Stylomycin', NULL, NULL, '3055', 'Chemotherapy', 'Antitumor antibiotic'),
(1469, 'PV701', NULL, NULL, 'NO', 'Phase I Therapeutic virus. Pro-Virus.', 'PV 701', 'Other cancer', NULL, '700553', 'Chemotherapy', 'Oncolytic virus'),
(1470, 'PX-12', NULL, NULL, 'NO', 'Phase I Thirodoxin inhibitor. Apoptosis stimulator.  Prolix Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent-thioredoxin inhibitor'),
(1471, 'Pyran copolymer', NULL, NULL, 'NO', NULL, 'Divema , Pyran , Pyran XA 124-177 , XA 146-85-2', NULL, NULL, '46015', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1472, 'Pyrantel Pamoate', NULL, NULL, 'YES', 'An anthelmintic agent.', 'Antiminth , Combantrin , JAA Pyral , One Step Pinworm Treatment , Pin-Rid , Pin-X , Pinworm , Pinworm Medicine , Pyrantel Embonate , Reese\'s Pinworm Medicine', NULL, NULL, NULL, 'AIDS drug', NULL),
(1473, 'Pyrazinamide', NULL, NULL, 'YES', 'Antitubercular.', 'D-50 , MK-56 , PMS Pyrazinamide , Tebrazid', NULL, 'PZA', NULL, 'Ancillary Agent;AIDS drug', NULL),
(1474, 'Pyrazine diazohydroxide', NULL, NULL, 'NO', NULL, NULL, 'Leukemia', 'PZDH', '361456', 'Chemotherapy', 'Miscellaneous agent'),
(1475, 'Pyrazofurin', NULL, NULL, 'NO', NULL, '47599 , Antibiotic A 23813 , Pirazofurin , Pyrazomycin', NULL, 'PRZF, PZF', '143095', 'Chemotherapy', 'Antimetabolite and enzyme inhibitor'),
(1476, 'Pyrazoloacridine', NULL, NULL, 'NO', 'Phase II Topoisomerase I/II ibhibitor. NCI, Pfizer.', NULL, 'Brain, breast cancer', NULL, '366140', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1477, 'Pyrazoloimidazole compound', NULL, NULL, 'NO', NULL, 'Pyridazole imidazole', NULL, 'IMPY', '51143', 'Chemotherapy', 'Antimetabolite'),
(1478, 'Pyridoxine Hydrochloride', NULL, NULL, 'YES', 'Vitamin; reduces neurotoxicity', 'Adermine hydrochloride , B6-250 , Beesix , Hexa-betalin , Marlyn Formula 50 , Nestrex , Pyridoxal hydrochloride , Releaf for PMS , Rodex , Vitamin B6', NULL, NULL, '36225', 'Ancillary Agent', NULL),
(1479, 'Pyrimethamine', NULL, NULL, 'YES', 'Antiprotozoal agent, antimalaria, antiparasitic. Rx of toxoplasmosis', 'BW 50-63 , Chloridin , Chloridine , Component of Fansidar , Dapaprim , Darapram , Daraprim , Daraprime , Diaminopyritamin , Erbaprelina , Malocide , Pirimecidan , Pirimetamina , Tindurin', NULL, NULL, '3061', 'Ancillary Agent;AIDS drug', NULL),
(1480, 'Quadrakine', NULL, NULL, 'NO', 'Phase I Interleukin-4. Schering-Plough.', NULL, 'Gastric cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Interleukin'),
(1481, 'Quinacrine', NULL, NULL, 'YES', 'Drug of choice for giardiasis. Antiprotozoal agent, antimalarial. Effective in neoplastic effusion.', 'Acrichine , Acrinamine , Acriquin , Acriquine , Akrichin , Antimalarina , Atabrine , Atabrine HCl , Haffkinine , Haffkynine , Italchine , Mepacrine , Mepacrine Hydrochloride , Quinacrine Hydrochloride , Quinactine', NULL, 'Atab, QUIN', '14229', 'Ancillary Agent;AIDS drug', NULL),
(1482, 'Quinestrol', NULL, NULL, 'NO', 'The 3-cyclopentyl ether of ethinyl estradiol (estrogen); a synthetic estrogen that has been reported to result in remission of postmenopausal symptoms in many patients.', 'Estrovis , W-3566', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen'),
(1483, 'Quingestanol Acetate', NULL, NULL, 'NO', 'Progestin', 'W-4540', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(1484, 'Quingestrone', NULL, NULL, 'NO', 'Progestin', 'W-3399', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'No longer in use'),
(1485, 'Quinidine', NULL, NULL, 'YES', 'An antiarrhythmic agent; chemosensitizing agent.  Antimalarial.', 'Apo-Quinidine , Biquin Durules , Cardioquin , Cin-Quin , Duraquin , Natisedine , Novoquinidin , Quin-Release , Quinaglute Dura-Tabs , Quinalan , Quinate , Quinatime , Quinidex Extentabs , Quinobarb , Quinora , SK-Quinidine Sulfate', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1486, 'Quizartinib', NULL, NULL, 'NO', 'This investigational drug is currently in clinical trials for AML with specific genetic mutations.', NULL, 'Acute myeloid leukemia, AML', NULL, NULL, 'Chemotherapy', NULL),
(1487, 'R-Verapamil HCl', NULL, NULL, 'YES', 'Calcium channel blocking agent', NULL, NULL, NULL, '632821', 'Ancillary Agent', NULL),
(1488, 'R04929097', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', NULL, 'advanced breast, NSCLC, pediatric neuroblastoma, solid tumors', NULL, NULL, 'Chemotherapy', 'Gamma-secretase inhibitor'),
(1489, 'R440', NULL, NULL, 'NO', 'Phase II Cell cycle inhibitor. Hoffmann-La Roche.', NULL, 'Breast, colorectal, lung cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1490, 'Radiation', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Radiation', 'Code in Radiation field'),
(1491, 'Radiolabeled J591', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Millenium Pharmaceuticals.', NULL, 'Prostate cancer', NULL, NULL, 'Radiation', 'Radioisotope conjugated to monoclonal antibody'),
(1492, 'radiotherapy', NULL, NULL, 'NO', 'Listed in some regimens', NULL, NULL, NULL, NULL, 'Radiation', 'Code in Radiation field'),
(1493, 'Raloxifene', NULL, NULL, 'NO', 'Phase III Selective estrogen receptor modulator (SERM). Eli Lilly.', 'Evista , Keoxifene Hydrochloride , Ly 139481 , LY 156758 , LY-139481 (raloxifene) , LY-156758 , LY139481 , LY156758 , Raloxifene , Raloxifene Hydrochloride', 'Breast cancer', NULL, '706725', 'Hormones and hormonal mechanisms', 'SERM'),
(1494, 'Ranitidine Hydrochloride', NULL, NULL, 'YES', 'Ranitidine is effective in the treatment of peptic ulcer disease and pathological hypersecretory diseases, such as Zollinger-Ellison syndrome. Ranitidine has also been used in combination with antibiotics for the treatment of Helicobacter pylori.', 'Alti-Ranitidine , Apo-Ranitidine , Novo-Ranitidine , Nu-Ranit , Ranital , Zantac', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1495, 'Ranomustine', NULL, NULL, 'YES', 'This drug approved in Japan only. There are no US clinical trials for this agent.', 'Cymerin , MCNU , Ranimustine', NULL, NULL, NULL, 'Chemotherapy', 'Nitrosourea alkylating agent'),
(1496, 'RAS 5-17 Peptide Vaccine', NULL, NULL, 'NO', 'Phase I NCI.', NULL, 'Colorectal, lung, other, pancreatic, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1497, 'Rasburicase', NULL, NULL, 'YES', 'Controls hyperuricemia from tumor lysis.', 'Elitek , Fasturtec', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1498, 'Razoxane', NULL, NULL, 'NO', 'Radiosensitizer, cardioprotectant, and carcinogenic drug.  Not found in Drugdex drug evaluation.', 'ICI-59118 , ICRF-159 , Tepirone', NULL, NULL, '129943', 'Chemotherapy', 'Antineoplastic no longer in use'),
(1499, 'RB894', NULL, NULL, 'NO', 'Preclinical Adenovirus. Introgen Therapeutics.', NULL, 'Head & neck cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Adenovirus'),
(1500, 'RC-3095', NULL, NULL, 'NO', 'Phase I Bomesin receptor antagonist. AEterna Laboratories.', 'RC 3095 , RC3095', 'Colorectal, gastric, lung, pancreatic, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Bombesin/gastrin releasing peptide antagonist'),
(1501, 'rCD4', NULL, NULL, 'YES', NULL, 'Reception (Recombinant Soluble CD4)', NULL, NULL, NULL, 'AIDS drug', NULL),
(1502, 'Rebeccamycin', NULL, NULL, 'NO', NULL, 'DEAE Rebeccamycin , Rebeccamycin Analog , BMS-181176 , BMS181176 , XL119 , XL-119 , XL 119', 'Gall Bladder, Cholangiocarcinoma, Brain, Breast, Colorectal, Kidney, Liver, Small Cell Lung Cancer (SCLC)', NULL, '655649', 'Chemotherapy', 'Antineoplastic antibiotic'),
(1503, 'recMAGE-A3+AS15', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', NULL, 'Melanoma, NSCLC', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Antigen-specific immunotherapy'),
(1504, 'Recombinant Fowlpox gp100P209', NULL, NULL, 'NO', 'Phase II', 'rv-gp100P209', NULL, NULL, '702138', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1505, 'Recombinant HumanThyrotropin', NULL, NULL, 'SEE_REMARKS', 'Used as an adjunct to radioiodine scanning in the follow-up of thyroid carcinoma.  Stimulates the secretion of pituitary thyroid stimulating hormone from the anterior pituitary and has been shown that protirelin increases secretion of prolactin.\r\n\r\nThis drug is probably not being given as a cancer directed agent. Verify with the attending MD before coding.', 'Protirelin , Recombinant human thyrotrophin , Recombinant human TSH , rhTSH , Thyrogen', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Thyroid stimulating hormone.  Probably not cancer directed--verify with attending MD.'),
(1506, 'Recombinant Soluble Human CD4', NULL, NULL, 'NO', 'Orphan drug.', 'rCD4', 'AIDS, Opportunistic infection', 'rCD4', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1507, 'Recombinant Soluble PSMA Vaccine', NULL, NULL, 'NO', 'Phase I Progenics Pharmaceuticals.', NULL, 'Pancreatic  caner', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1508, 'Recombinant Soluble T4', NULL, NULL, 'NO', NULL, 'sT4', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1509, 'Recombinant Tumor Necrosis Factor', NULL, NULL, 'NO', NULL, 'rTNF (produced by recombination)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1510, 'Regorafenib', NULL, NULL, 'NO', 'Stivarga received FDA approval September 27, 2012 to treat colorectal cancer.\r\n\r\n4/28/2017: FDA expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.', 'Stivarga', 'Breast, Colorectal, Liver', NULL, '900003', 'Chemotherapy', 'Multi-kinase inhibitor'),
(1511, 'Relacatib', NULL, NULL, 'NO', 'Phase II GlaxoSmithKline.', 'GSK 462795 , GSK-462795 , GSK462795', 'Bone metastases', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--cathepsin-K inhibitor'),
(1512, 'Rencarex', NULL, NULL, 'NO', 'Phase II Monoclonal antibody. Wilex AG.', 'WX G250 , WX-G250 , WXG250', 'Kidney cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1513, 'Reolysin', NULL, NULL, 'NO', 'Feb. 2015: FDA granted Orphan Drug Designation to Reolysin for the treatment of pancreatic cancer. It has previously received Orphan Drug Recognition for the treatment of ovarian, fallopian tube, and primary peritoneal cancers.', 'Reovirus', 'Brain cancer, Ovary, Pancreatic', NULL, '729968', 'Chemotherapy', 'Cytotoxic human reovirus'),
(1514, 'Resmycin', NULL, NULL, 'NO', 'Phase II Cytotoxic. Battelle Pharma, Zivena.', 'Doxorubicin HCl inhalation solution', 'Sarcoma', NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(1515, 'Retacrit', NULL, NULL, 'YES', '5/18/2018 The FDA approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/ Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.', 'epoetin alfa-epbx', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1516, 'Retinyl Acetate', NULL, NULL, 'YES', 'Vitamin.', 'Antixerophthalmic Vitamin , Aquasol A , Arovit , Axerophtholum , Del-Vi-A , Oleovitamin A , Palmitate-A , Pedi-Vit-A , Retinol , Retinyl Palmitate , Vitamin A , Vitamin A1', NULL, 'RA, Vit A', NULL, 'Differentiation inducing agent', NULL),
(1517, 'Retrovector', NULL, NULL, 'NO', 'Phase I Retroviral vector. Chiron.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Exogenous cytokine'),
(1518, 'rF-gp100', NULL, NULL, 'NO', 'Phase II melanoma Recombinant fowlpox vaccine. NCI, Therion Biologics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1519, 'rF-MART-1', NULL, NULL, 'NO', 'Phase II melanoma Vaccine. Therion Biologics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1520, 'rF-Mgp100', NULL, NULL, 'NO', 'Phase II Therion Biologics.', NULL, 'Skin cancer', NULL, '697854', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1521, 'rF-Tyrosine Vaccine', NULL, NULL, 'NO', 'Phase II melanoma Vaccine. NCI, Therion Biologics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1522, 'rgp120 CHO', NULL, NULL, 'YES', NULL, 'Biocine', NULL, NULL, NULL, 'AIDS drug', NULL),
(1523, 'rgp120/HIV-1 (IIIB)', NULL, NULL, 'YES', 'Genetically engineered form of envelope glycoprotein gp120 derived from HIV-1 strain IIIB', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1524, 'Rhenium 186 Etidronate', NULL, NULL, 'YES', 'A bone-seeking radiopharmaceutical for metastatic bone pain; Not recommended until additional data available.', 'Re-186 HEDP , Rhenium-186 HEDP', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1525, 'Rhenium-186', NULL, NULL, 'YES', 'Palliative for skeletal metastases', NULL, NULL, 'HEDP', NULL, 'Ancillary Agent', NULL),
(1526, 'Rhizoxin', NULL, NULL, 'NO', NULL, NULL, NULL, 'RZN', '332598', 'Chemotherapy', 'Antimitotic agent'),
(1527, 'Ribavirin', NULL, NULL, 'YES', 'A synthetic nucleoside with antiviral activity.', 'Rebetol , Viramid , Virazol , Virazole', NULL, NULL, '163039;609473', 'AIDS drug', NULL),
(1528, 'Ribociclib', NULL, NULL, 'NO', '7/18/2018: FDA expanded the indication for ribociclib (Kisqali) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. \r\n\r\n3/17/2017: FDA approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.\r\n\r\nAugust 23, 2016: FDA granted Breakthrough Therapy Designation to Ribociclib as first line treatment for HR+/HER2- advanced or metastatic breast cancer.', 'LEE011 , Kisqali', 'Breast', NULL, NULL, 'Chemotherapy', 'CDK 4/6 Inhibitor'),
(1529, 'Riboflavin', NULL, NULL, 'YES', 'A B-complex vitamin; cancer preventative', 'Lactoflavin , Vitamin B2 , Vitamin G', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1530, 'Riboprine', NULL, NULL, 'NO', NULL, 'SQ 22558', NULL, 'IPA', '105546', 'Chemotherapy', NULL),
(1531, 'Rifabutin', NULL, NULL, 'YES', 'Rifabutin is indicated for the prevention of Mycobacterium Avium complex (MAC) in patients with advanced HIV. It has been used in combination with other drugs for the treatment of MAC in patients with AIDS. It has also been used to treat other mycobacterial infections.', 'Ansamycin , LM427 , Mycobutin , Rifabutine', NULL, NULL, '113926', 'AIDS drug', NULL),
(1532, 'Rifampin', NULL, NULL, 'YES', 'Treatment of opportunistic mycobacterial infections; antibiotic. Under investigation for Rx of MAC. Rx of tuberculosis', 'Ba-41166/E , L-5103 , Rifadin , Rifadin IV , Rifaldazine , Rifamate , Rifampicin , Rifamycin AMP , Rifater , Rimactane , Rofact', NULL, NULL, '113926', 'AIDS drug;Ancillary Agent', 'Ancillary antibiotic'),
(1533, 'RIGScanCR49', NULL, NULL, 'YES', 'Phase I Monoclonal antibody diagnostic. RIG=Radioimmuno guided surgery. Neoprobe Oncology Surgery.', NULL, 'Colorectal cancer', NULL, NULL, 'Ancillary Agent', 'Diagnostic only'),
(1534, 'Rindopepimut', NULL, 'Glioblastoma Multiforme', 'SEE_REMARKS', 'Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the epidermal growth factor receptor (EGFR) variant (EGFRvIII). this drug is currently in phase III clinical trials and has not received final FDA approval as of December 2015.\r\n\r\nCoding information: Until Rindopepimut receives final FDA approval, code in Other Treatment and assign code 2. If approval if granted, then this agent will be coded as BRM/Immunotherapy.', 'CDX-110 , Rintega', 'Brain', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccination'),
(1535, 'Risedronate sodium', NULL, NULL, 'YES', 'Inhibits osteoclast-mediated bone resorption and modulates bone metabolism', 'Actonel', NULL, NULL, '722598', 'Ancillary Agent', NULL),
(1536, 'Rituximab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE:  This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.\r\nFDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.\r\nFDA approved 9/2006 for non-Hodgkin\'s B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.\r\nFDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.\r\nFDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who acheived response to rituximab in combination with chemotherapy.\r\nJune 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.  \r\n.', 'Anti-CD20 monoclonal antibodies , C2B8 monoclonal antibody , IDEC-C2B8 , MabThera , Monoclonal antibody IDEC-C2B8 , Rituxan', 'Leukemia, NHL', NULL, '687451', 'Biologic therapy (BRM, immunotherapy)', 'Cytostatic monoclonal antibody'),
(1537, 'Ro 24-7429', NULL, NULL, 'YES', 'Code name for a benzodiazepine derivative with anti-HIV activity (TAT gene inhibitor)', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1538, 'Ro-03-8799', NULL, NULL, 'YES', 'Radiosensitizer', 'Pimonidazole', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1539, 'RO5072759', NULL, NULL, 'NO', 'Phase I&III New drug currently in trials, code in Other Therapy', 'RO5072759', 'CLL, NHL', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Anti CD20 Antibody'),
(1540, 'RO5185426', NULL, NULL, 'NO', 'Phase I&II', 'RO5185426', 'Malignant Melanoma', NULL, NULL, 'Chemotherapy', 'B-raf Kinase Inhibitor'),
(1541, 'Rofecoxib', NULL, NULL, 'YES', 'Possible anti-angiogenic (see also celebrex)', 'Vioxx', NULL, NULL, '720256', 'Ancillary Agent', NULL),
(1542, 'Roscovitine', NULL, NULL, 'NO', 'As of March 2012, roscovitine is currently in clinical trials for NSCLC, AML and B-cell lymphomas. Code in \"Other Treatment\" until approval received from FDA.', 'CYC202 , R-roscovitine , Seliciclib', 'Acute myelogenous leukemia (AML), B-cell lymphomas, Non small cell lung cancer (NSCLC)', NULL, NULL, 'Chemotherapy', 'CDK inhibitor- see remarks'),
(1543, 'Rozlytrek', NULL, NULL, 'NO', 'August 15, 2019 FDA granted accelerated approval to entrectinib (ROZLYTREK) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. \r\n\r\nRozlytrek was also approved for the treatment of adults with non-small cell lung cancer whose tumors are ROS1-positive (mutation of the ROS1 gene) and has spread to other parts of the body (metastatic).', 'Entrectinib', NULL, NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1544, 'RS7', NULL, NULL, 'NO', 'Phase I Humanized monoclonal antibody. Immunomedics.', 'hRS7', 'Other cancer', NULL, NULL, 'Radiation', 'Radioisotope conjugated to monoclonal antibody'),
(1545, 'RSR13', NULL, NULL, 'NO', 'Phase III brain metastases, Phase II (breast, NSCLC) Synthetic allosteric hemoglobin radiosensitizer. Allos Therapeutics.', 'Efaproxyn , RSR-13', 'Brain, breast, lung cancer', NULL, '722758', 'Ancillary Agent', 'Radiosensitizer'),
(1546, 'RSU 1069', NULL, NULL, 'NO', 'Radiosensitizer', NULL, NULL, NULL, NULL, 'Ancillary Agent', 'Radiosensitizer'),
(1547, 'RTA744', NULL, NULL, 'NO', 'Phase I malig CNS 2007 Anthracycline that penetrates blood-brain barrier.  Reata Pharmaceuticals', 'RTA 744 , RTA-744 , WP 744 , WP-744 , WP744', 'Malignant CNS tumors', NULL, NULL, 'Chemotherapy', 'Topoisomerase II inhibitor'),
(1548, 'Rubitecan', NULL, NULL, 'NO', 'Phase II, Phase II MDS, CML, Phase III pancreatic Topoisomerase I inhibitor. SuperGen.', '9-Nitrocamptothecin , Orathecin , RFS 2000 , RFS2000', 'Brain, breast, cervical, colorectal, gastric, head & neck, leukemia, liver, lung, lymphoma, melanoma, ovarian, pancreatic, prostate cancer', '9-NC', '603070', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1549, 'Rubraca', NULL, NULL, 'NO', 'December 19, 2016 The U.S. Food and Drug Administration granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.\r\nBRCA genes are involved with repairing damaged DNA and normally work to prevent tumor development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an \r\nenzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the \r\ncancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth.\r\n\r\nApril 6, 2018: The FDA approved rucaparib (Rubraca), a PARP inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.', 'Rucaparib', 'Ovary', NULL, NULL, 'Chemotherapy', 'PARP (poly-ADP-ribose polymerase)'),
(1550, 'Ruxience', NULL, NULL, 'NO', '7/23/2019\r\n FDA approved Ruxience (rituximab-pvvr), a biosimilar to U.S.-licensed Rituxan (rituximab) for the treatment of adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy, and CD20-positive Chronic Lymphocytic Leukemia (CLL) in combination with chemotherapy\r\n\r\nRuxience is indicated for the treatment of adult patients with:\r\n•	Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent;\r\n•	Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; and\r\n•	Non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy;\r\n•	Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens;\r\n•	Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC);', 'Rituximab-pvvr', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Biosimilar'),
(1551, 'Ruxolitinib', NULL, 'Polycythemia vera (PV)', 'NO', 'May 24, 2019: FDA approved ruxolitinib (JAKAFI) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older\r\n\r\nDecember 4, 2014: Ruxolitinib received FDA approval for treatment of polycythemia vera (PV) \r\n\r\nNovember 16, 2011: Ruxolitinib received FDA approval for treatment of myelofibrosis. It has been designated an Orphan Drug.', 'Jakafi , Jakavi , Ruxolitinib', 'Bone marrow (myelofibrosis)', NULL, NULL, 'Chemotherapy', 'JAK 1 and JAK 2 (Janus Kinase Inhibitor)'),
(1552, 'rV-GP100', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. Therion Biologics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1553, 'rV-MART-1', NULL, NULL, 'NO', 'Phase I melanoma Vaccine. Therion Biologics.', NULL, 'Skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1554, 'Samarium SM 153', NULL, NULL, 'NO', NULL, 'Quadramet', 'Bone mets', NULL, NULL, 'Radiation', 'Radioisotope'),
(1555, 'Saquinavir Mesylate', NULL, NULL, 'YES', 'An inhibitor of human immunodeficiency virus (HIV) protease.', 'Fortovase , Invirase , Ro-31-8959/003 , Saquinavir', NULL, NULL, '722663', 'AIDS drug', NULL),
(1556, 'Saracatinib', NULL, NULL, 'NO', 'As of Jan 2015, this drug is currently in clinical trials for several different cancer sites including breast, gastric, leukemia, and pancreatic.', 'AZD 0530 , AZD-0530', 'Breast, CML, Pancreas, Stomach', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--dual Src/Abl kinase inhibitor'),
(1557, 'SarCNU', NULL, NULL, 'NO', 'Phase II NCI.', NULL, 'Colon cancer', NULL, '364432', 'Chemotherapy', 'Alkylating agent'),
(1558, 'Satraplatin', NULL, NULL, 'NO', 'Phase II SCLC Phase III prostate Third generation platinum compound. NeoOncoRx, NeoTherapeutics.', 'BMS-182751 , BMY-45594 , JM 216 , JM-216 , JM216 , Orplatna', 'Lung, ovarian, prostate cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent;Platinum compound'),
(1559, 'SB-1518', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', NULL, 'AML, CML, MDS', NULL, NULL, 'Chemotherapy', 'JAK-2 inhibitor'),
(1560, 'SB249553', NULL, NULL, 'NO', 'Phase II Recombinant Therapeutic Vaccine. GlaxoSmithKline.', 'SB 249553 , SB-249553', 'Lung, melanoma, skin cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1561, 'SB408075', NULL, NULL, 'NO', 'Phase II Monoclonal antibody; tumor activated pro-drug. GlaxoSmithKline.', NULL, 'Colorectal, lung cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic chemotherapy conjugated to monoclonal antibody'),
(1562, 'SC-1', NULL, NULL, 'NO', 'Phase II H3 Pharma', NULL, 'Gastric cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1563, 'SCH-900776', NULL, NULL, 'NO', 'I New drug currently in trials, code in other therapy', NULL, 'ALL, AML, CML, Hodgkin, NHL', NULL, 'NCT00779584', 'Chemotherapy', 'Cell cycle inhibitor'),
(1564, 'SCH619734', NULL, NULL, 'YES', 'Anti-emetic.  Schering-Plough', 'SCH 619734 , SCH-619734', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1565, 'SCIO-469', NULL, NULL, 'NO', 'Phase II Scios.  Also investigated for rheumatoid arthritis', 'SCIO 469 , SCIO469', 'Multiple myeloma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--protein kinase inhibitor'),
(1566, 'SDX-101', NULL, NULL, 'NO', 'Phase II CLL Salmedix.', 'R-Etodolac', 'Leukemia', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1567, 'Selenium', NULL, NULL, 'YES', 'NCI clinical trial as prostate preventative', 'Selenium methionine', NULL, NULL, '724226', 'Ancillary Agent', 'Preventative'),
(1568, 'Semaxanib', NULL, NULL, 'NO', 'Phase III (colorectal) Phase III NSCLC Flk-1/KDR angiogenesis inhibitor. Sugen. Development discontinued', 'SU 5416 , SU-5416 , SU5416', 'Breast, colorectal, lung cancer, other cancer, sarcoma', NULL, '696819', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1569, 'Semustine', NULL, NULL, 'NO', 'Not found in Drugdex drug evaluation.', 'Methyl CCNU , Methyl-CCNU , trans-Methyl CCNU , WR-220076', NULL, 'MCCNU, MCNU, MeCCNU', '95441;095441', 'Chemotherapy', 'Alkylating agent'),
(1570, 'SERM III', NULL, NULL, 'NO', 'Phase III Eli Lilly.', NULL, 'Breast, endometrial cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Selective estrogen receptor modulator (SERM)'),
(1571, 'Serotonin', NULL, NULL, 'YES', 'Ondansetron Hydrochloride antagonist.', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1572, 'SGN 17/19', NULL, NULL, 'NO', 'Phase I melanoma Monoclonal antibody plus prodrug melphalan. Seattle Genetics.', 'SGN-17/19 , SGN17/19', 'Skin cancer', NULL, NULL, 'Chemotherapy', 'Alkylating agent'),
(1573, 'SGN-00101', NULL, NULL, 'NO', 'Phase II Stressgen Biotechnologies.', 'HspE7', 'Cervical, colorectal cancer', NULL, '713219', 'Ancillary Agent', 'Chemoprevention'),
(1574, 'SGN-10', NULL, NULL, 'NO', 'Phase I NSCLC Single chain immunotoxin (SCIT). Seattle Genetics.', 'BR96sFv-PE40 , SGN 10 , SGN10', 'Breast, colorectal, lung, ovarian, pancreatic, prostate cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1575, 'SGN-15', NULL, NULL, 'NO', 'Phase I/II (ovarian) Phase II NSCLC, prostate Monoclonal antibody. Seattle Genetics, NCI.', 'cBR96-doxorubicin immunoconjugate , SGN 15 , SGN15', 'Breast, colorectal, lung, ovarian, prostate cancer', NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic conjugated to monoclonal Antibody'),
(1576, 'SGN-25', NULL, NULL, 'NO', 'Pre-clinical Antibody drug conjugate. Seatle Genetics.', NULL, 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Antimitotic agent conjugated to monoclonal Antibody'),
(1577, 'SGN-30', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Seattle Genetics.', NULL, 'ALCL, Lymphoma', NULL, '731636', 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1578, 'sibrotuzumab', NULL, NULL, 'NO', 'Phase I Monoclonal antibody with cytostatic properties. (human FAP (fibro-blast activation protein) Boehringer-Ingelheim Pharmaceuticals.', 'BIBH1', 'Breast, colorectal, lung, other cancer, pancreatic', 'BIBH-1', NULL, 'Chemotherapy', 'Cytostatic agent--monoclonal antibody'),
(1579, 'Silandrone', NULL, NULL, 'NO', 'Androgen', 'SC-16148', NULL, NULL, '95147', 'Hormones and hormonal mechanisms', 'No longer in use'),
(1580, 'Simtrazene', NULL, NULL, 'NO', NULL, 'Centrazene , CL 26193', NULL, 'MPT', '083799;86491', 'Chemotherapy', 'No longer in use'),
(1581, 'Simvastatin', NULL, NULL, 'NO', 'Zocor (Simvastatin) causes tumors and metastasis to regress in hepatomas and also colon cancers. It is also prescribed as treatment to lower cholestrol.', 'Zocor', 'Hepatoma', NULL, NULL, 'Chemotherapy', 'Antiangiogenic agent;Cytostatic agent--Ras inhibitor'),
(1582, 'Siplizumab', NULL, NULL, 'YES', 'Phase II NHL, Hodgkin\'s Used to prevent Graft/Host syndrome in Bone Marrow Transplant pts.  Monoclonal antibody. BioTransplant.', 'AlloMune , MEDI 507 , MEDI-507 , MEDI507', 'Lymphoma', NULL, NULL, 'Ancillary Agent', 'Anti-rejection drug in BMT'),
(1583, 'Sirolimus', NULL, NULL, 'YES', 'Rapamycin is a drug used to keep the body from rejecting organ and bone marrow transplants. Rapamycin blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus. \r\n\r\nPER the FDA this drug is used to treat GVHD (graft versus host disease) in transplant patients.\r\n\r\n**Important note: even though the subcategory of this drug is mTOR inhibitor, this category does not automatically mean the drug is chemotherapy. This applies to certain hormonal drugs as well.', 'Rapamune , Rapamycin', NULL, NULL, '226080', 'Ancillary Agent', 'mTOR inhibitor;antibiotic'),
(1584, 'SJG-136', NULL, NULL, 'NO', 'Phase I advanced solid tumors 2007', 'SJG 136 , SJG136', 'Solid tumors', NULL, '694501', 'Chemotherapy', 'Alkylating agent'),
(1585, 'Skeletal Targeted Radiotherapy', NULL, NULL, 'NO', 'Phase I/II/III NeoRx.', NULL, 'Multiple myeloma, sarcoma', 'STR', NULL, 'Radiation', 'Radioisotope'),
(1586, 'SKI-606', NULL, NULL, 'NO', 'Dual protein kinase inhibitor', 'Bosulif , Bosutinib , SKI 606 , SKI606', 'AML', NULL, NULL, 'Chemotherapy', 'Protein kinase inhibitor'),
(1587, 'SL-11047', NULL, NULL, 'NO', 'Phase I refractory lymphoma 2007 Second generation polyamine analog that may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth.  SLIL Biomedical.', 'SL 11047 , SL11047', 'Lymphoma', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1588, 'SNS-595', NULL, NULL, 'NO', 'Phase II Sunesis.', 'SNS 595 , SNS595', 'NSC lung', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent--S phase apoptosis initiator'),
(1589, 'SNX-1012', NULL, NULL, 'YES', 'Protectant for oral mucositis due to chemotherapy.  Serenex.', 'SNX 1012 , SNX1012', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1590, 'Soblidotin', NULL, NULL, 'NO', 'Phase II Advanced or mets soft tissue sarcoma, advanced or metastatic non-small cell lung cancer', 'Soblidotin , TZT 1027', 'Lung, soft tissue', NULL, NULL, 'Chemotherapy', 'Tubuline inhibitor'),
(1591, 'Sodium Butyrate', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'Differentiation inducing agent', NULL),
(1592, 'Sodium Chloride', NULL, NULL, 'YES', 'Chemoprotective agent; reduces nephrotoxicity', '4-Way Saline Moisturizing Mist , Abboject Sodium Chloride , Adsorbonac , Afrin Saline Mist , Ak-NaCl , Ak-Salt , Ayr Baby , Ayr Nasal Drops , Ayr Nasal Mist , Bacteriostatic Sodium Chloride , Breathe Free , Cordema , Entsol , Eye & Skin Buffered Flushing Solution , Hep-Pak 2: Sodium Chloride Solution , Humist , In A Wink , Iocare , Marine Mist , Muro-128 , Mycinaire , Nasal Saline , Neo-synephrene Nasal Saline Moisturizer , Normal Saline Flush , Opti-One , Physiological saline , Py-Co-Pay Disclosing , Saline , Saline Nasal Mist , Salinex , Salt , Sea Mist , Slo-Salt , Wound Wash Saline', NULL, NULL, NULL, 'Ancillary Agent', 'Chemoprotective'),
(1593, 'Sodium Fluoride', NULL, NULL, 'YES', 'Prevention or decrease of dental caries. In the treatment of osteoporosis.', 'Floridine , Fluor-d-day , Fluorabon , Fluoritab , Fluorodex , Fluotic , Flura , Flura-Drops , Flura-loz , Flurol , Luride , Luride-SF , Nafrinse , PDF , Pedi-Dent , Pediaflor , Pergantene , Phos-Flur , Point-Two , Prevident , SFT Reduced Urine Preservative , Solu-Flur , Thera-Flur-N , Xaridium , Zymafluor', NULL, NULL, '77385', 'Ancillary Agent', NULL),
(1594, 'Sodium Iodide', NULL, NULL, 'YES', 'Iodine radioisotope. FDA approved use for thyroid carcinoma.', 'I 131 Idotope , Sodium Iodide I 131', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1595, 'Sodium Phenylacetate', NULL, NULL, 'YES', 'Orphan drug, for use as an adjunct to surgery, radiation therapy and chemo. for the treatment of patients with primary or recurrent malignant glioma.', 'Component of Ammonul , Component of Ucephan , Sodium salt', NULL, NULL, '3039', 'Differentiation inducing agent', NULL),
(1596, 'Sodium Phosphate P 32', NULL, NULL, 'NO', 'Phosphorus-32, given as sodium phosphate ((32)P), is used intravenously in the treatment of polycythaemia vera. Sodium phosphate ((32)P) is also employed intravenously in the treatment of chronic myeloid and chronic lymphocytic leukemia and in the palliative treatment of bone metastases; radioactive agent, diagnostic aid.', NULL, NULL, NULL, NULL, 'Radiation', 'Radioisotope'),
(1597, 'Sodium stibogluconate', NULL, NULL, 'NO', 'Phase I melanoma 2007 Enzyme blocker.  Information from NCI', NULL, 'Melanoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent'),
(1598, 'Sodium Thiosulfate', NULL, NULL, 'YES', 'An antidote for cyanide, bromate, cisplatin, and nitroprusside poisoning, has some usefulness in arsenic poisoning, and has been used as an antifungal; reduces nephrotoxicity', 'Adasept , Cyanide Antidote package , Komed , Sulfactol# , Tinver , Versiclear', NULL, NULL, '45624', 'Ancillary Agent', NULL),
(1599, 'Somatostatin', NULL, NULL, 'NO', 'Growth hormone release inhibiting factor;  primarily produced by the and by the delta cells of the pancreatic islets; they inhibit release of growth hormone, thyrotropin, and corticotropin by the adenohypophysis, of insulin and glucagon by the pancreas, of gastrin by the gastric mucosa, of secretin by the intestinal mucosa, and of renin by the kidney', 'GH-RIF , GH-RIH , Growth hormone release-inhibiting factor , Growth hormone release-inhibiting hormone , Hypothalamic hormone , Reducin , Somatropin release-inhibiting factor , SRIF , Stilamin', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Growth hormone releasing hormone inhibitor.  Probably not cancer directed--verify with attending MD.'),
(1600, 'Somatrem', NULL, NULL, 'NO', 'A growth hormone derived from recombinant DNA technology; rHGH, growth hormone; used to stimulate growth in children who do not produce enough growth hormone of their own.', 'Human growth hormone , Met-HGH , Methionyl human growth hormone , Protropin , Recombinant growth hormone , Somatotropin', 'AIDS, Opportunistic infection', NULL, '648119', 'Hormones and hormonal mechanisms', 'Growth hormone.  Probably not cancer directed--verify with attending MD.'),
(1601, 'Sonazoid', NULL, NULL, 'YES', 'Phase II Ultrasound imaging agent. Nycomed Amersham.', 'Decafluorobutane lipid microspheres , NC100100 , Perfluorobutane', 'Liver, Prostate cancer', NULL, NULL, 'Ancillary Agent', 'Ultrasound contrast agent'),
(1602, 'Sorafenib', NULL, NULL, 'NO', 'FDA approval 2005 for renal cell carcinoma (RCC)\r\nFDA approval 2007 for hepatocellular carcinoma\r\nFDA approval 2013 for thyroid carcinoma\r\nMaybe used to treat other neoplasms and primary sites.', 'BAY 43-9006 , BAY 439006 , BAY439006 , Nexavar', 'Kidney, Leukemia, colon, liver, lymphoma, other cancer, prostate, thyroid', NULL, NULL, 'Chemotherapy', 'Targeted therapy--raf kinase inhibitor'),
(1603, 'SP-PG', NULL, NULL, 'YES', 'Inhibits angiogenesis; under investigation for Rx of Kaposis\'s sarcoma', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1604, 'SP1049C', NULL, NULL, 'NO', 'Phase II Anthracycline in combination with biotransport carrier technology. Supratek Pharma.', NULL, 'Head & neck cancer', NULL, NULL, 'Chemotherapy', 'Anthracycline'),
(1605, 'Sparfloxacin', NULL, NULL, 'YES', 'A fluoroquinolone antibiotic; antimycobacterial', 'AT-4140 , CI-978 , PD-131501 , RP-64206 , Zagam', 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(1606, 'Sparfosate Sodium', NULL, NULL, 'NO', 'Antineoplastic agent. Miscellaneous agent.  Not found in Drugdex drug evaluation.', 'CI-882 , PALA Disodium', NULL, 'PALA', '224131', 'Chemotherapy', 'Antimetabolite'),
(1607, 'Sparsomycin', NULL, NULL, 'NO', NULL, 'U 19183 , U-19183 , U19183', NULL, NULL, '59729', 'Chemotherapy', 'Antitumor antibiotic'),
(1608, 'SPD424', NULL, NULL, 'NO', 'Phase II GnRH agonist. Shire Pharmaceuticals.', 'Histrelin implant , LHRH-Hydrogel implant , RL 0903 , SPD 424 , Vantas', 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH agonist'),
(1609, 'Spiramycin', NULL, NULL, 'YES', 'A macrolide antibiotic; Rx of cryptosporidiosis', 'Acetylspiramycin , Espiramicina , IL-5902 , Leucomycin , Ovamycin , RP-5337 , Spiramycin HCl', 'AIDS, Opportunistic infection', NULL, '055926;064393;64393 (hydrochloride);55926', 'Ancillary Agent;AIDS drug', NULL),
(1610, 'Spirogermanium', NULL, NULL, 'NO', 'For clinical study this agent can be obtained through Unimed of The Investigation Drug Branch NCI. Not found in Drugdex drug evaluation.', 'Spiro-32 , Spirogermanium Hydrochloride', NULL, 'SPG', '192965', 'Ancillary Agent', 'No longer in use'),
(1611, 'Spiromustine', NULL, NULL, 'NO', 'Alkylating agent', 'Spirohydantoin mustard#', NULL, NULL, '172112', 'Chemotherapy', 'Alkylating agent'),
(1612, 'Spironolactone', NULL, NULL, 'YES', 'This drug is a diuretic. It also blocks production of aldosterone which is produced in excess by various types of malignant and benign tumors. It is used in the treatment of edema due to congestive heart failure or hepatic or renal disease, in the treatment of hypokalemia, in the management of primary hyperaldosteronism, and, usually in combination with other drugs, in the treatment of hypertension.', 'Alatone , Aldactone , Component of Aldactazide , Novo-Spiroton , SC-9420 , Sincomen , Spiresis , Spiridon , Spirolactone , Spirone , Uractone , Verospirone', NULL, 'SPL', '150399', 'Hormones and hormonal mechanisms', 'Aldosterone antagonist'),
(1613, 'Spiroplatin', NULL, NULL, 'NO', NULL, 'TNO 6 , TNO-6 , TNO6', NULL, NULL, '311056', 'Chemotherapy', 'Miscellaneous agent'),
(1614, 'Squalamine', NULL, NULL, 'NO', 'Phase II Anti-anigiogenic. Genaera.', 'MSI-1256F , sualamine lactate', 'Brain, lung, ovarian, prostate cancer', NULL, '716435', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1615, 'SR 271425', NULL, NULL, 'NO', 'Phase I Thioxanthone. Sanofi-Synthelabo.', '9H-Thioxanthen-9-one , BCN326862 , SR-271425 , SR271425 , Thiaxanthenone , Thioxanthe-9-one , Thioxanthone , WIN71425', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytolytic agent'),
(1616, 'SR27897', NULL, NULL, 'NO', 'Phase II Cholecystokinin A receptor agonist. Sanofi-Synthelabo.', 'SR 27897 , SR-27897', 'Pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Protein kinase agonist'),
(1617, 'SR48692', NULL, NULL, 'NO', 'Phase II Neurotensin (NT) receptor antagonist. Sanofi-Synthelabo.', 'SR 48692 , SR-48692', 'Pancreatic, prostate cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic neurotensin antagonist'),
(1618, 'SSI(dsFv)-PE38', NULL, NULL, 'NO', 'In Clinical Trials Anti-mesothelin monoclonal antibody toxin. NeoPharm.', NULL, 'Cervical, head & neck, lung, ovarian cancer', NULL, '726388', 'Chemotherapy', 'Immunotoxin conjugated with monoclonal antibody'),
(1619, 'sT4', NULL, NULL, 'YES', NULL, 'Recombinant Soluble T4', NULL, NULL, NULL, 'AIDS drug', NULL),
(1620, 'STA-4783', NULL, NULL, 'NO', 'Phase III melanoma 2007 Activates oxidative stress in cells triggering apoptosis and activating NK-cell mediated killing of cancer cells.  Synta Pharmaceuticals.', 'STA 4783 , STA4783', 'Melanoma', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1621, 'STA-9090', NULL, NULL, 'NO', 'Phase I, II, and III trials', 'Ganetespib , STA-9090', 'GIST, Leukemia, MDS, solid tumors', NULL, NULL, 'Chemotherapy', 'HSP 90 inhibitor'),
(1622, 'Stanolone', NULL, NULL, 'NO', 'A semisynthetic form of dihydrotestosterone, having the same actions and uses as testosterone. It is used for its anabolic and antineoplastic actions in inoperable breast cancer and in postoperative metastatic breast cancer. Not found in Drugdex drug evaluation.', 'Dihydrotestosterone , Neodrol', 'Breast cancer', NULL, '10972', 'Hormones and hormonal mechanisms', 'Anabolic steroid'),
(1623, 'Stanozolol', NULL, NULL, 'NO', 'Androgenic nabolic steroid, is a synthetic 17-alpha alkylated derivative of testosterone; used orally, especially to increase hemoglobin levels in some patients with aplastic (congenital and idiopathic) anemia.', 'Win-14833 , Winstrol', NULL, NULL, '043193;43193', 'Hormones and hormonal mechanisms', 'Anabolic steroid'),
(1624, 'Stavudine', NULL, NULL, 'YES', 'An antiretroviral (nucleoside reverse transcriptive inhibitor) agent used in the treatment of AIDS.', 'BMY-27857 , d4T , Zerit', NULL, NULL, '163661', 'AIDS drug', NULL),
(1625, 'STEMGEN', NULL, NULL, 'YES', 'Phase I AA Stem cell stimulator. Amgen.', 'Ancestim , Kit Ligand , SCF , Stem Cell Factor', 'Leukemia', NULL, '653545', 'Ancillary Agent', 'Stem cell factor therapy'),
(1626, 'Stilboestrol Dipropionate', NULL, NULL, 'NO', 'Synthetic nonsteroidal estrogen having activity similar to but greater than that of estrone. It is used for many purposes, including relief of menopausal symptoms; suppression of lactation; treatment of amenorrhea, dysmenorrhea, senile vaginitis, and pruritus vulvae; palliative treatment of female breast carcinoma; relief of symptoms of prostatic carcinoma; and formerly for prevention of threatened or habitual abortion and premature labor. Administered intramuscularly.  Not found in Drugdex drug evaluation.', 'Diethylstilbestrol Dipropionate', 'Breast, prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Estrogen'),
(1627, 'Streptomycin', NULL, NULL, 'NO', 'An aminoglycoside antimicrobial.', 'D-Streptamine , Streptomycin Sulfate , Streptosol 25%', NULL, NULL, NULL, 'AIDS drug', 'Antimicrobial'),
(1628, 'Streptonigrin', NULL, NULL, 'NO', NULL, '5278 R.P. , Bruneomycin , Methyl streptonigrin , Nigrin , Rufochromomycin , Rufocromo-mycin', NULL, 'SN, STN, STP', '45383', 'Chemotherapy', 'Antitumor antibiotic'),
(1629, 'Streptozocin', NULL, NULL, 'NO', 'A methyl nitrosourea alkylating antineoplastic agent. FDA approved use on panceatic islet cell carcinoma.', 'Streptozocin , Streptozoticin , Streptozotocin , U-9889 , Zanosar', NULL, 'STR, Strept, STZ, SZ, SZC', '085998;85998', 'Chemotherapy', 'Alkylating agent'),
(1630, 'Strontium', NULL, NULL, 'NO', 'Phase II Radioisotope. Amersham Health.', 'Metastron , Sms-2-PA , Stronscan-85 , Strontium Chloride Sr 89 , Strontium-89', NULL, NULL, '721349', 'Radiation', 'Radioisotope'),
(1631, 'SU-101', NULL, NULL, 'YES', 'Phase III (brain) Phase II (NSCLC ovarian, prostate) Signal transcription inhibitor of platelet derived growth factor. SuperGen.', 'Arava , HWA-486 , Leflunomide , RS-34821', 'Brain, Lung, Ovarian, Prostate cancer', NULL, '677411', 'Ancillary Agent', 'No activity in cancer (arthritis medication)'),
(1632, 'SU5415', NULL, NULL, 'NO', 'Phase II/III Anti-angiogenic. Sugen', 'SU 5415 , SU-5415', 'Colorectal cancer', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1633, 'SU6668', NULL, NULL, 'NO', 'Phase I Anti-angiogenic. Sugen, Pharmacia.', NULL, 'Colorectal, other cancer', NULL, '702827', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1634, 'Sucralfate', NULL, NULL, 'YES', 'An oral anti-ulcer agent.', 'Apo-Sucrafate , Carafate , Dom-Sucralfate , Novo-Sucralate , PMS-Sucralfate', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1635, 'Sulfadiazine', NULL, NULL, 'YES', 'A sulfonamide antiinfective used to treat urinary tract infections, toxoplasmosis in AIDS patients, rheumatic fever prophylaxis (non-labeled indication), malaria and other various infections. The drug has received Orphan drug status for use in the treatment of toxoplasma gondii encephalitis in combination with pyrimethamine.', 'Neotrizine , Ovoquinol , Sodium Sulfadiazine , Soluble Sulphadiazine , sulfadiazinum natricum , Sulphadiazine , Sulphadiazine sodium , Triple Sulfa No. 2 , Trisulfaminic , Trisulfapyrimidines', 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent;AIDS drug', NULL);
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1636, 'Sulfamethoxazole', NULL, NULL, 'YES', 'An intermediate-acting sulfonamide used primarily in treating urinary tract infections; Rx for PCP.', 'Component of Bactrim , Component of Cotrim , Component of Septra , Component of Sulfatrim , Gantanol , Sulfamethoxazole Oral Suspension USP 26 , Sulfamethoxazolum , Sulfamethoxzole Tablets USP 26 , Sulfisomezole , Sulphamethoxazole , Urobak', 'AIDS, Opportunistic infection', NULL, NULL, 'Ancillary Agent;AIDS drug', NULL),
(1637, 'Sulindac', NULL, NULL, 'YES', 'A nonsteroidal antiinflammatory analgesic.', 'Apo-Sulin , Clinoril , MK-231 , Novo-Sundac', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1638, 'Sulofenur', NULL, NULL, 'NO', 'Has been investigated for its antineoplastic properties.', 'LY 186641 , LY-186641 , LY186641', NULL, NULL, NULL, 'Chemotherapy', 'Antineoplastic unclassified'),
(1639, 'Sunitinib maleate', NULL, NULL, 'NO', 'Nov. 16, 2017: FDA approved Sutent (sunitinib) for the adjuvant treatment of adult patients with high risk of recurrent renal cell carcinoma following nephrectomy.\r\n\r\nMay 20, 2011 FDA approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or have spread to other parts of the body (metastatic). \r\nFDA approved 2006 GIST, renal; Phase II urothelial, breast, stomach 2007\r\nPfizer.', 'SU 11248 , SU-11248 , SU011248 , SU11248 , Sutent', 'breast, GIST, pancreas, Renal cell, stomach, Urothelial ca', NULL, '736511', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1640, 'Suramin Sodium', NULL, NULL, 'NO', 'Phase I/II Anti-angiogenic. NCI, Pfizer.', 'Antrypol , Bayer-205 , Forneau-309 , Germanin , Metaret , Moranyl , Naganin , Naganinum , Naganol , Naphuride Sodium , Sodium Suramin', NULL, NULL, '34936;034936', 'Chemotherapy', 'Growth factor inhibitor'),
(1641, 'T-Cell Therapy', NULL, NULL, 'NO', 'Phase II Cancer Therapeutics.', NULL, 'Other cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1642, 'T138067', NULL, NULL, 'NO', 'Phase II (breast, liver, NSCLC), Phase I (colorectal) Microtubular inhibitor. Tularik.', 'T 138067 , T-138067', 'Breast, colorectal, liver, lung cancer', 'T67', NULL, 'Chemotherapy', 'Cytostatic agent--mitotic inhibitor'),
(1643, 'T900607', NULL, NULL, 'NO', 'Phase I  liver, other Phase II gastric Tubulin antagonist. Tularik.', 'T 607 , T 900607 , T-607 , T-900607 , T607', 'Gastric, liver, other cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--mitotic inhibitor'),
(1644, 'T904064', NULL, NULL, 'NO', 'Phase II (breast, head & neck, melanoma, NSCLC) Phase III sarcoma Antifolate (neuroprotective). Tularik.', 'Lometrexol , T 904064 , T-904064 , T64', 'Breast, head & neck, lung, sarcoma, skin cancer', NULL, NULL, 'Chemotherapy', 'Antifolate'),
(1645, 'TA-HPV', NULL, NULL, 'NO', 'Phase II Vaccine. Xenova Group.', NULL, 'Cervical cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1646, 'Tacrolimus', NULL, NULL, 'YES', 'Immunosuppressant for transplants', 'Prograf', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1647, 'Tagraxofusp-erzs', NULL, 'blastic plasmacytoid dendritic cell neoplasm (BPDCN)', 'NO', '12/21/2018 FDA approved tagraxofusp-erzs (ELZONRIS™), a CD123-directed cytotoxin, for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older', 'Elzonris', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1648, 'Tagrisso', NULL, 'Non-small cell lung cancer (NSCLC)', 'NO', 'April 19, 2018: FDA approved osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.  \r\n\r\n4/23/2017: FDA granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy.\r\n\r\nNovember 13, 2015: The U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.', 'Osimertinib', 'Lung', NULL, NULL, 'Chemotherapy', 'EGFR-TKI inhibitor'),
(1649, 'Talabostat', NULL, NULL, 'NO', 'Failed Phase III trial for lung; still in clinical trials for other sites Point Therapeutics', 'PT 100 , PT-100 , PT100', 'brain, Lung, melanoma, pancreas', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent--enzyme inhibitor'),
(1650, 'Talacotuzumab', NULL, NULL, 'SEE_REMARKS', 'July 2017: Talacotuzumab is currently in clinical trials and has not been approved by the FDA. Code in \"Other Treatment\" data field and assign code 2.', 'CSL362', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(1651, 'Talactoferrin', NULL, NULL, 'NO', 'Currently being studied in the treatment of kidney cancer that has spread. It is also being studied in the treatment of other types of cancer and other conditions. Code in Other Therapy until FDA approval.', 'Talactoferrin alfa', 'kidney, other sites', 'TLF', NULL, 'Biologic therapy (BRM, immunotherapy)', 'oral recombinant human lactoferrin'),
(1652, 'Talampanel', NULL, NULL, 'NO', 'Phase II NCI', 'GYKI-53773', 'Brain gliomas', NULL, '729898', 'Chemotherapy', 'Cytostatic agent--AMPA receptor antagonist'),
(1653, 'Talaporfin sodium', NULL, NULL, 'YES', 'Radiosensitizer.  Light Sciences Oncology.', 'LS 11 , LS-11 , LS11 , Litx , ME 2906 , Taporfin', NULL, NULL, NULL, 'Ancillary Agent', 'Radiosensitizer'),
(1654, 'Talazoparib', NULL, NULL, 'NO', 'October 16, 2018: FDA approved talazoparib (TALZENNA), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2 negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib', 'Talzenia', 'Breast', NULL, NULL, 'Chemotherapy', 'PARP inhibitor'),
(1655, 'Talc', NULL, NULL, 'YES', 'Intrapleural talc is effective for the treatment of pneumothorax and malignant and nonmalignant pleural effusions. It is considered the agent of choice for chemical pleurodesis. FDA approved sclerosing agent for pleural effusion.', 'Sclerosol', NULL, NULL, NULL, 'Ancillary Agent', 'Sclerosing agent'),
(1656, 'Talisomycin', NULL, NULL, 'NO', NULL, 'BU-2231A , Tallysomycin A#', NULL, NULL, NULL, 'Chemotherapy', 'Antitumor antibiotic'),
(1657, 'Tamoxifen', NULL, NULL, 'NO', 'A nonsteroidal antiestrogenic agent with combined partial-estrogen-agonist activity. FDA approved uses on breast cancer and risk reduction for women with high risk of developing breast cancer.\r\n\r\nLiterature shows that Tamoxifen is being prescribed for recurrent/relapsed ovarian cancer.', 'Alpha-Tamoxifen , Apo-Tamox , Dom-Tamoxifen , Gen-Tamoxifen , ICI-46474 , Nolvadex , Nolvadex-D , Novo-Tamoxifen , PMS-Tamoxifen , Tamofen , Tamone , Tamoplex , Tamoxifen , Tamoxifen Citrate , Soltamox', 'Breast', 'TAM, TMX', '180973', 'Hormones and hormonal mechanisms', 'Nonsteroidal antiestrogen'),
(1658, 'Tanespimycin', NULL, NULL, 'NO', 'Phase II 2007 NCI.', 'KOS-953', 'advanced solid tumors, CLL, NHL, prolymphocytic leukemia', '17-AAG', '330507', 'Chemotherapy', 'Targeted therapy--heat shock protein 90 inhibitor'),
(1659, 'Tapet-CD', NULL, NULL, 'NO', 'Phase II Imidazotetrazine. Schering-Plough, Vion Pharmaceuticals.', 'Tumin Amplified Protein Expression Therapy , VNP20009', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Cytotoxic agent conjugated to weakened bacteria'),
(1660, 'Tariquidar', NULL, NULL, 'YES', 'Phase II/III lung; Phase II ovarian, cervix, lung 2007 P-glycoprotein pump inhibitor. QLT, Xenova Group.', 'XR 9576 , XR-9576 , XR9576', 'Breast, Cervix, Lung, Ovarian cancer', NULL, NULL, 'Ancillary Agent', 'Reverses drug resistance'),
(1661, 'Taurolin', NULL, NULL, 'YES', 'Phase I (breast, lung) Phase II (brain) Phase III (ovarian) Broad spectrum antibiotic apoptosis. No apparent activity against malignancy.  Carter-Wallace, Bristol-Myers Squibb.', 'TAS-103 , Taurolidine', 'Brain, Breast, Lung, Ovarian cancer', NULL, NULL, 'Ancillary Agent', 'Anti-infective'),
(1662, 'Tavokinogene telsaplasmid', NULL, 'Metastatic melanoma', 'NO', 'June 16, 2017 FDA has granted the orphan drug designation for pIL-12, otherwise known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma. Tavokinogene telsaplasmid is the active biologic agent in OncoSec’s lead product candidate, ImmunoPulse IL-12.', 'pIL-12', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1663, 'Taxane IV', NULL, NULL, 'NO', 'Phase I NSCLC Taxoid. Bayer Pharmaceuticals.', NULL, 'Brain, lung cancer', NULL, NULL, 'Chemotherapy', 'Taxane'),
(1664, 'Taxoprexin', NULL, NULL, 'NO', 'Phase II, Phase II NSCLC, Phase II/III melanoma Taxane. Protarga.', 'DHA-paclitaxel', 'Breast, colorectal, gastric, kidney, lung, pancreatic, prostate, skin cancer', NULL, NULL, 'Chemotherapy', 'Taxane'),
(1665, 'Taxotere and Calcitriol', NULL, NULL, 'NO', 'Phase II Taxane and synthetic vitamin D analog. Aventis Pharmaceuticals.', NULL, 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'combination chemo'),
(1666, 'Taxotere, Adriamycin & Cytoxan', NULL, NULL, 'NO', 'Phase III Taxane, anthracycline antibiotic and antineoplastic agent. Aventis.', NULL, 'Breast cancer', NULL, NULL, 'Chemotherapy', 'combination chemo'),
(1667, 'Tazemetostat', NULL, 'Malignant rhabdoid tumors', 'SEE_REMARKS', 'February 12, 2016: The FDA granted orphan drug status to tazemetostat, and EZH2 inhibitor for malignant rhabdoid tumors.\r\n\r\nCODING: this drug is currently in phase I and phase II studies. Code in Other Treatment, assign code 2.', 'EPZ-6438', NULL, NULL, NULL, 'Chemotherapy', 'EZH2 inhibitor'),
(1668, 'Tazobactam', NULL, NULL, 'YES', 'A penicillinanic acid sulfone derivative and beta-lactamase inhibitor; given I.V. in combination with piperacillin sodium to treat bacterial infections.', 'CL-307579 , Tazobactam sodium , Tazocin , YTR 830', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1669, 'Tazverik', NULL, 'Epithelioid sarcoma', 'NO', 'January 23, 2020 The FDA granted accelerated approval to tazemetostat (TAZVERIK) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.', 'Tazemetostat hydrobromide', 'Soft tissue', NULL, NULL, 'Chemotherapy', 'SAM inhibitor'),
(1670, 'TBC-CEA', NULL, NULL, 'NO', 'Phase I/II (colorectal) Phase I/II NSCLC Vaccine. Therion Biologics.', 'Recombinant Vaccinia--CEA', 'Colorectal, lung cancer', NULL, '678893', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1671, 'Tegafur', NULL, NULL, 'NO', 'Antineoplastic agent.', 'Florafur , Fluaid , Fluorofur , FT-207 , Ftorafur , Futraful , MJF-12264 , Uracil , WR-220066', NULL, 'FT, UFT', '148958;719164', 'Chemotherapy', 'Antimetabolite'),
(1672, 'Telcyta', NULL, NULL, 'NO', 'Phase II, Phase II NSCLC Cytotoxic (anti-GST-P1-1). Telik, NCI, SuperGen.', 'TLK286', 'Breast, colorectal, lung, ovarian cancer', NULL, NULL, 'Chemotherapy', 'Glutathione analog'),
(1673, 'Telintra', NULL, NULL, 'YES', 'Phase II MDS de novo AML Small molecule myelostimulant. Telik.', 'TLK199', 'Leukemia', NULL, NULL, 'Ancillary Agent', 'Stimulates production of white blood cells in marrow'),
(1674, 'Telomerase Cancer Vaccine', NULL, NULL, 'NO', 'Phase I Geron.', 'GRN163L telomerase inhibitor , Imetelstate', 'Pancreatic  caner', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immuntherapy active'),
(1675, 'Temozolomide', NULL, NULL, 'NO', 'Phase II NSCLC An alkylating agent. FDA approved therapy in anaplastic astrocytoma. Schering-Plough.', 'CCRG-81045 , MB-39831 , Methazolastone , RP-46161 , Sch-52365 , Temodal , Temodar', 'Lung, other cancer', NULL, '021029;362856', 'Chemotherapy', 'Alkylating agent'),
(1676, 'Tempostatin', NULL, NULL, 'NO', 'Phase II Extracellular matrix protein inhibitor. Collgard Pharmaceuticals.', NULL, 'Bladder cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--extracellular matrix protein inhibitor'),
(1677, 'Temsirolimus', NULL, NULL, 'NO', 'FDA approved for renal cell carcinoma of the kidney 2007; in trials for  breast, colorectal, lung, pancreatic, prostate, sarcoma.  Second generation mTOR inhibitor.\r\n\r\nNOTE: this drug is a type of rapamycin analog/rapamycin ester and should not be confused with the drug \"Rapamycin, NOS\" which is used to treat GVHD (graft versus host disease) for transplant patients. Careful review of the medical record should be done to dtermine which drug was given and for what reason.', 'AP23573 , CCI 779 , CCI-779 , CCI779 , Torisel , rapamycin analog , rapamycin ester', 'Kidney, Mantle cell lymphoma, breast, colorectal, lung, ovarian, pancreatic, prostate cancer, sarcoma', NULL, '683864', 'Chemotherapy', 'Cytostatic agent--antiangiogenic agent;mTOR inhibitor'),
(1678, 'Teniposide', NULL, NULL, 'NO', 'Derivative of podophyllotoxin with antineoplastic activity; plant alkaloid. FDA approved use in pediatric refractory ALL.', 'Epipodophyllotoxin , Thenylidene , Thenylidene-lignan-P , Vee M-26 , Vehem , VM-26 , Vumon', NULL, 'EPT, PTG', '122819', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1679, 'Terameprocol', NULL, NULL, 'NO', 'Phase I solid tumors 2007; Phase II gliomas 2007 Transcription inhibitor.  Prevents cell replication and enhances body\'s ability to eliminate abnormal cells through cell death. Erimos Pharmaceuticals.', 'EM-1421', 'Gliomas, solid tumors', 'NGDA', NULL, 'Chemotherapy', 'Cytostatic agent--apoptosis inducer'),
(1680, 'Terconazole', NULL, NULL, 'YES', 'A triazole antifungal agent (topical) for the treatment of vulvovaginal candidiasis.', 'R-42470 , Terazol , Triaconazole', NULL, NULL, NULL, 'AIDS drug', NULL),
(1681, 'Terephthalamidine', NULL, NULL, 'NO', NULL, 'Glycidyl isocyanurate , Henkel\'s compound , Symetamine Alpha TGI , Triazinetrione-triepoxide , XB 2615', NULL, NULL, '57155', 'Chemotherapy', 'Unclassified antineoplastic'),
(1682, 'Teroxirone', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '296934', 'Chemotherapy', 'Alkylating agent'),
(1683, 'Tesmilifene Hydrochloride', NULL, NULL, 'YES', 'Phase II Intracellular histamine antagonist. YM Biosciences.', 'BMS-217380-01 , BMY-33419', 'Breast, Prostate cancer', 'DPPE', NULL, 'Ancillary Agent', 'Chemopotentiator'),
(1684, 'Testolactone', NULL, NULL, 'NO', 'A synthetic testosterone derivative.   Produced by microbial transformation of progesterone, testosterone, or other steroidal substances, FDA approved use as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women; administered orally or by intramuscular injection.', '1-Dehydrotestololactone , Fludestrin , SQ-9538 , Teolit , Teslac , Teslak , Testolacton', 'Breast cancer', 'TL', '023759;23759', 'Hormones and hormonal mechanisms', 'Androgen'),
(1685, 'Testosterone', NULL, NULL, 'YES', 'An androgenic anabolic steroid; the major androgenic hormone produced by the interstitial cells of the testes in response to stimulation by the luteinizing hormone of the adenohypophysis; it regulates gonadotropic secretion and wolffian duct differentiation (formation of the epididymis, vas deferens, and seminal vesicle), and stimulates skeletal muscle.', 'Andro 100 , Androderm , Androgel , Android , Androlan Aqueous , Androlin , Andronag-50 , Androplex , Component of Androgyn L.A. , Depotest , Histerone , Malogen Aqueous , Mertestate# , Oreton# , Shotest , Sterotate , Synandrol F , Tesamone , Tesandro , Testalong , Testoderm , Testoject , Testolin , Testopel , Testosteroid', NULL, NULL, '9700', 'Hormones and hormonal mechanisms', 'Androgen'),
(1686, 'Testosterone Cypionate', NULL, NULL, 'NO', 'Androgen; an ester of testosterone, having the same actions as the free alcohol but a prolonged duration of effect; used chiefly in the treatment of male hypogonadism, frigidity, and inoperable female breast cancer, to suppress lactation, and as an anabolic agent, administered by intramuscular injection.', 'Andro-Cyp 200 , Andronaq-LA , Andronate , Component of Depo-Testadiol , DepAndro , DepAndro 100 , DepAndro 200 , Depo-Testosterone , Depo-Testosterone Cypionate , Depostomead , Depotest , Depovirin# , Durandro , Duratest , Laogen Cyp , Scheinpharm Testone-Cyp , T-Cypionate , T-Ionate PA , Testa-C , Testamone , Testred , Virilon', 'Breast cancer', NULL, '9157', 'Hormones and hormonal mechanisms', 'Androgen'),
(1687, 'Testosterone Enanthate', NULL, NULL, 'YES', 'Androgen; an ester of testosterone, having the same actions as the free alcohol but a prolonged duration of effect; used chiefly in the treatment of male hypogonadism, oligospermia, and the symptoms of male climacteric, administered by intramuscular injection.', 'Andro LA 200 , Androgen L.A. , Andropository , Andryl , Arderone , Component of Androgyn L.A. , Component of Deladumone , Component of Ditate# , Delatest , Delatestryl , Durathate , Everone , Malogen LA , Malogex , PMS-Testosterone Enanthate , Testate , Testone LA , Testosterone Heptanoate , Testostroval PA , Testrin PA , Testrone CA', NULL, NULL, '017591;17591', 'Hormones and hormonal mechanisms', 'Androgen'),
(1688, 'Testosterone Ketolaurate', NULL, NULL, 'YES', 'Androgen; an ester of testosterone, having the same actions as the other esters.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen'),
(1689, 'Testosterone Phenylacetate', NULL, NULL, 'YES', 'Androgen; an ester of testosterone, having the same actions as the other esters.', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'No longer in use'),
(1690, 'Testosterone Propionate', NULL, NULL, 'NO', 'Androgen; an ester of testosterone, having the same actions as the free alcohol but with a relatively short duration of effect; used chiefly in the treatment of male hypogonadism, symptoms of male climacteric, postpubertal cryptorchidism, and inoperable female breast cancer, and to prevent postpartum breast engorgement; administered buccally or intramuscularly.', 'Androlan in oil , Malogen in oil , Oreton Propionate , Synandrol , Synerone# , Testex', 'Breast cancer', 'TP', '009166;9166', 'Hormones and hormonal mechanisms', 'Androgen'),
(1691, 'Testosterone Undecanoate', NULL, NULL, 'YES', 'Androgen; an ester of testosterone, having the same actions as the other esters.', 'Andriol', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Androgen'),
(1692, 'Tetrahydrocannabinol', NULL, NULL, 'YES', 'Psychoactive cannabinoid, antiemetic.', 'Cannabinol , Delta-9-THC , Dronabinol , Marihuana , Marijuana , Marinol , SP-104', NULL, 'THC', '134454', 'Ancillary Agent', NULL),
(1693, 'Tetrahydrouridine', NULL, NULL, 'NO', 'Phase I advanced solid tumors 2007 Cytidine deaminase inhibitor.', NULL, 'Advanced solid tumors', 'H4URD, THU', '112907', 'Chemotherapy', 'Antimetabolite'),
(1694, 'Tetrandrine', NULL, NULL, 'NO', NULL, 'D-Tetrandrine , LKT-T1777 , Tetrandirine , Tetrandrin', NULL, NULL, '77037', 'Chemotherapy', 'Apoptosis inducer'),
(1695, 'Tetraplatin', NULL, NULL, 'NO', NULL, '233 , Ormaplatin , U 77233 , U-77 , U-77233 , U77233', NULL, NULL, '363812', 'Chemotherapy', 'Miscellaneous agent'),
(1696, 'Tetrathiomolydate', NULL, NULL, 'NO', 'Phase II Used in breast cancer. neoadjevant treatment with radiation for esophageal cancer. Code in Other therapy', 'Tetrathiomolydate , TM', 'Breast, esophageal', NULL, NULL, 'Chemotherapy', 'Antiangiogenic agent'),
(1697, 'Teverlix', NULL, NULL, 'NO', 'Phase I LNRH antagonist. AEterna Laboratories.', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'LHRH antagonist'),
(1698, 'Tezacitabine', NULL, NULL, 'NO', 'Phase I/II (colorectal, other) Phase II (AML, NSCLC, ovarian) Nucleotide analog. Matrix Pharmaceuticals; Chiron.', 'FMdC , KW-2331 , MDL 101731', 'Colorectal, leukemia, lung, other cancer, ovarian', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1699, 'tgDCC-E1A', NULL, NULL, 'NO', 'Phase II E1A tumor suppressor gene therapy. Targeted Genetics.', NULL, 'Head & neck, ovarian cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1700, 'TGF-Beta', NULL, NULL, 'NO', 'Phase I Vaccine. Immune Response Corp.', NULL, 'Brain cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1701, 'TH-302', NULL, NULL, 'NO', 'Phase I&II', 'HAP TH-302', 'lung, pancreas, prostate, Soft tissue', NULL, NULL, 'Chemotherapy', 'Hypoxia-activated prodrug'),
(1702, 'Thalicarpine', NULL, NULL, 'NO', NULL, 'Taliblastine , Thaliblastine , Thalicarpin', NULL, 'TC', '68075', 'Chemotherapy', 'Plant product'),
(1703, 'Thalidomide', NULL, NULL, 'NO', 'FDA approved for multiple myeloma 2006; Phase II brain, kidney, liver, lung, leukemia, HD, NHL,  melanoma Phase III prostate Tumor Necrosis Factor inhibitor; angiogenesis inhibitor; immunomodulator. Celgene, NCI.', 'K-17 , Kevadon , Synovir , Thalomid', 'Brain, kidney, leukemia, liver, lung, lymphoma, multiple myeloma, prostate, skin cancer', NULL, '66847', 'Biologic therapy (BRM, immunotherapy)', 'Antiangiogenic agent for most indications'),
(1704, 'Theophylline', NULL, NULL, 'YES', 'A bronchial smooth muscle relaxant and a suppressor of non-bronchodilator response of airways to stimuli (bronchodilator).', 'Aerolate , Elixophyllin , Quibron , Respbid , Slo-bid , Slo-Phyllin , Somophyllin , Theo-24 , Theo-Dur , Theo-X , Theolair , Uni-Dur , Uniphyl', NULL, NULL, '2066', 'Ancillary Agent', NULL),
(1705, 'Theprubicin', NULL, NULL, 'NO', NULL, NULL, NULL, 'THP', NULL, 'Chemotherapy', 'Anthracycline'),
(1706, 'TheraFab', NULL, NULL, 'NO', 'Phase I Fab2 fragment of Pemtumomab linked to Y-90. Antisoma.', 'AS 1403 , AS-1403 , AS1403', 'Lung cancer', NULL, NULL, 'Radiation', 'Radioisotope conjugated to monoclonal antibody'),
(1707, 'Therasphere', NULL, NULL, 'NO', 'Yttrium 90  imbedded in glass microspheres embolized in liver near the tumor.  MDS Nordion', NULL, 'Liver', NULL, NULL, 'Radiation', 'Radioisotope'),
(1708, 'Theratope and Detox-B', NULL, NULL, 'NO', 'Phase III Vaccine for adenocarcinoma. Biomira', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'combination immunotherapy'),
(1709, 'Theratope Vaccine', NULL, NULL, 'NO', 'Phase III Biomira.', NULL, 'Breast, colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1710, 'Therex', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. Antisoma.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunomodulator'),
(1711, 'Thiabendazole', NULL, NULL, 'YES', 'An antiparasitic agent for the treatment of various helminths; Rx of strongyloidiasis', 'Mintezol', NULL, NULL, NULL, 'AIDS drug', NULL),
(1712, 'Thiamiprine', NULL, NULL, 'NO', NULL, 'BW-57-323 , Guaneran , Tiamiprine', NULL, 'ITG', '38887', 'Chemotherapy', 'Antimetabolite'),
(1713, 'Thioguanine', NULL, NULL, 'NO', 'A purine analogue antineoplastic agent; antimetabolite. FDA approved use for acute non-lymphocytic leukemia.', '6-Mercaptoguanine , 6-Thioguanine , Lanvis , Tabloid , Tioguanin , WR-1141', NULL, '6-TG, TG, TT-6, TT-G', '752;000752', 'Chemotherapy', 'Antimetabolite'),
(1714, 'Thiotepa', NULL, NULL, 'NO', 'Cell cycle nonspecific chemotherapeutic agent. FDA approved uses on intravesicular bladder carcinoma, breast adenocarcinoma, malignant intracavitary effusions, Hodgkin\'s lymphoma, lymphosarcoma, and ovarian adenocarcinoma. Alkylating agent.', 'Oncotepa , Oncotiotepa , Tepa , Tespa , Tespa-min , Tespamine , Thio , Thio-tepa , Thiofozil , Thiophosphamide , Thioplex , Thiotef , Tifosyl , Tio-TEF , Tiofosfamid , Tiofosyl (Sweden) , Tiofozil , Triethylene thiophosphoramide , WR-45312', NULL, 'STEPA, TESP, TESPA, Thio-TEPA, TSP, TSPA', '006396;6396', 'Chemotherapy', 'Alkylating agent'),
(1715, 'Thymic Humoral Factor', NULL, NULL, 'YES', 'Thymic humoral factor possesses immunomodulator properties and was undergoing phase I studies in HIV-positive patients (Anon, 1989). Adria Laboratories (Dublin, OH), the manufacturer of thymic humoral factor, is discontinuing further research and distribution of this agent effective at the end of 1995. Increases number of T-lymphocytes and augments cell-mediated immunity.', NULL, NULL, 'THF', NULL, 'AIDS drug', NULL),
(1716, 'Thymidine', NULL, NULL, 'NO', 'Has not proven useful as an antineoplastic agent (from Drug Consults).', '5-Methyldeoxyuridine , Deoxythymidine , Thymidin , Thymine deoxyriboside', NULL, 'DT, DThyd, TdR', '21548;021548', 'Chemotherapy', NULL),
(1717, 'Thymitaq', NULL, NULL, 'NO', 'Phase II (colorectal, NSCLC, pancreatic) Phase III (liver) Thymidine synthase inhibitor. Zarix, Eximias Pharmaceuticals..', 'AG 337 , AG-337 , AG337 , Nolatrexed Dihydrochloride', 'Colorectal, liver, lung, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1718, 'Thymopentin', NULL, NULL, 'YES', 'A derivative of thymopoietin. It possesses immunomodulatory activity. Regulates and enhances function of peripheral T cells', 'Imunox , ORF 15244', NULL, 'TP-5', '645363', 'AIDS drug', NULL),
(1719, 'Thymosin alpha 1', NULL, NULL, 'NO', 'Pre-clinical (breast) Phase II (liver, melanoma) A thymic peptide with immunomodulatory activity. SciClone Pharmaceuticals.', 'Human thymosin-fraction Alpha 1 (Mammalian biological product) (Thymosins) , Thymalfasin , Timosin , Zadaxin', 'Breast, liver, skin cancer', NULL, '337793', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1720, 'Thymosin fraction 5', NULL, NULL, 'NO', 'A thymic peptide with immunomodulatory activity. Designated an orphan product for use in the treatment of chronic active hepatitis B, hepatocellular carcinoma and DiGeorge anomaly with immune defects. Thymalfasin is a component of thymosin fraction 5 (a crude thymus gland extract).', NULL, NULL, 'TF5', '350391', 'Biologic therapy (BRM, immunotherapy);AIDS drug', NULL),
(1721, 'Thyroglobulin', NULL, NULL, 'NO', 'A natural hormone derived from animal sources. No longer recommended due to the superiority of synthetic agents.  An iodine-containing glycoprotein of high molecular weight found in the colloid of thyroid gland follicles; it is made by the follicular cells and secreted into the follicular lumen where it is iodinated, after which its iodinated tyrosyl moieties form the iodothyronines thyroxine and triiodothyronine. Thyroglobulins are then taken up by endocytosis into the follicular cells, where the iodothyronines are liberated by proteolysis, followed by release into the extracellular fluid and then to the blood stream.', 'Proloid , Thyractin# , Thyroprotein#', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Thyroid hormone.  Probably not cancer directed--verify with attending MD.'),
(1722, 'Thyroid', NULL, NULL, 'NO', 'Synthetic thyroid agents preferred.  A slang name for the cleaned, dried, and powdered thyroid gland, previously deprived of connective tissue and fat, obtained from domesticated food animals; formerly used as a source of thyroid hormones in the treatment of hypothyroidism.', 'Armour Thyroid , Dry thyroid , Nature Thyroid , Noroxine , S-P-T , Thyrar , Thyreoidin , Thyro-Teric , Thyrocrine , Thyroid , Thyroid Enseals , Thyroid extract , Thyroid gland , Thyroid Strong , Thyroidea , Thyroideum siccum , Tiroide secca , Westhroid', NULL, NULL, '26492;026492', 'Hormones and hormonal mechanisms', 'Thyroid hormone.  Probably not cancer directed--verify with attending MD.'),
(1723, 'Thyrotropin', NULL, NULL, 'NO', 'A highly purified and lyophilized thyrotropic hormone isolated from bovine anterior pituitary.  Glycoprotein hormone that promotes the growth of, sustains, and stimulates the hormonal secretion of the thyroid gland.', 'Thyroid stimulating hormone , Thyrotrophic hormone , Thyrotrophin , Thytropar , TSH', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Thyroid hormone.  Probably not cancer directed--verify with attending MD.'),
(1724, 'TI Lymphs-N2-transduced', NULL, NULL, 'NO', NULL, 'TIL transduced with NEOR Gene IL-2 (NHLBI)', NULL, NULL, '622283', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1725, 'Tiazofurin', NULL, NULL, 'NO', 'Phase III CML  Phase II MM C-nucleoside. ICN Pharmaceuticals.', 'CI 909 , CI-909 , CI909 , Riboxamide , Tiazole', 'Leukemia, multiple myeloma', 'TCAR', '286193', 'Chemotherapy', 'Antimitotic'),
(1726, 'TIBO derivatives', NULL, NULL, 'YES', 'Non-nucleoside reverse transcriptase inhibitor', 'R 62913 , R-62913 , R62913', NULL, NULL, NULL, 'AIDS drug', NULL),
(1727, 'TIC-mustard', NULL, NULL, 'NO', 'Miscellaneous agent', 'Imidazole mustard , Imididazole-carboximide , TIC NH2', NULL, 'BIC, BTIC, TIC', '82196', 'Chemotherapy', 'Alkylating agent'),
(1728, 'Ticilimumab', NULL, NULL, 'NO', 'Monoclonal antibody that activates T-cells to seek out and destroy cancer cells.  Pfizer, Abgenix.', '206 , CP-675 , CP-675206 , CP675206 , Tremelimumab', 'Melanoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1729, 'Tigestol', NULL, NULL, 'NO', 'Progestin', NULL, 'Prostate cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Progestin'),
(1730, 'TIL Transd TIL (GTI)', NULL, NULL, 'NO', 'Tumor infiltrating lymphocytes transduced with the tumor necrosis factor gene (Retrovirus vector TNF-NeoR-GTI); TIL transduced/gene coding for TNF', NULL, NULL, NULL, '637656', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1731, 'TIL transduced with NEOR Gene IL-2/IL (Cetus/Sterling/GTI)', NULL, NULL, 'NO', NULL, 'TIL transduced with NEOR Gene IL-2/IL (Cetus/Sterling/GTI)', NULL, NULL, '622283', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1732, 'TIL transduced with NEOR Gene IL-2/IL-4 (Cetus/Sterling)', NULL, NULL, 'NO', NULL, 'TIL transduced with NEOR Gene IL-2/IL-4 (Cetus/Sterling)', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1733, 'TIL transduced/Gene coding for TNF', NULL, NULL, 'NO', NULL, 'TIL transduced/Gene coding for TNF', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1734, 'TIL transduced/Gene coding for TNF (Cetus)', NULL, NULL, 'NO', NULL, 'TIL transduced/Gene coding for TNF (Cetus)', NULL, NULL, '636228', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1735, 'TIL/TNF', NULL, NULL, 'NO', 'Retroviral vector carrying gene coding for tumor necrosis factor (PA 317/LTNFSN) (Cetus)', NULL, NULL, NULL, '636228', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1736, 'Tilorone', NULL, NULL, 'NO', '(Synthetic Chemical) (Immunomodulator and Interferon inducer', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1737, 'Timp-2', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, 'Chemotherapy', 'Tissue inhibitor of metalloproteinases'),
(1738, 'Tioconazole', NULL, NULL, 'YES', 'Antifungal; nonprescription (over-the-counter) drug in the United States.', 'Gynecure , Gyno-Trosyd , Monistat 1 , Trosyd , Vagistat , Vagistat-1', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1739, 'Tipifarnib', NULL, NULL, 'NO', 'Phase II/III (breast, cervical, colorectal, AML, NSCLC, pancreatic) Phase II MM Farnesyl transferase inhibitor. Janssen Pharm., OrthoBiotech, Johnson & Johnson.', 'R115777 , Zarnestra', 'Breast, cervical, colorectal, leukemia, lung, multiple myeloma, pancreatic cancer', NULL, '702818', 'Chemotherapy', 'Cytostatic agent--farnesyl transferase inhibitor'),
(1740, 'Tirapazamine', NULL, NULL, 'NO', 'Phase III NSCLC, ovarian, pancreatic A bioreductive antitumor agent. Has been investigated primarily in combination with cisplatin. Antitumor activity of the combination has been observed in non-small-cell lung cancer and malignant melanoma. Sanofi-Synthetlabo.', 'SR-4233 , Tirazone , WIN-59075', 'Lung, ovarian, pancreatic cancer', NULL, '130181', 'Ancillary Agent', 'Radiosensitizer'),
(1741, 'Tisagenlecleucel', NULL, 'Acute lymphoblastic leukemia, DLBCL', 'NO', '5/1/2018 FDA approved tisagenlecleucel (KYMRIAH) a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma\r\n\r\nSeptember 1, 2017: Kymriah (tisagenlecleucel) became the first gene therapy available in the United States.  The agent, sponsored by Novartis Pharmaceuticals Corp., was approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia.', 'Kymriah', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1742, 'Tivantinib', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', 'ARQ 197', 'hepatocellular, lung, solid tumors', NULL, NULL, 'Chemotherapy', 'Tyrosine kinase inhibitor'),
(1743, 'TL-139', NULL, NULL, 'NO', 'Phase I lung, Preclinical other Taxane. Wyeth Pharmaceuticals.', 'MAC 321 , MAC-321 , MAC321 , TL 139 , TL139', 'Lung, other cancer', NULL, NULL, 'Chemotherapy', 'Taxane'),
(1744, 'TLC ELL-12', NULL, NULL, 'NO', 'Phase I NSCLC, other Liposomal ether lipid. Liposome Co, Elan Pharmaceuticals..', 'ELL-12 , L-ET-18-OCH(3)', 'Breast, lung and prostate cancers, melanoma', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(1745, 'TLC G-65', NULL, NULL, 'YES', 'Rx of Mycobacterium Avium Complex', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1746, 'TMCA', NULL, NULL, 'NO', NULL, 'Citostal , Methyl ether , SKF 104864-A', NULL, 'TNCA', '36354', 'Chemotherapy', 'No longer in use'),
(1747, 'TNF alpha gene therapy', NULL, NULL, 'NO', 'Phase I Gene therapy. GenVec', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1748, 'TNFerade', NULL, NULL, 'NO', 'Phase II gastric, pancreatic Phase I sarcoma TNFa gene radiation and responsive promoter. GenVec.', NULL, 'Esophageal, gastric, pancreatic cancer, sarcoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Gene therapy'),
(1749, 'TNP-470', NULL, NULL, 'NO', 'Phase II Angiogenesis inhibitor. TAP Pharmaceuticals.', 'AGM-1470# , Fumagillin , TNM 470 , TNP470', 'Other cancer', NULL, '642492', 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1750, 'Toca 511', NULL, 'Glioblastoma, anaplastic astrocytoma', 'SEE_REMARKS', 'July 19, 2015: U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. This drug has not yet received final approval. code as Other Treatment and assign code 2.', 'Toca FC', 'Brain', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1751, 'Tocladesine bC1.cAMP', NULL, NULL, 'NO', 'Phase I ICN Pharmaceuticals.', NULL, 'Colon cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--protein kinase inhibitor'),
(1752, 'TOCOSOL', NULL, NULL, 'NO', 'Phase II Taxane. Sonus Pharmaceuticals.', 'S-8184 , TOCOSOL Paclitaxel', 'Bladder, breast, colorectal, lung, ovarian cancers', NULL, NULL, 'Chemotherapy', 'Taxane'),
(1753, 'Tomudex', NULL, NULL, 'NO', 'Phase II other, Phase III colorectal Antimetabolite. AstraZeneca.', 'Paltitrexed , Raltitrexed , ZD-1694', 'Colorectal, other cancer', NULL, '639186', 'Chemotherapy', 'Antimetabolite'),
(1754, 'Topotecan', NULL, NULL, 'NO', 'Phase II (colorectal, NSCLC) Phase II/III SCLC Phase III MDS, ovarian Topoisomerase I inhibitor. FDA approved use on small cell lung cancer and ovarian cancer. GlaxoSmithKline.', '11C topotecan , Hycamtin , SKF-104864 , Topotecan Hydrochloride', 'cervix, Colorectal, leukemia, lung, ovarian cancer, small cell lung', 'SKFS', '609699', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1755, 'Toremifene Citrate', NULL, NULL, 'NO', 'Phase III An antiestrogen agent chemically related to tamoxifen. FDA approved for advanced breast cancer. Orion', 'Fareston , FC-1157a', 'Breast', NULL, NULL, 'Hormones and hormonal mechanisms', 'Antiestrogen'),
(1756, 'Total body irradiation', NULL, NULL, 'NO', 'Listed in some regimens', NULL, NULL, 'TBI', NULL, 'Radiation', 'Code in Radiation field'),
(1757, 'Toyocamycin', NULL, NULL, 'NO', NULL, 'Antibiotic 1037 , Antibiotic E 212 , Toyokamycin , Unamycin B , Vengicide', NULL, NULL, '63701', 'Chemotherapy', 'Antitumor antibiotic'),
(1758, 'TP OKT 3 Lymphocytes', NULL, NULL, 'YES', 'Ortho-Biotech.  Immunosuppressant. Monoclonal antibody reduces body\'s natural immunity in patients who receive organ (for example, kidney) transplants.', 'Muromonab CD3 , Orthoclone OKT3 , Tumor primed OKT3', NULL, NULL, '618843', 'Ancillary Agent;Biologic therapy (BRM, immunotherapy)', 'Immunosuppressant for transplantation'),
(1759, 'TP-38', NULL, NULL, 'NO', 'Phase II Recombinant chimeric protein. Ivax Corp.', 'TP 38 , TP38', 'Brain cancer', NULL, '726586', 'Chemotherapy', 'Immunotoxin conjugated with protein'),
(1760, 'Trabectedin', NULL, NULL, 'NO', 'This drug treats a variety of tumors. It has recently received orphan drug status for the treatment of soft tissue sarcoma including liposarcoma and leiomyosarcoma subtypes.', 'ET-743 , ET743 , Ecteinascidin 743 , R 279741 , R-279741 , R279741 , Yondelis', 'Breast, Ewing\'s family of tumors, endometrial, leiomyosarcoma, melanoma, other, ovarian cancer, sarcoma, soft tissue sarcoma', NULL, '648766', 'Chemotherapy', 'Natural product'),
(1761, 'TRAIL-R1 MoAb', NULL, NULL, 'NO', 'Phase I Human Mab for TRAIL receptor 1 protein. Human Genome Sciences.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(1762, 'TRAIL-R2 MoAb', NULL, NULL, 'NO', 'Pre-clinical Human Mab for TRAIL receptor 2 protein. Human Genome Sciences.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(1763, 'TRAIL/AP02 Ligand', NULL, NULL, 'NO', 'Phase II NSCLC 2007 Tumor necrosis factor.  TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing ligand).  Genentech, Immunex.', 'AMG 951 , AMG-951 , AMG951 , rhApo2L/TRAIL', 'NSCLC, other cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(1764, 'Tralonide', NULL, NULL, 'NO', 'Glucocorticoid', NULL, NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'No longer in use'),
(1765, 'Trametinib', NULL, NULL, 'NO', 'Trametinib received FDA approval May 29, 2013 for the treatment of metastatic or unresectable melanoma.\r\nJune 30, 2017 FDA granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist) administered in combination for patients with metastatic non-small cell lung cancer with BRAF V600E mutation as detected by an FDA-approved test. The two agents, sponsored by Novartis, are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC.\r\n\r\n5/4/2018 The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).', 'Mekinist', 'Melanoma, Thyroid', NULL, '763093', 'Chemotherapy', 'MEK inhibitor'),
(1766, 'Trans-Retinoic Acid', NULL, NULL, 'YES', 'Phase II Retinoid. NCI.', NULL, 'Leukemia, skin cancer', NULL, NULL, 'Differentiation inducing agent', NULL),
(1767, 'TransMID-107R', NULL, NULL, 'NO', 'Phase III Transferin mediated delivery of diphtheria toxin. KS Biomedix.', NULL, 'Brain cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin conjugated with transferin'),
(1768, 'Trastuzumab', NULL, NULL, 'NO', 'JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Herceptin is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Herceptin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this as chemotherapy.\r\n\r\nPhase II (breast, colorectal, lung) Phase III (ovarian, prostate)\r\nAnti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI.\r\nFDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarinoma who have not received prior treatment for metastatic disease.', 'Anti-c-erbB2 monoclonal antibody , Anti-erbB2 monoclonal antibody , Anti-HER2 monoclonal antibody , Anti-HER2/c-erbB2 monoclonal antibody , Anti-p185-HER2 monoclonal antibody , HER2 Mab , HER2 monoclonal antibody , HER2/neu Mab , HER2/neu monoclonal antibody , Herceptin', 'Breast, colorectal, lung, ovarian, pancreatic, prostate cancer', NULL, '688097', 'Biologic therapy (BRM, immunotherapy)', 'Targeted therapy--epidermal growth factor receptor'),
(1769, 'Trastuzumab Deruxtecan', NULL, NULL, 'NO', 'December 17, 2019 The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.', 'fam-trastuzumab deruxtecan nxki', 'Breast', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'antibody drug-conjugate;monoclonal antibody'),
(1770, 'Trastuzumab-DM1', NULL, NULL, 'NO', 'Pre-clinical Toxin conjugated HER2 monoclonal antibody. Genentech.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Conjugate'),
(1771, 'Trazimera', NULL, NULL, 'NO', '3/11/2019 FDA today approved Trazimera (trastuzumab-qyyp), a biosimilar to U.S.-licensed Herceptin (trastuzumab).', 'trastuzumab-qyyp', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Biosimilar'),
(1772, 'Treosulfan', NULL, NULL, 'NO', 'Phase II AML, ALL, MDS 2007 Alkylating agent is used for the treatment of ovarian carcinoma.', 'CB-2562', 'ALL, AML, MDS', NULL, '39069', 'Chemotherapy', 'Alkylating agent'),
(1773, 'Trestolone Acetate', NULL, NULL, 'YES', 'Antineoplastic; androgen', '614 , Nortestosterone , U-15', NULL, NULL, '69948', 'Hormones and hormonal mechanisms', 'No longer in use'),
(1774, 'Tretinoin', NULL, NULL, 'SEE_REMARKS', 'Tretinoin is FDA approved for treatment of acute promyelocytic leukemia (APL). It is a retinoid/differentiation agent and at this time the precise mechanism of action has not been fully elucidated so it cannot be assigned to chemotherapy, hormone or BRM/immunotherapy. Code this agent as treatment in the \"Other Therapy\" data field (using code 1).\r\n\r\nPhase II (head & neck)\r\nAdministered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness.  Under investigation for treatment of Kaposi sarcoma lesions.  FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the \"Other Therapy\" data field (using code 1).', 'Aberel , Airol , All-trans-retinoic acid , Avita , Dermairol , Eudyna , Renova , Retin-A , Retinoic acid , Retisol-A , Stieva-A , Vesanoid , Vitamin A Acid , Vitinoin', 'Acute Promyelocytic leukemia (APL), AIDS, head & neck cancer, Opportunistic infection', 'ATRA, Vit A', '122758', 'Differentiation inducing agent', NULL),
(1775, 'TriAb (anti-idiotype antibody)', NULL, NULL, 'NO', 'Phase II (breast ovarian) Phase I (lung) Monoclonal antibody. Titan Pharmaceuticals.', NULL, 'Breast, lung, ovarian cancer', NULL, '724593', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1776, 'TRIAL Receptor 1 Mab', NULL, NULL, 'NO', 'Phase I Human Genome Sciences.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Apoptosis inducer'),
(1777, 'Triamcinolone', NULL, NULL, 'NO', 'A fluorinated prednisolone derivative with less mineralocorticoid activity than prednisolone; a synthetic glucocorticoid used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered orally.', 'Aristo-Pak , Aristocort , Atolone , CL-106359 , CL-61965 , Fluoxiprednisolonum , Kenacort , SK-Triamcinolone', NULL, NULL, '13397', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1778, 'Triamcinolone Acetonide', NULL, NULL, 'NO', 'Glucocorticoid; the acetonide ester of triamcinolone; applied topically to the skin or oral mucosa as an anti-inflammatory, and administered by inhalation for the chronic treatment of bronchial asthma, and by intra-articular, intradermal, intralesional, or intramuscular injection as an anti-inflammatory and immunosuppressant in a wide variety of disorders.', 'Amcort , Aristocort A , Aristocort C , Aristocort D , Aristocort HP , Aristocort R , Azmacort , Cenocort A-40 , Cinalog , Cinalone , Cinoide 40 , Component of Myco-Triacet II , Component of Mycolog II , Component of Mytrex , Cremocort , Delta-Tritex , Flutex , Flutone# , Kenac , Kenaject , Kenalog , Kenalog H , Kenalog in Orabase , Kenalone , Kenonel , Nasacort , Oracort , Oralone Dental , Respicort , Scheinpharm Triamcine-A , Tac , TAC-3 , TAC-40# , Tramacin# , Tri-Kort , Tri-Nasal , Triacet , Triaderm , Triam Forte , Triam-A , Triamalone , Triamcinair , Triamcinolone Dental , Triamonide 40 , Trianide , Tricilone , Triderm , Trilog , Tristoject , Trymex , Trymex#', NULL, NULL, '21916', 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1779, 'Triamcinolone Acetonide Sodium Phosphate', NULL, NULL, 'NO', 'Glucocorticoid; the diacetate ester of triamcinolone, used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered orally and by intra-articular, intradermal, intralesional or intramuscular injection.', 'CL-106359 , CL-61965', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1780, 'Triamcinolone Diacetate', NULL, NULL, 'NO', 'Glucocorticoid; the diacetate ester of triamcinolone, used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered orally and by intra-articular, intradermal, intralesional or intramuscular injection.', 'Amcort , Aristocort , Aristocort Forte , Articulose LA , Cenocort Forte , Cinalone 40 , Cino 40 , Cort-A , Kenacort , Kenacort Diacetate , Sholog-A , TAC-D# , Tracilon , Triacin 40 , Triacort , Triam , Triam Forte , Triamolone , Triamolone 40 , Triamolone Diacetate , Trilone , Tristoject', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1781, 'Triamcinolone Hexacetonide', NULL, NULL, 'NO', 'Glucocorticoid; hexacetonide ester of triamcinolone, used as an anti-inflammatory and immunosuppressant in a wide variety of disorders; administered by intra-articular, intralesional, or sublesional injection.', 'Aristospan , CL-34433 , TATBA', NULL, 'TATBA', NULL, 'Hormones and hormonal mechanisms', 'Glucocorticoid'),
(1782, 'Triapine', NULL, NULL, 'NO', 'Phase II biliary, gallbladde, lymphoma, advanced solid tumors 2007 Ribonucleoside reductase inhibitor. Vion Pharmaceuticals.', NULL, 'biliary, Breast, colorectal, gallbladder, head & neck, leukemia, lung, prostate, skin cancer', '3-AP', '663249', 'Chemotherapy', 'Cytostatic agent--ribonucleotide reductase inhibitor'),
(1783, 'Triazine antifol', NULL, NULL, 'NO', NULL, 'Dihydrotriazine derivative , Triazinate', NULL, NULL, '127755', 'Chemotherapy', 'Antimetabolite'),
(1784, 'Trichosanthin', NULL, NULL, 'YES', 'Phase I and Phase II clinical studies were carried out by Genelabs; however, no further studies will be done.', 'Compound Q , GLQ-223', NULL, NULL, NULL, 'AIDS drug', NULL),
(1785, 'Triciribine', NULL, NULL, 'NO', NULL, 'API 2 , API-2 , API2 , Triciribine phosphate', NULL, 'TCN, TCN-P', '280594;154020', 'Chemotherapy', 'Cytostatic agent--protein kinase inhibitor'),
(1786, 'Triethylenemelamine', NULL, NULL, 'NO', 'Alkylating agent. Triethylenemelamine used in manufacturing and in cancer chemo. (from ReproTox). Not found in Drugdex drug evaluation.', 'Ho 1/193 , M-9500 , Persistol , R-246 , SK-1133 , Tretamine , Triamelin', NULL, 'TEM, TET', '9706', 'Chemotherapy', 'Alkylating agent'),
(1787, 'Triflupromazine Hydrochloride', NULL, NULL, 'YES', 'Antiemetic and antipsychotic.', 'Fluopromazine , Vesprin', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1788, 'Trifluridine', NULL, NULL, 'YES', 'A fluorinated pyrimidine nucleoside with antiviral activity. Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to the herpes simplex virus types 1 and 2.', 'Trifluorothymidine F3TdR , Viroptic', NULL, 'F3T, F3TDR, TFT', '075520;75520', 'AIDS drug', NULL),
(1789, 'TriGem', NULL, NULL, 'NO', 'Phase II lung, stage III melanoma Vaccine. Titan Pharmaceuticals.', NULL, 'Lung, skin cancer', NULL, '724594', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1790, 'Triglycidylurazol', NULL, NULL, 'NO', 'Most recent PubMed citation 1991.', 'Anaxirone', NULL, 'TGU', '332488', 'Chemotherapy', 'No longer in use'),
(1791, 'Trilostane', NULL, NULL, 'NO', 'An adrenal inhibitor (adrenocortical suppressant), which is used primarily in the treatment of Cushing\'s syndrome.  Used experimentally to inhibit aldosterone synthesis and raise potassium levels in patients with adrenal hyperfunction and in hypertensive patients undergoing diuretic therapy', 'Modrastane , Modrenal , Win-24540', NULL, NULL, NULL, 'Hormones and hormonal mechanisms', 'Adrenocortical suppressant.  Probably not cancer directed--verify with attending MD.');
INSERT INTO `cancer_drugs` (`id`, `Name`, `EVS_ID`, `Histology`, `Do_not_code`, `Remarks`, `Alternate_Name`, `Primary_Site`, `Abbreviation`, `NSC_number`, `Category`, `Subcategory`) VALUES
(1792, 'Trimethobenzamide Hydrochloride', NULL, NULL, 'YES', 'Antiemetic agent available orally, rectally, and parenterally.', 'Arrestin , Emergent-EZ , Stemetic , Tebamide , Ticon , Tigan , Trimazide', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1793, 'Trimethoprim', NULL, NULL, 'YES', 'Antimicrobial agent; Rx or prophylaxis of PCP.', 'Bactrim , Component of the following: Cotrim- Septra- Sulfatrim , Proloprim , Trimpex', 'AIDS, Opportunistic infection', 'TMP', '106568', 'Ancillary Agent;AIDS drug', NULL),
(1794, 'Trimetrexate Glucuronate', NULL, NULL, 'NO', 'Phase II (breast, gastric, lung, prostate) Phase III (colorectal) Antineoplastic and antimicrobial agent. Non-classical folate antagonist. MedImmune Oncology.  Salvage therapy for PCP', 'CI-898 , JB-11 , Neutrexin , TMQ , Trimetrexate', 'Breast, colorectal, gastric, lung, prostate cancer', 'TMTX', '352122;249008', 'Chemotherapy;AIDS drug', 'Antimetabolite'),
(1795, 'Trioxifene Mesylate', NULL, NULL, 'NO', 'Anti-estrogen', 'Compound 133314', 'Breast cancer', NULL, NULL, 'Hormones and hormonal mechanisms', 'Anti-estrogen'),
(1796, 'Triptorelin', NULL, NULL, 'NO', 'A luteinizing hormone-releasing hormone (LHRH) agonist; a synthetic analogue of gonadorelin .', 'AY-25650 , BIM-21003 , BN-52014 , CL-118532 , Trelstar Depot , Triptorelin pamoate , Triptoreline , Tryptoreline', 'Ovarian, prostate cancers', NULL, '724666', 'Hormones and hormonal mechanisms', 'LHRH agonist'),
(1797, 'Trisenox', NULL, NULL, 'NO', 'Phase II FDA approved use on acute promyelocytic leukemia. Cell Therapeutics.', 'Arsenic trioxide injection', 'Cervical, kidney, leukemia, multiple myeloma, neuroblastoma, prostate cancer', NULL, '706363', 'Chemotherapy', 'Miscellaneous agent'),
(1798, 'Trityl cysteine', NULL, NULL, 'NO', NULL, 'Tritylcysteine , Tritylthioalanine', NULL, NULL, '83265', 'Chemotherapy', 'Antimitotic'),
(1799, 'Trofosfamide', NULL, NULL, 'NO', 'Alkylating agent. Although additional studies are needed, oral trofosfamide monotherapy should be considered in non-Hodgkin\'s lymphoma patients who have progressed on or relapsed after front-line combination chemo. regimens, particularly the elderly.', 'A-4828 , Trilophosphamide , Trophosphamide , Z-4828', NULL, NULL, '109723', 'Chemotherapy', 'Alkylating agent'),
(1800, 'Trogarzo', NULL, NULL, 'YES', 'March 6, 2018: The FDA approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).', 'Ibalizumab-uiyk', NULL, NULL, NULL, 'AIDS drug', 'Antiretroviral'),
(1801, 'Tropisetron', NULL, NULL, 'YES', 'Antiemetic, serotonin antagonist.', 'ICS 205-930', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1802, 'Trospectomycin Sulfate', NULL, NULL, 'YES', 'An analogue of spectinomycin. Antibiotic for Rx of oral chlamydia and gonorrhea; under investigation for Rx of Mycobacterium Avium Complex.      Trospectomycin is under investigation for treatment of other bacterial infections, but published clinical data are lacking.', 'Spexil , Trospectinomycin , U-63366', NULL, NULL, NULL, 'AIDS drug', NULL),
(1803, 'TroVax', NULL, NULL, 'NO', 'Phase III renal cell 2007 MVA: Modified Vaccinia Ankara. Oxford BioMedica', NULL, 'Kidney', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1804, 'Troxacitabine', NULL, NULL, 'NO', 'Pre-clinical (breast) Phase II (kidney, leukemia, NSCLC, ovarian, pancreatic, prostate) Phase III (colorectal, melanoma) Dioxolane nucleoside analog. BioChem Pharma.', 'BCH-4556 , Troxatyl', 'acute myelogenous leukemia, Breast, colorectal, kidney, lung, ovarian, pancreatic, prostate, skin cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite'),
(1805, 'TRP-2:180-188 Peptide Vaccine', NULL, NULL, 'NO', 'Phase II NCI.', NULL, 'Skin cancer', NULL, '720621', 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1806, 'Truxima', NULL, 'NHL', 'NO', '11/28/2018: FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab, Genentech Inc.) for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.', 'Ritximab-abbs', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Biosimilar for rituximab'),
(1807, 'Tubercidine', NULL, NULL, 'NO', NULL, '12 , 540 , 7-Deaza-adenosine , Antibiotic XK 101-1 , Aplisol , Sparsomycin A , Tubercidin , U-10071', NULL, NULL, '56408', 'Chemotherapy', 'Antitumor antibiotic'),
(1808, 'Tumor necrosis factor', NULL, NULL, 'NO', NULL, 'TNF , Tumor necrosis factor', NULL, 'TNF', '606515;635257', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1809, 'Tumor Necrosis Factor-alpha', NULL, NULL, 'NO', 'Phase III melanoma Tumor necrosis factor. NCI, Boehringer Ingelheim Pharmaceuticals.', NULL, 'Skin cancer', NULL, '697068', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1810, 'Tumor primed Anti-CD3', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '618843', 'Biologic therapy (BRM, immunotherapy)', NULL),
(1811, 'Tumor specific Fusion Vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. Genzyme Molecular Oncology.', NULL, 'Breast cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1812, 'Type 1 5-alpha Reductase Inhibitor', NULL, NULL, 'NO', 'Phase I Serona.', NULL, 'Prostate cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--alpha reductase inhibitor'),
(1813, 'Tyrosinase 368-376 (370D) Peptide Vaccine', NULL, NULL, 'NO', 'Phase II NCI.', NULL, 'Skin cancer', NULL, '699048', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1814, 'U-85961', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1815, 'U-87201E', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1816, 'U-90152', NULL, NULL, 'YES', NULL, 'BHAP compound', NULL, NULL, NULL, 'AIDS drug', NULL),
(1817, 'Ubenimex', NULL, NULL, 'NO', 'Tried as an adjuvant to tegafur and uracil in the treatment of bladder cancer. Immunomodulator.', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunomodulator'),
(1818, 'UBITh', NULL, NULL, 'NO', 'Phase I Immunotherapeutic. United Biomedical, Inc.', NULL, 'Prostate cancer', NULL, NULL, 'Ancillary Agent;Biologic therapy (BRM, immunotherapy)', 'Allergy vaccine'),
(1819, 'UCN-01', NULL, NULL, 'NO', 'Phase II 2007 NCI, Kyowa Hakko Kogyo.', NULL, 'advanced solid tumors, Pancreatic cancer', NULL, '638850', 'Chemotherapy', 'Protein kinase inhibitor'),
(1820, 'Udenvca', NULL, NULL, 'YES', '11/2/18 FDA approved Udenyca (pegfilgrastim-cbqv), a biosimilar to Neulasta (pegfilgrastim).', 'pegfilgrastin-cbgv', NULL, NULL, NULL, 'Ancillary Agent', 'Biosilimar'),
(1821, 'Ultraviolet A', NULL, NULL, 'NO', 'If stated as tanning bed or sunlamp, do not code.', 'ultraviolet radiation therapy , UV radiation', NULL, NULL, NULL, 'Other therapy', 'Code to \'Other\' Therapy when used with psoralen (PUVA therapy)'),
(1822, 'Unituxin', NULL, 'Neuroblastoma', 'NO', 'March 2015: FDA approved dinutuximab in combination with GM-CSF, Interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.\r\n\r\nThe FDA granted dinutuximab orphan drug status and also rare pediatric disease priority.', 'Ch14.18 , MOAB Ch14.18 , dinutuximab , monoclonal antibody Ch14.18', 'Brain', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'monoclonal antibody'),
(1823, 'Uracil Mustard', NULL, NULL, 'NO', 'A polyfunctional, cycle nonspecific alkylating agent. FDA approved uses in palliative therapy of chronic lymphocytic leukemia, chronic myelogenous leukemia, mycosis fungoides, and non-Hodgkin\'s lymphoma.', 'U-8344 , Uracil , Uramustin , Uramustine', NULL, 'UHN2', '34462;034462', 'Chemotherapy', 'Alkylating agent'),
(1824, 'Uredepa', NULL, NULL, 'NO', NULL, 'AB-100 , Avinar# , Urethimine', NULL, NULL, '37095', 'Chemotherapy', 'Alkylating agent'),
(1825, 'Urethane', NULL, NULL, 'NO', 'Urethane is an antineoplastic agent that is rarely used now (from Teris). Not found in Drugdex drug evaluation.', 'Ethyl Carbamate#', NULL, NULL, '746', 'Chemotherapy', 'No longer in use'),
(1826, 'Uridine', NULL, NULL, 'NO', 'It has been reported to be of benefit in reducing fluorouracil toxicity. Not found in Drugdex drug evaluation.', 'Uracil Riboside , Urd , Uridin', NULL, NULL, '20256', 'Chemotherapy', 'Chemoprotective'),
(1827, 'Urokinase', NULL, NULL, 'YES', 'A hydrolase enzyme which catalyzes the conversion of plasminogen to plasmin. Thromboembolytic therapy', 'Abbokinase , Plasminogen activator', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1828, 'Vaccine for helicobacter pylori', NULL, NULL, 'NO', 'Phase III Vaccine. Antex Biologics.', NULL, 'Gastric cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1829, 'Vaccinia TRICOM', NULL, NULL, 'NO', 'Phase II Information from NCI', 'rV-CEA(6D)-TRICOM , Vaccinia-CEA(6D)/TRICOM vaccine', 'Colorectal', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1830, 'Vaccinia-CEA (vaccine 180KD)', NULL, NULL, 'NO', 'Phase I Vaccine. Therion Biologics, NCI. Tricom.', 'rV-CEA(6D)', 'Breast, gastric, lung cancer', NULL, '710067', 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy active'),
(1831, 'Vaccinia-MUC-1 Vaccine', NULL, NULL, 'NO', 'Phase I Therapeutic vaccine. Centacor, Therion Biologics, Corixa, NCI.', 'rV-MUC-1', 'Breast, pancreatic cancer', NULL, '694449', 'Biologic therapy (BRM, immunotherapy)', 'Immuontherapy active'),
(1832, 'VAL-083', NULL, 'Glioma, glioblastoma', 'SEE_REMARKS', 'January 15, 2016: VAL-083 is currently in phase II clinical studies at MD Anderson for treatment of first recurrence/progression of GBM.\r\n\r\nApril 2016: The FDA granted Orphan Drug Designation to VAL-083 in the treatment of ovarian cancer. \r\n\r\nCODE: code as Other Treatment, assign code 2', NULL, 'Brain', NULL, NULL, 'Other therapy', NULL),
(1833, 'Valacyclovir Hydrochloride', NULL, NULL, 'YES', 'An antiviral prodrug of acyclovir.', '256U , 256U87 , BW256U87 , L-Valine , Valtrex', NULL, NULL, NULL, 'AIDS drug', NULL),
(1834, 'Valproic acid', NULL, NULL, 'SEE_REMARKS', 'Phase I Valproic acid is a treatment for bipolar disorder and an anticonvulsant for epilepsy that has shown recent anti-tumor activity as an HDAC inhibitor.  Verify that the patient is on a clinical trial for cancer before coding in \"Other treatment\".  Do Not code as chemotherapy until FDA approval.', NULL, 'AML, CLL, lymphocytic lymphoma', 'VPA', NULL, 'Chemotherapy', 'Cytostatic agent--histone deacetylation inhibitor'),
(1835, 'Valrubicin', NULL, NULL, 'NO', 'FDA approved 9/25/98 Approved intravesical therapy of BCG-refractory carcinoma in situ for patients who cannot tolerate surgery. Anthra Pharmaceuticals.', 'AD-32 , Valstar', 'Bladder cancer', NULL, '246131', 'Chemotherapy', 'Antitumor antibiotic'),
(1836, 'Vamidex', NULL, NULL, 'NO', 'Phase II, Phase II NSCLC Non-polyglutamatable thymidylate synthase (TS) inhibitor. AstraZeneca.', 'Vamydex , ZD 9331 , ZD-9331 , ZD9331', 'Colorectal, lung, other cancer, ovarian, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Antimetabolite;thymidylate synthase inhibitor'),
(1837, 'Vandetanib', NULL, NULL, 'NO', 'April 6, 2011: Received FDA approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.\r\nPhase III Lung\r\nVascular endothelial cell growth factor receptor tyrosine kinase (VEGFR TKI) inhibitor.  AstraZeneca.', 'AZD6474 , Caprelsa , Zactima , ZD 6474 , ZD-6474 , ZD6474', 'Breast, cervical, endometrial, NSC lung cancer, ovarian, prostate, Thyroid', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1838, 'Vapreotide', NULL, NULL, 'NO', 'A somatostatin analogue similar to octreotide. It is under investigation in the management of various       gastrointestinal and neoplastic disorders. Not found in Drugdex drug evaluation.', 'BMY-41606 , Octastatin , RC-160', NULL, NULL, NULL, 'Chemotherapy', 'somatostatin analogue'),
(1839, 'Varubi', NULL, NULL, 'YES', 'September 25, 2015: the FDA approved Varubi to prevent delayed phase chemotherapy-induced nausea and vomiting.', 'Rolapitant', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1840, 'Vatalanib', NULL, NULL, 'NO', 'Colorectal Phase II; Brain Phase I; Phase II myeloma 2007 Tyrosine kinase inhibitor and anti-VEGFr.  Multi-VEGFR inhibitor. Novartis. Schering.', 'PTK 787 , PTK787 , ZK 222584 , ZK222584', 'brain, Colorectal, Myeloma, other cancer', NULL, '719335', 'Chemotherapy', 'Cytostatic agent--antiangiogenesis agent'),
(1841, 'Vaxid', NULL, NULL, 'NO', 'Phase I/II NHL B-cell mantle cell Vaccine. Vical, Inc..', 'Anti-idiotype naked DNA vaccine', 'Lymphoma', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1842, 'VaxSyn', NULL, NULL, 'NO', NULL, 'an envelope protein from HIV , GP160 vaccine , Recombinant , Recombinant GP160', NULL, NULL, NULL, 'AIDS drug', NULL),
(1843, 'VB2-011', NULL, NULL, 'NO', 'Phase I/II Monoclonal antibody. Viventia Biotech.', 'H-11 , H11 , VB2011', 'Other cancer', NULL, NULL, 'Chemotherapy', 'Immunotoxin conjugated to protein'),
(1844, 'Vemurafenib', NULL, NULL, 'NO', 'Received FDA approval 8/17/2011for treatment of metastatic melanoma with BRAF mutation as detected by a FDA approved test.\r\n\r\nNovember 6, 2017: The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.', 'PLX4032 , Zelboraf', NULL, NULL, NULL, 'Chemotherapy', 'Kinase Inhibitor'),
(1845, 'Venclexta', NULL, 'Chronic lymphocytic leukemai (CLL)', 'NO', 'May 15, 2019: FDA approved venetoclax (VENCLEXTA) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\r\n\r\nApril 11, 2016: FDA approved  for treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy.  This agent is not usually given as first course treatment. \r\n\r\nFebruary 5, 2016: the FDA granted Venetoclax Breakthrough Designation for use in combination with hypomethylating agents for patients with untreated acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy. \r\n\r\n6/8/2018 FDA granted regular approval to venetoclax  for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy', 'Venetoclax , ABT 0199 , ABT 199 , GDC-0199', NULL, NULL, NULL, 'Chemotherapy', 'Cl-2 inhibitor'),
(1846, 'Vendexta', NULL, 'Lymphoma', 'NO', '6/15/2018: FDA has approved, under priority review, Venclexta (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy', 'Venetoclax', NULL, NULL, NULL, 'Chemotherapy', 'BCL2 Inhibitor'),
(1847, 'Verapamil', NULL, NULL, 'YES', 'A calcium channel blocker with vasodilatory and antiarrhythmic effects. Chemosensitizer.', 'Apo-Verap , Calan , Calan SR , Covera HS , Iproveratril , Isoptin , Isoptin hydrochloride , Isoptin SR , Izoptin , Novo-Veramil , Nu-Verap , Verapamil Hydrochloride , Verelan', NULL, NULL, '256325', 'Ancillary Agent', NULL),
(1848, 'Verteporfin', NULL, NULL, 'YES', 'DO NOT CODE this drug as treatment. It is used to treat non-melanoma skin cancer.\r\nPhase II/III nonmelanoma\r\nPhotosensitzing agent. Novartis.', NULL, 'Skin cancer', NULL, NULL, 'Other therapy', 'Ocular drug for macular degeneration'),
(1849, 'VHL Peptide Vaccine', NULL, NULL, 'NO', 'Phase I Vaccine. NCI.', NULL, 'Kidney cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immuntherapy active'),
(1850, 'Vibrio cholera neuraminidase', NULL, NULL, 'NO', NULL, 'Malignant cell antigens , Mammalian biological product', NULL, 'VCN', NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1851, 'Vidarabine', NULL, NULL, 'YES', 'Antiviral drug.', 'Adenine Arabinoside , Ara-adenosine , Arabinosyladenine , CI-673 , Spongo-adenosine , Vidarabin , Vidarabin-Thilo , Vira-A , Vira-A Parenteral , Vitarabin , Vitarin', NULL, 'Ara-A', '404241', 'AIDS drug', 'Antiviral opthalmic'),
(1852, 'Vidaza', NULL, NULL, 'NO', 'Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.', '496 , 5-Azacitidine , 5-Azacytidine , Antibiotic U-18 , Azacitidine , Azacytidine , Ladakamycin', 'Myelodysplastic syndromes', '5-AC, 5-AZA, 5-AZAC, 5-AZCR, AZA-CR, AZC', '102816', 'Chemotherapy', 'Antimetabolite'),
(1853, 'Vinblastine', NULL, NULL, 'NO', 'A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin\'s lymphoma, Kaposi\'s sarcoma, mycosis fungoides, palliative in non-Hodgkin\'s histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.', '29060-LE , Alkaban , LE-29060 , Velban , Velbe , Velsar , Vinblastine , Vinblastine sulfate', NULL, 'VBL, VELB, VLB', '049842;49842', 'Chemotherapy', 'Plant alkaloid'),
(1854, 'Vincristine', NULL, NULL, 'NO', 'Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm\'s tumor.', 'Compound 37231 , Leurocristine Sulfate , Oncovin , Vincasar , Vincasar PFS , Vincristine Sulfate , Vincrystine , Vinkristin', NULL, 'LCR, VCR, VNCR', '067574;67574', 'Chemotherapy', 'Plant alkyloid--antimetabolite'),
(1855, 'Vindesine', NULL, NULL, 'NO', 'Vindesine has activity in a wide variety of malignancies including colorectal, lung, breast, and esophageal carcinomas; it also has activity in lymphomas and leukemias, glioma, and melanoma. Neurotoxicity (dose-limiting and cumulative) and cross-resistance with vincristine have limited the usefulness of this agent. Although vindesine in combination with cisplatin is one of the most active regimens for non-small cell lung cancer.', 'Compound 112531 , Eldesine , Eldisine , Lilly 99094 , LY-099094 , Vincaleukoblastine , Vindesine sulfate', NULL, 'DAVA, DVA', '245467', 'Chemotherapy', 'Plant alkyloid'),
(1856, 'Vinepidine Sulfate', NULL, NULL, 'NO', NULL, 'LY 119863 , LY-119863 , LY119863', NULL, NULL, NULL, 'Chemotherapy', 'Plant alkyloid'),
(1857, 'Vinflunine', NULL, NULL, 'NO', 'Phase II breast 2007 Third generation vinca alkyloid.  Pierre Fabre Medicament S.A.; Bristol Myers Squibb.', 'Javlor', 'Bladder, breast, lung, other', NULL, NULL, 'Chemotherapy', 'Plant alkyloid'),
(1858, 'Vinglycinate Sulfate', NULL, NULL, 'NO', NULL, NULL, NULL, '49040', NULL, 'Chemotherapy', 'Plant alkyloid'),
(1859, 'Vinleurosine Sulfate', NULL, NULL, 'NO', NULL, '32645 , Leurosine , Vinleurosine', NULL, NULL, '90636;528004', 'Chemotherapy', 'No longer in use'),
(1860, 'Vinorelbine', NULL, NULL, 'NO', 'Phase III NSCLC Vinca alkaloid; mitotic inhibitor. FDA approved use on NSCLC. GlaxoSmithKline.', 'Navelbine , Navelbine ditartrate , Vinorelbine Ditartrate , Vinorelbine Tartrate', 'Breast, lung cancer', 'VNB', '608210', 'Chemotherapy', 'Plant alkyloid'),
(1861, 'Vinrosidine Sulfate', NULL, NULL, 'NO', NULL, '3678l', NULL, NULL, NULL, 'Chemotherapy', 'No longer in use'),
(1862, 'Vinzolidine  Sulfate', NULL, NULL, 'NO', 'Vinca plant alkaloid derivative', 'LY 104208 , LY-104208 , LY104208', NULL, 'VZL', NULL, 'Chemotherapy', 'Plant alkyloid'),
(1863, 'Virulizin', NULL, NULL, 'NO', 'Phase III Macrophage activator. Lorus Therapeutics.', NULL, 'Pancreatic cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immune system activator'),
(1864, 'Vismodegib', NULL, NULL, 'NO', 'Received FDA approval January 30, 2012 for the treatment of basal cell carcinoma (BCC). Is currently in clinical trials for advanced stomach cancer, pancreatic cancer, small-cell lung cancer, colorectal cancer, medulloblastoma and chondrosarcoma.', 'Erivedge , GDC-0449', 'Basal cell carcinoma, skin', NULL, '747691', 'Chemotherapy', 'Hedgehog signaling pathway targeting agent;cyclopamine-competitive antagonist othe the smoothened receptor (SMO)'),
(1865, 'Vistogard', NULL, NULL, 'YES', 'December 11, 2015: The FDA approved Vistogard for the emergency treatment of adults children who receive an overdose of the cancer treatment fluoroucil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.', 'uridine triacetate', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1866, 'Vitamin D', NULL, NULL, 'YES', 'Functions as a hormone', 'Cholecalciferol', NULL, NULL, '62792', 'Ancillary Agent', NULL),
(1867, 'Vitamin E', NULL, NULL, 'YES', 'A fat-soluble vitamin; anti-fibrosis therapy', 'Alpha tocopherol , Amino-Opti-E , Aquasol E , Tocopherol', NULL, NULL, '20812', 'Ancillary Agent', NULL),
(1868, 'Vitaxin', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. MedImmune.', 'Medi 522 , Murine LM609', 'Colorectal, other cancer', NULL, '719850', 'Chemotherapy', 'Angiogenesis inhibitor'),
(1869, 'Volasertib', NULL, NULL, 'NO', 'As of 1/1/2013,  in multiple clinical trials (both phase I and II) for AML, ovarian tumors and solid tumors. Volasertib is the second in a novel class of drugs call dihydropteridinone derivatives.', 'BI 6727', 'AML trials, Ovarian trials, Solid tumors trials', NULL, NULL, 'Chemotherapy', 'PLK Inhibitor'),
(1870, 'Voraxase', NULL, NULL, 'YES', 'Ancillary treatment for methotrexate toxicity', NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1871, 'Voriconazole', NULL, NULL, 'YES', 'Therapeutic options in resistant aspergillosis are limited. Although more clinical experience with voriconazole is needed, data are sufficient to recommend its use in patients with invasive aspergillosis who have failed to respond to agents of choice (ie, conventional or liposomal amphotericin B, itraconazole). The drug may also be useful in patients with therapy-limiting toxicity associated with conventional regimens. Additional studies to assess the optimal dose, pharmacokinetics, and interaction potential of voriconazole are required. Data are too limited to suggest a role in candidiasis.', 'UK-109496', 'AIDS, Opportunistic infection', NULL, NULL, 'AIDS drug', NULL),
(1872, 'Vorinostat', NULL, NULL, 'NO', 'Phase I colorectal, advanced solid tumors 2007 Merck, Aton Pharma.  FDA fast track and orphan status 2006 for CTCL.  HDAC inhibitor', 'Zolinza', 'advanced solid tumors, colorectal, CTCL, Leukemia, other cancer', 'SAHA', '701852', 'Chemotherapy', 'Cytostatic agent--histone deacetylase (HDAC) inhibitor'),
(1873, 'VX-853', NULL, NULL, 'YES', 'Phase II Multidrug resistance inhibitor. Vertex Pharmaceuticals.', NULL, 'Other cancer', NULL, NULL, 'Ancillary Agent', 'Reverses drug resistance'),
(1874, 'Vyxeos', NULL, 'Acute myeloid leukemia', 'NO', 'August 3, 2017: FDA granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.', NULL, NULL, NULL, NULL, 'Chemotherapy', NULL),
(1875, 'Warfarin Sodium', NULL, NULL, 'SEE_REMARKS', '**June 6, 2016: Based on information from the National Cancer Institute and the FDA, aspirin and or other blood thinners are NOT valid treatment for Polycythemia Vera and MDS. These drugs are often given to relieve symptoms of the disease such as bone pain or side-effects of standard treatments including blood clots. The treatment information found on page 22 (2016 coding manual) will be updated and ICD-O-3 codes 9950/3 and 9975/3 will be removed from the list.\r\n\r\n\r\nPer the 2012 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual (page 10), blood thinners and/or anti-clotting agents are to be coded as treatment (Other Therapy) for the following histologies:\r\n9740/4 Mast cell sarcoma\r\n9741/3 Systemic mastocytosis\r\n9742/3 Mast cell leukemia\r\n9875/3 Chronic myelogenous leukemia BCR/ABL 1 positive\r\n9961/3 Primary myelofibrosis\r\n9962/3 Essential thrombocythemia\r\n9963/3 Chronic neutrophilic leukemia', 'Carfin , Coumadin , Panwarfin , Sofarin , Warfilone , Warnerin', NULL, NULL, '59813', 'Ancillary Agent', 'Do not code- anticoagulant;Exception for select hematopoietic diseases: SEE REMARKS'),
(1876, 'WF10', NULL, NULL, 'YES', 'Phase II Dimehaid Research, OXO Chemie.', 'Oxoferin', 'Lymphoma', 'TCDO', NULL, 'AIDS drug', NULL),
(1877, 'Wobenzym', NULL, NULL, 'YES', 'Suppresses inflammatory response in AIDS patients', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1878, 'WR 2026', NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1879, 'WR 6026', NULL, NULL, 'YES', 'Therapy for Pneumocystis carinii pneumonia', NULL, NULL, NULL, NULL, 'AIDS drug', NULL),
(1880, 'WT-1 peptide vaccine', NULL, 'Malignant pleural mesothelioma', 'SEE_REMARKS', 'March 4, 2016: The FDA granted Orphan Drug designation to the WT! Cancer Vaccine developed by SELLAS Life Science Group for the treatment of patients with malignant pleural mesothelioma.  This was based on the positive results from phase II clinical trials. Phase IIb/III trials will be initiated. \r\n\r\nCODING: code this vaccine in Other Treatment, assign code 2', 'OCV-501', 'Pleura', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Vaccine'),
(1881, 'WX-UK1', NULL, NULL, 'NO', 'Phase I/II Urokinase inhibitor. Wilex.', 'WX UK1 , WXUK1', 'Gastric, ovarian, pancreatic cancer', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--Urokinase-type Plasminogen Activator (uPA) inhibitor'),
(1882, 'Xaliproden', NULL, NULL, 'YES', 'Neurotrophic; reduces neurotoxicity', 'SR 57746A , SR-57746A , SR57746A', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1883, 'Xalkori', NULL, NULL, 'NO', 'Crizotinib received FDA approval 8/26/11 for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.\r\n\r\n March 11, 2016 FDA approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.', 'Crizotinib', 'Non Small Cell Lung Cancer (NSCLC)', NULL, NULL, 'Chemotherapy', 'Kinase inhibitor;Targeted therapy anaplastic lymphoma kinase'),
(1884, 'Xcellerate', NULL, NULL, 'NO', 'Phase I/II T-cell activator. Xcyte Therapies.', NULL, 'Kidney, prostate cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'T-cell activator'),
(1885, 'Xcytrin', NULL, NULL, 'YES', 'Phase III, Phase III NSCLC Texaphyrins radiosensitizer. Pharmacyclics, NCI.', NULL, 'Brain, Lung cancer', NULL, '695238', 'Ancillary Agent', 'Radiosensitizer'),
(1886, 'Xeloda', NULL, NULL, 'NO', 'Xeloda is a drug composed of doxifluridine and 5-FU.  IT is often used as part of a regimen but if given alone, code to chemotherapy, single agent (1).', 'Xelox , Capecitabine', NULL, 'CAPE', NULL, 'Chemotherapy', NULL),
(1887, 'Xerecept', NULL, NULL, 'NO', 'Phase I completed Synthetic corticotropic. Neurobiological Technologies.', 'Corticotropic releasing factor , CRF', 'Brain cancer', NULL, NULL, 'Ancillary Agent', 'Controls peritumoral edema in brain'),
(1888, 'Xermelo', NULL, 'Carcinoid', 'YES', '3/1/2017: The FDA approved Xermelo (telotristat ethyl) as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors.\r\nCarcinoid syndrome is a cluster of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare and often slow-growing. Carcinoid syndrome occurs in <10% of patients with carcinoid tumors, usually after the tumor has spread to the liver. The tumors in these patients release excess amounts of the hormone serotonin, resulting in diarrhea. Complications of uncontrolled diarrhea include weight loss, malnutrition, dehydration, and electrolyte imbalance.', 'Telotristat ethyl', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1889, 'XIAP antisense', NULL, NULL, 'NO', 'Phase II AML 2007 XIAP (X-linked Inhibitor-of-Apoptosis); apoptosis inducer.  Aegera Therapeutics', 'AEG 35156 , AEG-35156 , AEG35156 , GEM 640 , GEM-640 , GEM640', 'AML', NULL, NULL, 'Chemotherapy', 'Targeted therapy--antisense'),
(1890, 'XK-469', NULL, NULL, 'NO', 'Phase I NCI, Bristol-Myers Squibb.', NULL, 'Other cancer', NULL, NULL, 'Chemotherapy', 'Topoisomerase inhibitor'),
(1891, 'XK469', NULL, NULL, 'NO', 'Phase I lymphoma; advanced solid tumors 2007 Information from NCI', 'R(+)XK469 , XK 469 , XK-469', 'advanced solid tumors, Lymphoma', NULL, '656889', 'Chemotherapy', 'Topoisomerase II inhibitor'),
(1892, 'XL-139', NULL, NULL, 'NO', 'I New drug currently in trials, code in other therapy', NULL, 'GE and esophageal adenocarcinoma, inoperable stomach, mets gastric, multiiple myeloma, SCLC', NULL, NULL, 'Chemotherapy', 'SMO inhibitor'),
(1893, 'XL-147', NULL, NULL, 'NO', 'New drug currently in trials, code in other therapy', NULL, 'Advanced Endometrium, lymphoma, Mets breast, NSCLC, ovarian', NULL, NULL, 'Chemotherapy', 'P13K inhibitor'),
(1894, 'XL-184', NULL, NULL, 'NO', 'I, II, III New drug currently in trials, code in other therapy', NULL, 'GBM, NSCLC, solid tumors, Thyroid', NULL, NULL, 'Chemotherapy', 'RTK inhibitor'),
(1895, 'XL-281', NULL, NULL, 'NO', 'I, II New drug currently in trials, code in other therapy', NULL, 'colorectal, melanoma, NSC, papillary thyroid', NULL, NULL, 'Chemotherapy', 'RAF kinase inhibitor'),
(1896, 'XL-765', NULL, NULL, 'NO', 'I, II New drug currently in trials, code in other therapy', NULL, 'breast, Malignant glioma, NSCLC', NULL, NULL, 'Chemotherapy', 'P13K inhibitor'),
(1897, 'XL-888', NULL, NULL, 'NO', 'I New drug currently in trials, code in other therapy', NULL, 'Failed first course, melanoma, mets, NSCLC, or unresectable: breast', NULL, NULL, 'Chemotherapy', 'HSP90 inhibitor'),
(1898, 'Xofigo', NULL, NULL, 'NO', 'July 2013 UPDATE: Radium Ra 223 dichloride received FDA approval for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no know visceral metastatic disease. This radioisotope is administered via injection and should be coded in the Radiation Therapy data fields. Because the drug emits radioactive particles, it has to be given by a radiation oncologist or nuclear medicine specialist.', 'Radium 223 , Radium Ra 223 dichloride', 'Metastatic prostate cancer', NULL, NULL, 'Radiation', 'Alpha-particle emitting radio-theraputic drug'),
(1899, 'Xpovio', NULL, 'Multiple myeloma', 'NO', 'July 3, 2019.FDA granted accelerated approval to selinexor (XPOVIO) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.', 'selinexor', NULL, NULL, NULL, 'Chemotherapy', 'CRM1 Inhibitor'),
(1900, 'Xyotax', NULL, NULL, 'NO', 'Phase II, Phase II NSCLC, Phase II/II ovarian Taxane. Cell Therapeutics.', 'CT-2103 , PG-TXL , Polyglutamate paclitaxel', 'Breast, colorectal, lung, ovarian cancer', NULL, '724773', 'Chemotherapy', 'Taxane'),
(1901, 'Y-CEA-Cide', NULL, NULL, 'NO', 'Phase I/II Immunomedics.', 'Y-Iabetuzumab', 'Pancreatic cancer', NULL, NULL, 'Radiation', 'Radioisotope conjugated to monoclonal antibody'),
(1902, 'Yescarta', NULL, 'B-cell lymphoma', 'NO', 'October 18, 2017: FDA granted regular approval to axicabtagene ciloleucel (YESCARTA)for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is an autologous CAR T-cell therapy in which T cells are isolated from a patient’s blood and engineered to target the CD19 protein that is found on lymphoma cells.', 'axicabtagene ciloleucel', NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'CAR T cell therapy'),
(1903, 'YM598', NULL, NULL, 'NO', 'Phase II Yamanouchi Pharma America.', NULL, 'Pancreatic  caner', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1904, 'YMB-1003MAb', NULL, NULL, 'NO', 'Phase I Monoclonal antibody. YM Biosciences.', NULL, 'Colorectal cancer', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1905, 'Yoshi-864', NULL, NULL, 'NO', NULL, NULL, NULL, NULL, '102627', 'Chemotherapy', 'Alkylating agent'),
(1906, 'Zalcitabine', NULL, NULL, 'YES', 'Antiviral agent, HIV reverse transcriptase inhibitor.', 'DDC , ddCyd , Dideoxycytidine , Hivid , Ro-24-2027 , Ro-24-2027/000', NULL, NULL, '606170', 'AIDS drug', NULL),
(1907, 'Zaltrap', NULL, NULL, 'NO', 'The FDA approved Zaltrap for use in combination with a FOLFIRI chemotherapy regimen on August 3, 2012.', 'Ziv-Aflibercept', 'Colorectal', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1908, 'Zalutumumab', NULL, NULL, 'NO', 'The company that makes this agent have decided not to continue to develop the drug and are looking for a partner to continue as th the expenses for the drug and trials is overwhelming. This drug has not received FDA approval and is not approved for use in Eurpoe.\r\nPhase II H&N, NSCLC 2007\r\nHuman monoclonal anti-EGFR.  Genmab', 'HuMax-EGFr', 'H&N, NSCLC', NULL, NULL, 'Chemotherapy', 'Cytostatic agent--anti-EGFR'),
(1909, 'Zamyl', NULL, NULL, 'NO', 'Phase III AML Anti-CD33 monoclonal antibody. Protein Design Labs.', 'SMART M195', 'Leukemia', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', NULL),
(1910, 'Zanolimumab', NULL, NULL, 'NO', 'Phase III Amgen, Genmab.  Orphan drug, fast-track status.  Targets CD4 receptor on T-cells.', 'HU-MAX-CD4 , HuMax CD4 , HuMax-CD4', 'Cutaneous T-cell lymphoma, mycosis fungoides', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Monoclonal antibody'),
(1911, 'Zanubrutinib', NULL, 'Mantle cell lymphoma', 'NO', 'November 14, 2019\r\nFDA granted accelerated approval to zanubrutinib (BRUKINSA) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.', 'BRUKINSA', NULL, NULL, NULL, 'Chemotherapy', 'Bruton\'s tyrosine kinase inhibitor'),
(1912, 'ZD0473', NULL, NULL, 'NO', 'Phase II NSCLC Phase III ovarian New generation platinum for platinum resistance. AstraZeneca, AnorMED.', 'ZD 0473 , ZD-0473', 'Lung, ovarian Cancer', NULL, NULL, 'Chemotherapy', 'Miscellaneous agent--platinum compound'),
(1913, 'ZD6126', NULL, NULL, 'NO', 'Phase I Anti-angiogenic. AstraZeneca.', 'ZD 6126 , ZD-6126', 'Breast, cervical, endometrial, other cancer, ovarian', NULL, NULL, 'Chemotherapy', 'Angiogenesis inhibitor'),
(1914, 'Zeniplatin', NULL, NULL, 'NO', NULL, '558 , CL 286 , CL 286558', NULL, NULL, NULL, 'Chemotherapy', 'Miscellaneous agent'),
(1915, 'Zevalin', NULL, NULL, 'NO', 'FDA approved NHL B-cell 2/19/02 Radioimmunotherapy. FDA approved use on non-Hodgkin\'s lymphoma. IDEC Pharmaceuticals.', 'IDEC-2B8 (ibritumomab tiuxetan) , IDEC-In2B8 (indium-111-ibritumomab tiuxetan) , IDEC-Y2B8 (Y90-ibritumomab tiuxetan) , Yttrium 90 ibritumomab tiuxetan', 'Lymphoma', NULL, '710085', 'Radiation', 'Radiolabled monoclonal antibody'),
(1916, 'Zidovudine', NULL, NULL, 'YES', 'Antiretroviral agent.', 'Apo-Zidovudine , Azidothymidine , BWA509U , Compound S , Retrovir , Vovo-AZR', NULL, 'AZT', '602670', 'AIDS drug', NULL),
(1917, 'Ziextenzo', NULL, NULL, 'YES', '11/5/209\r\nThe FDA approved Ziextenzo (pegfilgrastim-bmez), a biosimilar to U.S.-licensed Neulasta (pegfilgrastim).', 'pegfilgrastim-bmez', NULL, NULL, NULL, 'Ancillary Agent', 'bio-similar'),
(1918, 'Zinostatin', NULL, NULL, 'NO', NULL, 'Neocarcinostatin , Neocarzinostatin# , Vinostatin', NULL, 'NCS, NZS', '157365', 'Chemotherapy', 'Antitumor antibiotic'),
(1919, 'Zirabev', NULL, NULL, 'NO', '6/28/2019\r\nFDA has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent, or metastatic cervical cancer.', NULL, NULL, NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'biosimilar'),
(1920, 'ZK Epothilone', NULL, NULL, 'NO', 'Phase II breast, prostate 2007 Synthetic epothilone.  Bayer.', 'SH-Y03757A , ZK 219477 , ZK-219477 , ZK219477', 'breast, Prostate', 'ZK-EPO', NULL, 'Chemotherapy', 'Antimitotic agent'),
(1921, 'Zoledronic acid', NULL, NULL, 'YES', NULL, 'Zoledronate , Zometa', NULL, NULL, '721517', 'Ancillary Agent', 'Bisphosphonate'),
(1922, 'Zorubicin', NULL, NULL, 'NO', 'Treatment of acute leukemias.', '050 hydrochloride , 22050 R.P. , RP 22 , RP 22050 , Rubidaz , Rubidazone , Rubidazone monohydrochloride , Zorubicin hydrochloride', NULL, 'RBD, RUB', '164011', 'Chemotherapy', 'Topoisomerase inhibitor'),
(1923, 'Zosuquidar', NULL, NULL, 'YES', 'Reverses resistance to chemotherapy; multidrug resistance modulator', 'LY 335979 , RS 33295-198', NULL, NULL, NULL, 'Ancillary Agent', NULL),
(1924, 'ZYC300', NULL, NULL, 'NO', 'Phase I for several solid tumors 2007 Stimulates body\'s own immune response against cells expressing CYP1B1.  Zycos, MGI Pharma', 'ZYC 300 , ZYC-300', 'Breast, colon, kidney, ovary, prostate', NULL, NULL, 'Biologic therapy (BRM, immunotherapy)', 'Immunotherapy'),
(1925, 'Zydelig', NULL, 'Chronic lymphocytic leukemia (CLL)', 'NO', 'July 23, 2014 FDA approved idelalisib for the treatment of patients with relapsed CLL in combination with rituximab.', 'idelalisib', NULL, NULL, NULL, 'Chemotherapy', 'PI3K delta inhibitor'),
(1926, 'Zykadia', NULL, NULL, 'NO', 'May 26, 2017: FDA granted regular approval to ceritinib (ZYKADIA) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.\r\n\r\nApril 29, 2014 FDA granted accelerated (breakthrough therapy designation) to ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) with disease progression while on or who are not tolerant to crizotinib.', 'ceritinib', 'Lung', NULL, NULL, 'Chemotherapy', 'ALK tyrosine kinase inhibitor');

--
-- Indexes for dumped tables
--

--
-- Indexes for table `cancer_drugs`
--
ALTER TABLE `cancer_drugs`
  ADD PRIMARY KEY (`id`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `cancer_drugs`
--
ALTER TABLE `cancer_drugs`
  MODIFY `id` int(10) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=1927;
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
